[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Tearscience, Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":393},{"warningLetters":4,"total":392},[5,31,51,73,97,120,140,160,180,200,218,238,255,273,292,312,331,351,373],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},975,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2025-04-01T04:00:00Z\">04\u002F01\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-21T05:00:00Z\">02\u002F21\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnext-science-llc-698114-02212025\">Next Science LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jon E. Swanson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>COO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Next Science LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>10550 Deerwood Park Blvd. Ste 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jacksonville\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>32256\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@nextscience.com\"> (b)(6)@nextscience.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@nextscience.com\"> (b)(6)@nextscience.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 698114\u003C\u002Fp>\u003Cp>February 21, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Swanson:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Jacksonville, Florida on August 12 through September 5, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures wound gels under the brand names SURGX® and BLASTX®, and wound irrigation solutions under the brand names XPERIENCE® and Bactisure®. These products include devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>Lack of Marketing Authorization\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection and review of your firm’s website (https:\u002F\u002Fwww.nextscience.com\u002F) determined that the XPERIENCE®, BLASTX® and SURGX® products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the products, as described and marketed. These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the products into interstate commerce for commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a product requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b).\u003C\u002Fp>\u003Cp>The kind of information that your firm needs to submit in order to obtain approval or clearance for a device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed. Our office requests that your firm cease any activities that result in the misbranding or adulteration of the products.\u003C\u002Fp>\u003Cp>\u003Cu>XPERIENCE®\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your XPERIENCE® product was cleared under K203835 as MIS Solution with the following indications for use: “MIS Solution is indicated for use in cleansing and removal of debris, including microorganisms, from wounds.” However, based on our inspection and review of your firm’s website, FDA is aware that you are marketing these products without clearance or approval for the following uses in your marketing materials and website (https:\u002F\u002Fwww.nextscience.com\u002Fxperience\u002F), including but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>“XPERIENCE rinses away debris and microorganisms from the surgical wound site.”\u003C\u002Fli>\u003Cli>“XPERIENCE does not have cytotoxic effects on osteoblasts. Cell viability and bone growth and healing were shown to be more favorable compared to 10% Betadine.”\u003C\u002Fli>\u003Cli>“XPERIENCE is cleared for use in a variety of orthopedic surgeries, including arthroplasty, orthopedic trauma, spine, podiatric, and plastics.”\u003C\u002Fli>\u003Cli>“XPERIENCE is compatible with most commonly used implants, including hydroxyapatite (HA) coated implants, and closure methods.”\u003C\u002Fli>\u003Cli>“XPERIENCE compatibility with surgical implants and closure methods (316 Stainless Steel, Chrome Alloy, Nylon Sutures, Polyethylene Sutures, Polyethylene, Polydimethylsulfoxide, Polyethylene Sutures, Polysulphone, Silk Sutures, Titanium, Tivanium and Hydroxyapatit Implants).”\u003C\u002Fli>\u003Cli>“5+ hours of ongoing, broad-spectrum efficacy.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These claims were not reviewed as part of your premarket notification materials submitted to FDA and do not appear to be within the scope of the clearance issued under K203835. These claims also appear to constitute major changes or modifications in the intended use and could significantly affect the safety or effectiveness of the product that would require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by the Center for Drug Evaluation and Research (CDER) and subject to drug requirements. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\u003C\u002Fp>\u003Cp>The agency previously expressed concerns with the use of XPERIENCE® in deep (surgical) wounds. However, you continue to market XPERIENCE® with the cited claims. For example:\u003C\u002Fp>\u003Cul>\u003Cli>On March 3, 2019, the FDA provided feedback in K203835, Additional Information Letter which stated that the intended use of your device is for use on breached or compromised skin. Any claims regarding the use of the XPERIENCE® product for deep wound cavities, fissures and wound pockets are not cleared under product code FRO (dressing, wound, drug), and require submission of a 510(k) for FDA review.\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> to conduct an Investigational Device Exemption Study to expand the use of the XPERIENCE® product for the use in colorectal surgical wounds. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the FDA communicated our concern regarding the hemocompatibility of XPERIENCE® product, indicating that it is likely hemolytic. The FDA raised concern that hemocompatibility testing or scientific rationale is needed to evaluate the risk of using the XPERIENCE® product in surgical wounds. You have not provided any additional hemocompatibility report and have not been granted clearance for use of XPERIENCE® in deep (surgical) wounds.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>BLASTX®\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your BLASTX® product was cleared under K150792 as Next ScienceTM Wound Gel for Over-The-Counter Use with the following indications for use: “Next ScienceTM Wound Gel is indicated for the management of skin abrasions, lacerations, minor irritations, cuts, exit sites and intact skin.” However, based on our inspection and review of your firm’s website, FDA is aware that your firm is marketing this product without clearance or approval for the following uses in your marketing materials and website (https:\u002F\u002Fwww.nextscience.com\u002Fblastx-wound-gel\u002F), including but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>“BLASTX® can be applied once daily for up to 30 days.”\u003C\u002Fli>\u003Cli>“BLASTX® has been shown to suppress inflammation and repair the skin’s barrier function.”\u003C\u002Fli>\u003Cli>“BLASTX® inactivates matrix Metalloproteases (MMPs), leading to stopping the cytokine cascade. Also, BLASTX® inactivates proteases production by the bacteria, which prevents tissue destruction and inflammation by the same mechanism.”\u003C\u002Fli>\u003Cli>“Lowers inflammation allowing transition to proliferative stage.”\u003C\u002Fli>\u003Cli>“BLASTX® Results in Fewer Days with Wounds, Fewer Amputations.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These claims were not reviewed as part of your premarket notification materials submitted to FDA and are outside the scope of the clearance issued under K150792. These claims also appear to constitute major changes or modifications in the intended use of the product that require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by CDER. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\u003C\u002Fp>\u003Cp>\u003Cu>SURGX®\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your SURGX® product was cleared under K163188 as Next Science nonsterile wound gel for Prescription Use and with the following indications for use: “Next Science Wound Gel (Rx) is indicated for the management of wounds such as Stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first- and second-degree burns, grafted and donor sites.” However, based on our inspection and review of your firm’s website, FDA is aware that your firm is marketing this product without clearance or approval for the following uses in your marketing materials and website, including but not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>“SURGX® Sterile Antimicrobial Gel as sterilized by gamma radiation for one time use.”\u003C\u002Fli>\u003Cli>“SURGX® is designed to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-encased bacteria within the gel. The proprietary, non-toxic formulation conforms to the postoperative wound to provide proven broad spectrum and sustained effectiveness for up to 5 days.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These claims were not reviewed as part of your premarket notification materials submitted to FDA and are outside the scope of the clearance issued under K163188. These claims also appear to constitute major changes or modifications in the intended use of the product that require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by CDER. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\u003C\u002Fp>\u003Cp>Additionally, your firm is currently marketing the XPERIENCE®, BLASTX® and SURGX® products as powered by XBIO® Technology. Our inspection and the review of your website (https:\u002F\u002Fwww.nextscience.com\u002F) indicates you are making the following claims for XBIO® Technology:\u003C\u002Fp>\u003Cul>\u003Cli>“Since 2012, Next Science has been developing revolutionary material science-based technology that is non-toxic with proven efficacy against bacteria and microorganisms. This technology is called XBIO®.”\u003C\u002Fli>\u003Cli>“XBIO™ Technology deconstructs biofilm by removing the metal ions holding it together.”\u003C\u002Fli>\u003Cli>“XBIO Technology takes an innovative approach to solving the problem of bacterial biofilms. The unique, non-toxic technology attacks and deconstructs the structure of the biofilm by removing the metal ions that hold the EPS together. This exposes the bacteria within the biofilm, making them more vulnerable to eradication. Bacteria that are enveloped within the XBIO Technology are then destroyed by the combination of a surfactant and high osmotic imbalance across the bacterial cell wall. XBIO Technology’s broad-spectrum efficacy helps defend from biofilm reformation, reducing the rate of reoccurrence by over 100X. Due to this unique mechanism of action there is no known resistance to XBIO Technology.”\u003C\u002Fli>\u003Cli>“XBIO gives physicians the transformational technology to help improve surgical outcomes for even their most at-risk patients.”\u003C\u002Fli>\u003Cli>“Through our anti-biofilm solutions, it is our purpose to help reduce infections and combat the rising problem of antimicrobial resistance.”\u003C\u002Fli>\u003Cli>“At Next Science, we are leading a paradigm shift with a unique approach to eradicating both biofilm bacteria and planktonic bacteria with our XBIO Technology. XBIO disrupts the biofilm’s extracellular polymeric substance and exposes the bacteria, once protected by the biofilm, leaving it more vulnerable to attack.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>From the review of your marketing material, you claim XBIO® Technology deconstructs biofilm by removing the metal ions holding biofilm together. The claims indicate that XBIO® Technology has effect on biofilm. XPERIENCE®, BLASTX® and SURGX® have not been evaluated for safety and effectiveness against biofilm. As communicated to you during the regulatory meeting held on May 5, 2022, the antimicrobial component found in your 510(k) cleared products are intended to function as a preservative that inhibits growth of microorganisms in the products and claims of effectiveness against biofilm are outside the clearance of XPERIENCE®, BLASTX® and SURGX®. Additionally, the claims found in our inspection and review of your website go beyond the types of claims appropriate for wound dressings and wound washes categorized under the FRO product code. Further, the claims raise jurisdictional issues, and if you intend to continue making such claims, we note that the products may be regulated by CDER and subject to drug requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality System Regulation (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection also revealed that these products are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received your responses dated September 26, 2024, November 21, 2024, and January 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and include testing of production units under actual or simulated use conditions, and include risk analysis where appropriate, as required by, 21 CFR 820.30(g). Specifically,\u003C\u002Fp>\u003Cp>a. Your firm did not provide evidence to demonstrate that the design of XPERIENCE® was validated for the uses claimed in the product labeling and marketing material. Design validation activities for XPERIENCE® (MIS Solution FDA 510(k) K203835) were conducted for cleansing and removal of debris, including microorganisms, from external topical wounds, but your firm markets the solution as “cleared for use in a variety of orthopedic surgeries, including arthroplasty, orthopedic trauma, spine, podiatric, and plastics,” areas that may pose a greater risk and potential adverse effects because of the access to blood vessels and bone. Your firm did not conduct additional blood compatibility studies when establishing the biocompatibility assessment of XPERIENCE® that would be relevant for the uses marketed by your firm. Without this information, there are outstanding questions related to hemolysis risks from the use of this product as marketed by your firm.\u003C\u002Fp>\u003Cp>b. Your firm did not present design validation studies to support the biofilm disruption mechanism of action currently promoted on your products’ labeling and marketing material. Specifically, your firm’s wound gels and irrigation solutions are labeled as “Powered by XBio®.” Your firm’s website explains that XBio® is a proprietary non-toxic technology platform that disrupts the biofilm’s EPS matrix by removing the metal ions holding it together without inhibiting new tissue growth, offers no known opportunity for bacteria resistance, and removes bacteria from the treated surface and defends against biofilm recurrence.\u003C\u002Fp>\u003Cp>c. Your firm failed to conduct design validation studies to support the website claim that SURGX® provides broad-spectrum efficacy and multi-log reduction within the gel for fungus \u003Cem>C. albicans and A. brasiliensis\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>Your responses indicate that you have opened CAPA 0029 in response to this observation and that the marketing materials were placed on your firm’s website by a marketing associate without going through the formal review and approval process. Your responses indicate that your firm did not intend to plan and promote these products for the uses described above. Your responses also indicate that you have corrected your website and that your firm will review all currently approved marketing materials to verify that there is supporting evidence for each claim and will remove any claims without such evidence. Your responses indicate that you have hired a Director of Marketing with experience related to medical devices. In addition, your responses stated that you have reopened your Risk Management Plan and initiated a comprehensive reevaluation of risk management activities in accordance with ISO 14971 to better evaluate potential harms associated with known conditions of use. Your responses also indicated that you will update your firm’s website to clearly differentiate the use of XBIO® Technology in non-FDA regulated applications. In addition, your January 15, 2025, response indicates that your firm has updated several applicable procedures. However, at this time, the adequacy of your corrections cannot be determined at this time. Your corrections are ongoing, and a follow-up inspection will verify the effectiveness of your corrective actions.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example:\u003Cbr>Your firm’s procedure QOP-85-03, Customer Complaints, assigns responsibilities and provides a system and instructions for receiving and processing customer complaints relating to the product. This procedure was not adequately established in that:\u003C\u002Fp>\u003Cp>a. Information collected by your company from February 2022 through January 2023 regarding excessive bleeding caused by XPERIENCE® was not comprehensively evaluated to determine its relationship to the product and to understand the underlying potential mode or mechanism of failure when using the product on breast soft tissue. Specifically, your firm’s Medical Science Liaison Manager informed a clinical site on January 24, 2023, the following about the bleeding reports: “The fluid action coupled with the surfactant and citrates may loosen micro-clots. Moreover, a cleaner space than you usually see with just N\u002FS may make any extant bleeders more obvious. The general approach seems to be to simply slow down and allow those clots to stabilize before commencing aggressive irrigation.” There is no evidence that this information was further investigated to identify failure mode, risk of using the product on breast soft tissue, and any corrective action needed to preclude the bleeding and oozing adverse events.&nbsp;\u003C\u002Fp>\u003Cp>b. Complaints reporting several events under one report are entered in your complaint system as one complaint, limiting the extent of the investigation to be conducted for each individual case. Specifically, complaints received for XPERIENCE® reporting excessive bleeding did not include the nature and details of each individual case. In addition, data for complaint trending may be artificially lowered by grouping several events under one complaint, for example:\u003C\u002Fp>\u003Cp>i. Complaint # 00265- a surgeon reported three cases of bleeding he encountered at two different surgery centers.\u003Cbr>ii. Complaint # 00266- a surgeon reported two cases of increase in bleeding within the first five minutes after irrigating on capsulectomy cases.\u003Cbr>iii. Complaint # 00274- a surgeon reported three cases of oozing and bleeding and one case of hematoma.\u003Cbr>iv. Complaint # 00278- a surgeon reported three cases of diffuse bleeding and oozing.\u003Cbr>v. Complaint # 00299- a surgeon reported two cases of diffuse bleeding and one hematoma requiring drainage.\u003C\u002Fp>\u003Cp>Your responses indicate that you have opened CAPA 0033 and that you have updated your complaint handling module to ask whether new information has been received on a previously closed investigation that would warrant further investigation. Your responses also indicate that you have created a new procedure for Issue Impact Assessments QOP 85-05, and that training was conducted. In addition, your responses indicate that a retrospective review of complaints for all product families and new individual complaint events was opened. Also, your January 15, 2025, response indicates that your firm has updated QOP-82-01 to redefine the process, roles, and responsibilities for the act of reviewing publications, articles, literature reviews and opening complaint report records. We cannot determine the adequacy of your corrective actions at this time. A follow-up inspection will need to be conducted to evaluate the adequacy of the implementation and the effectiveness of your corrective actions.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, per your Corrective and Preventive Action procedure QOP-85-004, a reported failure that may pose a significant patient safety risk and\u002For presents an upward trend of reported events are to be considered sources of corrective and preventive actions. Your firm did not follow this procedure for the XPERIENCE® bleeding complaints in that a CAPA was not opened after receiving at least twenty reports of excessive bleeding after using XPERIENCE® to rinse the breast pocket in breast surgery cases.\u003C\u002Fp>\u003Cp>Your responses indicate that you have opened CAPA 0036 and determined that the failure occurred because the relevant procedures did not properly trigger CAPA escalation. Your responses indicate that you have modified your procedures and conducted a retrospective review of complaints based on the updated procedures to determine if CAPAs need to be initiated for certain failures. Your January 15, 2025, response indicated that your firm concluded that no new issues required escalation to CAPA when compared against updated Customer Complaints procedure QOP-85-03. Your responses also indicate that you have developed a new procedure QOP-85-05 Issue Impact Assessment in order to have a documented determination for elevation to CAPA. Your responses indicate that the new procedure will require the Issue Impact Assessment be revisited (including CAPA determinations) when failure modes of a similar nature are detected. Your responses also indicate that you have developed a new work instruction that requires the reporting of trending of failure modes for adverse\u002Freportable\u002FIIA events. We cannot determine the adequacy of your corrective actions at this time. A follow-up inspection will need to be conducted to evaluate the implementation and the effectiveness of your corrective actions.\u003C\u002Fp>\u003Cp>\u003Cstrong>Medical Device Reporting (MDR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s XPERIENCE® solution is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the product that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example:\u003C\u002Fp>\u003Cp>a. The information included for Complaint# 0299 reasonably suggests that a patient sustained an injury (hematoma) following the breast reduction surgery involving your firm’s XPERIENCE® solution, which required percutaneous aspiration. There is no information included in the complaint that rules out that your firm’s XPERIENCE® solution may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on January 26, 2023, yet the corresponding MDR# 3012271775-2024-00002 was not received by the FDA until October 31, 2024, exceeding the required 30-calendar-day reporting timeframe.\u003C\u002Fp>\u003Cp>b. The information included for Complaint# 0276 reasonably suggests that a patient sustained an injury (diffuse bleeding) on one breast pocket during a bilateral breast augmentation procedure involving the application of your firm’s XPERIENCE® solution, which required a saline wash and cauterization of the bleeding tissue to manage the situation. There is no information included in the complaint that rules out that your firm’s XPERIENCE® solution may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on May 12, 2022, yet the corresponding MDR# 3012271775-2024-00004 was not received by the FDA until November 8, 2024, exceeding the required 30-calendar-day reporting timeframe.\u003C\u002Fp>\u003Cp>We received your responses dated September 26, 2024, November 21, 2024, and January 15, 2025. Your firm’s responses indicate that corrective actions have been taken to address this observation. These actions include streamlining the MDR reporting process by incorporating an MDR decision tree and conducting a retrospective review of XPERIENCE® complaints related to bleeding for MDR reportability. As a result, we acknowledge receipt of six newly identified MDRs. Additionally, your firm has completed a retrospective review of all complaints from the past three years and confirmed that no additional reportable events were identified. Please note that future FDA inspections or regulatory activities will assess the implementation and effectiveness of your corrective actions.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your products or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 698114 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>RDML Sean M. Boyd, MPH, USPHS\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nJon E. Swanson\n\nRecipient Title\n\nCOO\n\nNext Science LLC\n\n10550 Deerwood Park Blvd. Ste 300\n\nJacksonville, FL 32256\n\nUnited States\n\n(b)(6)@nextscience.com\n\n(b)(6)@nextscience.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 698114\nFebruary 21, 2025\nDear Mr. Swanson:\nDuring an inspection of your firm located in Jacksonville, Florida on August 12 through September 5, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures wound gels under the brand names SURGX® and BLASTX®, and wound irrigation solutions under the brand names XPERIENCE® and Bactisure®. These products include devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nLack of Marketing Authorization\nOur inspection and review of your firm’s website (https:\u002F\u002Fwww.nextscience.com\u002F) determined that the XPERIENCE®, BLASTX® and SURGX® products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the products, as described and marketed. These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the products into interstate commerce for commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a product requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b).\nThe kind of information that your firm needs to submit in order to obtain approval or clearance for a device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed. Our office requests that your firm cease any activities that result in the misbranding or adulteration of the products.\nXPERIENCE®\nYour XPERIENCE® product was cleared under K203835 as MIS Solution with the following indications for use: “MIS Solution is indicated for use in cleansing and removal of debris, including microorganisms, from wounds.” However, based on our inspection and review of your firm’s website, FDA is aware that you are marketing these products without clearance or approval for the following uses in your marketing materials and website (https:\u002F\u002Fwww.nextscience.com\u002Fxperience\u002F), including but not limited to:\n“XPERIENCE rinses away debris and microorganisms from the surgical wound site.”\n“XPERIENCE does not have cytotoxic effects on osteoblasts. Cell viability and bone growth and healing were shown to be more favorable compared to 10% Betadine.”\n“XPERIENCE is cleared for use in a variety of orthopedic surgeries, including arthroplasty, orthopedic trauma, spine, podiatric, and plastics.”\n“XPERIENCE is compatible with most commonly used implants, including hydroxyapatite (HA) coated implants, and closure methods.”\n“XPERIENCE compatibility with surgical implants and closure methods (316 Stainless Steel, Chrome Alloy, Nylon Sutures, Polyethylene Sutures, Polyethylene, Polydimethylsulfoxide, Polyethylene Sutures, Polysulphone, Silk Sutures, Titanium, Tivanium and Hydroxyapatit Implants).”\n“5+ hours of ongoing, broad-spectrum efficacy.”\nThese claims were not reviewed as part of your premarket notification materials submitted to FDA and do not appear to be within the scope of the clearance issued under K203835. These claims also appear to constitute major changes or modifications in the intended use and could significantly affect the safety or effectiveness of the product that would require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by the Center for Drug Evaluation and Research (CDER) and subject to drug requirements. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\nThe agency previously expressed concerns with the use of XPERIENCE® in deep (surgical) wounds. However, you continue to market XPERIENCE® with the cited claims. For example:\nOn March 3, 2019, the FDA provided feedback in K203835, Additional Information Letter which stated that the intended use of your device is for use on breached or compromised skin. Any claims regarding the use of the XPERIENCE® product for deep wound cavities, fissures and wound pockets are not cleared under product code FRO (dressing, wound, drug), and require submission of a 510(k) for FDA review.\n(b)(4) to conduct an Investigational Device Exemption Study to expand the use of the XPERIENCE® product for the use in colorectal surgical wounds. (b)(4), the FDA communicated our concern regarding the hemocompatibility of XPERIENCE® product, indicating that it is likely hemolytic. The FDA raised concern that hemocompatibility testing or scientific rationale is needed to evaluate the risk of using the XPERIENCE® product in surgical wounds. You have not provided any additional hemocompatibility report and have not been granted clearance for use of XPERIENCE® in deep (surgical) wounds.\nBLASTX®\nYour BLASTX® product was cleared under K150792 as Next ScienceTM Wound Gel for Over-The-Counter Use with the following indications for use: “Next ScienceTM Wound Gel is indicated for the management of skin abrasions, lacerations, minor irritations, cuts, exit sites and intact skin.” However, based on our inspection and review of your firm’s website, FDA is aware that your firm is marketing this product without clearance or approval for the following uses in your marketing materials and website (https:\u002F\u002Fwww.nextscience.com\u002Fblastx-wound-gel\u002F), including but not limited to:\n“BLASTX® can be applied once daily for up to 30 days.”\n“BLASTX® has been shown to suppress inflammation and repair the skin’s barrier function.”\n“BLASTX® inactivates matrix Metalloproteases (MMPs), leading to stopping the cytokine cascade. Also, BLASTX® inactivates proteases production by the bacteria, which prevents tissue destruction and inflammation by the same mechanism.”\n“Lowers inflammation allowing transition to proliferative stage.”\n“BLASTX® Results in Fewer Days with Wounds, Fewer Amputations.”\nThese claims were not reviewed as part of your premarket notification materials submitted to FDA and are outside the scope of the clearance issued under K150792. These claims also appear to constitute major changes or modifications in the intended use of the product that require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by CDER. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\nSURGX®\nYour SURGX® product was cleared under K163188 as Next Science nonsterile wound gel for Prescription Use and with the following indications for use: “Next Science Wound Gel (Rx) is indicated for the management of wounds such as Stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first- and second-degree burns, grafted and donor sites.” However, based on our inspection and review of your firm’s website, FDA is aware that your firm is marketing this product without clearance or approval for the following uses in your marketing materials and website, including but not limited to:\n“SURGX® Sterile Antimicrobial Gel as sterilized by gamma radiation for one time use.”\n“SURGX® is designed to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-encased bacteria within the gel. The proprietary, non-toxic formulation conforms to the postoperative wound to provide proven broad spectrum and sustained effectiveness for up to 5 days.”\nThese claims were not reviewed as part of your premarket notification materials submitted to FDA and are outside the scope of the clearance issued under K163188. These claims also appear to constitute major changes or modifications in the intended use of the product that require submission of a new marketing application. We also note that some of the claims raise jurisdictional issues, and if you intend to continue making such claims, the product may be regulated by CDER. Please note that the claims and indications for a product can impact the regulatory pathway of the product, as well as the classification of or jurisdiction of FDA over the product.\nAdditionally, your firm is currently marketing the XPERIENCE®, BLASTX® and SURGX® products as powered by XBIO® Technology. Our inspection and the review of your website (https:\u002F\u002Fwww.nextscience.com\u002F) indicates you are making the following claims for XBIO® Technology:\n“Since 2012, Next Science has been developing revolutionary material science-based technology that is non-toxic with proven efficacy against bacteria and microorganisms. This technology is called XBIO®.”\n“XBIO™ Technology deconstructs biofilm by removing the metal ions holding it together.”\n“XBIO Technology takes an innovative approach to solving the problem of bacterial biofilms. The unique, non-toxic technology attacks and deconstructs the structure of the biofilm by removing the metal ions that hold the EPS together. This exposes the bacteria within the biofilm, making them more vulnerable to eradication. Bacteria that are enveloped within the XBIO Technology are then destroyed by the combination of a surfactant and high osmotic imbalance across the bacterial cell wall. XBIO Technology’s broad-spectrum efficacy helps defend from biofilm reformation, reducing the rate of reoccurrence by over 100X. Due to this unique mechanism of action there is no known resistance to XBIO Technology.”\n“XBIO gives physicians the transformational technology to help improve surgical outcomes for even their most at-risk patients.”\n“Through our anti-biofilm solutions, it is our purpose to help reduce infections and combat the rising problem of antimicrobial resistance.”\n“At Next Science, we are leading a paradigm shift with a unique approach to eradicating both biofilm bacteria and planktonic bacteria with our XBIO Technology. XBIO disrupts the biofilm’s extracellular polymeric substance and exposes the bacteria, once protected by the biofilm, leaving it more vulnerable to attack.”\nFrom the review of your marketing material, you claim XBIO® Technology deconstructs biofilm by removing the metal ions holding biofilm together. The claims indicate that XBIO® Technology has effect on biofilm. XPERIENCE®, BLASTX® and SURGX® have not been evaluated for safety and effectiveness against biofilm. As communicated to you during the regulatory meeting held on May 5, 2022, the antimicrobial component found in your 510(k) cleared products are intended to function as a preservative that inhibits growth of microorganisms in the products and claims of effectiveness against biofilm are outside the clearance of XPERIENCE®, BLASTX® and SURGX®. Additionally, the claims found in our inspection and review of your website go beyond the types of claims appropriate for wound dressings and wound washes categorized under the FRO product code. Further, the claims raise jurisdictional issues, and if you intend to continue making such claims, we note that the products may be regulated by CDER and subject to drug requirements.\nQuality System Regulation (QSR) Violations\nThis inspection also revealed that these products are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received your responses dated September 26, 2024, November 21, 2024, and January 15, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for validating the device design to ensure that devices conform to defined user needs and intended uses and include testing of production units under actual or simulated use conditions, and include risk analysis where appropriate, as required by, 21 CFR 820.30(g). Specifically,\na. Your firm did not provide evidence to demonstrate that the design of XPERIENCE® was validated for the uses claimed in the product labeling and marketing material. Design validation activities for XPERIENCE® (MIS Solution FDA 510(k) K203835) were conducted for cleansing and removal of debris, including microorganisms, from external topical wounds, but your firm markets the solution as “cleared for use in a variety of orthopedic surgeries, including arthroplasty, orthopedic trauma, spine, podiatric, and plastics,” areas that may pose a greater risk and potential adverse effects because of the access to blood vessels and bone. Your firm did not conduct additional blood compatibility studies when establishing the biocompatibility assessment of XPERIENCE® that would be relevant for the uses marketed by your firm. Without this information, there are outstanding questions related to hemolysis risks from the use of this product as marketed by your firm.\nb. Your firm did not present design validation studies to support the biofilm disruption mechanism of action currently promoted on your products’ labeling and marketing material. Specifically, your firm’s wound gels and irrigation solutions are labeled as “Powered by XBio®.” Your firm’s website explains that XBio® is a proprietary non-toxic technology platform that disrupts the biofilm’s EPS matrix by removing the metal ions holding it together without inhibiting new tissue growth, offers no known opportunity for bacteria resistance, and removes bacteria from the treated surface and defends against biofilm recurrence.\nc. Your firm failed to conduct design validation studies to support the website claim that SURGX® provides broad-spectrum efficacy and multi-log reduction within the gel for fungus C. albicans and A. brasiliensis.\nYour responses indicate that you have opened CAPA 0029 in response to this observation and that the marketing materials were placed on your firm’s website by a marketing associate without going through the formal review and approval process. Your responses indicate that your firm did not intend to plan and promote these products for the uses described above. Your responses also indicate that you have corrected your website and that your firm will review all currently approved marketing materials to verify that there is supporting evidence for each claim and will remove any claims without such evidence. Your responses indicate that you have hired a Director of Marketing with experience related to medical devices. In addition, your responses stated that you have reopened your Risk Management Plan and initiated a comprehensive reevaluation of risk management activities in accordance with ISO 14971 to better evaluate potential harms associated with known conditions of use. Your responses also indicated that you will update your firm’s website to clearly differentiate the use of XBIO® Technology in non-FDA regulated applications. In addition, your January 15, 2025, response indicates that your firm has updated several applicable procedures. However, at this time, the adequacy of your corrections cannot be determined at this time. Your corrections are ongoing, and a follow-up inspection will verify the effectiveness of your corrective actions.\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example:\nYour firm’s procedure QOP-85-03, Customer Complaints, assigns responsibilities and provides a system and instructions for receiving and processing customer complaints relating to the product. This procedure was not adequately established in that:\na. Information collected by your company from February 2022 through January 2023 regarding excessive bleeding caused by XPERIENCE® was not comprehensively evaluated to determine its relationship to the product and to understand the underlying potential mode or mechanism of failure when using the product on breast soft tissue. Specifically, your firm’s Medical Science Liaison Manager informed a clinical site on January 24, 2023, the following about the bleeding reports: “The fluid action coupled with the surfactant and citrates may loosen micro-clots. Moreover, a cleaner space than you usually see with just N\u002FS may make any extant bleeders more obvious. The general approach seems to be to simply slow down and allow those clots to stabilize before commencing aggressive irrigation.” There is no evidence that this information was further investigated to identify failure mode, risk of using the product on breast soft tissue, and any corrective action needed to preclude the bleeding and oozing adverse events.\nb. Complaints reporting several events under one report are entered in your complaint system as one complaint, limiting the extent of the investigation to be conducted for each individual case. Specifically, complaints received for XPERIENCE® reporting excessive bleeding did not include the nature and details of each individual case. In addition, data for complaint trending may be artificially lowered by grouping several events under one complaint, for example:\ni. Complaint # 00265- a surgeon reported three cases of bleeding he encountered at two different surgery centers.\nii. Complaint # 00266- a surgeon reported two cases of increase in bleeding within the first five minutes after irrigating on capsulectomy cases.\niii. Complaint # 00274- a surgeon reported three cases of oozing and bleeding and one case of hematoma.\niv. Complaint # 00278- a surgeon reported three cases of diffuse bleeding and oozing.\nv. Complaint # 00299- a surgeon reported two cases of diffuse bleeding and one hematoma requiring drainage.\nYour responses indicate that you have opened CAPA 0033 and that you have updated your complaint handling module to ask whether new information has been received on a previously closed investigation that would warrant further investigation. Your responses also indicate that you have created a new procedure for Issue Impact Assessments QOP 85-05, and that training was conducted. In addition, your responses indicate that a retrospective review of complaints for all product families and new individual complaint events was opened. Also, your January 15, 2025, response indicates that your firm has updated QOP-82-01 to redefine the process, roles, and responsibilities for the act of reviewing publications, articles, literature reviews and opening complaint report records. We cannot determine the adequacy of your corrective actions at this time. A follow-up inspection will need to be conducted to evaluate the adequacy of the implementation and the effectiveness of your corrective actions.\n3. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, per your Corrective and Preventive Action procedure QOP-85-004, a reported failure that may pose a significant patient safety risk and\u002For presents an upward trend of reported events are to be considered sources of corrective and preventive actions. Your firm did not follow this procedure for the XPERIENCE® bleeding complaints in that a CAPA was not opened after receiving at least twenty reports of excessive bleeding after using XPERIENCE® to rinse the breast pocket in breast surgery cases.\nYour responses indicate that you have opened CAPA 0036 and determined that the failure occurred because the relevant procedures did not properly trigger CAPA escalation. Your responses indicate that you have modified your procedures and conducted a retrospective review of complaints based on the updated procedures to determine if CAPAs need to be initiated for certain failures. Your January 15, 2025, response indicated that your firm concluded that no new issues required escalation to CAPA when compared against updated Customer Complaints procedure QOP-85-03. Your responses also indicate that you have developed a new procedure QOP-85-05 Issue Impact Assessment in order to have a documented determination for elevation to CAPA. Your responses indicate that the new procedure will require the Issue Impact Assessment be revisited (including CAPA determinations) when failure modes of a similar nature are detected. Your responses also indicate that you have developed a new work instruction that requires the reporting of trending of failure modes for adverse\u002Freportable\u002FIIA events. We cannot determine the adequacy of your corrective actions at this time. A follow-up inspection will need to be conducted to evaluate the implementation and the effectiveness of your corrective actions.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm’s XPERIENCE® solution is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the product that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to submit a report to FDA no later than 30 calendar days after the day that your firm received or otherwise became aware of information, from any source, that reasonably suggests that a device that your firm markets may have caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). For example:\na. The information included for Complaint# 0299 reasonably suggests that a patient sustained an injury (hematoma) following the breast reduction surgery involving your firm’s XPERIENCE® solution, which required percutaneous aspiration. There is no information included in the complaint that rules out that your firm’s XPERIENCE® solution may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on January 26, 2023, yet the corresponding MDR# 3012271775-2024-00002 was not received by the FDA until October 31, 2024, exceeding the required 30-calendar-day reporting timeframe.\nb. The information included for Complaint# 0276 reasonably suggests that a patient sustained an injury (diffuse bleeding) on one breast pocket during a bilateral breast augmentation procedure involving the application of your firm’s XPERIENCE® solution, which required a saline wash and cauterization of the bleeding tissue to manage the situation. There is no information included in the complaint that rules out that your firm’s XPERIENCE® solution may not have caused or contributed to the referenced injury. Further, the information described in the complaint meets the definition of serious injury under 21 CFR 803.3(w) because medical intervention was necessary to preclude permanent impairment of a body function or permanent damage to a body structure. Your firm became aware of the event on May 12, 2022, yet the corresponding MDR# 3012271775-2024-00004 was not received by the FDA until November 8, 2024, exceeding the required 30-calendar-day reporting timeframe.\nWe received your responses dated September 26, 2024, November 21, 2024, and January 15, 2025. Your firm’s responses indicate that corrective actions have been taken to address this observation. These actions include streamlining the MDR reporting process by incorporating an MDR decision tree and conducting a retrospective review of XPERIENCE® complaints related to bleeding for MDR reportability. As a result, we acknowledge receipt of six newly identified MDRs. Additionally, your firm has completed a retrospective review of all complaints from the past three years and confirmed that no additional reportable events were identified. Please note that future FDA inspections or regulatory activities will assess the implementation and effectiveness of your corrective actions.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your products or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director at CDRHenforcement@fda.hhs.gov. Please include in the subject line, CMS case # 698114 when replying. If you have any questions about the contents of this letter, please contact: Demetria Lueneburg, Compliance Officer at Demetria.Lueneburg@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely yours,\n\u002FS\u002F\nRDML Sean M. Boyd, MPH, USPHS\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Next Science LLC","next-science-llc-698114-02212025","2026-08-18T06:42:28.676509+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnext-science-llc-698114-02212025","2026-10-26T08:09:33.109663+00:00","Warning Letter","Issued","2025-04-01","698114","Medical Devices","Jon E. Swanson","2026-08-19T16:53:57.644+00:00","VIA Electronic Mail","2025-02-21",{"id":32,"raw":33,"subject":37,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":42,"fei_number":19,"letter_url":43,"updated_at":44,"action_type":22,"case_status":23,"posted_date":45,"marcs_cms_no":46,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":47,"body_fetched_at":48,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":50,"medical_device_id":19,"response_letter_date":19},1534,[34,35,36,11,37,13,13,13],"\u003Ctime datetime=\"2024-04-02T13:20:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-21T04:00:00Z\">03\u002F21\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagena-bioscience-inc-665159-03212024\">Agena Bioscience, Inc.\u003C\u002Fa>","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Roman Haehn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President and General Manager of Clinical Genomics\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Agena Bioscience, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4755 Eastgate Mall\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>San Diego\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92121\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Roman.Haehn@agenabio.com\"> Roman.Haehn@agenabio.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd> Division of Medical Device and Radiological Health Operations West\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 665159\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 21, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Haehn,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located at 4755 Eastgate Mall, San Diego, CA on June 7, 2023, through June 13, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the MassARRAY4 System (MA4) and the iPLEX HS chemistry panels including the iPLEX HS Colon Panel in vitro diagnostic (IVD) products. Based on the inspection and our review of your firm’s website, it appears the iPLEX HS Colon Panel intended for use with the MA4 is intended for clinical diagnostic use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>The evidence reveals that the iPLEX HS Colon Panel intended for use with the MA4 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>You currently have clearance for the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) under 21 CFR 864.7280 for the following indications:\u003C\u002Fp>\n\n\u003Cp>The IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test is a qualitative in vitro diagnostic device intended for use in the detection and genotyping of a single point mutation (G1691A, referred to as the Factor V Leiden mutation or FVL) of the Factor V gene, located on Chromosome 1q23, and a single point mutation (G20210A) of the prothrombin gene (referred to as Factor II or FII), located on Chromosome 11p11-q12, from genomic DNA isolated from EDTA anti-coagulated human whole blood samples. The test is to be performed on the IMPACT Dx™ System and is indicated for use as an aid in diagnosis of patients with suspected thrombophilia.\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm’s Director of Regulatory and Quality made verbal statements to the FDA investigator that your firm no longer sells the cleared Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System and has since only marketed and distributed the MA4.\u003C\u002Fp>\n\n\u003Cp>Based on evidence obtained during the inspection and a review of your firm’s website the iPLEX HS Colon Panel intended for use with the MA4 appears intended for clinical diagnostic use. Such evidence includes:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Verbal statements made to the FDA investigator during the inspection on behalf of your firm by your firm’s Director of Regulatory and Quality indicating that your firm no longer sells the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) and has instead replaced it with a new system, the MA4, and admitting that your firm sells the MA4 and reagent panels to companies who analyze patient samples that are used for clinical diagnosis.\u003C\u002Fli>\n\t\u003Cli>Distribution records and a customer list obtained during inspection that indicates your firm shipped MA4 Systems and iPLEX HS Colon Panels to clinical testing laboratories.\u003C\u002Fli>\n\t\u003Cli>A customer notification your firm sent to customers dated June 1, 2021, regarding distributed iPLEX HS Colon Panels that alerted customers of an increase in false negative results of certain reagent lots and stated that Agena was taking steps “to not impact your laboratory workflow.” This customer notification was sent to a clinical hospital in Texas and there is no evidence that these reagents were intended for research use only.\u003C\u002Fli>\n\t\u003Cli>A copy of the iPLEX HS Panels User Guide obtained during inspection that included instructions for preparing and testing samples as well as instructions for interpreting iPLEX HS Reports including the iPLEX HS Colon Panel intended for use with the MA4.\u003C\u002Fli>\n\t\u003Cli>Your firm’s website (last accessed on March 20, 2024) includes product descriptions and statements that the iPLEX HS Colon Panel “enables tumor profiling studies of colorectal cancer specimens”, and that, with the iPLEX HS Colon Panel, users can “Detect more than 80 clinically relevant variants across BRAF, EGFR, KRAS, NRAS, and PIK3CA” and “Identify variants at as low as 1% variant allele frequency.” [https:\u002F\u002Fwww.agenabio.com\u002Fproducts\u002Fpanel\u002Fiplex-hs-colon-panel\u002F]\u003C\u002Fli>\n\t\u003Cli>Your firm’s website (last accessed on March 20, 2024) includes customer stories from clients of Agena that indicate your MA4 System is intended for clinical diagnostic use. For instance, on the “FEATURED CUSTOMER STORIES” page, a portion of a testimonial reads, “Accurate, Cost-effective Newborn Screening for the Illinois Department of Health on the MassARRAY [MA4]…” And a statement from your CEO reads, “We are proud to have the MassARRAY System [MA4] chosen to be an integral part of one of the top newborn screening programs in the country…” [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fhgt\u002Faccurate-cost-effective-cftr-variant-detection-newborn-screening\u002F]. Another customer story comes from a client that is identified as a hospital system that uses your MA4 and iPLEX HS chemistry panels in tumor profiling and can deliver a quick and cost-effective test for clinically informative variants with a statement that other labs should explore the MassARRAY (MA4) for rapid, low-cost tumor profiling panels with a link to a product page for the iPLEX HS Colon Panel. [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fonc\u002Fmassarray-enables-sensitivity-quick-turnaround-tumor-profiling-bsw\u002F].\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm’s Director of Regulatory and Quality indicated that your firm markets the MA4 as a research use only (RUO) product and that your firm sells and distributes the MA4 to both research and clinical diagnostic companies. Your firm’s Director of Regulatory and Quality also indicated that labeling distributed with your MA4 products, and the labeling obtained during the inspection for your iPLEX HS Colon Panel, included the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” Your firm’s website also includes the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” But, as discussed in this letter, on numerous occasions your iPLEX HS Colon Panel and your MA4 were not being shipped or delivered for an investigation (21 CFR 809.10(c)). And these devices were not for use in the laboratory research phase of development but rather were represented as effective IVDs (21 CFR 809.10(c)(2)(i)). Your disclaimers that the MA4 and your iPLEX HS Colon Panel are intended for research use only (RUO) are inconsistent with the evidence obtained during the inspection and statements identified on your firm’s website as identified above and FDA has determined that your MA4 and iPLEX HS Colon Panel are intended for clinical diagnostic use.\u003C\u002Fp>\n\n\u003Cp>Your iPLEX HS Colon Panel intended for use with the MA4 appears to be a tumor profiling test intended for the diagnosis of colorectal cancer. You were required to submit to FDA a 510(k) for this device, because it either is a new device (21 CFR 807.81(a)(1)) or, if your iPLEX HS Colon Panel intended for use with the MA4 represents a change or modification from the device cleared in K132978 (which is indicated for use as an aid in diagnosis of patients with suspected thrombophilia), has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\u003Cbr>\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s iPLEX HS Colon Panel is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, failure to submit a written report to FDA of any correction or removal of a device initiated to reduce a risk to health posed by the device, as required by 21 CFR Part 806.10. For example:\u003C\u002Fp>\n\n\u003Cp>On June 1, 2021, your firm issued a Customer Notification alerting customers that certain lots of your iPLEX HS Colon v1.0 Panel did not include the A nucleotide termination in Well #8 which your firm determined could result in false negative results for three target variant alleles. Your firm instructed customers to not use the results for the impacted variants and that your firm would reformulate and verify the termination mix and provide further updates on availability. Your firm did not submit a written report of this removal to the agency, as required by 21 CFR 806.10.\u003C\u002Fp>\n\n\u003Cp>We request that your firm immediately cease any activities that result in the misbranding or adulteration of your devices. Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to both: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov and to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS # 665159 when replying. If you have any questions about the contents of this letter, please contact: Jeff R. Wooley, Compliance Officer, at 214-253-5251 or jeffrey.wooley@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific concerns noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney Lias, Ph.D.\u003Cbr>\nActing Director\u003Cbr>\nOHT 7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director, Division 3\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOffice of Regulatory Affairs\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: Glen Wise\u003Cbr>\nDirector, Quality and Regulatory\u003Cbr>\nGlenn.wise@agenabio.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRoman Haehn\n\nRecipient Title\n\nVice President and General Manager of Clinical Genomics\n\nAgena Bioscience, Inc.\n\n4755 Eastgate Mall\n\nSan Diego, CA 92121\n\nUnited States\n\nRoman.Haehn@agenabio.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nDivision of Medical Device and Radiological Health Operations West\n\nUnited States\n\nWARNING LETTER\n\nCMS # 665159\n\nMarch 21, 2024\n\nDear Mr. Haehn,\n\nDuring an inspection of your firm located at 4755 Eastgate Mall, San Diego, CA on June 7, 2023, through June 13, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer of the MassARRAY4 System (MA4) and the iPLEX HS chemistry panels including the iPLEX HS Colon Panel in vitro diagnostic (IVD) products. Based on the inspection and our review of your firm’s website, it appears the iPLEX HS Colon Panel intended for use with the MA4 is intended for clinical diagnostic use. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThe evidence reveals that the iPLEX HS Colon Panel intended for use with the MA4 is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nYou currently have clearance for the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) under 21 CFR 864.7280 for the following indications:\n\nThe IMPACT Dx™ Factor V Leiden and Factor II Genotyping Test is a qualitative in vitro diagnostic device intended for use in the detection and genotyping of a single point mutation (G1691A, referred to as the Factor V Leiden mutation or FVL) of the Factor V gene, located on Chromosome 1q23, and a single point mutation (G20210A) of the prothrombin gene (referred to as Factor II or FII), located on Chromosome 11p11-q12, from genomic DNA isolated from EDTA anti-coagulated human whole blood samples. The test is to be performed on the IMPACT Dx™ System and is indicated for use as an aid in diagnosis of patients with suspected thrombophilia.\n\nDuring the inspection, your firm’s Director of Regulatory and Quality made verbal statements to the FDA investigator that your firm no longer sells the cleared Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System and has since only marketed and distributed the MA4.\n\nBased on evidence obtained during the inspection and a review of your firm’s website the iPLEX HS Colon Panel intended for use with the MA4 appears intended for clinical diagnostic use. Such evidence includes:\n\nVerbal statements made to the FDA investigator during the inspection on behalf of your firm by your firm’s Director of Regulatory and Quality indicating that your firm no longer sells the Impact Dx™ Factor V Leiden and Factor II Genotyping Test on the IMPACT Dx™ System (K132978) and has instead replaced it with a new system, the MA4, and admitting that your firm sells the MA4 and reagent panels to companies who analyze patient samples that are used for clinical diagnosis.\n\nDistribution records and a customer list obtained during inspection that indicates your firm shipped MA4 Systems and iPLEX HS Colon Panels to clinical testing laboratories.\n\nA customer notification your firm sent to customers dated June 1, 2021, regarding distributed iPLEX HS Colon Panels that alerted customers of an increase in false negative results of certain reagent lots and stated that Agena was taking steps “to not impact your laboratory workflow.” This customer notification was sent to a clinical hospital in Texas and there is no evidence that these reagents were intended for research use only.\n\nA copy of the iPLEX HS Panels User Guide obtained during inspection that included instructions for preparing and testing samples as well as instructions for interpreting iPLEX HS Reports including the iPLEX HS Colon Panel intended for use with the MA4.\n\nYour firm’s website (last accessed on March 20, 2024) includes product descriptions and statements that the iPLEX HS Colon Panel “enables tumor profiling studies of colorectal cancer specimens”, and that, with the iPLEX HS Colon Panel, users can “Detect more than 80 clinically relevant variants across BRAF, EGFR, KRAS, NRAS, and PIK3CA” and “Identify variants at as low as 1% variant allele frequency.” [https:\u002F\u002Fwww.agenabio.com\u002Fproducts\u002Fpanel\u002Fiplex-hs-colon-panel\u002F]\n\nYour firm’s website (last accessed on March 20, 2024) includes customer stories from clients of Agena that indicate your MA4 System is intended for clinical diagnostic use. For instance, on the “FEATURED CUSTOMER STORIES” page, a portion of a testimonial reads, “Accurate, Cost-effective Newborn Screening for the Illinois Department of Health on the MassARRAY [MA4]…” And a statement from your CEO reads, “We are proud to have the MassARRAY System [MA4] chosen to be an integral part of one of the top newborn screening programs in the country…” [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fhgt\u002Faccurate-cost-effective-cftr-variant-detection-newborn-screening\u002F]. Another customer story comes from a client that is identified as a hospital system that uses your MA4 and iPLEX HS chemistry panels in tumor profiling and can deliver a quick and cost-effective test for clinically informative variants with a statement that other labs should explore the MassARRAY (MA4) for rapid, low-cost tumor profiling panels with a link to a product page for the iPLEX HS Colon Panel. [https:\u002F\u002Fwww.agenabio.com\u002Fstories\u002Fonc\u002Fmassarray-enables-sensitivity-quick-turnaround-tumor-profiling-bsw\u002F].\n\nYour firm’s Director of Regulatory and Quality indicated that your firm markets the MA4 as a research use only (RUO) product and that your firm sells and distributes the MA4 to both research and clinical diagnostic companies. Your firm’s Director of Regulatory and Quality also indicated that labeling distributed with your MA4 products, and the labeling obtained during the inspection for your iPLEX HS Colon Panel, included the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” Your firm’s website also includes the statement that these devices are “For Research Use Only. Not for use in diagnostic procedures.” But, as discussed in this letter, on numerous occasions your iPLEX HS Colon Panel and your MA4 were not being shipped or delivered for an investigation (21 CFR 809.10(c)). And these devices were not for use in the laboratory research phase of development but rather were represented as effective IVDs (21 CFR 809.10(c)(2)(i)). Your disclaimers that the MA4 and your iPLEX HS Colon Panel are intended for research use only (RUO) are inconsistent with the evidence obtained during the inspection and statements identified on your firm’s website as identified above and FDA has determined that your MA4 and iPLEX HS Colon Panel are intended for clinical diagnostic use.\n\nYour iPLEX HS Colon Panel intended for use with the MA4 appears to be a tumor profiling test intended for the diagnosis of colorectal cancer. You were required to submit to FDA a 510(k) for this device, because it either is a new device (21 CFR 807.81(a)(1)) or, if your iPLEX HS Colon Panel intended for use with the MA4 represents a change or modification from the device cleared in K132978 (which is indicated for use as an aid in diagnosis of patients with suspected thrombophilia), has been significantly changed or modified in design, components, method of manufacture, or intended use (21 CFR 807.81(a)(3)). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at\n\nhttp:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOur inspection also revealed that your firm’s iPLEX HS Colon Panel is misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, failure to submit a written report to FDA of any correction or removal of a device initiated to reduce a risk to health posed by the device, as required by 21 CFR Part 806.10. For example:\n\nOn June 1, 2021, your firm issued a Customer Notification alerting customers that certain lots of your iPLEX HS Colon v1.0 Panel did not include the A nucleotide termination in Well #8 which your firm determined could result in false negative results for three target variant alleles. Your firm instructed customers to not use the results for the impacted variants and that your firm would reformulate and verify the termination mix and provide further updates on availability. Your firm did not submit a written report of this removal to the agency, as required by 21 CFR 806.10.\n\nWe request that your firm immediately cease any activities that result in the misbranding or adulteration of your devices. Your firm should take prompt action to address any violations. Failure to adequately address the matters discussed in this letter may result in legal action being initiated by the FDA without further notice. These actions may include, but are not necessarily limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the concerns noted in this letter. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for requiring additional time and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to both: Jessica Mu, Director of Compliance Branch, at oradevices3firmresponse@fda.hhs.gov and to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS # 665159 when replying. If you have any questions about the contents of this letter, please contact: Jeff R. Wooley, Compliance Officer, at 214-253-5251 or jeffrey.wooley@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of any deficiencies at your firm’s facility or associated with your firm’s devices. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific concerns noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nCourtney Lias, Ph.D.\n\nActing Director\n\nOHT 7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director, Division 3\n\nOffice of Medical Device and Radiological Health\n\nOffice of Regulatory Affairs\n\nCC: Glen Wise\n\nDirector, Quality and Regulatory\n\nGlenn.wise@agenabio.com","Agena Bioscience, Inc.","agena-bioscience-inc-665159-03212024","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fagena-bioscience-inc-665159-03212024","2026-10-26T08:07:51.129425+00:00","2024-04-02","665159","Roman Haehn","2026-08-20T00:12:02.998+00:00","VIA UNITED PARCEL SERVICE","2024-03-21",{"id":52,"raw":53,"subject":58,"body_html":59,"body_text":60,"firm_name":61,"letter_id":62,"created_at":63,"fei_number":19,"letter_url":64,"updated_at":65,"action_type":22,"case_status":23,"posted_date":66,"marcs_cms_no":67,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},21638,[54,55,56,57,58,13,13,13],"\u003Ctime datetime=\"2026-09-01T04:00:00Z\">09\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-24T04:00:00Z\">08\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnuscience-peptides-llc-733652-08242026\">NuScience Peptides LLC\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drugs\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joseph and Ratsamy DeRosa\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managers\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>NuScience Peptides LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>20311 Chartwell Center Dr., Suite 212\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cornelius\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>28031\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@nusciencepeptides.com\"> info@nusciencepeptides.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>August 24, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 733652\u003C\u002Fp>\u003Cp>To Joseph and Ratsamy DeRosa:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>These products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website nusciencepeptides.com in July 2026. Based on our review, “GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,” “Survodutide,” “Mazdutide,” “PT-141 Peptide (Bremelanotide),” “Tesamorelin Research Peptide,” “Tesamorelin Ipamorelin Blend,” and “Bacteriostatic water for Peptides (BAC Water)” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on a review of your website, “GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,” “Survodutide,” “Mazdutide,” “PT-141 Peptide (Bremelanotide),” “Tesamorelin Research Peptide,” “Tesamorelin Ipamorelin Blend,” and “Bacteriostatic water for Peptides (BAC Water)” are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>GLP-2 Tirz Peptide\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fglp-2-tz-2\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“GLP-2 Tirz, a research peptide of significant interest, is known for its dual agonist activity on glucagon-like peptide-2 (GLP-2) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This peptide has been extensively studied in rodent models, particularly rats, to explore its metabolic effects and potential therapeutic applications in various conditions. Researchers use these models to gain valuable insights into the complex mechanisms of metabolic regulation and the integrated actions of incretin hormones.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP-1 Sema Research Peptide\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fpubchem.ncbi.nlm.nih.gov\u002Fcompound\u002F56843331#datasheet=LCSS (hyperlinked from https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fglp-1-sm\u002F):\u003C\u002Fp>\u003Cul>\u003Cli>“**Mechanism of cardiovascular benefit and weight loss** In hypercholesterolemia, semaglutide is believed to reduce the progression of atherosclerosis via decreased gut permeability and decreased inflammation. Weight loss is believed to occur via the reduction of appetite and food cravings after semaglutide administration.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>GLP-3 RT (Retatrutide) Research Peptide\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fglp-3-rt\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“GLP-3 RT (Retatrutide) is a novel investigational peptide being explored for its potential research applications in metabolic disorders, particularly obesity and type 2 diabetes. Also known as LY3437943, it functions as a triple receptor agonist — a glp3 peptide that targets the GLP-1, GIP, and glucagon receptor pathways simultaneously”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Survodutide\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fsurvodutide\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Survodutide (BI 456906) is a dual agonist targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), developed for laboratory research into obesity and type 2 diabetes metabolic pathways. Preclinical studies in rodent models have demonstrated its efficacy in promoting weight loss and improving glycemic control.”\u003C\u002Fli>\u003Cli>“In conclusion, survodutide’s dual GCGR\u002FGLP-1R agonism offers a multifaceted approach to treating metabolic disorders. Its efficacy in preclinical models supports further investigation and development as a subject of investigation for obesity and metabolic disorder research.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Mazdutide\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fmazdutide\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Mazdutide (IBI362), a dual agonist targeting both GLP-1 and glucagon receptors, has shown promising results in clinical trials for weight management and metabolic disorders. This mazdutide peptide has been extensively studied in humans, but preclinical research, particularly in rat models, remains limited.”\u003C\u002Fli>\u003Cli>“Furthermore, mazdutide has been associated with reductions in liver fat content and improvements in insulin sensitivity in clinical trials, highlighting its potential for treating non-alcoholic fatty liver disease and type 2 diabetes.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>PT-141 Peptide (Bremelanotide)\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fpt-141-bremelanotide\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“PT-141, also known as bremelanotide, is a synthetic PT-141 peptide classified as a non-selective agonist of melanocortin receptors, with primary activity at MC3R and MC4R. This research peptide has been widely examined in preclinical models to better understand melanocortin-mediated signaling pathways involved in sexual behavior and neuroendocrine regulation.”\u003C\u002Fli>\u003Cli>“Additional studies examining melanocortin receptor agonists support the role of PT-141 in modulating sexual behaviors across sexes through central nervous system pathways. The involvement of the melanocortin system highlights the relevance of PT-141 peptide in experimental research exploring neural control of sexual function.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Tesamorelin Research Peptide and Tesamorelin Ipamorelin Blend\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Ftesamorelin\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Beyond metabolic effects, tesamorelin has demonstrated the ability to reduce muscle fat and increase muscle area in clinical studies . . . [s]uch findings are particularly relevant for exploring interventions in muscle-wasting conditions.”\u003C\u002Fli>\u003Cli>“Furthermore, research indicates that tesamorelin may enhance cognitive function, including improvements in executive function and verbal memory.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Ftesamorelin-ipamorelin\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, has been shown to significantly reduce visceral adipose tissue and improve liver health by decreasing liver fat and preventing fibrosis progression.”\u003C\u002Fli>\u003Cli>“[R]esearch has indicated that ipamorelin can counteract glucocorticoid-induced reductions in bone formation, suggesting its potential in mitigating bone density loss associated with glucocorticoid therapy.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Bacteriostatic water for Peptides (BAC Water)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your firm offers “Bacteriostatic water for Peptides (BAC Water)” for sale to be used to reconstitute the peptide products sold on your website, which are drugs intended for injection, including the above-mentioned products. The sale of these products together demonstrates that you intend for your “Bacteriostatic water for Peptides (BAC Water)” to be used in combination for injection. Therefore, your “Bacteriostatic water for Peptides (BAC Water)” is a drug.\u003C\u002Fp>\u003Cp>“GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,” “Survodutide,” “Mazdutide,” “PT-141 Peptide (Bremelanotide),” “Tesamorelin Research Peptide,” “Tesamorelin Ipamorelin Blend,” and “Bacteriostatic water for Peptides (BAC Water)” are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “733652” in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Despite statements on your product labeling marketing your products “for laboratory, research, and analytical use” and “not intended for human or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. In addition to the cited drug claims, you market bacteriostatic water alongside a “peptide calculator,” a resource that provides the means to prepare an injectable drug for human administration.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJoseph and Ratsamy DeRosa\n\nRecipient Title\n\nManagers\n\nNuScience Peptides LLC\n\n20311 Chartwell Center Dr., Suite 212\n\nCornelius, NC 28031\n\nUnited States\n\ninfo@nusciencepeptides.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nAugust 24, 2026\nWARNING LETTER\nReference Number: 733652\nTo Joseph and Ratsamy DeRosa:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nThese products are especially concerning from a public health perspective because injectable drug products can pose risks of serious harm to users. Injectable products are delivered directly into the body, sometimes directly into the bloodstream, and therefore, bypass some of the body’s key defenses against toxins and microorganisms that can lead to serious and life-threatening conditions.\nFDA Review\nViolations were identified and documented during a review of your website nusciencepeptides.com in July 2026. Based on our review, “GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,” “Survodutide,” “Mazdutide,” “PT-141 Peptide (Bremelanotide),” “Tesamorelin Research Peptide,” “Tesamorelin Ipamorelin Blend,” and “Bacteriostatic water for Peptides (BAC Water)” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website, “GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,” “Survodutide,” “Mazdutide,” “PT-141 Peptide (Bremelanotide),” “Tesamorelin Research Peptide,” “Tesamorelin Ipamorelin Blend,” and “Bacteriostatic water for Peptides (BAC Water)” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.1 Examples from your product labeling, including on your website, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nGLP-2 Tirz Peptide\nOn the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fglp-2-tz-2\u002F:\n“GLP-2 Tirz, a research peptide of significant interest, is known for its dual agonist activity on glucagon-like peptide-2 (GLP-2) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This peptide has been extensively studied in rodent models, particularly rats, to explore its metabolic effects and potential therapeutic applications in various conditions. Researchers use these models to gain valuable insights into the complex mechanisms of metabolic regulation and the integrated actions of incretin hormones.”\nGLP-1 Sema Research Peptide\nOn the webpage https:\u002F\u002Fpubchem.ncbi.nlm.nih.gov\u002Fcompound\u002F56843331#datasheet=LCSS (hyperlinked from https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fglp-1-sm\u002F):\n“**Mechanism of cardiovascular benefit and weight loss** In hypercholesterolemia, semaglutide is believed to reduce the progression of atherosclerosis via decreased gut permeability and decreased inflammation. Weight loss is believed to occur via the reduction of appetite and food cravings after semaglutide administration.”\nGLP-3 RT (Retatrutide) Research Peptide\nOn the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fglp-3-rt\u002F:\n“GLP-3 RT (Retatrutide) is a novel investigational peptide being explored for its potential research applications in metabolic disorders, particularly obesity and type 2 diabetes. Also known as LY3437943, it functions as a triple receptor agonist — a glp3 peptide that targets the GLP-1, GIP, and glucagon receptor pathways simultaneously”\nSurvodutide\nOn the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fsurvodutide\u002F:\n“Survodutide (BI 456906) is a dual agonist targeting both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R), developed for laboratory research into obesity and type 2 diabetes metabolic pathways. Preclinical studies in rodent models have demonstrated its efficacy in promoting weight loss and improving glycemic control.”\n“In conclusion, survodutide’s dual GCGR\u002FGLP-1R agonism offers a multifaceted approach to treating metabolic disorders. Its efficacy in preclinical models supports further investigation and development as a subject of investigation for obesity and metabolic disorder research.”\nMazdutide\nOn the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fmazdutide\u002F:\n“Mazdutide (IBI362), a dual agonist targeting both GLP-1 and glucagon receptors, has shown promising results in clinical trials for weight management and metabolic disorders. This mazdutide peptide has been extensively studied in humans, but preclinical research, particularly in rat models, remains limited.”\n“Furthermore, mazdutide has been associated with reductions in liver fat content and improvements in insulin sensitivity in clinical trials, highlighting its potential for treating non-alcoholic fatty liver disease and type 2 diabetes.”\nPT-141 Peptide (Bremelanotide)\nOn the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Fpt-141-bremelanotide\u002F:\n“PT-141, also known as bremelanotide, is a synthetic PT-141 peptide classified as a non-selective agonist of melanocortin receptors, with primary activity at MC3R and MC4R. This research peptide has been widely examined in preclinical models to better understand melanocortin-mediated signaling pathways involved in sexual behavior and neuroendocrine regulation.”\n“Additional studies examining melanocortin receptor agonists support the role of PT-141 in modulating sexual behaviors across sexes through central nervous system pathways. The involvement of the melanocortin system highlights the relevance of PT-141 peptide in experimental research exploring neural control of sexual function.”\nTesamorelin Research Peptide and Tesamorelin Ipamorelin Blend\nOn the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Ftesamorelin\u002F:\n“Beyond metabolic effects, tesamorelin has demonstrated the ability to reduce muscle fat and increase muscle area in clinical studies . . . [s]uch findings are particularly relevant for exploring interventions in muscle-wasting conditions.”\n“Furthermore, research indicates that tesamorelin may enhance cognitive function, including improvements in executive function and verbal memory.”\nOn the webpage https:\u002F\u002Fnusciencepeptides.com\u002Fproduct\u002Ftesamorelin-ipamorelin\u002F:\n“Tesamorelin, a growth hormone-releasing hormone (GHRH) analog, has been shown to significantly reduce visceral adipose tissue and improve liver health by decreasing liver fat and preventing fibrosis progression.”\n“[R]esearch has indicated that ipamorelin can counteract glucocorticoid-induced reductions in bone formation, suggesting its potential in mitigating bone density loss associated with glucocorticoid therapy.”\nBacteriostatic water for Peptides (BAC Water)\nYour firm offers “Bacteriostatic water for Peptides (BAC Water)” for sale to be used to reconstitute the peptide products sold on your website, which are drugs intended for injection, including the above-mentioned products. The sale of these products together demonstrates that you intend for your “Bacteriostatic water for Peptides (BAC Water)” to be used in combination for injection. Therefore, your “Bacteriostatic water for Peptides (BAC Water)” is a drug.\n“GLP-2 Tirz Peptide,” “GLP-1 Sema Research Peptide,” “GLP-3 RT (Retatrutide) Research Peptide,” “Survodutide,” “Mazdutide,” “PT-141 Peptide (Bremelanotide),” “Tesamorelin Research Peptide,” “Tesamorelin Ipamorelin Blend,” and “Bacteriostatic water for Peptides (BAC Water)” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Identify your response with reference number “733652” in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n__________________________\n1 Despite statements on your product labeling marketing your products “for laboratory, research, and analytical use” and “not intended for human or veterinary use,” evidence obtained from your website establishes that your products are intended to be drugs for human use. In addition to the cited drug claims, you market bacteriostatic water alongside a “peptide calculator,” a resource that provides the means to prepare an injectable drug for human administration.","NuScience Peptides LLC","nuscience-peptides-llc-733652-08242026","2026-09-07T05:14:13.57002+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnuscience-peptides-llc-733652-08242026","2026-10-26T08:09:35.792898+00:00","2026-09-01","733652","Drugs","Joseph and Ratsamy DeRosa","2026-09-07T05:14:37.271+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-08-24",{"id":74,"raw":75,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":91,"closeout_date":19,"issuing_office":92,"recipient_name":93,"body_fetched_at":94,"delivery_method":95,"recipient_title":19,"reference_number":19,"action_taken_date":96,"medical_device_id":19,"response_letter_date":19},2232,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2023-01-31T14:20:00Z\">01\u002F31\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-01-24T05:00:00Z\">01\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-life-science-llc-635400-01242023\">Adept Life Science, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations East IV","CGMP\u002FDietary Supplement\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FDietary Supplement\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Michael T. Shields and Ms. Windy N. Shields\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owners\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Adept Life Science, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2215 E Germann Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Chandler\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85286\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>January 24, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER 635400\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nIn reply, refer to CMS 635400\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Michael T. Shields and Ms. Windy N. Shields:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 2215 E Germann Rd, Chandler, Arizona, from April 11 through April 27, 2022. Based on the inspectional findings we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links in FDA's home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>The inspection of your facility revealed serious violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your dietary supplement products to be adulterated within the meaning of section 402(g)(1) of the Act [21 United States Code (U.S.C.) § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. In addition, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> sizes) dietary supplement products that you manufacture are misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343].\u003C\u002Fp>\n\n\u003Cp>FDA acknowledges the receipt of your e-mail correspondence dated May 20, 2022 and June 23, 2022, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. Not all of the items on the issued Form FDA 483 were addressed in your response. We address your response below, in relation to the applicable violations to which you responded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Dietary Supplement CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your significant violations of CGMP requirements are as follows:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish an identity specification for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. Your raw material data sheet for \u003Cstrong>(b)(4)\u003C\u002Fstrong> states “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Potency” as the specification for identity, but this does not establish standards to confirm the identity of the component used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, as required in 21 CFR 111.70(b)(1). Additionally, your raw material data sheet for \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product has five minerals in the blend but your purported ICP-MS specification for identity lists “mineral detected” as the specification and fails to establish standards which can be used to confirm the identity of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> component, as required in 21 CFR 111.70(b)(1).\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish component specifications that are necessary to ensure that specifications for the purity and composition of the dietary supplement manufactured using the components are met, as required in 21 CFR 111.70(b)(2). For example, you have not established specifications for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Premix used in the manufacture of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product and specifications for several of the components used in the manufacture of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product to ensure that specifications for purity and composition of these products are met.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your June 23, 2022 response to the form FDA 483. We are unable to evaluate the adequacy of your response because you did not provide documentation demonstrating you have established specifications in accordance with 21 CFR 111.70(b)(1) and 21 CFR 111.70(b)(2). You provide documents you describe as revised finished product specifications for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. We note that these documents do not demonstrate that you have established specifications that provide standards to confirm the identity, purity, strength, and composition of the finished batch of your dietary supplements. For example, the finished product specification for \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product lists an “identification” specification of “Conforms to Standard” with a test method of “Eurofins or eq.” and a frequency of “Rotational.” “Conforms to standard” does not specify the extent to which the component must conform. “Eurofins or eq.” is not a test method and “Rotational” does not describe the frequency of when testing is to occur.\u003C\u002Fp>\n\n\u003Cp>Similarly, the finished product specification for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product states testing “Frequency” as “Rotation” for several components, and does not describe the frequency of when testing is to occur.\u003C\u002Fp>\n\n\u003Cp>3. You failed to establish and follow laboratory control processes that are reviewed and approved by quality control personnel, for use of criteria for selecting standard reference materials used in performing tests and examinations, as required by 21 CFR 111.315(d). Specifically, the FTIR analysis performed by your third-party laboratory uses previous shipments of components as the reference for testing and they do not own a reference library for the FTIR tests. Testing components against previous shipments of the component may confirm receipt of the same component but this does not ensure the identity, purity, quality, and strength of the component is thoroughly characterized .\u003C\u002Fp>\n\n\u003Cp>4. Your quality control operations did not approve and release, or reject, each finished batch for distribution as required by 21 CFR 111.123(a)(8). Specifically, your firm distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, without quality control review, approval and release of the finished batch for distribution.\u003C\u002Fp>\n\n\u003Cp>5. Your quality control personnel must not approve and release for distribution any batch of dietary supplement, including any reprocessed batch, that does not meet all product specifications established in accordance with 21 CFR 111.70(e), as required by 21 CFR 111.123(b)(2). Your quality control personnel released \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, when the specification for pH was not met. Specifically, your established finished product specification for pH for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the pH of the product in Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong> released for distribution was 6.34.\u003C\u002Fp>\n\n\u003Cp>6. Your quality control personnel neither rejected a component or dietary supplement when that component or dietary supplement failed to meet a specification established in accordance with 21 CFR 111.70, nor did they approve a treatment, an in-process adjustment, or reprocessing, as permitted in 21 CFR 111.77, in accordance with 21 CFR 111.113(b)(2). Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> as components. Testing of these two components by a third-party laboratory found both were not within your established specifications. Your quality control personnel failed to reject these components used in the manufacturing of your finished product and failed to reject the \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>7. Your quality control operations failed to approve, and release from quarantine, all components, before they are used as required by 21 CFR 111.120(e). Specifically, your quality control operations approved, and released from quarantine several components used in the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and components used in the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>. For example, the raw material data sheets for the components \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the raw material data sheets for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the manufacture of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, Lot # \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>do not show a disposition by your quality control operations to approve, and release these components for use in manufacturing your finished products.\u003C\u002Fp>\n\n\u003Cp>8. You failed to prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, which includes all required information, as required by 21 CFR 111.205(a) and 21 CFR 111.210. Specifically, the Master Manufacturing Records for the following \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand products which you manufacture were missing the following required elements:\u003C\u002Fp>\n\n\u003Cp>a. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Item # \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003Cbr>\n&nbsp; i. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process and the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary. (21 CFR 111.210(f)).\u003Cbr>\n&nbsp; ii. Procedures for sampling and a cross-reference to procedures for tests or examinations. (21 CFR 111.210(h)(2)).\u003C\u002Fp>\n\n\u003Cp>b. \u003Cstrong>(b)(4)\u003C\u002Fstrong> Item # \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003Cbr>\n&nbsp; i. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process and the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary. (21 CFR 111.210(f)).\u003Cbr>\n&nbsp; ii. Procedures for sampling and a cross-reference to procedures for tests or examinations. (21 CFR 111.210(h)(2)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbrand Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> sizes) products are misbranded within the meaning of section 403(q)(5)(F) of the Act (21 U.S.C. 343 (q)(5)(F)) in that the presentation of the nutrition information on the labeling of your product does not comply with 21 CFR 101.36. For example,\u003C\u002Fp>\n\n\u003Cp>&nbsp; a. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes a Supplement Facts label with columns for “Amount per Serving (29.6 mL),” “Ages 4+ yrs,” “Pregnant and Lactating,” “Per serving (2.5 mL),” and “Ages 2-3 yrs.” Your “Suggested Use” panel includes different serving instructions for “2-3 Years,” “4-10 Years,” “11-17 Years,” “18 Years+,” and “Pregnant\u002FLactating &amp; Seniors (65+).” Therefore, your Supplement Facts label fails to list all of the groups of individuals, by age or status (Pregnant\u002FLactating). for which the products are intended.\u003C\u002Fp>\n\n\u003Cp>&nbsp; b. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) includes a Supplement Facts label with columns for “Amount per Serving” and “% DV” for unspecified intended consumers; however, your “Suggested Use” panel lists several intended consumers, including “children, 1-3 years,” “Children, 4-13 years,” “Adults, 14-64 years” (the serving size indicated on the Supplement Facts label), and “Pregnant\u002FLactating and Seniors, 65+.” Therefore, your Supplement Facts label fails to list all of the groups of individuals, by age or status (Pregnant\u002FLactating), for which the products are intended.\u003C\u002Fp>\n\n\u003Cp>&nbsp; c. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) product labels use the incorrect unit of measurement for copper for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> serving size. The amount must use the unit of measurement given in 21 CFR 101.9(c)(8)(iv), as required by 21 CFR 101.36(b)(2)(ii)(B).\u003C\u002Fp>\n\n\u003Cp>2. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> sizes) products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Specifically, your product labels only list the serving size for one of the intended consumer groups listed in the “Suggested Use” panel. As your products are intended for several other age groups\u002Fcategories of individual (Pregnant\u002FLactating or Senior), you must list the serving size for each group\u002Fcategory in your Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>3. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) and \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) products are misbranded within the meaning of section 403(q)(1)(B) of the Act [21 U.S.C. § 343(q)(1)(B)] because the number of servings per container declared on the label is incorrect. Specifically, your product labels only list the number of servings for one of the intended consumer groups listed in the “Suggested Use” panel. As your products are intended for several other age groups\u002Fcategories of individuals, you must list the number of servings for each group\u002Fcategory in your Supplement Facts label.\u003C\u002Fp>\n\n\u003Cp>4. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> brand \u003Cstrong>(b)(4)\u003C\u002Fstrong> (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, the label declares trace minerals as part of the proprietary blend, but this is not the common or usual name of a dietary ingredient.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>We also have the following comment:\u003C\u002Fp>\n\n\u003Cp>Based on further review of your product and process information, your firm’s “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” products appear to meet the definition of an acidified food (AF) and your firm’s “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” products appear to meet the definition of a low-acid canned food (LACF) as defined in 21 CFR Parts 108, 113 and 114. Consequently, your firm may be required to register as an LACF\u002FAF processor and file the necessary scheduled processes with FDA. We recommend working with a process authority to further evaluate your products in order to establish and file scheduled processes in accordance with 21 CFR Part 108.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, DFC Bldg 20 - W. 6th Ave &amp; Kipling St., P.O. Box 25087, Denver, CO 80225, CO, to the attention of Jennifer A. Hicks, Director of Compliance Branch. If you need additional information or have questions concerning any products distributed through your website, please contact me at 303-236-9723 or at the above address or via email at: Jennifer.Hicks@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Foods–\u003Cbr>\nWest Division 4\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDietary Supplements\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Michael T. Shields and Ms. Windy N. Shields\n\nRecipient Title\n\nOwners\n\nAdept Life Science, LLC\n\n2215 E Germann Rd\n\nChandler, AZ 85286\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East IV\n\nUnited States\n\nJanuary 24, 2023\n\nWARNING LETTER 635400\n\nIn reply, refer to CMS 635400\n\nDear Mr. Michael T. Shields and Ms. Windy N. Shields:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) conducted an inspection of your facility located at 2215 E Germann Rd, Chandler, Arizona, from April 11 through April 27, 2022. Based on the inspectional findings we have identified serious violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links in FDA's home page at www.fda.gov.\n\nThe inspection of your facility revealed serious violations of FDA’s regulations for Current Good Manufacturing Practice (CGMP) in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements under Title 21, Code of Federal Regulations (CFR), Part 111 (21 CFR Part 111). These violations cause your dietary supplement products to be adulterated within the meaning of section 402(g)(1) of the Act [21 United States Code (U.S.C.) § 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet CGMP requirements for dietary supplements. In addition, the (b)(4) brand (b)(4) and (b)(4) brand (b)(4) (in (b)(4) and (b)(4) sizes) dietary supplement products that you manufacture are misbranded within the meaning of section 403 of the Act [21 U.S.C. § 343].\n\nFDA acknowledges the receipt of your e-mail correspondence dated May 20, 2022 and June 23, 2022, written in response to the Form FDA 483, Inspectional Observations, issued to you at the close of the inspection. Not all of the items on the issued Form FDA 483 were addressed in your response. We address your response below, in relation to the applicable violations to which you responded.\n\nDietary Supplement CGMP Violations\n\nYour significant violations of CGMP requirements are as follows:\n\n1. You failed to establish an identity specification for your (b)(4) used in the manufacture of the (b)(4) brand (b)(4) product. Your raw material data sheet for (b)(4) states “(b)(4) Potency” as the specification for identity, but this does not establish standards to confirm the identity of the component used in the manufacture of your (b)(4) brand (b)(4) product, as required in 21 CFR 111.70(b)(1). Additionally, your raw material data sheet for (b)(4) used in the manufacture of the (b)(4) brand (b)(4) product has five minerals in the blend but your purported ICP-MS specification for identity lists “mineral detected” as the specification and fails to establish standards which can be used to confirm the identity of the (b)(4) component, as required in 21 CFR 111.70(b)(1).\n\n2. You failed to establish component specifications that are necessary to ensure that specifications for the purity and composition of the dietary supplement manufactured using the components are met, as required in 21 CFR 111.70(b)(2). For example, you have not established specifications for the (b)(4) Premix used in the manufacture of the (b)(4) brand (b)(4) product and specifications for several of the components used in the manufacture of the (b)(4) brand (b)(4) product to ensure that specifications for purity and composition of these products are met.\n\nWe have reviewed your June 23, 2022 response to the form FDA 483. We are unable to evaluate the adequacy of your response because you did not provide documentation demonstrating you have established specifications in accordance with 21 CFR 111.70(b)(1) and 21 CFR 111.70(b)(2). You provide documents you describe as revised finished product specifications for the (b)(4) brand (b)(4) product and (b)(4) brand (b)(4) product. We note that these documents do not demonstrate that you have established specifications that provide standards to confirm the identity, purity, strength, and composition of the finished batch of your dietary supplements. For example, the finished product specification for (b)(4) brand (b)(4) product lists an “identification” specification of “Conforms to Standard” with a test method of “Eurofins or eq.” and a frequency of “Rotational.” “Conforms to standard” does not specify the extent to which the component must conform. “Eurofins or eq.” is not a test method and “Rotational” does not describe the frequency of when testing is to occur.\n\nSimilarly, the finished product specification for your (b)(4) brand (b)(4) product states testing “Frequency” as “Rotation” for several components, and does not describe the frequency of when testing is to occur.\n\n3. You failed to establish and follow laboratory control processes that are reviewed and approved by quality control personnel, for use of criteria for selecting standard reference materials used in performing tests and examinations, as required by 21 CFR 111.315(d). Specifically, the FTIR analysis performed by your third-party laboratory uses previous shipments of components as the reference for testing and they do not own a reference library for the FTIR tests. Testing components against previous shipments of the component may confirm receipt of the same component but this does not ensure the identity, purity, quality, and strength of the component is thoroughly characterized .\n\n4. Your quality control operations did not approve and release, or reject, each finished batch for distribution as required by 21 CFR 111.123(a)(8). Specifically, your firm distributed (b)(4) brand (b)(4) product, Lot # (b)(4), without quality control review, approval and release of the finished batch for distribution.\n\n5. Your quality control personnel must not approve and release for distribution any batch of dietary supplement, including any reprocessed batch, that does not meet all product specifications established in accordance with 21 CFR 111.70(e), as required by 21 CFR 111.123(b)(2). Your quality control personnel released (b)(4) brand (b)(4), Lot # (b)(4), when the specification for pH was not met. Specifically, your established finished product specification for pH for the (b)(4) brand (b)(4) product is (b)(4) and the pH of the product in Lot # (b)(4) released for distribution was 6.34.\n\n6. Your quality control personnel neither rejected a component or dietary supplement when that component or dietary supplement failed to meet a specification established in accordance with 21 CFR 111.70, nor did they approve a treatment, an in-process adjustment, or reprocessing, as permitted in 21 CFR 111.77, in accordance with 21 CFR 111.113(b)(2). Specifically, (b)(4) brand (b)(4), Lot # (b)(4), uses (b)(4) and (b)(4) as components. Testing of these two components by a third-party laboratory found both were not within your established specifications. Your quality control personnel failed to reject these components used in the manufacturing of your finished product and failed to reject the (b)(4) brand (b)(4) product, Lot # (b)(4).\n\n7. Your quality control operations failed to approve, and release from quarantine, all components, before they are used as required by 21 CFR 111.120(e). Specifically, your quality control operations approved, and released from quarantine several components used in the manufacture of (b)(4) brand (b)(4) product, Lot # (b)(4), and components used in the manufacture of (b)(4) brand (b)(4), Lot # (b)(4). For example, the raw material data sheets for the components (b)(4), and (b)(4) used in the manufacture of your (b)(4) brand (b)(4), Lot # (b)(4), and the raw material data sheets for the (b)(4) and the (b)(4) used in the manufacture of your (b)(4) brand (b)(4) product, Lot # (b)(4) do not show a disposition by your quality control operations to approve, and release these components for use in manufacturing your finished products.\n\n8. You failed to prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, which includes all required information, as required by 21 CFR 111.205(a) and 21 CFR 111.210. Specifically, the Master Manufacturing Records for the following (b)(4) brand products which you manufacture were missing the following required elements:\n\na. (b)(4) Item # (b)(4):\n\ni. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process and the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary. (21 CFR 111.210(f)).\n\nii. Procedures for sampling and a cross-reference to procedures for tests or examinations. (21 CFR 111.210(h)(2)).\n\nb. (b)(4) Item # (b)(4):\n\ni. A statement of theoretical yield of a manufactured dietary supplement expected at each point, step, or stage of the manufacturing process and the maximum and minimum percentages of theoretical yield beyond which a deviation investigation of a batch is necessary. (21 CFR 111.210(f)).\n\nii. Procedures for sampling and a cross-reference to procedures for tests or examinations. (21 CFR 111.210(h)(2)).\n\nMisbrand Dietary Supplements\n\n1. Your (b)(4) brand (b)(4) and (b)(4) brand (b)(4) and (b)(4) sizes) products are misbranded within the meaning of section 403(q)(5)(F) of the Act (21 U.S.C. 343 (q)(5)(F)) in that the presentation of the nutrition information on the labeling of your product does not comply with 21 CFR 101.36. For example,\n\na. Your (b)(4) brand (b)(4) ((b)(4)) includes a Supplement Facts label with columns for “Amount per Serving (29.6 mL),” “Ages 4+ yrs,” “Pregnant and Lactating,” “Per serving (2.5 mL),” and “Ages 2-3 yrs.” Your “Suggested Use” panel includes different serving instructions for “2-3 Years,” “4-10 Years,” “11-17 Years,” “18 Years+,” and “Pregnant\u002FLactating & Seniors (65+).” Therefore, your Supplement Facts label fails to list all of the groups of individuals, by age or status (Pregnant\u002FLactating). for which the products are intended.\n\nb. Your (b)(4) brand (b)(4) ((b)(4)) includes a Supplement Facts label with columns for “Amount per Serving” and “% DV” for unspecified intended consumers; however, your “Suggested Use” panel lists several intended consumers, including “children, 1-3 years,” “Children, 4-13 years,” “Adults, 14-64 years” (the serving size indicated on the Supplement Facts label), and “Pregnant\u002FLactating and Seniors, 65+.” Therefore, your Supplement Facts label fails to list all of the groups of individuals, by age or status (Pregnant\u002FLactating), for which the products are intended.\n\nc. Your (b)(4) brand (b)(4) ((b)(4)) product labels use the incorrect unit of measurement for copper for the (b)(4) serving size. The amount must use the unit of measurement given in 21 CFR 101.9(c)(8)(iv), as required by 21 CFR 101.36(b)(2)(ii)(B).\n\n2. Your (b)(4) brand (b)(4) ((b)(4) and (b)(4)) and (b)(4) brand (b)(4) ((b)(4) and (b)(4) sizes) products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the label is incorrect. Specifically, your product labels only list the serving size for one of the intended consumer groups listed in the “Suggested Use” panel. As your products are intended for several other age groups\u002Fcategories of individual (Pregnant\u002FLactating or Senior), you must list the serving size for each group\u002Fcategory in your Supplement Facts label.\n\n3. Your (b)(4) brand (b)(4) ((b)(4)) and (b)(4) brand (b)(4) ((b)(4) and (b)(4)) products are misbranded within the meaning of section 403(q)(1)(B) of the Act [21 U.S.C. § 343(q)(1)(B)] because the number of servings per container declared on the label is incorrect. Specifically, your product labels only list the number of servings for one of the intended consumer groups listed in the “Suggested Use” panel. As your products are intended for several other age groups\u002Fcategories of individuals, you must list the number of servings for each group\u002Fcategory in your Supplement Facts label.\n\n4. Your (b)(4) brand (b)(4) ((b)(4)) are misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4. Specifically, the label declares trace minerals as part of the proprietary blend, but this is not the common or usual name of a dietary ingredient.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nWe also have the following comment:\n\nBased on further review of your product and process information, your firm’s “(b)(4)” products appear to meet the definition of an acidified food (AF) and your firm’s “(b)(4)” products appear to meet the definition of a low-acid canned food (LACF) as defined in 21 CFR Parts 108, 113 and 114. Consequently, your firm may be required to register as an LACF\u002FAF processor and file the necessary scheduled processes with FDA. We recommend working with a process authority to further evaluate your products in order to establish and file scheduled processes in accordance with 21 CFR Part 108.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, DFC Bldg 20 - W. 6th Ave & Kipling St., P.O. Box 25087, Denver, CO 80225, CO, to the attention of Jennifer A. Hicks, Director of Compliance Branch. If you need additional information or have questions concerning any products distributed through your website, please contact me at 303-236-9723 or at the above address or via email at: Jennifer.Hicks@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nProgram Division Director\n\nOffice of Human and Animal Foods–\n\nWest Division 4","Adept Life Science, LLC","adept-life-science-llc-635400-01242023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-life-science-llc-635400-01242023","2026-10-26T08:07:50.072651+00:00","2023-01-31","635400","Dietary SupplementsFood & Beverages","Division of Human and Animal Food Operations East IV","Mr. Michael T. Shields and Ms. Windy N. Shields","2026-08-20T01:16:44.743+00:00","VIA UPS","2023-01-24",{"id":98,"raw":99,"subject":104,"body_html":106,"body_text":107,"firm_name":108,"letter_id":109,"created_at":86,"fei_number":19,"letter_url":110,"updated_at":111,"action_type":22,"case_status":112,"posted_date":113,"marcs_cms_no":114,"product_type":68,"closeout_date":115,"issuing_office":103,"recipient_name":116,"body_fetched_at":117,"delivery_method":118,"recipient_title":19,"reference_number":19,"action_taken_date":119,"medical_device_id":19,"response_letter_date":19},2357,[100,101,102,103,104,13,105,13],"\u003Ctime datetime=\"2022-11-08T14:20:00Z\">11\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-31T04:00:00Z\">10\u002F31\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabraxis-bioscience-llc-633713-10312022\">Abraxis Bioscience LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabraxis-bioscience-llc-633713-01182024\">\u003Ctime datetime=\"2024-03-25T04:00:00Z\">03\u002F25\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL CONFIRMED DELIVERY\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Giovanni Caforio\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Abraxis Bioscience LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>620 N 51st Ave.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85043\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Giovanni.Caforio@bms.com\"> Giovanni.Caforio@bms.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 31, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Caforio:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Abraxis Bioscience, LLC, FEI 3006441852, at 620 N 51st Ave., Phoenix, AZ from March 28 to April 6, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 27, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to effectively implement corrective actions and preventive actions (CAPA) and return your aseptic processing line and manufacturing operations to a state of control. Multiple media fill failures occurred between April and October 2021, when simulating aseptic processing operations on the filling line used for your drug product Abraxane (a sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug).\u003C\u002Fp>\n\n\u003Cp>Your firm failed to perform a sufficiently comprehensive evaluation and remediation upon this loss of state of control in your aseptic operations. In December 2021, you released batches potentially impacted by these failures following \u003Cstrong>(b)(4)\u003C\u002Fstrong> successful media fill run (conducted in November 2021).\u003C\u002Fp>\n\n\u003Cp>Your investigations into the following media fill failures were inadequate in that they lacked sufficient rigor in determining root causes and scope of impact after the media fills revealed serious non-sterility risks in your aseptic process operations.\u003C\u002Fp>\n\n\u003Cp>Specifically,\u003C\u002Fp>\n\n\u003Cp>1) On April 20, 2021, you conducted a media fill using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. On the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of incubation, you observed a very high number (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of contaminated units. Ten different microbes were identified from samples of contaminated units including sporeforming, vegetative, gram-negative, and gram-positive microbes. Your investigation attributed the root cause to \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the filling manifold that included a damaged \u003Cstrong>(b)(4)\u003C\u002Fstrong> that was contaminated during \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>equipment cleaning step. The investigation indicated that the valve harbored such excessive bioburden that it apparently enabled numerous bacteria to survive the subsequent filling equipment sterilization cycle, and the contaminated valve then caused the extensive contamination of units during the media fill. The investigation failed to adequately address how not only sporeforming microbes, but also vegetative microbes with far \u003Cstrong>(b)(4)\u003C\u002Fstrong>, presumably survived your validated sterilization cycle. Also, you did not explain whether the sterilization cycle design allows for robust \u003Cstrong>(b)(4)\u003C\u002Fstrong> and reproducible exposure of all equipment parts in your sterilizer loads.\u003C\u002Fp>\n\n\u003Cp>2) On July 12, 2021, you conducted a repeat media fill using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which revealed multiple \u003Cstrong>(b)(4)\u003C\u002Fstrong> contaminated units. You attributed the root cause of the media fill failure to personnel gowning, poor disinfection of the inner Restricted Access Barrier System(RABS), and contaminated forceps used during the stopper bowl interventions in your RABS. However, the CAPA did not sufficiently expand to more holistic remediation of the root causes, including but not limited to, ensuring a comprehensive evaluation of the frequency, specificity, sufficiency, and robustness of your disinfection and decontamination program for the RABS and the surrounding cleanroom(s).\u003C\u002Fp>\n\n\u003Cp>3) On October 5, 2021, you conducted a media fill using \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>as part of your process improvement. Although you aborted the run due to “unloading equipment failure,” you again observed a high number (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of contaminated units. Your firm observed this contamination, which was present in \u003Cstrong>(b)(4)\u003C\u002Fstrong> shelves, while unloading the units from the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You attributed the root cause to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and stated that the bacterial contamination was introduced via the \u003Cstrong>(b)(4)\u003C\u002Fstrong> performed with \u003Cstrong>(b)(4)\u003C\u002Fstrong> apparatus that consists of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> for purposes of sample collection. Notably, your process has incorporated multiple pieces of \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment on your sterile processing line rather than traditional reusable equipment. As with traditional equipment, high standards for robustness and integrity are essential for each of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> elements of your sterile operation.\u003C\u002Fp>\n\n\u003Cp>The investigation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> failure was insufficient. For example, it lacked sufficient evaluation of the ruggedness of these disposable systems, which your firm states are intended to be “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” while adding that they can be contaminated by the operator manipulations in the ISO 7 (Grade B) environment. While the investigation acknowledges “vulnerability of the syringe sampling system” and inadequate instructions for use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as factors contributing to the contamination of the sterile product process stream, the CAPA did not include a broader review of suitability for their intended use of other \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;equipment, adequacy of their instructions, and potential hazards posed when sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> are exposed to lower area classifications than ISO 5 (Grade A).\u003C\u002Fp>\n\n\u003Cp>4) On November 15, 2021, you conducted a media fill using the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as part of qualification of this new system. You observed one turbid vial on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of incubation. You attributed the contamination to inadequate disinfection of the area below the work surface that contaminated the pump apparatus after equipment changeover, which in turn may have contaminated RABS gloves used for unplanned mechanical interventions. However, you did not address the extent of other equipment underneath the filling line worksurface that can pose a contamination risk due to insufficient disinfection.\u003C\u002Fp>\n\n\u003Cp>These \u003Cstrong>(b)(4)\u003C\u002Fstrong> media fill contaminations indicate your aseptic manufacturing operations were not in control. Without a comprehensive assessment of contamination hazards, and a CAPA that builds more holistic risk mitigation into your operational design, there is no assurance that you can prevent recurrence of sterility problems due to various latent or active failure modes in your operation.\u003C\u002Fp>\n\n\u003Cp>We acknowledge that your firm took significant steps in response to the media fill failures, including a Field Alert Report, batch rejections, and suspension of operations.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate. You state that “... the media fill investigations determined root cause of each media fill event, supported the establishment of CAPA to prevent future recurrence as well as the decisions made in relation to the product under scope of the events.” However, you continued to observe contaminated units in subsequent media fills. The recurring incidents of contaminated units in media fills are an indicator of an adverse trend in your aseptic filling line. You did not provide a comprehensive assessment of contamination risk factors in your aseptic processing operations that support robust and holistic remediations to your aseptic processing operation design. Systemic remediations are essential to address a pattern of recurring contamination events and ensure sustainable control of your aseptic processing operations.\u003C\u002Fp>\n\n\u003Cp>The response also lacks adequate justification to support the sufficiency of your CAPA activities. For example, regarding the October 5, 2021, media fill, your response fails to adequately explain how your CAPA will ensure the \u003Cstrong>(b)(4)\u003C\u002Fstrong> syringe in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> will no longer cause contamination of the sterile product pathway. This type of fragility questions the basic functionality and selection of a system that is explicitly designed to maintain sterility. You also did not adequately address whether you intend to revisit the area classification, the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>equipment choice or supplier of this system considering the media fill finding.\u003C\u002Fp>\n\n\u003Cp>In response to the letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o&nbsp; All human interactions within the ISO 5 area.\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Equipment placement and ergonomics.\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Air quality in the ISO 5 area and surrounding room.\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Facility layout.\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations).\u003Cbr>\n&nbsp; &nbsp; o&nbsp; Other variables that have potential to cause contamination in your operations (e.g., insufficient \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization frequency).\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\n\t\u003Cli>Your CAPA plan to implement routine, vigilant operations and management oversight of facilities and equipment. This plan should include, among other things, improved management of operations that assures prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\u003C\u002Fli>\n\t\u003Cli>A thorough evaluation of the suitability of each \u003Cstrong>(b)(4)\u003C\u002Fstrong> apparatus for its intended use. Your evaluation of all of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> equipment should include a determination of whether they are appropriate, durable, and maintain integrity. Also, regarding the media fill failure that involved \u003Cstrong>(b)(4)\u003C\u002Fstrong> difficulties, include an assessment of sampling robustness based upon its purpose and associated hazards, and discuss the feasibility of a lower risk sampling location.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>A detailed description of the degree of involvement of quality assurance (QA) staff in evaluation, oversight, performance, and guiding of the content and depth of your investigations. Among other things, explain whether quality assurance plays a lead role throughout each investigation or only at certain specified intervals. Also explain the role and authority of the QA function in assuring appropriate root cause determinations and identification of an effective CAPA plan.\u003C\u002Fli>\n\t\u003Cli>A retrospective evaluation by a qualified third party of investigations and failure modes related to the capability of your aseptic processing operation to robustly produce sterile drugs, including, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o&nbsp; All media fill contamination events, and all sterility positives, since January 1, 2019,regardless of whether the batch was shipped to the United States.\u003Cbr>\n&nbsp; o&nbsp; Identification of all potential failure modes associated with these media fill and sterility positives.\u003Cbr>\n&nbsp; o&nbsp; A detailed evaluation and description of each aseptic connection and operation made down stream of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including, but not limited to, the manipulations at sampling ports in the product flow pathway \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n&nbsp; o&nbsp; A comparison of your aseptic manufacturing process to the process simulation protocol to identify areas in which media fills may be improved to simulate actual operations more accurately.\u003Cbr>\n&nbsp; o&nbsp; Media fill criteria used by your firm, and adequacy of provisions to ensure thorough investigation of any contamination.\u003Cbr>\n&nbsp; o&nbsp; All changes implemented to your aseptic operations in response to any aseptic process simulation incidents and sterility failures since 2019, including an evaluation of their adequacy and sufficiency, and a risk assessment of any distributed product affected by deficient aseptic processing operations that occurred during this period.\u003Cbr>\n&nbsp; o&nbsp; Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and its support operations.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\n\t\u003Cli>An independent review of the validity and robustness of your equipment parts sterilizationcycles. This review should include:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o&nbsp; A comprehensive assessment, including load configurations, pre-assembled parts, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, biological indicator placement in worst-case locations, correlation of heat and biological kill, and other factors.\u003C\u002Fp>\n\n\u003Cp>&nbsp; o&nbsp; A thorough evaluation of the ability of the vegetative microbes, named in your April 2021, media fill investigation to survive the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization cycle used for equipment parts. The review should also re-evaluate whether vegetative microbes may have been introduced to that media fill through other routes of contamination.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A complete list of complaints received for Abraxane drug products since January 2019.Include the lot number, date of manufacture, sufficient narrative regarding the nature of the complaint, any CAPA steps taken, and conclusions.\u003C\u002Fli>\n\t\u003Cli>An updated risk assessment that addresses any product quality or patient safety risks related to batches of Abraxane (manufactured between October 2020 and April 2021) in U.S. distribution, including potential customer notification and recalls.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with the unique identifier: \u003Cstrong>CMS# 633713\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to ORAPHARM4_RESPONSES@fda.hhs.gov with ATTN: CDR Steven E. Porter, Jr. or mail your written response to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, CA 92612-2506\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the content of this letter, please contact Jamie Dion, compliance officer, at 303-236-3133, or by email at Jamie.Dion@fda.hhs.gov. www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>CC: Nathan Trembath (via email Nathan.Trembath@bms.com)\u003Cbr>\nExecutive Director, Site Head\u003Cbr>\nAbraxis Bioscience LLC\u003Cbr>\n620 N 51st Ave.\u003Cbr>\nPhoenix, AZ 85043\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL CONFIRMED DELIVERY\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Giovanni Caforio\n\nRecipient Title\n\nChief Executive Officer\n\nAbraxis Bioscience LLC\n\n620 N 51st Ave.\n\nPhoenix, AZ 85043\n\nUnited States\n\nGiovanni.Caforio@bms.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWARNING LETTER\n\nOctober 31, 2022\n\nDear Mr. Caforio:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Abraxis Bioscience, LLC, FEI 3006441852, at 620 N 51st Ave., Phoenix, AZ from March 28 to April 6, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your April 27, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following:\n\nYour firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYou failed to effectively implement corrective actions and preventive actions (CAPA) and return your aseptic processing line and manufacturing operations to a state of control. Multiple media fill failures occurred between April and October 2021, when simulating aseptic processing operations on the filling line used for your drug product Abraxane (a sterile (b)(4) drug).\n\nYour firm failed to perform a sufficiently comprehensive evaluation and remediation upon this loss of state of control in your aseptic operations. In December 2021, you released batches potentially impacted by these failures following (b)(4) successful media fill run (conducted in November 2021).\n\nYour investigations into the following media fill failures were inadequate in that they lacked sufficient rigor in determining root causes and scope of impact after the media fills revealed serious non-sterility risks in your aseptic process operations.\n\nSpecifically,\n\n1) On April 20, 2021, you conducted a media fill using the (b)(4). On the (b)(4) of incubation, you observed a very high number ((b)(4)) of contaminated units. Ten different microbes were identified from samples of contaminated units including sporeforming, vegetative, gram-negative, and gram-positive microbes. Your investigation attributed the root cause to (b)(4) in the filling manifold that included a damaged (b)(4) that was contaminated during (b)(4) equipment cleaning step. The investigation indicated that the valve harbored such excessive bioburden that it apparently enabled numerous bacteria to survive the subsequent filling equipment sterilization cycle, and the contaminated valve then caused the extensive contamination of units during the media fill. The investigation failed to adequately address how not only sporeforming microbes, but also vegetative microbes with far (b)(4), presumably survived your validated sterilization cycle. Also, you did not explain whether the sterilization cycle design allows for robust (b)(4) and reproducible exposure of all equipment parts in your sterilizer loads.\n\n2) On July 12, 2021, you conducted a repeat media fill using the (b)(4), which revealed multiple (b)(4) contaminated units. You attributed the root cause of the media fill failure to personnel gowning, poor disinfection of the inner Restricted Access Barrier System(RABS), and contaminated forceps used during the stopper bowl interventions in your RABS. However, the CAPA did not sufficiently expand to more holistic remediation of the root causes, including but not limited to, ensuring a comprehensive evaluation of the frequency, specificity, sufficiency, and robustness of your disinfection and decontamination program for the RABS and the surrounding cleanroom(s).\n\n3) On October 5, 2021, you conducted a media fill using (b)(4) as part of your process improvement. Although you aborted the run due to “unloading equipment failure,” you again observed a high number ((b)(4)) of contaminated units. Your firm observed this contamination, which was present in (b)(4) shelves, while unloading the units from the (b)(4). You attributed the root cause to (b)(4) and stated that the bacterial contamination was introduced via the (b)(4) performed with (b)(4) apparatus that consists of a (b)(4) for purposes of sample collection. Notably, your process has incorporated multiple pieces of (b)(4) equipment on your sterile processing line rather than traditional reusable equipment. As with traditional equipment, high standards for robustness and integrity are essential for each of the (b)(4) elements of your sterile operation.\n\nThe investigation of the (b)(4) failure was insufficient. For example, it lacked sufficient evaluation of the ruggedness of these disposable systems, which your firm states are intended to be “(b)(4)” while adding that they can be contaminated by the operator manipulations in the ISO 7 (Grade B) environment. While the investigation acknowledges “vulnerability of the syringe sampling system” and inadequate instructions for use of the (b)(4) as factors contributing to the contamination of the sterile product process stream, the CAPA did not include a broader review of suitability for their intended use of other (b)(4) equipment, adequacy of their instructions, and potential hazards posed when sterile (b)(4) are exposed to lower area classifications than ISO 5 (Grade A).\n\n4) On November 15, 2021, you conducted a media fill using the (b)(4), as part of qualification of this new system. You observed one turbid vial on the (b)(4) of incubation. You attributed the contamination to inadequate disinfection of the area below the work surface that contaminated the pump apparatus after equipment changeover, which in turn may have contaminated RABS gloves used for unplanned mechanical interventions. However, you did not address the extent of other equipment underneath the filling line worksurface that can pose a contamination risk due to insufficient disinfection.\n\nThese (b)(4) media fill contaminations indicate your aseptic manufacturing operations were not in control. Without a comprehensive assessment of contamination hazards, and a CAPA that builds more holistic risk mitigation into your operational design, there is no assurance that you can prevent recurrence of sterility problems due to various latent or active failure modes in your operation.\n\nWe acknowledge that your firm took significant steps in response to the media fill failures, including a Field Alert Report, batch rejections, and suspension of operations.\n\nYour firm’s response is inadequate. You state that “... the media fill investigations determined root cause of each media fill event, supported the establishment of CAPA to prevent future recurrence as well as the decisions made in relation to the product under scope of the events.” However, you continued to observe contaminated units in subsequent media fills. The recurring incidents of contaminated units in media fills are an indicator of an adverse trend in your aseptic filling line. You did not provide a comprehensive assessment of contamination risk factors in your aseptic processing operations that support robust and holistic remediations to your aseptic processing operation design. Systemic remediations are essential to address a pattern of recurring contamination events and ensure sustainable control of your aseptic processing operations.\n\nThe response also lacks adequate justification to support the sufficiency of your CAPA activities. For example, regarding the October 5, 2021, media fill, your response fails to adequately explain how your CAPA will ensure the (b)(4) syringe in your (b)(4) will no longer cause contamination of the sterile product pathway. This type of fragility questions the basic functionality and selection of a system that is explicitly designed to maintain sterility. You also did not adequately address whether you intend to revisit the area classification, the (b)(4) equipment choice or supplier of this system considering the media fill finding.\n\nIn response to the letter, provide:\n\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\n\no All human interactions within the ISO 5 area.\n\no Equipment placement and ergonomics.\n\no Air quality in the ISO 5 area and surrounding room.\n\no Facility layout.\n\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations).\n\no Other variables that have potential to cause contamination in your operations (e.g., insufficient (b)(4) sterilization frequency).\n\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\n\nYour CAPA plan to implement routine, vigilant operations and management oversight of facilities and equipment. This plan should include, among other things, improved management of operations that assures prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review. Your plan should also ensure that appropriate actions are taken throughout the company network.\n\nA thorough evaluation of the suitability of each (b)(4) apparatus for its intended use. Your evaluation of all of your (b)(4) equipment should include a determination of whether they are appropriate, durable, and maintain integrity. Also, regarding the media fill failure that involved (b)(4) difficulties, include an assessment of sampling robustness based upon its purpose and associated hazards, and discuss the feasibility of a lower risk sampling location.\n\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nA detailed description of the degree of involvement of quality assurance (QA) staff in evaluation, oversight, performance, and guiding of the content and depth of your investigations. Among other things, explain whether quality assurance plays a lead role throughout each investigation or only at certain specified intervals. Also explain the role and authority of the QA function in assuring appropriate root cause determinations and identification of an effective CAPA plan.\n\nA retrospective evaluation by a qualified third party of investigations and failure modes related to the capability of your aseptic processing operation to robustly produce sterile drugs, including, but not be limited to:\n\no All media fill contamination events, and all sterility positives, since January 1, 2019,regardless of whether the batch was shipped to the United States.\n\no Identification of all potential failure modes associated with these media fill and sterility positives.\n\no A detailed evaluation and description of each aseptic connection and operation made down stream of the (b)(4), including, but not limited to, the manipulations at sampling ports in the product flow pathway (b)(4).\n\no A comparison of your aseptic manufacturing process to the process simulation protocol to identify areas in which media fills may be improved to simulate actual operations more accurately.\n\no Media fill criteria used by your firm, and adequacy of provisions to ensure thorough investigation of any contamination.\n\no All changes implemented to your aseptic operations in response to any aseptic process simulation incidents and sterility failures since 2019, including an evaluation of their adequacy and sufficiency, and a risk assessment of any distributed product affected by deficient aseptic processing operations that occurred during this period.\n\no Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality unit oversight (e.g., audit) during aseptic processing and its support operations.\n\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\n\nAn independent review of the validity and robustness of your equipment parts sterilizationcycles. This review should include:\n\no A comprehensive assessment, including load configurations, pre-assembled parts, (b)(4), biological indicator placement in worst-case locations, correlation of heat and biological kill, and other factors.\n\no A thorough evaluation of the ability of the vegetative microbes, named in your April 2021, media fill investigation to survive the (b)(4) sterilization cycle used for equipment parts. The review should also re-evaluate whether vegetative microbes may have been introduced to that media fill through other routes of contamination.\n\nA complete list of complaints received for Abraxane drug products since January 2019.Include the lot number, date of manufacture, sufficient narrative regarding the nature of the complaint, any CAPA steps taken, and conclusions.\n\nAn updated risk assessment that addresses any product quality or patient safety risks related to batches of Abraxane (manufactured between October 2020 and April 2021) in U.S. distribution, including potential customer notification and recalls.\n\nAdditional Guidance on Aseptic Processing\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of these violations and for preventing their recurrence or the occurrence of other violations.\n\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease identify your response with the unique identifier: CMS# 633713.\n\nSend your electronic response to ORAPHARM4_RESPONSES@fda.hhs.gov with ATTN: CDR Steven E. Porter, Jr. or mail your written response to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food and Drug Administration\n\n19701 Fairchild Road\n\nIrvine, CA 92612-2506\n\nIf you have questions regarding the content of this letter, please contact Jamie Dion, compliance officer, at 303-236-3133, or by email at Jamie.Dion@fda.hhs.gov. www.fda.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nCC: Nathan Trembath (via email Nathan.Trembath@bms.com)\n\nExecutive Director, Site Head\n\nAbraxis Bioscience LLC\n\n620 N 51st Ave.\n\nPhoenix, AZ 85043","Abraxis Bioscience LLC","abraxis-bioscience-llc-633713-10312022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabraxis-bioscience-llc-633713-10312022","2026-10-26T08:07:49.018355+00:00","Closed Out","2022-11-08","633713","2024-03-25","Mr. Giovanni Caforio","2026-08-20T01:27:18.294+00:00","VIA EMAIL CONFIRMED DELIVERY","2022-10-31",{"id":121,"raw":122,"subject":127,"body_html":128,"body_text":129,"firm_name":130,"letter_id":131,"created_at":132,"fei_number":19,"letter_url":133,"updated_at":134,"action_type":22,"case_status":23,"posted_date":135,"marcs_cms_no":136,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":137,"body_fetched_at":138,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":139,"medical_device_id":19,"response_letter_date":19},357,[123,124,125,11,126,13,13,13],"\u003Ctime datetime=\"2026-01-27T05:00:00Z\">01\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-12-22T05:00:00Z\">12\u002F22\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmeridian-bioscience-inc-720826-12222025\">Meridian Bioscience, Inc \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tony Serafini-Lamanna\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President of Diagnostics \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Meridian Bioscience, Inc \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3471 Riverhills Dr.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cincinnati\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>45244\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Tony.Serafini-Lamanna@meridianbioscience.com\"> Tony.Serafini-Lamanna@meridianbioscience.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 720826\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>December 22, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Serafini-Lamanna:\u003C\u002Fp>\u003Cp>During an inspection of your firm, Magellan Diagnostics, Inc. located in North Billerica, MA from August 5, 2025, through August 26, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures in-vitro diagnostics (IVD) kits that measure blood lead levels, including the LeadCare II Blood Lead Analyzer and Test Kit. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received responses from Vernon Brown Director – Quality Assurance and Regulatory Affairs, Meridian Biosciences, Inc. dated September 17, 2025, October 3, 2025, October 17, 2025, November 14, 2025, November 26, 2025, and December 12, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address your responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for implementing corrective and preventive action. The procedures shall include requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to follow its CAPA procedure, SOP 128, Rev 15, Effective March 27, 2025, including opening CAPAs as required by your procedure. Section 2 of this SOP indicates CAPA’s can arise from “A systemic issue identified through trend monitoring.” For example:\u003C\u002Fp>\u003Cp>A) Your firm failed to open a CAPA in October 2024, when you began trending an increase in patient false positive complaints (PATFP) associated with the use of certain third-party (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) collection tubes used with your LeadCare II Blood Lead Test Kit. From October 7, 2024, to August 14, 2025, you identified approximately 179 of these PATFP complaints. We are also aware that you did not take these complaints into account with a previous CAPA 1288 which was initiated on May 3, 2023, to address increased patient false positive complaints (PATFP) for the LeadCare II Blood Lead Test Kit. This CAPA 1288 was closed out on May 22, 2025, noting that “current complaint trending reports confirm that the PATFP complaint rate has reached a steady state.” However, your firm received 31 complaints of false positives after this date and did not take any further action, such as the opening of a new CAPA, as required by your procedure.\u003C\u002Fp>\u003Cp>B) Your firm failed to open a CAPA to address at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> out-of-range control complaints (\"COORLO\") received for your LeadCare II Blood Lead Test Kit from June 22, 2021, to July 2025.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and concluded they are not adequate. We understand that you have revised product labeling to indicate that the customer must use only the capillary tubes included in the LeadCare II Blood Lead Test Kit for blood collection and that you plan to send customers a letter to inform them of this update. Please be aware that this action would require a report to be submitted to FDA as required by 21 CFR 806. However, your firm has not provided copies of the CAPAs opened in response to this observation to demonstrate your proposed corrective actions will be effective, nor did it indicate that it will be performing any retrospective review of previous complaints or trends to ensure CAPAs have been opened appropriately and as required by your procedure.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient. The procedures shall include a mechanism for addressing incomplete, ambiguous, or conflicting requirements. The design input requirements shall be documented and shall be reviewed and approved by a designated individual(s). The approval, including the date and signature of the individual(s) approving the requirements, shall be documented, as required by 21 CFR 820.30(c).\u003C\u002Fp>\u003Cp>For example, your firm failed to establish design inputs for the Level 1 and Level 2 Controls used in LeadCare II Blood Lead Testing Systems as required by your Design Control Procedure, SOP 131, Revision 13, Effective Date June 6, 2021. The Instructions for Use for LeadCare II Blood Lead Testing System states that Level 1 and Level 2 controls are intended \"to verify system performance and accuracy before testing patient results.\" Yet, the Design Requirement Matrix, Rev G, dated July 1, 2020, which was provided as the latest specification for LeadCare II testing system, fails to establish specific and separate design requirements for the Level 1 or Level 2 Controls that are part of the LeadCare II testing system.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and concluded they are not adequate. Your firm indicated that a CAPA will be opened to evaluate the level 1 and 2 controls and will also include a retrospective review of complaints to further evaluate the issue. However, your firm did not provide a copy of the CAPA to demonstrate your proposed corrective actions will be effective. Also, your response did not include a timeline for revising your design documents nor any plans for assessing your design control program to mitigate the above observation.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for validating the device design. Design validation shall be performed under \u003Cstrong>(b)(4)\u003C\u002Fstrong> operating conditions on \u003Cstrong>(b)(4)\u003C\u002Fstrong> production units, lots, or batches, or their equivalents. Design validation shall ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions. Design validation shall include software validation and risk analysis, where appropriate. The results of the design validation, including identification of the design, method(s), the date, and the individual(s) performing the validation, shall be documented in the DHF, as required by 21 CFR 820.30(g). For example:\u003C\u002Fp>\u003Cp>A) Your firm did not validate the cleaning and decontamination instructions written in the Instructions for Use (IFU) for Blood Lead Testing Systems - LeadCare II, LeadCare Ultra, and LeadCare Plus Analyzers.\u003C\u002Fp>\u003Cp>B) Your firm failed to adequately establish your Risk Management Procedure SOP 159, Rev 08, dated March 12, 2025, which requires the Risk Management File to be updated periodically or when previously unrecognized hazards are present. For example:\u003C\u002Fp>\u003Cp>o Your firm failed to update your risk files for your LeadCare II test system, after becoming aware of an increase in false positive complaints associated with the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tubes from October 7, 2024, to August 14, 2025. Specifically, your DFMEA dated December 1, 2022, PFMEA dated November 5, 2020, and UFMEA dated June 18, 2020, were not updated to include this previously unrecognized hazard.\u003C\u002Fp>\u003Cp>o Your firm failed to update your risk files for their LeadCare II test system, after becoming aware of two separate labeling control failures during manufacturing in March of 2023 and again in May of 2024 that resulted in mislabeled products being distributed. Specifically, the PFMEA dated November 5, 2020, was not updated to identify any risks associated with the mislabeling of products being released.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and concluded they are not adequate. Your firm indicated it will validate the cleaning process and expect this to be completed by January 9, 2026. Your firm’s response noted a CAPA will be opened for review and revision of the risk management files, but did not provide any details, including a copy of the CAPA to demonstrate your proposed corrective actions will be effective. Also, the responses did not include a plan to perform any retrospective review of ECO’s to ensure risk management files will be updated appropriately.\u003C\u002Fp>\u003Cp>4. Failure to validate a process with a high degree of assurance and approved according to established procedures, when the results of a process cannot be fully verified by subsequent inspection and test. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, shall be documented, as required by 21 CFR 820.75(a). For example:\u003C\u002Fp>\u003Cp>A) Your firm failed to have validation data to demonstrate how calibration verification with only \u003Cstrong>(b)(4)\u003C\u002Fstrong> of data can ensure reliable device performance across the reportable range for a diagnostic device. Your calibration verification procedure 65055, allows exclusion of up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> of test results when they exceed the reportable range. This procedure includes instructions for operators to \"leave blank\" any \"High\" results and exclude \"obvious outliers or contaminated samples,\" and if remaining data fails bias specification, it allows \u003Cstrong>(b)(4)\u003C\u002Fstrong> calibration adjustments.\u003C\u002Fp>\u003Cp>B) Your firm failed to validate the revised manufacturing process which included new acceptance criteria to include \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to demonstrate consistent manufacturing capability. Engineering Change Order (ECO) 7378 was initiated on June 30, 2023, to “Update Procedures for \"LC II Sensor Calibration Verification\" (Document Reference 650055) and \"LeadCare Ultra Sensor Calibration Verification Procedure\" (Document Reference 65064) to include release requirements for \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> based on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing data obtained.” The ECO noted this process change was considered a low risk, and no additional validation was performed, even though this is critical acceptance criteria.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses, and concluded they are not adequate. Your responses indicated CAPAs were opened to address the above items; however, they did not provide a copy of the CAPAs to demonstrate your proposed corrective actions will be effective or a plan to ensure re-validation is performed, as necessary, when manufacturing operations are revised, including anytime acceptance criteria is modified.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures for acceptance of incoming product. Incoming product shall be inspected, tested, or otherwise verified as conforming to specified requirements. Acceptance or rejection shall be documented, as required by 21 CFR 820.80(b).\u003C\u002Fp>\u003Cp>For example, your firm failed to establish adequate incoming inspection procedures for capillary collection tubes used with your blood lead testing kits. The current procedure requires a sample of \u003Cstrong>(b)(4)\u003C\u002Fstrong> tubes from lot sizes of \u003Cstrong>(b)(4)\u003C\u002Fstrong> units per \u003Cstrong>(b)(4)\u003C\u002Fstrong> for packaging verification only. Your Incoming Inspection Procedure, SOP 105, Rev 10, Effective Date April 18, 2025, does not specify inspection of any critical quality attributes for these capillary tubes.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined at this time. We understand that you plan to revise specifications for LCII Blood Collection Capillary – Plungers Kit, and plan to initiate incoming inspection on these components, including testing the tubes for lead, however, these revisions are still in progress. We will need to verify that your firm is performing sufficient inspections to ensure these components meet their required specifications.\u003C\u002Fp>\u003Cp>6. Failure to have written sampling plans that are based on a valid statistical rationale. Each manufacturer shall establish and maintain procedures to ensure that sampling methods are adequate for their intended use and to ensure that when changes occur the sampling plans are reviewed. These activities shall be documented, as required by 21 CFR 820.250(b).\u003C\u002Fp>\u003Cp>For example, your firm failed to follow your Statistical Methods &amp; Analysis of Data Procedure, SOP 139, Rev 04, Effective Date November 16, 2020, Section 6.5, which requires adequate sample size justification for process\u002Fproduct verification\u002Fvalidation\u002Ftest method validation studies. Validation testing performed on August 30, 2023, to validate mold modification of caps through \u003Cstrong>(b)(4)\u003C\u002Fstrong> Caps (P\u002FN \u003Cstrong>(b)(4)\u003C\u002Fstrong>), inspected only 10 caps from Cavity \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Cavity \u003Cstrong>(b)(4)\u003C\u002Fstrong> (5 each) without describing lot size or providing valid statistical rationale for the sample size chosen.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and the adequacy cannot be determined at this time. You indicated a CAPA was opened to review your procedures related to statistical evaluation, but you did not provide any additional documentation, including a copy of the CAPA to demonstrate your proposed corrective actions will be effective.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Medical Device Reporting (MDR) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s LeadCare Plus Blood Lead Testing Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 ‐ Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to report to us the information required by § 803.52 in accordance with the\u003Cbr>requirements of § 803.12(a), no later than 30 calendar days after the day that your firm receives or otherwise become aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example:\u003C\u002Fp>\u003Cul>\u003Cli>The information included for Complaint #MAG-CC-05942 describes an event where the pediatric patient experienced a false negative result while using your firm’s LeadCare Plus blood lead testing system, as a result of a device malfunction (e.g., corroded sensor pin). We believe this malfunction resulted in the device’s failure to perform its essential function and compromise the device’s diagnostic effectiveness and would be likely to cause or contribute to a death or serious injury. There’s no information included for the complaint indicating that the malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Accordingly, the complaint represents an MDR-reportable malfunction, as defined in 21 CFR 803.3. Your firm became aware of the event on October 30, 2023, and firm failed to submit the MDR within the required 30-calendar-day timeframe.\u003C\u002Fli>\u003Cli>The information included for Complaint # MAG-CC-06971, describes a malfunction (i.e., analyzer emitting a burning smell) involving your firm’s LeadCare Plus Blood Lead Testing System. Your firm became aware of MAG-CC-06971 on July 17, 2024, and submitted a malfunction MDR for the event. FDA received the corresponding MDR# 1218996-2025-00006 on January 29, 2025, which is beyond the 30-calendar day timeframe after becoming aware.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Your firm has not yet submitted an MDR for complaint #MAG-CC-05942. In addition, the response states that your firm plans to initiate a CAPA to evaluate and optimize the MDR reporting process and conduct a retrospective review to address the issue in accordance with the revised process. However, your firm has not provided documentation or evidence demonstrating that the systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your firm’s LeadCare II Blood Lead Test Kits devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit any report required within 10 working days of initiating a correction or removal, as required by 21 CFR 806.10. For example: Magellan Diagnostics, Inc. became aware of labelling error during assembly of LeadCare II Blood Lead Test Kits, halted assembly and conducted a “Stop Shipment.” Your firm sent a customer communication titled “MEDICAL DEVICE FIELD CORRECTION” dated 5\u002F8\u002F2024, to notify customers that \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the LeadCare II Testing Kit calibration button was incorrectly labeled as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which could result in inaccurate results and patient testing could be delayed. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA within 10 working days of initiation. As of the date of the close of the inspection, August 26, 2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>Your firm’s responses adequately satisfy this citation. Magellan Diagnostics, Inc. notified customers of the problem, initiated a medical device removal, and submitted a Report of Correction or Removal to FDA as of October 27, 2025.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>We are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of the device Quality System regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\u003C\u002Fp>\u003Cul>\u003Cli>Initial certifications by consultant and establishment – July 31, 2026\u003C\u002Fli>\u003Cli>Subsequent certifications – July 31, 2027, and July 31, 2028.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 720826” when replying. If you have any questions about the contents of this letter, please contact: Karen Archdeacon, Compliance Officer at karen.archdeacon@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Vernon Brown, Director – Quality Assurance and Regulatory Affairs, vernon.brown@meridianbioscience.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nTony Serafini-Lamanna\n\nRecipient Title\n\nPresident of Diagnostics\n\nMeridian Bioscience, Inc\n\n3471 Riverhills Dr.\n\nCincinnati, OH 45244\n\nUnited States\n\nTony.Serafini-Lamanna@meridianbioscience.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 720826\nDecember 22, 2025\nDear Mr. Serafini-Lamanna:\nDuring an inspection of your firm, Magellan Diagnostics, Inc. located in North Billerica, MA from August 5, 2025, through August 26, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures in-vitro diagnostics (IVD) kits that measure blood lead levels, including the LeadCare II Blood Lead Analyzer and Test Kit. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received responses from Vernon Brown Director – Quality Assurance and Regulatory Affairs, Meridian Biosciences, Inc. dated September 17, 2025, October 3, 2025, October 17, 2025, November 14, 2025, November 26, 2025, and December 12, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address your responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for implementing corrective and preventive action. The procedures shall include requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems, as required by 21 CFR 820.100(a).\nSpecifically, your firm failed to follow its CAPA procedure, SOP 128, Rev 15, Effective March 27, 2025, including opening CAPAs as required by your procedure. Section 2 of this SOP indicates CAPA’s can arise from “A systemic issue identified through trend monitoring.” For example:\nA) Your firm failed to open a CAPA in October 2024, when you began trending an increase in patient false positive complaints (PATFP) associated with the use of certain third-party ((b)(4)) collection tubes used with your LeadCare II Blood Lead Test Kit. From October 7, 2024, to August 14, 2025, you identified approximately 179 of these PATFP complaints. We are also aware that you did not take these complaints into account with a previous CAPA 1288 which was initiated on May 3, 2023, to address increased patient false positive complaints (PATFP) for the LeadCare II Blood Lead Test Kit. This CAPA 1288 was closed out on May 22, 2025, noting that “current complaint trending reports confirm that the PATFP complaint rate has reached a steady state.” However, your firm received 31 complaints of false positives after this date and did not take any further action, such as the opening of a new CAPA, as required by your procedure.\nB) Your firm failed to open a CAPA to address at least (b)(4) out-of-range control complaints (\"COORLO\") received for your LeadCare II Blood Lead Test Kit from June 22, 2021, to July 2025.\nWe reviewed your firm’s responses and concluded they are not adequate. We understand that you have revised product labeling to indicate that the customer must use only the capillary tubes included in the LeadCare II Blood Lead Test Kit for blood collection and that you plan to send customers a letter to inform them of this update. Please be aware that this action would require a report to be submitted to FDA as required by 21 CFR 806. However, your firm has not provided copies of the CAPAs opened in response to this observation to demonstrate your proposed corrective actions will be effective, nor did it indicate that it will be performing any retrospective review of previous complaints or trends to ensure CAPAs have been opened appropriately and as required by your procedure.\n2. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient. The procedures shall include a mechanism for addressing incomplete, ambiguous, or conflicting requirements. The design input requirements shall be documented and shall be reviewed and approved by a designated individual(s). The approval, including the date and signature of the individual(s) approving the requirements, shall be documented, as required by 21 CFR 820.30(c).\nFor example, your firm failed to establish design inputs for the Level 1 and Level 2 Controls used in LeadCare II Blood Lead Testing Systems as required by your Design Control Procedure, SOP 131, Revision 13, Effective Date June 6, 2021. The Instructions for Use for LeadCare II Blood Lead Testing System states that Level 1 and Level 2 controls are intended \"to verify system performance and accuracy before testing patient results.\" Yet, the Design Requirement Matrix, Rev G, dated July 1, 2020, which was provided as the latest specification for LeadCare II testing system, fails to establish specific and separate design requirements for the Level 1 or Level 2 Controls that are part of the LeadCare II testing system.\nWe reviewed your firm’s responses and concluded they are not adequate. Your firm indicated that a CAPA will be opened to evaluate the level 1 and 2 controls and will also include a retrospective review of complaints to further evaluate the issue. However, your firm did not provide a copy of the CAPA to demonstrate your proposed corrective actions will be effective. Also, your response did not include a timeline for revising your design documents nor any plans for assessing your design control program to mitigate the above observation.\n3. Failure to establish and maintain procedures for validating the device design. Design validation shall be performed under (b)(4) operating conditions on (b)(4) production units, lots, or batches, or their equivalents. Design validation shall ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions. Design validation shall include software validation and risk analysis, where appropriate. The results of the design validation, including identification of the design, method(s), the date, and the individual(s) performing the validation, shall be documented in the DHF, as required by 21 CFR 820.30(g). For example:\nA) Your firm did not validate the cleaning and decontamination instructions written in the Instructions for Use (IFU) for Blood Lead Testing Systems - LeadCare II, LeadCare Ultra, and LeadCare Plus Analyzers.\nB) Your firm failed to adequately establish your Risk Management Procedure SOP 159, Rev 08, dated March 12, 2025, which requires the Risk Management File to be updated periodically or when previously unrecognized hazards are present. For example:\no Your firm failed to update your risk files for your LeadCare II test system, after becoming aware of an increase in false positive complaints associated with the use of (b)(4) Tubes from October 7, 2024, to August 14, 2025. Specifically, your DFMEA dated December 1, 2022, PFMEA dated November 5, 2020, and UFMEA dated June 18, 2020, were not updated to include this previously unrecognized hazard.\no Your firm failed to update your risk files for their LeadCare II test system, after becoming aware of two separate labeling control failures during manufacturing in March of 2023 and again in May of 2024 that resulted in mislabeled products being distributed. Specifically, the PFMEA dated November 5, 2020, was not updated to identify any risks associated with the mislabeling of products being released.\nWe reviewed your firm’s responses and concluded they are not adequate. Your firm indicated it will validate the cleaning process and expect this to be completed by January 9, 2026. Your firm’s response noted a CAPA will be opened for review and revision of the risk management files, but did not provide any details, including a copy of the CAPA to demonstrate your proposed corrective actions will be effective. Also, the responses did not include a plan to perform any retrospective review of ECO’s to ensure risk management files will be updated appropriately.\n4. Failure to validate a process with a high degree of assurance and approved according to established procedures, when the results of a process cannot be fully verified by subsequent inspection and test. The validation activities and results, including the date and signature of the individual(s) approving the validation and where appropriate the major equipment validated, shall be documented, as required by 21 CFR 820.75(a). For example:\nA) Your firm failed to have validation data to demonstrate how calibration verification with only (b)(4) of data can ensure reliable device performance across the reportable range for a diagnostic device. Your calibration verification procedure 65055, allows exclusion of up to (b)(4) of test results when they exceed the reportable range. This procedure includes instructions for operators to \"leave blank\" any \"High\" results and exclude \"obvious outliers or contaminated samples,\" and if remaining data fails bias specification, it allows (b)(4) calibration adjustments.\nB) Your firm failed to validate the revised manufacturing process which included new acceptance criteria to include (b)(4), to demonstrate consistent manufacturing capability. Engineering Change Order (ECO) 7378 was initiated on June 30, 2023, to “Update Procedures for \"LC II Sensor Calibration Verification\" (Document Reference 650055) and \"LeadCare Ultra Sensor Calibration Verification Procedure\" (Document Reference 65064) to include release requirements for (b)(4) and (b)(4) based on the (b)(4) testing data obtained.” The ECO noted this process change was considered a low risk, and no additional validation was performed, even though this is critical acceptance criteria.\nWe reviewed your firm’s responses, and concluded they are not adequate. Your responses indicated CAPAs were opened to address the above items; however, they did not provide a copy of the CAPAs to demonstrate your proposed corrective actions will be effective or a plan to ensure re-validation is performed, as necessary, when manufacturing operations are revised, including anytime acceptance criteria is modified.\n5. Failure to establish and maintain procedures for acceptance of incoming product. Incoming product shall be inspected, tested, or otherwise verified as conforming to specified requirements. Acceptance or rejection shall be documented, as required by 21 CFR 820.80(b).\nFor example, your firm failed to establish adequate incoming inspection procedures for capillary collection tubes used with your blood lead testing kits. The current procedure requires a sample of (b)(4) tubes from lot sizes of (b)(4) units per (b)(4) for packaging verification only. Your Incoming Inspection Procedure, SOP 105, Rev 10, Effective Date April 18, 2025, does not specify inspection of any critical quality attributes for these capillary tubes.\nWe reviewed your firm’s responses and the adequacy cannot be determined at this time. We understand that you plan to revise specifications for LCII Blood Collection Capillary – Plungers Kit, and plan to initiate incoming inspection on these components, including testing the tubes for lead, however, these revisions are still in progress. We will need to verify that your firm is performing sufficient inspections to ensure these components meet their required specifications.\n6. Failure to have written sampling plans that are based on a valid statistical rationale. Each manufacturer shall establish and maintain procedures to ensure that sampling methods are adequate for their intended use and to ensure that when changes occur the sampling plans are reviewed. These activities shall be documented, as required by 21 CFR 820.250(b).\nFor example, your firm failed to follow your Statistical Methods & Analysis of Data Procedure, SOP 139, Rev 04, Effective Date November 16, 2020, Section 6.5, which requires adequate sample size justification for process\u002Fproduct verification\u002Fvalidation\u002Ftest method validation studies. Validation testing performed on August 30, 2023, to validate mold modification of caps through (b)(4) Caps (P\u002FN (b)(4)), inspected only 10 caps from Cavity (b)(4) and Cavity (b)(4) (5 each) without describing lot size or providing valid statistical rationale for the sample size chosen.\nWe reviewed your firm’s responses and the adequacy cannot be determined at this time. You indicated a CAPA was opened to review your procedures related to statistical evaluation, but you did not provide any additional documentation, including a copy of the CAPA to demonstrate your proposed corrective actions will be effective.\nMedical Device Reporting (MDR) Violations\nOur inspection also revealed that your firm’s LeadCare Plus Blood Lead Testing Systems are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 ‐ Medical Device Reporting. Significant violations include, but are not limited to, the following:\nFailure to report to us the information required by § 803.52 in accordance with the\nrequirements of § 803.12(a), no later than 30 calendar days after the day that your firm receives or otherwise become aware of information, from any source, that reasonably suggests that a device that your firm markets has malfunctioned and this device or a similar device that it markets would be likely to cause or contribute to a death or serious injury, if the malfunction were to recur, as required by 21 CFR 803.50(a)(2). For example:\nThe information included for Complaint #MAG-CC-05942 describes an event where the pediatric patient experienced a false negative result while using your firm’s LeadCare Plus blood lead testing system, as a result of a device malfunction (e.g., corroded sensor pin). We believe this malfunction resulted in the device’s failure to perform its essential function and compromise the device’s diagnostic effectiveness and would be likely to cause or contribute to a death or serious injury. There’s no information included for the complaint indicating that the malfunction would not be likely to cause or contribute to a death or serious injury if it were to recur. Accordingly, the complaint represents an MDR-reportable malfunction, as defined in 21 CFR 803.3. Your firm became aware of the event on October 30, 2023, and firm failed to submit the MDR within the required 30-calendar-day timeframe.\nThe information included for Complaint # MAG-CC-06971, describes a malfunction (i.e., analyzer emitting a burning smell) involving your firm’s LeadCare Plus Blood Lead Testing System. Your firm became aware of MAG-CC-06971 on July 17, 2024, and submitted a malfunction MDR for the event. FDA received the corresponding MDR# 1218996-2025-00006 on January 29, 2025, which is beyond the 30-calendar day timeframe after becoming aware.\nThe adequacy of your firm’s responses cannot be determined at this time. Your firm has not yet submitted an MDR for complaint #MAG-CC-05942. In addition, the response states that your firm plans to initiate a CAPA to evaluate and optimize the MDR reporting process and conduct a retrospective review to address the issue in accordance with the revised process. However, your firm has not provided documentation or evidence demonstrating that the systemic corrective actions have been fully implemented, including completion of the retrospective review, as these activities are still ongoing.\nCorrections and Removals Violations\nOur inspection also revealed that your firm’s LeadCare II Blood Lead Test Kits devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\nFailure to submit any report required within 10 working days of initiating a correction or removal, as required by 21 CFR 806.10. For example: Magellan Diagnostics, Inc. became aware of labelling error during assembly of LeadCare II Blood Lead Test Kits, halted assembly and conducted a “Stop Shipment.” Your firm sent a customer communication titled “MEDICAL DEVICE FIELD CORRECTION” dated 5\u002F8\u002F2024, to notify customers that (b)(4) of the LeadCare II Testing Kit calibration button was incorrectly labeled as (b)(4), which could result in inaccurate results and patient testing could be delayed. This action meets the definition of a medical device correction or removal initiated to remedy a violation which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA within 10 working days of initiation. As of the date of the close of the inspection, August 26, 2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nYour firm’s responses adequately satisfy this citation. Magellan Diagnostics, Inc. notified customers of the problem, initiated a medical device removal, and submitted a Report of Correction or Removal to FDA as of October 27, 2025.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nWe are requesting that you submit to this office on the schedule below, certification by an outside expert consultant that he\u002Fshe has conducted an audit of your firm’s manufacturing and quality assurance systems relative to the requirements of the device Quality System regulation (21 CFR, Part 820). You should also submit a copy of the consultant's report, and certification by your establishment's Chief Executive Officer (if other than yourself) that he or she has reviewed the consultant's report and that your firm has initiated or completed all corrections called for in the report. The initial certifications of audit and corrections and subsequent certifications of updated audits and corrections (if required) should be submitted to this office by the following dates:\nInitial certifications by consultant and establishment – July 31, 2026\nSubsequent certifications – July 31, 2027, and July 31, 2028.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 720826” when replying. If you have any questions about the contents of this letter, please contact: Karen Archdeacon, Compliance Officer at karen.archdeacon@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Vernon Brown, Director – Quality Assurance and Regulatory Affairs, vernon.brown@meridianbioscience.com","Meridian Bioscience, Inc","meridian-bioscience-inc-720826-12222025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmeridian-bioscience-inc-720826-12222025","2026-10-26T08:09:24.106242+00:00","2026-01-27","720826","Tony Serafini-Lamanna","2026-08-19T07:16:48.363+00:00","2025-12-22",{"id":141,"raw":142,"subject":104,"body_html":147,"body_text":148,"firm_name":149,"letter_id":150,"created_at":18,"fei_number":19,"letter_url":151,"updated_at":152,"action_type":22,"case_status":23,"posted_date":153,"marcs_cms_no":154,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":155,"body_fetched_at":156,"delivery_method":157,"recipient_title":19,"reference_number":158,"action_taken_date":159,"medical_device_id":19,"response_letter_date":19},863,[143,144,145,57,146,13,13,13],"\u003Ctime datetime=\"2025-06-03T04:00:00Z\">06\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-30T04:00:00Z\">04\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frechon-life-science-ab-701040-04302025\">Rechon Life Science AB\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-68\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Roland Holmqvist\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rechon Life Science AB\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Soldattorpsvagen 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Limhamn\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>216 13\u003C\u002Fspan> \u003Cspan>Skane Lan\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sweden\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-68\u003C\u002Fp>\u003Cp>April 30, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Holmqvist:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Rechon Life Sciences AB, FEI 3002806978, at Soldattorpsvagen 5, Limhamn, Skane Lan, 216 13, Sweden, from August 26 to September 6, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your September 27, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to ensure adequate aseptic behavior and establish appropriate written procedures designed to prevent microbiological contamination risks during the manufacture of drug products purported to be sterile. On August 26, 2024, our investigators observed an operator touching the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with their gloved hand during the set up and assembly of the aseptic processing line.\u003C\u002Fp>\u003Cp>This unacceptable practice of touching the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with gloved hands was permitted in your standard operating procedure (SOP-0870-3.0) for filling and sealing on the ampoule line. For example, your procedure allowed the operator to adjust the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “with the fingertip” of a sanitized gloved hand.\u003C\u002Fp>\u003Cp>Your smoke studies simulated multiple adjustments of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with gloved hands during interventions and assembly. In one smoke study video, the operator made contact with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the ampoule line \u003Cstrong>(b)(4)\u003C\u002Fstrong> during the “Assembly” phase.\u003C\u002Fp>\u003Cp>In your response, you provide corrective actions and preventative actions (CAPAs), including awareness training for all operators, a deviation investigation that examined 2 years of \u003Cstrong>(b)(4)\u003C\u002Fstrong> swab samples, a procedure revision, and the rejection of the affected batch.\u003C\u002Fp>\u003Cp>Your response is inadequate. You state that there was no intentional or accidental contact of the gloved hand with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> during inspection. You also state the SOP for filling and sealing on the ampoule line “specifically stated that operators are not allowed to touch the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, this assertion conflicts with your procedure and operator practices demonstrated in your smoke study videos. You did not provide environmental monitoring trend data for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> swab samples. Furthermore, your revised procedure still allows for \u003Cstrong>(b)(4)\u003C\u002Fstrong> adjustments with sanitized, gloved fingertips, instructing operators to touch the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and to not “touch the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” It is important that personnel avoid direct contact of critical surfaces with any part of their gown or gloves. Only sterile instruments should be used for manipulations and interventions on the aseptic processing line when handling sterilized materials. These sterile instruments should be stored in ISO 5 conditions when not in use to prevent contamination.\u003C\u002Fp>\u003Cp>For additional guidance on aseptic processing see FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>o All human interactions within the ISO 5 area\u003Cbr>o Equipment placement and ergonomics\u003Cbr>o Air quality in the ISO 5 area and surrounding room\u003Cbr>o Facility layout\u003Cbr>o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to better assure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.\u003C\u002Fli>\u003Cli>A thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior, such as those observed during the inspection, may have affected quality and sterility of your drugs.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your investigations into environmental monitoring (EM) excursion results and out-of- specification (OOS) assay results were inadequate.\u003C\u002Fp>\u003Cp>A. Your CAPAs to the persistent contamination of objectionable microorganisms were not robust, as evidenced by the continued recovery of gram-negative organisms and spore formers in the ISO 5 and 7 areas and on personnel since 2022. This deficiency was also cited during the previous inspection when an adverse trend of gram-negative rods (\u003Cem>Moraxella osloensis\u003C\u002Fem>) were recovered from operators’ clothing.\u003C\u002Fp>\u003Cp>For example, your investigation into the trend of eight occurrences of gram-negative organisms recovered from either operators’ gowning or from an ISO 7 air sample, was inadequate. You concluded that the adverse trend was due to operators talking in the ISO 7 areas and an increase of staff illness. Your CAPA included awareness training for operators and a procedural update for persons who perform sampling in \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your investigation did not provide a holistic evaluation of all potential contamination sources and personnel practices in the facility contributing to the adverse trend.\u003C\u002Fp>\u003Cp>In your response, you state you will implement additional immediate actions, including the requirement for mouth covers in ISO 8 areas and having operators apply a second layer of shoe covers as they pass through the \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate. Although you state you do not have a “current issue related to objectionable microorganisms, i.e. spore formers and gram-negative bacteria,” you fail to provide sufficient evidence to support this statement. In addition, you do not address ill operators working in aseptic areas as noted in your deviation as the identified root cause for the trend.\u003C\u002Fp>\u003Cp>B. Your investigations into OOS results were inadequate because they lacked scientific rationale for root cause determinations. For example, you initiated an OOS investigation for \u003Cstrong>(b)(4)\u003C\u002Fstrong> assay content for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Injection, \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL, batch \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The specification for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content was \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL. The sample was injected \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and your initial test yielded an \u003Cstrong>(b)(4)\u003C\u002Fstrong> result of \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg\u002FmL \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your investigation concluded, without adequate scientific justification, that a non-functional injector syringe was the probable root cause. You invalidated the original results without an obvious laboratory error and no manufacturing assessment was performed. A new analysis was performed and the passing results were recorded.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that the laboratory investigations “contain gaps” and your procedure for conducting OOS investigations can be improved. You revised your procedures to include hypothesis testing during the laboratory investigations.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your revised procedures do not require a manufacturing investigation to be conducted prior to invalidating data unless it is an obvious laboratory error. In addition, your company did not conduct a retrospective review of invalidated laboratory data for drug products marketed in the United States to ensure the drug meets the identity, strength, quality and purity it purports.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive independent review of your personnel and environmental monitoring program, including but not limited to:\u003Cbr>o A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbial trends from your classified areas. Provide an updated timeline for implementation of your program, including procedural changes.\u003C\u002Fli>\u003Cli>A retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\u003Cbr>o Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\u003Cbr>o For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\u003Cbr>o For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\u003Cbr>o A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\u003Cbr>&nbsp; &nbsp; o Quality unit oversight of laboratory investigations.\u003Cbr>&nbsp; &nbsp; o Identification of adverse laboratory control trends.\u003Cbr>&nbsp; &nbsp; o Resolution of causes of laboratory variation.\u003Cbr>&nbsp; &nbsp; o Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified.\u003Cbr>&nbsp; &nbsp; o Adequately scoping of each investigation and its CAPA.\u003Cbr>&nbsp; &nbsp; o Revised OOS investigation procedures with these and other remediations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A. Your firm failed to validate and assess the effectiveness, distribution, and reproducibility of \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination to ensure it can safely achieve a state of control in aseptic rooms against objectionable microorganisms.\u003C\u002Fp>\u003Cp>For example, your firm utilized \u003Cstrong>(b)(4)\u003C\u002Fstrong> as an \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination of aseptic filling lines \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your investigation reported several instances of spore-forming bacteria during \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in ISO 7 areas. The identified bacteria included species such as \u003Cem>Paenibacillus provencensis\u002Fshunpengii\u002Furinalis, Bacillus infantis, Niallia circulans complex, Metabacillus halosaccharovorans, Peribacillus simplex, Bacillus subtilis\u003C\u002Fem> group and \u003Cem>Bacillus cereus\u003C\u002Fem> group. The root cause was identified as an “inadequate process for \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitization,” which was “unclear and may be causing the growth of spore forming bacteria in Grade B.” Additionally, the same \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination cycle showed positive biological indicators (BIs) on aseptic lines \u003Cstrong>(b)(4)\u003C\u002Fstrong> during \u003Cstrong>(b)(4)\u003C\u002Fstrong> periods (\u003Cstrong>(b)(4)\u003C\u002Fstrong>). The results indicate the \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination process is ineffective.\u003C\u002Fp>\u003Cp>In your response, you state the BIs were used for informational purposes only and not as an evaluation of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination process. You acknowledge the title of the SOP “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sanitization – Decontamination of rooms at Bulk Production” is misleading and the use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not implemented as a routine decontamination process. You corrected the title to be “Disinfection of grade A and B areas within Bulk Production with \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” You state that you will collaborate with your vendor to perform a mapping study to verify the effectiveness of the disinfection process.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide evidence the \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination process provides adequate surface coverage of all areas on the aseptic line, is compatible with materials, and ensures that residual \u003Cstrong>(b)(4)\u003C\u002Fstrong> that may remain on equipment does not affect product quality. Critical cleaning and sanitization agents must be validated. A mapping study is not validation of the disinfectant. Validation requires documented evidence that the disinfection process consistently removes or inactivates known or possible pathogens.\u003C\u002Fp>\u003Cp>B. Our investigators observed walls and floors of numerous ISO 8 production rooms were sticky and left visible \u003Cstrong>(b)(4)\u003C\u002Fstrong> residue when wiped by the hand. The investigators additionally noted fibers from disposable coveralls stuck to the walls in one of the production rooms. Such residual contamination can compromise product sterility and safety potentially resulting in patient harm.\u003C\u002Fp>\u003Cp>In your response, you state that your Quality Control Microbiology (QCM) group discovered the sticky floors and walls \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your deviation investigation concluded that the probable root causes were a build-up of new cleaning disinfectants and a possible interaction with materials in the facility. Your CAPA included wiping surfaces with \u003Cstrong>(b)(4)\u003C\u002Fstrong> after cleaning.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide the deviation investigation for the evaluation and identification of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> residue and a risk assessment of contamination to the drug product. Furthermore, you did not provide an assessment of your cleaning validation with regard to the new cleaning agents.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\u003Cbr>o Drugs with higher toxicities\u003Cbr>o Drugs with higher drug potencies\u003Cbr>o Drugs of lower solubility in their cleaning solvents\u003Cbr>o Drugs with characteristics that make them difficult to clean\u003Cbr>o Swabbing locations for areas that are most difficult to clean\u003Cbr>o Maximum hold times before cleaning\u003Cbr>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair (21 CFR 211.58).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not properly maintain classified areas and cleanrooms used in the manufacture of drug products. Our investigators observed peeling paint on the ceiling as well as bubbled paint and rust at the bottom of the door in ISO 7 room \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Room \u003Cstrong>(b)(4)\u003C\u002Fstrong> provides access into aseptic filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>These deficiencies were discussed with your management at the time of the walk-through of the aseptic areas. Management stated the peeling paint surfaces above the \u003Cstrong>(b)(4)\u003C\u002Fstrong> door may be caused by the surface material being incompatible with the cleaning agent used to clean the production facility. It is critical that the building is maintained to prevent exposure of sterile articles to potential contamination hazards in the manufacturing operation.\u003C\u002Fp>\u003Cp>In response to this letter, provide your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Rechon Life Science AB at Soldattorpsvagen 5, Limhamn, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3002806978 and ATTN: Erika V. Butler.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-25-68\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Roland Holmqvist\n\nRecipient Title\n\nChief Executive Officer\n\nRechon Life Science AB\n\nSoldattorpsvagen 5\n\nLimhamn\n\n216 13 Skane Lan\n\nSweden\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-68\nApril 30, 2025\nDear Mr. Holmqvist:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Rechon Life Sciences AB, FEI 3002806978, at Soldattorpsvagen 5, Limhamn, Skane Lan, 216 13, Sweden, from August 26 to September 6, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your September 27, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nYou failed to ensure adequate aseptic behavior and establish appropriate written procedures designed to prevent microbiological contamination risks during the manufacture of drug products purported to be sterile. On August 26, 2024, our investigators observed an operator touching the (b)(4) of the (b)(4) with their gloved hand during the set up and assembly of the aseptic processing line.\nThis unacceptable practice of touching the (b)(4) with gloved hands was permitted in your standard operating procedure (SOP-0870-3.0) for filling and sealing on the ampoule line. For example, your procedure allowed the operator to adjust the (b)(4), “with the fingertip” of a sanitized gloved hand.\nYour smoke studies simulated multiple adjustments of the (b)(4) with gloved hands during interventions and assembly. In one smoke study video, the operator made contact with the (b)(4) of the ampoule line (b)(4) during the “Assembly” phase.\nIn your response, you provide corrective actions and preventative actions (CAPAs), including awareness training for all operators, a deviation investigation that examined 2 years of (b)(4) swab samples, a procedure revision, and the rejection of the affected batch.\nYour response is inadequate. You state that there was no intentional or accidental contact of the gloved hand with the (b)(4) during inspection. You also state the SOP for filling and sealing on the ampoule line “specifically stated that operators are not allowed to touch the (b)(4).” However, this assertion conflicts with your procedure and operator practices demonstrated in your smoke study videos. You did not provide environmental monitoring trend data for the (b)(4) swab samples. Furthermore, your revised procedure still allows for (b)(4) adjustments with sanitized, gloved fingertips, instructing operators to touch the (b)(4) as “(b)(4)” and to not “touch the (b)(4).” It is important that personnel avoid direct contact of critical surfaces with any part of their gown or gloves. Only sterile instruments should be used for manipulations and interventions on the aseptic processing line when handling sterilized materials. These sterile instruments should be stored in ISO 5 conditions when not in use to prevent contamination.\nFor additional guidance on aseptic processing see FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\no All human interactions within the ISO 5 area\no Equipment placement and ergonomics\no Air quality in the ISO 5 area and surrounding room\no Facility layout\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to better assure routine and effective supervisory oversight for all production batches. Also, describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.\nA thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior, such as those observed during the inspection, may have affected quality and sterility of your drugs.\n2. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour investigations into environmental monitoring (EM) excursion results and out-of- specification (OOS) assay results were inadequate.\nA. Your CAPAs to the persistent contamination of objectionable microorganisms were not robust, as evidenced by the continued recovery of gram-negative organisms and spore formers in the ISO 5 and 7 areas and on personnel since 2022. This deficiency was also cited during the previous inspection when an adverse trend of gram-negative rods (Moraxella osloensis) were recovered from operators’ clothing.\nFor example, your investigation into the trend of eight occurrences of gram-negative organisms recovered from either operators’ gowning or from an ISO 7 air sample, was inadequate. You concluded that the adverse trend was due to operators talking in the ISO 7 areas and an increase of staff illness. Your CAPA included awareness training for operators and a procedural update for persons who perform sampling in (b)(4). However, your investigation did not provide a holistic evaluation of all potential contamination sources and personnel practices in the facility contributing to the adverse trend.\nIn your response, you state you will implement additional immediate actions, including the requirement for mouth covers in ISO 8 areas and having operators apply a second layer of shoe covers as they pass through the (b)(4).\nYour response is inadequate. Although you state you do not have a “current issue related to objectionable microorganisms, i.e. spore formers and gram-negative bacteria,” you fail to provide sufficient evidence to support this statement. In addition, you do not address ill operators working in aseptic areas as noted in your deviation as the identified root cause for the trend.\nB. Your investigations into OOS results were inadequate because they lacked scientific rationale for root cause determinations. For example, you initiated an OOS investigation for (b)(4) assay content for (b)(4) Injection, (b)(4) mg\u002FmL, batch (b)(4). The specification for (b)(4) content was (b)(4) mg\u002FmL. The sample was injected (b)(4), and your initial test yielded an (b)(4) result of (b)(4) mg\u002FmL (b)(4). Your investigation concluded, without adequate scientific justification, that a non-functional injector syringe was the probable root cause. You invalidated the original results without an obvious laboratory error and no manufacturing assessment was performed. A new analysis was performed and the passing results were recorded.\nIn your response, you acknowledge that the laboratory investigations “contain gaps” and your procedure for conducting OOS investigations can be improved. You revised your procedures to include hypothesis testing during the laboratory investigations.\nYour response is inadequate. Your revised procedures do not require a manufacturing investigation to be conducted prior to invalidating data unless it is an obvious laboratory error. In addition, your company did not conduct a retrospective review of invalidated laboratory data for drug products marketed in the United States to ensure the drug meets the identity, strength, quality and purity it purports.\nIn response to this letter, provide:\nA comprehensive independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality assurance unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive independent review of your personnel and environmental monitoring program, including but not limited to:\no A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbial trends from your classified areas. Provide an updated timeline for implementation of your program, including procedural changes.\nA retrospective, independent review of all invalidated OOS (including in-process and release\u002Fstability testing) results for U.S. products currently in the U.S. market and within expiry as of the date of this letter and a report summarizing the findings of the analysis, including the following for each OOS:\no Determine whether the scientific justification and evidence relating to the invalidated OOS result conclusively or inconclusively demonstrates causative laboratory error.\no For investigations that conclusively establish laboratory root cause, provide rationale and ensure that all other laboratory methods vulnerable to the same or similar root cause are identified for remediation.\no For all OOS results found by the retrospective review to have an inconclusive or no root cause identified in the laboratory, include a thorough review of production (e.g., batch manufacturing records, adequacy of the manufacturing steps, suitability of equipment\u002Ffacilities, variability of raw materials, process capability, deviation history, complaint history, batch failure history). Provide a summary of potential manufacturing root causes for each investigation, and any manufacturing operation improvements.\no A comprehensive review and remediation plan for your OOS result investigation systems. The CAPA should include, but not be limited to, addressing the following:\no Quality unit oversight of laboratory investigations.\no Identification of adverse laboratory control trends.\no Resolution of causes of laboratory variation.\no Initiation of thorough investigations of potential manufacturing causes whenever a laboratory cause cannot be conclusively identified.\no Adequately scoping of each investigation and its CAPA.\no Revised OOS investigation procedures with these and other remediations.\n3. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\nA. Your firm failed to validate and assess the effectiveness, distribution, and reproducibility of (b)(4) decontamination to ensure it can safely achieve a state of control in aseptic rooms against objectionable microorganisms.\nFor example, your firm utilized (b)(4) as an (b)(4) decontamination of aseptic filling lines (b)(4). Your investigation reported several instances of spore-forming bacteria during (b)(4), in ISO 7 areas. The identified bacteria included species such as Paenibacillus provencensis\u002Fshunpengii\u002Furinalis, Bacillus infantis, Niallia circulans complex, Metabacillus halosaccharovorans, Peribacillus simplex, Bacillus subtilis group and Bacillus cereus group. The root cause was identified as an “inadequate process for (b)(4) sanitization,” which was “unclear and may be causing the growth of spore forming bacteria in Grade B.” Additionally, the same (b)(4) decontamination cycle showed positive biological indicators (BIs) on aseptic lines (b)(4) during (b)(4) periods ((b)(4)). The results indicate the (b)(4) decontamination process is ineffective.\nIn your response, you state the BIs were used for informational purposes only and not as an evaluation of the (b)(4) decontamination process. You acknowledge the title of the SOP “(b)(4) Sanitization – Decontamination of rooms at Bulk Production” is misleading and the use of (b)(4) is not implemented as a routine decontamination process. You corrected the title to be “Disinfection of grade A and B areas within Bulk Production with (b)(4).” You state that you will collaborate with your vendor to perform a mapping study to verify the effectiveness of the disinfection process.\nYour response is inadequate. You do not provide evidence the (b)(4) decontamination process provides adequate surface coverage of all areas on the aseptic line, is compatible with materials, and ensures that residual (b)(4) that may remain on equipment does not affect product quality. Critical cleaning and sanitization agents must be validated. A mapping study is not validation of the disinfectant. Validation requires documented evidence that the disinfection process consistently removes or inactivates known or possible pathogens.\nB. Our investigators observed walls and floors of numerous ISO 8 production rooms were sticky and left visible (b)(4) residue when wiped by the hand. The investigators additionally noted fibers from disposable coveralls stuck to the walls in one of the production rooms. Such residual contamination can compromise product sterility and safety potentially resulting in patient harm.\nIn your response, you state that your Quality Control Microbiology (QCM) group discovered the sticky floors and walls (b)(4). Your deviation investigation concluded that the probable root causes were a build-up of new cleaning disinfectants and a possible interaction with materials in the facility. Your CAPA included wiping surfaces with (b)(4) after cleaning.\nYour response is inadequate. You did not provide the deviation investigation for the evaluation and identification of the (b)(4) residue and a risk assessment of contamination to the drug product. Furthermore, you did not provide an assessment of your cleaning validation with regard to the new cleaning agents.\nIn response to this letter, provide:\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include, but not be limited to, identification and evaluation of all worst-case:\no Drugs with higher toxicities\no Drugs with higher drug potencies\no Drugs of lower solubility in their cleaning solvents\no Drugs with characteristics that make them difficult to clean\no Swabbing locations for areas that are most difficult to clean\no Maximum hold times before cleaning\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n4. Your firm failed to maintain buildings used in the manufacture, processing, packing, or holding of drug products in a good state of repair (21 CFR 211.58).\nYour firm did not properly maintain classified areas and cleanrooms used in the manufacture of drug products. Our investigators observed peeling paint on the ceiling as well as bubbled paint and rust at the bottom of the door in ISO 7 room (b)(4). Room (b)(4) provides access into aseptic filling line (b)(4).\nThese deficiencies were discussed with your management at the time of the walk-through of the aseptic areas. Management stated the peeling paint surfaces above the (b)(4) door may be caused by the surface material being incompatible with the cleaning agent used to clean the production facility. It is critical that the building is maintained to prevent exposure of sterile articles to potential contamination hazards in the manufacturing operation.\nIn response to this letter, provide your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Rechon Life Science AB at Soldattorpsvagen 5, Limhamn, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3002806978 and ATTN: Erika V. Butler.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n___________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Rechon Life Science AB","rechon-life-science-ab-701040-04302025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frechon-life-science-ab-701040-04302025","2026-10-26T08:09:47.863026+00:00","2025-06-03","701040","Mr. Roland Holmqvist","2026-08-19T16:43:19.573+00:00","VIA EMAIL WITH READ RECEIPT","320-25-68","2025-04-30",{"id":161,"raw":162,"subject":166,"body_html":167,"body_text":168,"firm_name":169,"letter_id":170,"created_at":171,"fei_number":19,"letter_url":172,"updated_at":173,"action_type":22,"case_status":23,"posted_date":174,"marcs_cms_no":175,"product_type":176,"closeout_date":19,"issuing_office":57,"recipient_name":177,"body_fetched_at":178,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":179,"medical_device_id":19,"response_letter_date":19},21688,[163,164,165,57,166,13,13,13],"\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-01T04:00:00Z\">10\u002F01\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forganicare-llc-organicare-natures-science-llc-734925-10012026\">OrganiCare, LLC \u002F OrganiCare Nature’s Science, LLC\u003C\u002Fa>","Unapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Caroline Goodner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>OrganiCare, LLC \u002F OrganiCare Nature’s Science, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3900 Drossett Dr., Bldg 5, Suite G\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Austin\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>78744\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hello@femiclear.com\"> hello@femiclear.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 1, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference Number: 734925\u003C\u002Fp>\u003Cp>To Caroline Goodner:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Ffemiclear.com\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>As discussed below, the “HClear for him” and “FemiClear Genital Herpes Symptoms” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of your website https:\u002F\u002Ffemiclear.com\u002F in July 2026. We have also reviewed your Facebook and Instagram accounts at https:\u002F\u002Fwww.facebook.com\u002FFemiClear and \u003Ca href=\"https:\u002F\u002Fwww.instagram.com\u002Ffemiclear,\">https:\u002F\u002Fwww.instagram.com\u002Ffemiclear,\u003C\u002Fa> respectively, where you direct consumers to your https:\u002F\u002Ffemiclear.com\u002F website to purchase your products. Based on our review, “HClear for him” and “FemiClear Genital Herpes Symptoms” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an allinclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Based on a review of your website, “HClear for him” and “FemiClear Genital Herpes Symptoms” are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website and social media accounts, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>HClear for him\u003C\u002Fu>\u003Cbr>On the webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Fhclear-for-him-for-genital-herpes-symptoms-24-ea?selling_plan=3741548730:\u003C\u002Fp>\u003Cul>\u003Cli>On the image of the product\u003Cbr>o “&gt;90% OF USERS REPORTED LESS SEVERE OUTBREAKS”\u003Cbr>o “GENITAL HERPES SYMPTOMS”\u003Cbr>o “FAST-ACTING OUTBREAK SYMPTOM RELIEF ITCHING, TINGLING, PAIN &amp; BURNING”\u003C\u002Fli>\u003Cli>“Try the FemiClear topical ointment for men that kills 99.9% of the herpes simplex I &amp; II viruses”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On a September 10, 2024, post on your Facebook page https:\u002F\u002Fwww.facebook.com\u002FFemiClear\u002Fposts\u002Fpfbid02GZLSvy4rJUch7SvLwKcZbP8r5aAipKeCruw7qjkDnjKVLigQPhSu8i7CroLJf6cjl:\u003C\u002Fp>\u003Cul>\u003Cli>“Say goodbye to the discomfort of genital herpes symptoms with HClear for Him! This all-natural, organic ointment is designed specifically for men, targeting itching, tingling, and burning caused by herpes outbreaks. With a powerful formula that kills 99.9% of herpes simplex viruses (HSV1 &amp; HSV2), you can trust HClear to bring fast relief. Over 90% of users reported milder symptoms, and over 50% experienced no blisters when used at the first sign.”\u003C\u002Fli>\u003Cli>“Explore The Benefits HClear for Him for Genital Herpes Symptoms”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>FemiClear Genital Herpes Symptoms\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Ffemiclear-herpes-treatment-multi3symptom?selling_plan=3740434618:\u003C\u002Fp>\u003Cul>\u003Cli>On the image of the product\u003Cbr>o “Fast-acting ointment for recurring outbreak symptoms”\u003Cbr>o “&gt;90% OF USERS REPORTED LESS SEVERE OUTBREAKS”\u003C\u002Fli>\u003Cli>“Looking for genital herpes symptom relief? Try the FemiClear topical ointment that kills 99.9% of the herpes simplex I &amp; II viruses (HSV1 &amp; HSV2) and works fast to relieve Itching &amp; Tingling + Pain &amp; Burning symptoms caused by a herpes outbreak.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On a January 29, 2026, post on your Facebook page https:\u002F\u002Fwww.facebook.com\u002Fphoto.php?fbid=1343141094494950&amp;set=pb.100063972160769.-2207520000&amp;type=3:\u003C\u002Fp>\u003Cul>\u003Cli>On the image of the product\u003Cbr>o “GENITAL HERPES SYMPTOMS\u003Cbr>Fast-acting ointment for recurring outbreak symptoms”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>On an April 4, 2025, post on your Instagram page https:\u002F\u002Fwww.instagram.com\u002Fp\u002FDICmMYfOANa\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“Herpes Relief for Less”\u003C\u002Fli>\u003Cli>“Genital Herpes Symptoms”\u003C\u002Fli>\u003Cli>“We know managing outbreak symptoms can be tough. The last thing you need is a price tag standing between you and relief. That’s why we dropped the price of FemiClear for Genital Herpes Symptoms.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Additionally, your website contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the treatment of disease and\u002For to affect the structure or function of the body. Examples of such testimonials include, but are not limited to, the following from the Reviews section of the “FemiClear Genital Herpes Symptoms” product webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Ffemiclear-herpes-treatment-multisymptom?selling_plan=3740434618:\u003C\u002Fp>\u003Cul>\u003Cli>“Works like magic!\u003Cbr>I have had genital herpes for 35 years, and in the past 15 years, the outbreaks have been horrible and hard to get rid of. I won't take meds because they mess up my stomach. However, this ointment effectively eliminates the blisters within 24 hours. I have tried EVERYTHING, and this product truly works.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>“HClear for him” and “FemiClear Genital Herpes Symptoms” are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “734925” in the subject line of the email.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.fda.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We recognize that the “HClear for him” and “FemiClear Genital Herpes Symptoms” labeling describes the products as being “homeopathic.”\u003C\u002Fp>\u003Cp>First, we note that under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\u003C\u002Fp>\u003Cp>In addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States that potentially pose a higher risk to public health. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your products include lemongrass, which is not listed in the HPUS; thus, these products fall outside the scope of products addressed in this guidance.\u003C\u002Fp>\u003Cp>Notwithstanding, even if your above listed products were considered “homeopathic drug products\" under this guidance, these products would fall under the guidance’s category of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nCaroline Goodner\n\nRecipient Title\n\nChief Executive Officer\n\nOrganiCare, LLC \u002F OrganiCare Nature’s Science, LLC\n\n3900 Drossett Dr., Bldg 5, Suite G\n\nAustin, TX 78744\n\nUnited States\n\nhello@femiclear.com\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 1, 2026\nWARNING LETTER\nReference Number: 734925\nTo Caroline Goodner:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https:\u002F\u002Ffemiclear.com\u002F, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction.\nAs discussed below, the “HClear for him” and “FemiClear Genital Herpes Symptoms” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and\u002For their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional.\nFDA Review\nViolations were identified and documented during a review of your website https:\u002F\u002Ffemiclear.com\u002F in July 2026. We have also reviewed your Facebook and Instagram accounts at https:\u002F\u002Fwww.facebook.com\u002FFemiClear and https:\u002F\u002Fwww.instagram.com\u002Ffemiclear, respectively, where you direct consumers to your https:\u002F\u002Ffemiclear.com\u002F website to purchase your products. Based on our review, “HClear for him” and “FemiClear Genital Herpes Symptoms” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nThis review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an allinclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of your website, “HClear for him” and “FemiClear Genital Herpes Symptoms” are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including on your website and social media accounts, that provide evidence of the intended use (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nHClear for him\nOn the webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Fhclear-for-him-for-genital-herpes-symptoms-24-ea?selling_plan=3741548730:\nOn the image of the product\no “>90% OF USERS REPORTED LESS SEVERE OUTBREAKS”\no “GENITAL HERPES SYMPTOMS”\no “FAST-ACTING OUTBREAK SYMPTOM RELIEF ITCHING, TINGLING, PAIN & BURNING”\n“Try the FemiClear topical ointment for men that kills 99.9% of the herpes simplex I & II viruses”\nOn a September 10, 2024, post on your Facebook page https:\u002F\u002Fwww.facebook.com\u002FFemiClear\u002Fposts\u002Fpfbid02GZLSvy4rJUch7SvLwKcZbP8r5aAipKeCruw7qjkDnjKVLigQPhSu8i7CroLJf6cjl:\n“Say goodbye to the discomfort of genital herpes symptoms with HClear for Him! This all-natural, organic ointment is designed specifically for men, targeting itching, tingling, and burning caused by herpes outbreaks. With a powerful formula that kills 99.9% of herpes simplex viruses (HSV1 & HSV2), you can trust HClear to bring fast relief. Over 90% of users reported milder symptoms, and over 50% experienced no blisters when used at the first sign.”\n“Explore The Benefits HClear for Him for Genital Herpes Symptoms”\nFemiClear Genital Herpes Symptoms\nOn the webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Ffemiclear-herpes-treatment-multi3symptom?selling_plan=3740434618:\nOn the image of the product\no “Fast-acting ointment for recurring outbreak symptoms”\no “>90% OF USERS REPORTED LESS SEVERE OUTBREAKS”\n“Looking for genital herpes symptom relief? Try the FemiClear topical ointment that kills 99.9% of the herpes simplex I & II viruses (HSV1 & HSV2) and works fast to relieve Itching & Tingling + Pain & Burning symptoms caused by a herpes outbreak.”\nOn a January 29, 2026, post on your Facebook page https:\u002F\u002Fwww.facebook.com\u002Fphoto.php?fbid=1343141094494950&set=pb.100063972160769.-2207520000&type=3:\nOn the image of the product\no “GENITAL HERPES SYMPTOMS\nFast-acting ointment for recurring outbreak symptoms”\nOn an April 4, 2025, post on your Instagram page https:\u002F\u002Fwww.instagram.com\u002Fp\u002FDICmMYfOANa\u002F:\n“Herpes Relief for Less”\n“Genital Herpes Symptoms”\n“We know managing outbreak symptoms can be tough. The last thing you need is a price tag standing between you and relief. That’s why we dropped the price of FemiClear for Genital Herpes Symptoms.”\nAdditionally, your website contains evidence of intended use in the form of personal testimonials recommending or describing the use of your products for the treatment of disease and\u002For to affect the structure or function of the body. Examples of such testimonials include, but are not limited to, the following from the Reviews section of the “FemiClear Genital Herpes Symptoms” product webpage https:\u002F\u002Ffemiclear.com\u002Fproducts\u002Ffemiclear-herpes-treatment-multisymptom?selling_plan=3740434618:\n“Works like magic!\nI have had genital herpes for 35 years, and in the past 15 years, the outbreaks have been horrible and hard to get rid of. I won't take meds because they mess up my stomach. However, this ointment effectively eliminates the blisters within 24 hours. I have tried EVERYTHING, and this product truly works.”\n“HClear for him” and “FemiClear Genital Herpes Symptoms” are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products.1 Accordingly, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to FDAAdvisory@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. Identify your response with reference number “734925” in the subject line of the email.\nPlease note FDA posts warning letters on www.fda.gov.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n___________________\n1 We recognize that the “HClear for him” and “FemiClear Genital Herpes Symptoms” labeling describes the products as being “homeopathic.”\nFirst, we note that under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or FDA approval.\nIn addition, FDA issued a guidance in December 2022 that describes how the Agency intends to prioritize enforcement and regulatory actions for homeopathic drug products marketed in the United States that potentially pose a higher risk to public health. (See Homeopathic Drug Products: Guidance for FDA Staff and Industry, available at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F163755\u002Fdownload). For purposes of this guidance, FDA defines a “homeopathic drug product” as “a drug product that is labeled as ‘homeopathic,’ and is labeled as containing only active ingredients and dilutions (e.g., 10X, 20X) listed for those active ingredients in the Homeopathic Pharmacopeia of the United States (HPUS).” Your products include lemongrass, which is not listed in the HPUS; thus, these products fall outside the scope of products addressed in this guidance.\nNotwithstanding, even if your above listed products were considered “homeopathic drug products\" under this guidance, these products would fall under the guidance’s category of homeopathic drug products marketed without the required FDA approval that FDA views as potentially posing higher risks to public health, and thus intends to prioritize for enforcement and regulatory actions.","OrganiCare, LLC \u002F OrganiCare Nature’s Science, LLC","organicare-llc-organicare-natures-science-llc-734925-10012026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Forganicare-llc-organicare-natures-science-llc-734925-10012026","2026-11-17T01:02:03.701861+00:00","2026-10-06","734925","Drugs Over-the-Counter Drugs","Caroline Goodner","2026-10-14T12:33:25.038+00:00","2026-10-01",{"id":181,"raw":182,"subject":187,"body_html":188,"body_text":189,"firm_name":190,"letter_id":191,"created_at":192,"fei_number":19,"letter_url":193,"updated_at":194,"action_type":22,"case_status":23,"posted_date":195,"marcs_cms_no":196,"product_type":68,"closeout_date":19,"issuing_office":186,"recipient_name":197,"body_fetched_at":198,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":199,"medical_device_id":19,"response_letter_date":19},3326,[183,184,185,186,187,13,13,13],"\u003Ctime datetime=\"2021-05-28T14:00:00Z\">05\u002F28\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-05-27T04:00:00Z\">05\u002F27\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foclo-llcoclo-nanotechnology-science-614310-05272021\">OCLO LLC\u002FOCLO Nanotechnology Science\u003C\u002Fa>","Center for Drug Evaluation and Research","Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ricardo Garcia\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>OCLO LLC\u002FOCLO Nanotechnology Science\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>220 SW 9th Ave, #506\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hallandale\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33009\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:oclo@usa.com\"> oclo@usa.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n         \n          \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan> Federal Trade Commission\u003C\u002Fdd>\n\n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cb>\u003Cspan>WARNING LETTER\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>RE:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address \u003C\u002Fspan>\u003Cspan>https:\u002F\u002Fdioxidodecloro.us\u003C\u002Fspan> \u003Cspan>on April 15, 2021 and the Federal Trade Commission (FTC) reviewed the site as it appeared on that date. We also reviewed your social media website at https:\u002F\u002Ffacebook.com\u002FHallandale.Beach.2018\u002F where you direct consumers to your website, https:\u002F\u002Fdioxidodecloro.us, to purchase your products. Additionally, we reviewed your product listings on your eCrater storefront, which you operate under the name, OCLO. The FDA has observed that your website previously offered, and your eCrater storefront continues to offer, various chlorine dioxide products, including “OCLO 3000,” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa> in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&amp;C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&amp;C Act, 21 U.S.C. § 331(a) and (d).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003C\u002Fspan> \u003Cspan>Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Some examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Dióxido de Cloro . . . terapia alternativa efectiva contra el COVID-19, tratamiento de infecciones, algunas enfermedades autoinmunes y en terapias oxidativas para el fortalecimiento del sistema inmunológico.” “Chlorine Dioxide… effective alternative therapy against COVID-19, treatment of infections, some autoimmune diseases and oxidative therapies for strengthening the immune system.” (Translated) [from your eCrater storefront https:\u002F\u002Foclo.ecrater.com\u002Findex.php]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“El Dióxido de cloro en solución acuosa (CDS) es un potente agente oxidante antiséptico, que combate numerosas infecciones patógenas. Además, entre sus beneficios, fortalece el sistema inmune por oxigenación celular y se ha comprobado su eficacia en el tratamiento y prevención contra el actual CORONAVIRUS.” “Chlorine dioxide in aqueous solution (CDS) is a powerful antiseptic oxidizing agent, which fights numerous pathogenic infections. In addition, among its benefits, it strengthens the immune system by cellular oxygenation and its effectiveness in the treatment and prevention against the current CORONAVIRUS has been proven.” (Translated) [from your product listing on your eCrater storefront https:\u002F\u002Foclo.ecrater.com\u002Fp\u002F37646184\u002Fdioxido-de-cloro-cds-oclo-3000]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“OCLO 3000 (Gotero) – Immune Booster and Antiviral\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Dioxido de cloro (CDS) 3000 ppm \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>El dióxido de cloro en solución acuosa (CDS) es un potente agente oxigenante que potencia el sistema inmunológico además de resultar ser un antiseptico que permite eliminar un gran numero de patógenos. Esta solución puede ser utilizada para combatir un gran numero de infecciones virales incluyendo el COVID-19. “ \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“OCLO 3000 (Dropper) - Immune Booster and Antiviral\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Chlorine dioxide (CDS) 3000 ppm\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Chlorine dioxide in aqueous solution (CDS) is a powerful oxygenating agent that enhances the immune system as well as being an antiseptic that eliminates a large number of pathogens. This solution can be used to combat a large number of viral infections including COVID-19.” (Translated) [from your product listing on your eCrater storefront https:\u002F\u002Foclo.ecrater.com\u002Fp\u002F37864511\u002Fdixido-de-cloro-cds-oclo-3000]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Miles de personas se han utilizado el dióxido de cloro y se han recuperado de contagios provocados por los virus. Las autoridades sanitarias y gubernamentales demonizan este milagroso producto declarándolo como un peligroso desinfectante, confundiendo a las personas ignorantes de sus grandes beneficios. Este gas fácilmente soluble en agua en las concentraciones precisas puede combatir numerosos patógenos entre ellos, viruses y otros microorganismos dañinos a la salud.” “Thousands of people have used chlorine dioxide and have recovered from virus infections. Health and government officials demonize this miraculous product by declaring it a dangerous disinfectant, confusing ignorant people of its great benefits.&nbsp; This gas easily soluble in water at precise concentrations can combat numerous pathogens including viruses and other health-damaging microorganisms.” (Translated) This post provides a link to your webpage https:\u002F\u002Fdioxidodecloro.us [from a November 17, 2020 post on your Facebook social media webpage https:\u002F\u002Ffacebook.com\u002FHallandale.Beach.2018\u002F] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Some examples of the previous claims on your websites\u003C\u002Fspan>\u003Cspan> that established the intended use of your products and misleadingly represented them as safe and\u002For effective for the treatment or prevention of COVID-19 included: \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“B117…New variant of coronavirus, the most contagious and dangerous in the United States [,] Rescuing Chlorine Dioxide and its great curative potential against pathogens . . . OCLO Nanotechnology Science manufactures different products with chlorine dioxide in aqueous CDS solution, in order to combat numerous viruses and other pathogens, according to protocols established by the German scientist Dr. Andreas Kalcker as a result of his scientific research and extensive experience of (sic) practices. human clinics.” [from your webpage https:\u002F\u002Fdioxidodecloro.us, accessed April 15, 2021]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Scientific Results - Efficacy of Chlorine Dioxide\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Journal of Molecular Genetics Published March 8, 2021\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Determinación de la eficacia del dióxido de cloro en el tratamiento de COVID 19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Conclusion: El dióxido de cloro es eficaz en el tratamiento del COVID19 y en este trabajo se proponen los mecanismos de acción por los que actúa para conseguirlo” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Determination of the efficacy of chlorine dioxide in the treatment of COVID 19\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Conclusion: The chlorine dioxide is effective for the COVID19 treatment and this work proposes the mechanisms of action to achieve it.” (Translated) [from your webpage https:\u002F\u002Fdioxidodecloro.us, accessed April 15, 2021]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Antiviral efectivo . . . \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>El dióxido de cloro en su forma inicial como Mineral Miracle Solution (MMS) ha sido utilizado ampliamente y con una extraordinaria eficacia contra el virus de la malaria, que azota fuertemente algunos países del África. Recientemente fue permitido por las autoridades Bolivianas para ser utilizado en una gran parte de su población durante la pandemia del COVID-19, salvando numerosas vidas humanas . . .” \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Effective Antiviral . . .\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>The chlorine dioxide in its original form as Mineral Miracle Solution (MMS) has been used widely and with extraordinary efficacy against the malaria virus....and recently was permitted by the Bolivian authorities to be used in most of the country population during the COVID-19 pandemic, saving numerous human lives . . .” (Translated) [from your webpage https:\u002F\u002Fdioxidodecloro.us, accessed April 15, 2021]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Strong cellular oxygenating agent, could be used as an antiviral, antibacterial, in general disinfection, body detoxification killing pathogens and elimination of heavy metals.&nbsp; Add 15-20 drops to a glass of drinking water to prepare CSD 50 ppm” [from an image of your product label on your webpage https:\u002F\u002Fdioxidodecloro.us\u002Fproducts\u002Foclo-3000-dioxido-de-cloro-oral-gotas, accessed April 15, 2021]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\t\u003Cli>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>“Chlorine dioxide in aqueous solution (CDS) is a powerful oxygenating agent that enhances the immune system as well as being an antiseptic that eliminates a large number of pathogens. This solution can be used to combat a large number of viral infections including COVID-19 . . . \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Add 15 to 20 drops of the CDS solution to HALF GLASS of drinking water (120 mL) to obtain a solution of 25 to 30 ppm, a concentration indicated for human consumption safely.” [from your webpage https:\u002F\u002Fdioxidodecloro.us\u002Fproducts\u002Foclo-3000-dioxido-de-cloro-oral-gotas, accessed April 15, 2021\u003C\u002Fspan>\u003Cspan>] \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>We note that, as of the date of this letter, your internet website https:\u002F\u002Fdioxidodecloro.us has been removed\u003Cspan>\u003Cspan>\u003Cspan>. \u003C\u002Fspan>&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>Due to the serious public health concerns related to the marketing and sale of unapproved drugs for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, it is essential that these violations do not recur.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>You should take immediate action to address the violations cited in this letter.&nbsp; This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations.&nbsp; It is your responsibility to ensure that the products you sell are in compliance with the FD&amp;C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&amp;C Act\u003C\u002Fspan>\u003Cspan>. \u003Cb>Within 48 hours, please send an email to &nbsp;\u003C\u002Fb>\u003C\u002Fspan>\u003Ca href=\"mailto:COVID-19-Task-Force-CDER@fda.hhs.gov\">\u003Cb>\u003Cspan>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fb>\u003C\u002Fa>\u003Cb> \u003C\u002Fb>\u003Cspan>describing the specific steps you have taken to address these violations. &nbsp;Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation.&nbsp; \u003C\u002Fspan>\u003Cspan>Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19.&nbsp;Your firm will be added to a published list on \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan>FDA’s\u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>\u003Cspan> website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&amp;C Act.&nbsp;This list can be found at \u003C\u002Fspan>\u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\">\u003Cspan>http:\u002F\u002F\u003C\u002Fspan>\u003Cspan>www.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>\u003Cspan>. \u003C\u002Fspan>\u003C\u002Fspan>\u003Cspan>Once you have taken actions\u003C\u002Fspan>\u003Cspan> to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19,\u003C\u002Fspan>\u003Cspan> and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Please direct any inquiries to FDA at \u003C\u002Fspan>\u003Ca href=\"mailto:COVID-19-Task-Force-CDER@fda.hhs.gov\">\u003Cspan>COVID-19-Task-Force-CDER@fda.hhs.gov\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.&nbsp; &nbsp;&nbsp;\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>In addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above.&nbsp; Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims.&nbsp; Violations of the FTC Act may result in legal action seeking a Federal District Court injunction. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $43,792 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely, \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Donald D. Ashley\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Office of Compliance\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Center for Drug Evaluation and Research\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Food and Drug Administration\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Sincerely,\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u002FS\u002F\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Serena Viswanathan\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Associate Director\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Division of Advertising Practices&nbsp; \u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>Federal Trade Commission\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cdiv>\n\u003Chr>\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[1]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan> As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[2]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), \u003Ci>available at\u003C\u002Fi> \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">\u003Cspan>https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\u003Cdiv>\n\u003Cp>\u003Cspan>\u003Cspan>\u003Cspan>\u003Ca>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>\u003Cspan>[3]\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), \u003Ci>available at\u003C\u002Fi> \u003C\u002Fspan>\u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">\u003Cspan>https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fspan>\u003C\u002Fa>\u003Cspan>.\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fspan>\u003C\u002Fp>\n\u003C\u002Fdiv>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRicardo Garcia\n\nOCLO LLC\u002FOCLO Nanotechnology Science\n\n220 SW 9th Ave, #506\n\nHallandale, FL 33009\n\nUnited States\n\noclo@usa.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research\n\nUnited States\n\nFederal Trade Commission\n\nWARNING LETTER\n\nRE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fdioxidodecloro.us on April 15, 2021 and the Federal Trade Commission (FTC) reviewed the site as it appeared on that date. We also reviewed your social media website at https:\u002F\u002Ffacebook.com\u002FHallandale.Beach.2018\u002F where you direct consumers to your website, https:\u002F\u002Fdioxidodecloro.us, to purchase your products. Additionally, we reviewed your product listings on your eCrater storefront, which you operate under the name, OCLO. The FDA has observed that your website previously offered, and your eCrater storefront continues to offer, various chlorine dioxide products, including “OCLO 3000,” for sale in the United States and that these products are intended to mitigate, prevent, treat, diagnose, or cure COVID-19[1] in people. Based on our review, these products are unapproved new drugs sold in violation of section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a). Furthermore, these products are misbranded drugs under section 502 of the FD&C Act, 21 U.S.C. § 352. The introduction or delivery for introduction of these products into interstate commerce is prohibited under sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d).\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.[2] In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.[3] Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described below, you sell products that are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nSome examples of the claims on your website that establish the intended use of your products and misleadingly represent them as safe and\u002For effective for the treatment or prevention of COVID-19 include:\n\n“Dióxido de Cloro . . . terapia alternativa efectiva contra el COVID-19, tratamiento de infecciones, algunas enfermedades autoinmunes y en terapias oxidativas para el fortalecimiento del sistema inmunológico.” “Chlorine Dioxide… effective alternative therapy against COVID-19, treatment of infections, some autoimmune diseases and oxidative therapies for strengthening the immune system.” (Translated) [from your eCrater storefront https:\u002F\u002Foclo.ecrater.com\u002Findex.php]\n\n“El Dióxido de cloro en solución acuosa (CDS) es un potente agente oxidante antiséptico, que combate numerosas infecciones patógenas. Además, entre sus beneficios, fortalece el sistema inmune por oxigenación celular y se ha comprobado su eficacia en el tratamiento y prevención contra el actual CORONAVIRUS.” “Chlorine dioxide in aqueous solution (CDS) is a powerful antiseptic oxidizing agent, which fights numerous pathogenic infections. In addition, among its benefits, it strengthens the immune system by cellular oxygenation and its effectiveness in the treatment and prevention against the current CORONAVIRUS has been proven.” (Translated) [from your product listing on your eCrater storefront https:\u002F\u002Foclo.ecrater.com\u002Fp\u002F37646184\u002Fdioxido-de-cloro-cds-oclo-3000]\n\n“OCLO 3000 (Gotero) – Immune Booster and Antiviral\n\nDioxido de cloro (CDS) 3000 ppm\n\nEl dióxido de cloro en solución acuosa (CDS) es un potente agente oxigenante que potencia el sistema inmunológico además de resultar ser un antiseptico que permite eliminar un gran numero de patógenos. Esta solución puede ser utilizada para combatir un gran numero de infecciones virales incluyendo el COVID-19. “\n\n“OCLO 3000 (Dropper) - Immune Booster and Antiviral\n\nChlorine dioxide (CDS) 3000 ppm\n\nChlorine dioxide in aqueous solution (CDS) is a powerful oxygenating agent that enhances the immune system as well as being an antiseptic that eliminates a large number of pathogens. This solution can be used to combat a large number of viral infections including COVID-19.” (Translated) [from your product listing on your eCrater storefront https:\u002F\u002Foclo.ecrater.com\u002Fp\u002F37864511\u002Fdixido-de-cloro-cds-oclo-3000]\n\n“Miles de personas se han utilizado el dióxido de cloro y se han recuperado de contagios provocados por los virus. Las autoridades sanitarias y gubernamentales demonizan este milagroso producto declarándolo como un peligroso desinfectante, confundiendo a las personas ignorantes de sus grandes beneficios. Este gas fácilmente soluble en agua en las concentraciones precisas puede combatir numerosos patógenos entre ellos, viruses y otros microorganismos dañinos a la salud.” “Thousands of people have used chlorine dioxide and have recovered from virus infections. Health and government officials demonize this miraculous product by declaring it a dangerous disinfectant, confusing ignorant people of its great benefits. This gas easily soluble in water at precise concentrations can combat numerous pathogens including viruses and other health-damaging microorganisms.” (Translated) This post provides a link to your webpage https:\u002F\u002Fdioxidodecloro.us [from a November 17, 2020 post on your Facebook social media webpage https:\u002F\u002Ffacebook.com\u002FHallandale.Beach.2018\u002F]\n\nSome examples of the previous claims on your websites that established the intended use of your products and misleadingly represented them as safe and\u002For effective for the treatment or prevention of COVID-19 included:\n\n“B117…New variant of coronavirus, the most contagious and dangerous in the United States [,] Rescuing Chlorine Dioxide and its great curative potential against pathogens . . . OCLO Nanotechnology Science manufactures different products with chlorine dioxide in aqueous CDS solution, in order to combat numerous viruses and other pathogens, according to protocols established by the German scientist Dr. Andreas Kalcker as a result of his scientific research and extensive experience of (sic) practices. human clinics.” [from your webpage https:\u002F\u002Fdioxidodecloro.us, accessed April 15, 2021]\n\n“Scientific Results - Efficacy of Chlorine Dioxide\n\nJournal of Molecular Genetics Published March 8, 2021\n\nDeterminación de la eficacia del dióxido de cloro en el tratamiento de COVID 19\n\nConclusion: El dióxido de cloro es eficaz en el tratamiento del COVID19 y en este trabajo se proponen los mecanismos de acción por los que actúa para conseguirlo”\n\n“Determination of the efficacy of chlorine dioxide in the treatment of COVID 19\n\nConclusion: The chlorine dioxide is effective for the COVID19 treatment and this work proposes the mechanisms of action to achieve it.” (Translated) [from your webpage https:\u002F\u002Fdioxidodecloro.us, accessed April 15, 2021]\n\n“Antiviral efectivo . . .\n\nEl dióxido de cloro en su forma inicial como Mineral Miracle Solution (MMS) ha sido utilizado ampliamente y con una extraordinaria eficacia contra el virus de la malaria, que azota fuertemente algunos países del África. Recientemente fue permitido por las autoridades Bolivianas para ser utilizado en una gran parte de su población durante la pandemia del COVID-19, salvando numerosas vidas humanas . . .”\n\n“Effective Antiviral . . .\n\nThe chlorine dioxide in its original form as Mineral Miracle Solution (MMS) has been used widely and with extraordinary efficacy against the malaria virus....and recently was permitted by the Bolivian authorities to be used in most of the country population during the COVID-19 pandemic, saving numerous human lives . . .” (Translated) [from your webpage https:\u002F\u002Fdioxidodecloro.us, accessed April 15, 2021]\n\n“Strong cellular oxygenating agent, could be used as an antiviral, antibacterial, in general disinfection, body detoxification killing pathogens and elimination of heavy metals. Add 15-20 drops to a glass of drinking water to prepare CSD 50 ppm” [from an image of your product label on your webpage https:\u002F\u002Fdioxidodecloro.us\u002Fproducts\u002Foclo-3000-dioxido-de-cloro-oral-gotas, accessed April 15, 2021]\n\n“Chlorine dioxide in aqueous solution (CDS) is a powerful oxygenating agent that enhances the immune system as well as being an antiseptic that eliminates a large number of pathogens. This solution can be used to combat a large number of viral infections including COVID-19 . . .\n\nAdd 15 to 20 drops of the CDS solution to HALF GLASS of drinking water (120 mL) to obtain a solution of 25 to 30 ppm, a concentration indicated for human consumption safely.” [from your webpage https:\u002F\u002Fdioxidodecloro.us\u002Fproducts\u002Foclo-3000-dioxido-de-cloro-oral-gotas, accessed April 15, 2021]\n\nWe note that, as of the date of this letter, your internet website https:\u002F\u002Fdioxidodecloro.us has been removed. Due to the serious public health concerns related to the marketing and sale of unapproved drugs for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, it is essential that these violations do not recur.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the FD&C Act and FDA's implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and effective for a COVID-19-related use for which they have not been approved by FDA and that you do not make claims that misbrand the products in violation of the FD&C Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and\u002For effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA’s website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at http:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-covid-19-products. Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your product(s) referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDER@fda.hhs.gov.\n\nIn addition, it is unlawful under the FTC Act, 15 U.S.C. 41 et seq., to advertise that a product can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. For COVID-19, no such study is currently known to exist for the products identified above. Thus, any coronavirus-related prevention or treatment claims regarding such products are not supported by competent and reliable scientific evidence. You must immediately cease making all such claims. Violations of the FTC Act may result in legal action seeking a Federal District Court injunction. In addition, pursuant to the COVID-19 Consumer Protection Act, Section 1401, Division FF, of the Consolidated Appropriations Act, 2021, P.L. 116-260, marketers who make deceptive claims about the treatment, cure, prevention, or mitigation of COVID-19 are subject to a civil penalty of up to $43,792 per violation and may be required to pay refunds to consumers or provide other relief pursuant to Section 19(b) of the FTC Act, 15 U.S.C. § 57b(b). Within 48 hours, please send an email to Richard Cleland, Assistant Director of the FTC’s Division of Advertising Practices, via electronic mail at rcleland@ftc.gov describing the specific actions you have taken to address the FTC’s concerns. If you have any questions regarding compliance with the FTC Act, please contact Mr. Cleland at 202-326-3088.\n\nSincerely,\n\n\u002FS\u002F\n\nDonald D. Ashley\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nSincerely,\n\n\u002FS\u002F\n\nSerena Viswanathan\n\nAssociate Director\n\nDivision of Advertising Practices\n\nFederal Trade Commission\n\n[1] As explained in the next paragraph, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n[2] Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n[3] Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","OCLO LLC\u002FOCLO Nanotechnology Science","oclo-llcoclo-nanotechnology-science-614310-05272021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Foclo-llcoclo-nanotechnology-science-614310-05272021","2026-10-26T08:09:37.000934+00:00","2021-05-28","614310","Ricardo Garcia","2026-08-20T03:06:00.433+00:00","2021-05-27",{"id":201,"raw":202,"subject":205,"body_html":206,"body_text":207,"firm_name":208,"letter_id":209,"created_at":132,"fei_number":19,"letter_url":210,"updated_at":211,"action_type":22,"case_status":23,"posted_date":135,"marcs_cms_no":212,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":213,"body_fetched_at":214,"delivery_method":215,"recipient_title":19,"reference_number":216,"action_taken_date":217,"medical_device_id":19,"response_letter_date":19},364,[123,203,204,57,205,13,13,13],"\u003Ctime datetime=\"2026-01-13T05:00:00Z\">01\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcenter-immunology-science-llc-719933-01132026\">Center For Immunology Science, LLC\u003C\u002Fa>","Sponsor\u002FInvestigator","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-01-02\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Bruce S. Gillis, M.D., MPH\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Center For Immunology Science, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2109 Granville Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Los Angeles\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90025-6105\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 26-HFD-45-01-02\u003C\u002Fp>\u003Cp>Dear Dr. Gillis:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between October 7 and November 20, 2024. The investigator representing FDA reviewed the role of the Center for Immunology Science, LLC (Center for Immunology Science) as the sponsor of a clinical investigation (Protocol CISMX-001\u002FCISMX-001B,\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> “Use of Heat-Killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem> as a nutritional supplement\u002Fbiotic to boost immune system and microbiome health”) of the investigational drug, heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA Investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your November 27, 2024, written response to the Form FDA 483.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated November 27, 2024, it appears that the Center for Immunology Science did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312), governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>You failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA regulations require a sponsor to submit, and to have in effect, an IND before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) [see 21 CFR 312.20 and 312.40(a)] in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The Center for Immunology Science failed to comply with these requirements. Specifically, the Center for Immunology Science initiated and conducted Protocol CISMX-001, a clinical investigation of the investigational drug, heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem>, subject to section 505 of the FD&amp;C Act [21 U.S.C. 355], without submitting and having in effect an IND.\u003C\u002Fp>\u003Cp>In the Center for Immunology Science’s November 27, 2024, written response to the Form FDA 483, you stated that an IND is only required for a drug product. You further stated that under the Dietary Supplement Health and Education Act of 1994 (DSHEA), a dietary supplement is not considered a drug and is not subject to the premarket approval requirements for drugs if the intended use for which it is marketed is only to affect the structure or any function of the body. You also stated that whether an IND is needed for a clinical investigation evaluating a dietary supplement is determined by the intent of the clinical investigation, noting that if the clinical investigation is intended only to evaluate a dietary supplement’s effect on the structure or function of the body, an IND is not required. You stated that since the protocol describes heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem> as a nutritional supplement\u002Fbiotic intended to boost immune system and microbiome health, an IND was not required.\u003C\u002Fp>\u003Cp>For the reasons described below, we conclude that the evidence collected during the inspection shows that heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem> was intended for use as a drug, not as a dietary supplement, for the clinical investigation conducted under Protocol CISMX-001. Therefore, the Center for Immunology Science was required to submit an IND before initiating and conducting the clinical investigation.\u003C\u002Fp>\u003Cp>Section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)] defines drug, in part, as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease….” The Center for Immunology Science studied the efficacy of heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem> to treat or mitigate immune-deficiency diseases. As described in the protocol, the purpose of Protocol CISMX-001 was to determine if subjects with an immune-deficiency disease can benefit from taking heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem>. The protocol stated that \u003Cem>Mycobacteria smegmatis\u003C\u002Fem> has immune-modulating effects that can stimulate or suppress the immune system and may help the body fight cancer, infection, or other diseases. Protocol CISMX-001 also states that information from the study may be used to produce an over-the counter product to boost immune system and microbiome health that may help reduce symptoms associated with an immune-deficiency medical disease. Additionally, outcome assessments for the study, performed after the administration of heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem>, included weekly health questionnaires to evaluate changes in, or the frequency and severity of, subject-reported symptoms, including but not limited to fatigue, pain or tenderness, depression, anxiety, insomnia, headaches, abdominal pain, and respiratory problems. Therefore, Protocol CISMX-001 collected study data to assess the efficacy of heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem> in treating or mitigating the symptoms associated with immune-deficiency diseases.\u003C\u002Fp>\u003Cp>Whether an investigational article is a drug depends on the intent of the investigation. Based on the study design of Protocol CISMX-001, the investigational product, heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem>, as used in the clinical investigation, was a drug as defined in section 201(g)(1) of the FD&amp;C Act, because heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem> was studied for use in the treatment of immune-deficiency diseases.\u003C\u002Fp>\u003Cp>Thus, before initiating the clinical investigation of heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem> conducted under Protocol CISMX-001, under 21 CFR 312.40, the Center for Immunology Science was required to submit an IND to FDA and to have an IND in effect. FDA’s records indicate that the Center for Immunology Science failed to submit an IND before conducting Protocol CISMX-001, in which 200 human subjects received investigational drug.\u003C\u002Fp>\u003Cp>In your November 27, 2024, written response, you stated that the Center for Immunology Science is prepared to comply with all future obligations. However, your written response does not provide sufficient details about the Center for Immunology Science’s corrective and preventive action plan for developing and implementing procedures to comply with IND regulations, if the Center for Immunology Science should decide in the future to initiate another clinical investigation for which an IND is required. As a result, your response is inadequate. Without this information, we are unable to determine whether the Center for Immunology Science will comply with IND regulations in the future.\u003C\u002Fp>\u003Cp>As a sponsor, you are responsible for complying with IND requirements, which include submitting and having in effect an IND before initiating a clinical investigation. It is also your responsibility, as a sponsor, to be aware of and to follow all applicable FDA regulations. The Center for Immunology Science’s failure to submit, and to have in effect, an IND before initiating Protocol CISMX-001 with an investigational drug raises significant concerns about the safety and welfare of enrolled subjects, and raises concerns about the validity and integrity of data collected during the conduct of this clinical investigation.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Should you have any questions or concerns regarding this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\u003Cp>Brittany L. Garr, MPH\u003Cbr>Branch Chief\u003Cbr>Compliance Enforcement Branch\u003Cbr>Division of Enforcement and Postmarketing Safety\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003Cbr>Building 51, Room 5352\u003Cbr>10903 New Hampshire Avenue\u003Cbr>Silver Spring, MD 20993\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Protocol CISMX-001B was conducted in healthy human subjects.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Protocol CISMX-001 does not qualify for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312. To be IND-exempt under 21 CFR 312.2, the investigational product must, among other things, be lawfully marketed in the United States as a drug product. As stated in your November 27, 2024, written response, heat-killed \u003Cem>Mycobacteria smegmatis\u003C\u002Fem> is marketed as a dietary supplement, not as a drug product.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-01-02\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nBruce S. Gillis, M.D., MPH\n\nRecipient Title\n\nCEO\n\nCenter For Immunology Science, LLC\n\n2109 Granville Avenue\n\nLos Angeles, CA 90025-6105\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 26-HFD-45-01-02\nDear Dr. Gillis:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between October 7 and November 20, 2024. The investigator representing FDA reviewed the role of the Center for Immunology Science, LLC (Center for Immunology Science) as the sponsor of a clinical investigation (Protocol CISMX-001\u002FCISMX-001B,1 “Use of Heat-Killed Mycobacteria smegmatis as a nutritional supplement\u002Fbiotic to boost immune system and microbiome health”) of the investigational drug, heat-killed Mycobacteria smegmatis.\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\nAt the conclusion of the inspection, the FDA Investigator presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your November 27, 2024, written response to the Form FDA 483.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written response dated November 27, 2024, it appears that the Center for Immunology Science did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in Title 21 of the Code of Federal Regulations, part 312 (21 CFR 312), governing the conduct of clinical investigations and the protection of human subjects. We wish to emphasize the following:\nYou failed to submit an Investigational New Drug application (IND) for the conduct of a clinical investigation with an investigational new drug that is subject to 21 CFR 312.2(a) [21 CFR 312.20(a), 312.20(b), and 312.40(a)].\nFDA regulations require a sponsor to submit, and to have in effect, an IND before initiating a clinical investigation of a drug that is subject to 21 CFR 312.2(a) [see 21 CFR 312.20 and 312.40(a)] in human subjects, unless the clinical investigation qualifies for an IND exemption under 21 CFR 312.2.2 The Center for Immunology Science failed to comply with these requirements. Specifically, the Center for Immunology Science initiated and conducted Protocol CISMX-001, a clinical investigation of the investigational drug, heat-killed Mycobacteria smegmatis, subject to section 505 of the FD&C Act [21 U.S.C. 355], without submitting and having in effect an IND.\nIn the Center for Immunology Science’s November 27, 2024, written response to the Form FDA 483, you stated that an IND is only required for a drug product. You further stated that under the Dietary Supplement Health and Education Act of 1994 (DSHEA), a dietary supplement is not considered a drug and is not subject to the premarket approval requirements for drugs if the intended use for which it is marketed is only to affect the structure or any function of the body. You also stated that whether an IND is needed for a clinical investigation evaluating a dietary supplement is determined by the intent of the clinical investigation, noting that if the clinical investigation is intended only to evaluate a dietary supplement’s effect on the structure or function of the body, an IND is not required. You stated that since the protocol describes heat-killed Mycobacteria smegmatis as a nutritional supplement\u002Fbiotic intended to boost immune system and microbiome health, an IND was not required.\nFor the reasons described below, we conclude that the evidence collected during the inspection shows that heat-killed Mycobacteria smegmatis was intended for use as a drug, not as a dietary supplement, for the clinical investigation conducted under Protocol CISMX-001. Therefore, the Center for Immunology Science was required to submit an IND before initiating and conducting the clinical investigation.\nSection 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)] defines drug, in part, as “articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease….” The Center for Immunology Science studied the efficacy of heat-killed Mycobacteria smegmatis to treat or mitigate immune-deficiency diseases. As described in the protocol, the purpose of Protocol CISMX-001 was to determine if subjects with an immune-deficiency disease can benefit from taking heat-killed Mycobacteria smegmatis. The protocol stated that Mycobacteria smegmatis has immune-modulating effects that can stimulate or suppress the immune system and may help the body fight cancer, infection, or other diseases. Protocol CISMX-001 also states that information from the study may be used to produce an over-the counter product to boost immune system and microbiome health that may help reduce symptoms associated with an immune-deficiency medical disease. Additionally, outcome assessments for the study, performed after the administration of heat-killed Mycobacteria smegmatis, included weekly health questionnaires to evaluate changes in, or the frequency and severity of, subject-reported symptoms, including but not limited to fatigue, pain or tenderness, depression, anxiety, insomnia, headaches, abdominal pain, and respiratory problems. Therefore, Protocol CISMX-001 collected study data to assess the efficacy of heat-killed Mycobacteria smegmatis in treating or mitigating the symptoms associated with immune-deficiency diseases.\nWhether an investigational article is a drug depends on the intent of the investigation. Based on the study design of Protocol CISMX-001, the investigational product, heat-killed Mycobacteria smegmatis, as used in the clinical investigation, was a drug as defined in section 201(g)(1) of the FD&C Act, because heat-killed Mycobacteria smegmatis was studied for use in the treatment of immune-deficiency diseases.\nThus, before initiating the clinical investigation of heat-killed Mycobacteria smegmatis conducted under Protocol CISMX-001, under 21 CFR 312.40, the Center for Immunology Science was required to submit an IND to FDA and to have an IND in effect. FDA’s records indicate that the Center for Immunology Science failed to submit an IND before conducting Protocol CISMX-001, in which 200 human subjects received investigational drug.\nIn your November 27, 2024, written response, you stated that the Center for Immunology Science is prepared to comply with all future obligations. However, your written response does not provide sufficient details about the Center for Immunology Science’s corrective and preventive action plan for developing and implementing procedures to comply with IND regulations, if the Center for Immunology Science should decide in the future to initiate another clinical investigation for which an IND is required. As a result, your response is inadequate. Without this information, we are unable to determine whether the Center for Immunology Science will comply with IND regulations in the future.\nAs a sponsor, you are responsible for complying with IND requirements, which include submitting and having in effect an IND before initiating a clinical investigation. It is also your responsibility, as a sponsor, to be aware of and to follow all applicable FDA regulations. The Center for Immunology Science’s failure to submit, and to have in effect, an IND before initiating Protocol CISMX-001 with an investigational drug raises significant concerns about the safety and welfare of enrolled subjects, and raises concerns about the validity and integrity of data collected during the conduct of this clinical investigation.\nThis letter is not intended to be an all-inclusive list of deficiencies with your clinical study of an investigational drug. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nShould you have any questions or concerns regarding this letter or the inspection, please email FDA at CDER-OSI-Communications@fda.hhs.gov. Your written response and any pertinent documentation should be addressed to:\nBrittany L. Garr, MPH\nBranch Chief\nCompliance Enforcement Branch\nDivision of Enforcement and Postmarketing Safety\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nBuilding 51, Room 5352\n10903 New Hampshire Avenue\nSilver Spring, MD 20993\nSincerely yours,\n\u002FS\u002F\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n___________________\n1 Protocol CISMX-001B was conducted in healthy human subjects.\n2 Protocol CISMX-001 does not qualify for any of the exemptions listed at 21 CFR 312.2 from the application of 21 CFR 312. To be IND-exempt under 21 CFR 312.2, the investigational product must, among other things, be lawfully marketed in the United States as a drug product. As stated in your November 27, 2024, written response, heat-killed Mycobacteria smegmatis is marketed as a dietary supplement, not as a drug product.","Center For Immunology Science, LLC","center-immunology-science-llc-719933-01132026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcenter-immunology-science-llc-719933-01132026","2026-10-26T08:08:12.789102+00:00","719933","Bruce S. Gillis, M.D., MPH","2026-08-19T07:16:30.364+00:00","VIA UNITED PARCEL SERVICE AND VIA E-MAIL","26-HFD-45-01-02","2026-01-13",{"id":219,"raw":220,"subject":104,"body_html":225,"body_text":226,"firm_name":227,"letter_id":228,"created_at":86,"fei_number":19,"letter_url":229,"updated_at":230,"action_type":22,"case_status":23,"posted_date":231,"marcs_cms_no":232,"product_type":68,"closeout_date":19,"issuing_office":233,"recipient_name":234,"body_fetched_at":235,"delivery_method":236,"recipient_title":19,"reference_number":19,"action_taken_date":237,"medical_device_id":19,"response_letter_date":19},2157,[221,222,223,224,104,13,13,13],"\u003Ctime datetime=\"2023-03-21T13:20:00Z\">03\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-10T05:00:00Z\">03\u002F10\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmetic-science-laboratories-llc-645558-03102023\">Cosmetic Science Laboratories LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations IV","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Claudio A. Neustadt\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u002FChemist\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cosmetic Science Laboratories LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2908 Oregon Court, Suite I-6\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Torrance\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90503-2637\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations IV\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>March 10, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Neustadt:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration inspected your drug manufacturing facility, Cosmetic Science Laboratories LLC, FEI 3001697625, at 2908 Oregon Court, in Torrance, California, from September 6 to September 20, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, under section 510 of the Food Drug and Cosmetics Act (FD&amp;C Act) and under part 207 of Title 21 of the Code of Federal Regulations (CFR), owners or operators of drug manufacturing establishments are required to register their establishments with the FDA. Registrants are also required to list each drug manufactured at their establishment(s) intended for commercial distribution and to submit updated drug listing information to the FDA twice each year, in June and December, notifying the FDA if this information has changed.\u003C\u002Fp>\n\n\u003Cp>Upon the mentioned inspection, it was determined that your firm has been manufacturing 4-IN-1 Broad Spectrum SPF 50 Sunscreen (NDC 73561-001-01), Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-100-01), Oil Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-101-01), and SPF-30 \u003Cstrong>(b)(4)\u003C\u002Fstrong>. To date, the FDA has not received updated registration submission from Cosmetic Science Laboratories LLC, nor has it received a drug listing submission for the above-mentioned product SPF-30 \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cbr>\n\u003Cbr>\nWe reviewed your October 5, 2022 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to test your incoming active pharmaceutical ingredients (APIs) for identity prior to manufacturing your bulk over-the-counter (OTC) drug products, including SPF-50 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Sunscreen. Additionally, you relied on certificates of analysis (COAs) from your suppliers to use incoming APIs without establishing the reliability of the specifications and characteristics of each supplier’s COAs.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>Identity testing for each component lot used in drug product manufacturing is required, and you may only rely on certificates of analysis (COAs) for other component attributes by validating the suppliers’ test results at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess. Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.100 (a) and 21 CFR211.188).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Process Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm did not provide process validation documents for your contract manufactured over-the-counter (OTC) bulk drug products. During the inspection, you failed to provide your protocols, reports, or data to support that each OTC drug product met predetermined quality requirements consistently and reliably.\u003C\u002Fp>\n\n\u003Cp>You also failed to provide detailed process performance qualification (PPQ) protocols for the validation of your different OTC drug product manufacturing processes.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established.\u003C\u002Fp>\n\n\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Batch Production Records\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm lacked adequate batch records. You did not include specific information such as equipment identification and process parameters that demonstrate control in the manufacture of your bulk drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm could not provide investigators with evidence that you have performed cleaning validation and equipment qualification.\u003Cbr>\n\u003Cbr>\nYou manufacture drug products using the same equipment that you use to manufacture nonpharmaceutical products such as cosmetics. Chemical and microbiological residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\u003C\u002Fp>\n\n\u003Cp>Additionally, you lacked cleaning logs and usage logs for kettles and mixers used in compounding your bulk drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Water System\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water as a component to manufacture your drug products that are released for distribution to U.S. consumers. You did not establish that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system you use to manufacture your drug product is adequately designed, controlled, maintained, and monitored to ensure that it consistently produces water suitable for its intended use.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\n\t\u003Cli>A timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\u003C\u002Fli>\n\t\u003Cli>Include your process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\n\t\u003Cli>Provide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\n\t\u003Cli>Your master production and control records for your drug products, to demonstrate that they fully document each significant and validated manufacturing step.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your manufacturing operations, to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices, to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o&nbsp; &nbsp; drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o&nbsp; &nbsp; drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o&nbsp; &nbsp; drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o&nbsp; &nbsp; drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o&nbsp; &nbsp; swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o&nbsp; &nbsp; maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\t\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> water, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. In an affidavit dated September 20, 2022, you stated that you could not provide documents related to several CGMP activities such as, out-of-specification (OOS) results, non-conformances, deviations and investigations, annual product review, and CGMP training.\u003C\u002Fp>\n\n\u003Cp>In addition, you used \u003Cstrong>(b)(4)\u003C\u002Fstrong> hold-time studies to support a \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration date for bulk drug products, such as your SPF-30 Daily Protect Sunscreen. These \u003Cstrong>(b)(4)\u003C\u002Fstrong> hold-time studies do not support a \u003Cstrong>(b)(4)\u003C\u002Fstrong> hold time for bulk drug products. You have not determined the impact these inadequate hold-time studies may have had on the stability and quality attributes of your bulk drug products. Additionally, customers may rely on these claims to establish \u003Cstrong>(b)(4)\u003C\u002Fstrong> expiration dates on finished drug products.\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o&nbsp; &nbsp; A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o&nbsp; &nbsp; Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o&nbsp; &nbsp; A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o&nbsp; &nbsp; Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Registration and listing violations:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has been manufacturing 4-IN-1 Broad Spectrum SPF 50 Sunscreen (NDC 73561-001-01), Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-100-01), Oil Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-101-01), and SPF-30 \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Under section 510(i)(1) of the FD&amp;C Act (21 U.S.C. 360(i)(1)) Cosmetic Science Laboratories LLC is required to submit registration information annually by electronic means for each establishment it owns or operates that is engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is in commercial distribution in the United States. Under section 510 of the FD&amp;C Act as amended and 21 CFR (21 U.S.C. 360(j)(1), 21 CFR 207.17 and 207.41), all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with the FDA. You have failed to fulfill your establishment registration obligations as required under section 510 of the FD&amp;C Act, which is prohibited under section 301(p), 21 U.S.C 360 and 331(p). In addition, your firm, Cosmetic Science Laboratories LLC, failed to fulfill its listing obligations under section 510(j) of the FD&amp;C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). Failure to properly list a drug with the FDA also renders it misbranded under section 502(o) of the FD&amp;C Act, and in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 352(o) and 331(a).\u003C\u002Fp>\n\n\u003Cp>As a result, the drugs 4-IN-1 Broad Spectrum SPF 50 Sunscreen (NDC 73561-001-01), Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-100-01), Oil Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-101-01), and SPF-30 \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are misbranded under section 502(o) of the FD&amp;C Act, 21 U.S.C. 352(o).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease production of drugs at this facility and that you deregistered your facility as a drug manufacturer. As of March 7, 2023, your firm’s website, https:\u002F\u002Fwww.cosmeticsciencelabs.com\u002Four-services\u002F, continues to advertise your services as a drug contract manufacturer. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility in the future. If you plan to resume manufacturing drugs, notify this office before resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with the FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. The FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. The FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\u003C\u002Fp>\n\n\u003Cp>CDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003Cbr>\nU.S. Food &amp; Drug Administration\u003Cbr>\n19701 Fairchild Road\u003Cbr>\nIrvine, California 92612-2506\u003C\u002Fp>\n\n\u003Cp>Please identify your responses with the unique identifier: \u003Cstrong>CMS 645558\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Andrew Haack, compliance officer by telephone at 206-340-8212 or email at Andrew.Haack@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCDR Steven E. Porter, Jr.\u003Cbr>\nDirector, Division of Pharmaceutical Quality Operations IV\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Claudio A. Neustadt\n\nRecipient Title\n\nPresident\u002FChemist\n\nCosmetic Science Laboratories LLC\n\n2908 Oregon Court, Suite I-6\n\nTorrance, CA 90503-2637\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations IV\n\nUnited States\n\nWARNING LETTER\n\nMarch 10, 2023\n\nDear Mr. Neustadt:\n\nThe U.S. Food and Drug Administration inspected your drug manufacturing facility, Cosmetic Science Laboratories LLC, FEI 3001697625, at 2908 Oregon Court, in Torrance, California, from September 6 to September 20, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, under section 510 of the Food Drug and Cosmetics Act (FD&C Act) and under part 207 of Title 21 of the Code of Federal Regulations (CFR), owners or operators of drug manufacturing establishments are required to register their establishments with the FDA. Registrants are also required to list each drug manufactured at their establishment(s) intended for commercial distribution and to submit updated drug listing information to the FDA twice each year, in June and December, notifying the FDA if this information has changed.\n\nUpon the mentioned inspection, it was determined that your firm has been manufacturing 4-IN-1 Broad Spectrum SPF 50 Sunscreen (NDC 73561-001-01), Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-100-01), Oil Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-101-01), and SPF-30 (b)(4). To date, the FDA has not received updated registration submission from Cosmetic Science Laboratories LLC, nor has it received a drug listing submission for the above-mentioned product SPF-30 (b)(4).\n\nWe reviewed your October 5, 2022 response to our Form FDA 483 in detail. Your response is inadequate because it did not provide sufficient detail or evidence of corrective actions to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYou failed to test your incoming active pharmaceutical ingredients (APIs) for identity prior to manufacturing your bulk over-the-counter (OTC) drug products, including SPF-50 (b)(4) Sunscreen. Additionally, you relied on certificates of analysis (COAs) from your suppliers to use incoming APIs without establishing the reliability of the specifications and characteristics of each supplier’s COAs.\n\nYour response is inadequate.\n\nIdentity testing for each component lot used in drug product manufacturing is required, and you may only rely on certificates of analysis (COAs) for other component attributes by validating the suppliers’ test results at appropriate intervals.\n\nIn response to this letter, provide the following:\n\nA comprehensive review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s Certificates of Analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess. Your firm also failed to prepare batch production and control records with complete information relating to the production and control of each batch of drug product produced (21 CFR 211.100 (a) and 21 CFR211.188).\n\nProcess Validation\n\nYour firm did not provide process validation documents for your contract manufactured over-the-counter (OTC) bulk drug products. During the inspection, you failed to provide your protocols, reports, or data to support that each OTC drug product met predetermined quality requirements consistently and reliably.\n\nYou also failed to provide detailed process performance qualification (PPQ) protocols for the validation of your different OTC drug product manufacturing processes.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established.\n\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\n\nSee FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\nBatch Production Records\n\nYour firm lacked adequate batch records. You did not include specific information such as equipment identification and process parameters that demonstrate control in the manufacture of your bulk drug products.\n\nCleaning Validation\n\nDuring the inspection, your firm could not provide investigators with evidence that you have performed cleaning validation and equipment qualification.\n\nYou manufacture drug products using the same equipment that you use to manufacture nonpharmaceutical products such as cosmetics. Chemical and microbiological residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\n\nAdditionally, you lacked cleaning logs and usage logs for kettles and mixers used in compounding your bulk drug products.\n\n(b)(4) Water System\n\nYour firm uses (b)(4) Water as a component to manufacture your drug products that are released for distribution to U.S. consumers. You did not establish that the (b)(4) Water system you use to manufacture your drug product is adequately designed, controlled, maintained, and monitored to ensure that it consistently produces water suitable for its intended use.\n\n(b)(4) water must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes.\n\nYour response is inadequate.\n\nIn response to this letter, provide the following:\n\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification, and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\n\nA timeline for performing appropriate process performance qualification (PPQ) for each of your marketed drug products.\n\nInclude your process performance protocol(s), and written procedures for qualification of equipment and facilities.\n\nProvide a detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\n\nYour master production and control records for your drug products, to demonstrate that they fully document each significant and validated manufacturing step.\n\nA complete assessment of documentation systems used throughout your manufacturing operations, to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices, to ensure you retain attributable, legible, complete, original, accurate, and contemporaneous records throughout your operation.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no drugs with higher toxicities\n\no drugs with higher drug potencies\n\no drugs of lower solubility in their cleaning solvents\n\no drugs with characteristics that make them difficult to clean\n\no swabbing locations for areas that are most difficult to clean\n\no maximum hold times before cleaning\n\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\n\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces water that meets (b)(4) water, USP monograph specifications and appropriate microbial limits.\n\n3. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your OTC drug products. In an affidavit dated September 20, 2022, you stated that you could not provide documents related to several CGMP activities such as, out-of-specification (OOS) results, non-conformances, deviations and investigations, annual product review, and CGMP training.\n\nIn addition, you used (b)(4) hold-time studies to support a (b)(4) expiration date for bulk drug products, such as your SPF-30 Daily Protect Sunscreen. These (b)(4) hold-time studies do not support a (b)(4) hold time for bulk drug products. You have not determined the impact these inadequate hold-time studies may have had on the stability and quality attributes of your bulk drug products. Additionally, customers may rely on these claims to establish (b)(4) expiration dates on finished drug products.\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nYour response is inadequate.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nRegistration and listing violations:\n\nYour firm has been manufacturing 4-IN-1 Broad Spectrum SPF 50 Sunscreen (NDC 73561-001-01), Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-100-01), Oil Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-101-01), and SPF-30 (b)(4).\n\nUnder section 510(i)(1) of the FD&C Act (21 U.S.C. 360(i)(1)) Cosmetic Science Laboratories LLC is required to submit registration information annually by electronic means for each establishment it owns or operates that is engaged in the manufacture, preparation, propagation, compounding, or processing of a drug that is in commercial distribution in the United States. Under section 510 of the FD&C Act as amended and 21 CFR (21 U.S.C. 360(j)(1), 21 CFR 207.17 and 207.41), all drugs manufactured, prepared, propagated, compounded, or processed for U.S. commercial distribution must be listed with the FDA. You have failed to fulfill your establishment registration obligations as required under section 510 of the FD&C Act, which is prohibited under section 301(p), 21 U.S.C 360 and 331(p). In addition, your firm, Cosmetic Science Laboratories LLC, failed to fulfill its listing obligations under section 510(j) of the FD&C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). Failure to properly list a drug with the FDA also renders it misbranded under section 502(o) of the FD&C Act, and in violation of section 301(a) of the FD&C Act, 21 U.S.C. 352(o) and 331(a).\n\nAs a result, the drugs 4-IN-1 Broad Spectrum SPF 50 Sunscreen (NDC 73561-001-01), Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-100-01), Oil Daily Protect Sunscreen Moisturizer Broad Spectrum SPF 30 (NDC 73561-101-01), and SPF-30 (b)(4), are misbranded under section 502(o) of the FD&C Act, 21 U.S.C. 352(o).\n\nDrug Production Ceased\n\nWe acknowledge your commitment to cease production of drugs at this facility and that you deregistered your facility as a drug manufacturer. As of March 7, 2023, your firm’s website, https:\u002F\u002Fwww.cosmeticsciencelabs.com\u002Four-services\u002F, continues to advertise your services as a drug contract manufacturer. In response to this letter, clarify whether you intend to resume manufacturing any drugs at this facility in the future. If you plan to resume manufacturing drugs, notify this office before resuming your operations.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive audit of your entire operation for CGMP compliance and evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with the FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. The FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. The FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause the FDA to withhold issuance of Export Certificates. The FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease send your electronic reply to ORAPHARM4_Responses@FDA.HHS.GOV or mail your reply to:\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV\n\nU.S. Food & Drug Administration\n\n19701 Fairchild Road\n\nIrvine, California 92612-2506\n\nPlease identify your responses with the unique identifier: CMS 645558\n\nIf you have questions regarding the contents of this letter, please contact Andrew Haack, compliance officer by telephone at 206-340-8212 or email at Andrew.Haack@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Steven E. Porter, Jr.\n\nDirector, Division of Pharmaceutical Quality Operations IV","Cosmetic Science Laboratories LLC","cosmetic-science-laboratories-llc-645558-03102023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmetic-science-laboratories-llc-645558-03102023","2026-10-26T08:08:18.460106+00:00","2023-03-21","645558","Division of Pharmaceutical Quality Operations IV","Mr. Claudio A. Neustadt","2026-08-20T01:11:10.23+00:00","Via Email","2023-03-10",{"id":239,"raw":240,"subject":127,"body_html":244,"body_text":245,"firm_name":246,"letter_id":247,"created_at":192,"fei_number":19,"letter_url":248,"updated_at":249,"action_type":22,"case_status":23,"posted_date":250,"marcs_cms_no":251,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":252,"body_fetched_at":253,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":254,"medical_device_id":19,"response_letter_date":19},3206,[241,242,243,11,127,13,13,13],"\u003Ctime datetime=\"2021-08-17T13:20:00Z\">08\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-17T04:00:00Z\">06\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-bolang-science-technology-development-co-ltd-614851-06172021\">Tianjin Bolang Science-Technology Development Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Lin Qi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tianjin Bolang Science-Technology Development Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>D-401, Hi-Tech Green Industrial Base\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Huayuan Industrial Area\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Shi\u003C\u002Fspan>, \u003Cspan>300384\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nJune 17, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Qi:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Tianjin, China on March 22, 2021, through March 30, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Otoscopes, Rigid Laryngoscopes, and Rigid Nasopharyngoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from Mr. Zhang Li, Management Representative, dated April 19, 2021, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address your response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). For example, your firm has not established Design Control procedures for your firm’s private label manufactured endoscopic medical devices for the U.S. market, including the Class II Rigid Nasopharyngoscope. In addition, your firm did not conduct Design and Development activities for the Rigid Nasopharyngoscope. The activities not conducted include: Design Input, Design Output, Design Review, Design Verification, Design Validation, Design Transfer, Design Changes, and Design History File.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm identified its plan to establish a Design Control procedure according to 21 CFR 820.30, as well as establish a Design History File for products intended for distribution in the U.S. However, until your firm establishes Design Control procedures and a Design History File and provides a copy to the Agency for review, the adequacy of the response cannot be determined.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, your firm has not established procedures for corrective and preventive action (CAPAs) and did not conduct any CAPAs. Your firm has also not established a system for the identification and input of quality data which may require corrective and\u002For preventive action.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm described its plan to revise the Improved Control procedures to meet requirements of 21 CFR 820.100. Also, your firm identified a planned retrospective review of quality data for the previous two years, performing corrective and preventive measures as needed. The response is not adequate because your firm did not provide details such as processes, work operations, quality records and other quality data to be analyzed. Since the investigator was not able to review and inspect production and process controls, procedures and records, FDA has no assurance quality data exists in order to perform a retrospective review. Additionally, the response does not describe how the CAPA procedure will be maintained and implemented.\u003C\u002Fp>\n\n\u003Cp>3. Failure to maintain complaint files and to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, your firm has not established customer complaint handling procedures to ensure it is receiving complaints from its sole U.S. distributor, Ecleris. This U.S. distributor is marketing your firm’s manufactured, private label, Rigid Nasopharyngoscope. Also, your firm does not have a written agreement with its U.S. distributor requiring all complaints be provided for review and evaluation.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm indicated plans to update Measurement and Analysis of Customer Information Feedback Control procedures as required by 21 CFR 820.198 and to evaluate MDR reportable events as required by 21 CFR 803. However, during the inspection, complaint procedure and complaint records were not available for review. Therefore, a review of the procedures needs to be conducted in order to ensure it meets the requirements of 21 CFR 820.198 and details on how complaints will be retrospectively collected from customers, needs to be provided.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for control and distribution of finished devices to ensure that only those devices approved for release are distributed and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution, as required by 21 CFR 820.160. For example, your firm has not established procedures for the control and distribution of its private label manufactured endoscopic medical devices for the U.S. market including the Rigid Nasopharyngoscope to ensure only those devices approved for release are distributed.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm states that its customer related Process Control procedures will be revised to meet the requirements of 21 CFR 820.160. According to your firm, these revised procedures will include distribution requirements for product intended for the U.S. The response is not adequate because your firm has not identified a plan to establish and maintain procedures for the control and distribution of finished devices intended for the U.S.\u003C\u002Fp>\n\n\u003Cp>5. Failure to maintain device master records (DMR's) and to ensure that each DMR is prepared and approved in accordance with 21 CFR 820.40, as required by 21 CFR 820.181. For example, your firm has not maintained Device Master Records (DMR’s) for its private label manufactured endoscopic medical devices intended for the U.S. market, including the Rigid Nasopharyngoscope.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm stated that DMR Control procedures will be established in accordance with 21 CFR 820.181. The adequacy of the response cannot be determined until your firm establishes and maintains DMR Control procedures as required by 21 CFR 820.181, and provides a copy of the procedure to the Agency for review.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain procedures to ensure that device history records (DHR’s) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record (DMR) and the requirements of this part, as required by 21 CFR 820.184. For example, your firm has not established DHR procedures to ensure DHRs are maintained for each device batch, lot, or unit. Your firm also has not demonstrated DHRs are maintained for manufactured devices in accordance with specifications, including its private label Rigid Nasopharyngoscope.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm states that DHR control procedures will be established to meet the requirements of 21 CFR 820.184. Until your firm establishes and maintains a DHR to demonstrate its device is manufactured in accordance with the device DMR as required by 21 CFR 820.184, and provides a copy of the procedures to the Agency for review, the adequacy of the response cannot be determined.\u003C\u002Fp>\n\n\u003Cp>7. Failure to maintain a quality system record (QSR) which includes, or refers to the location of, procedures and the documentation of activities required by this part that are not specific to a particular type of device(s), including, but not limited to, the records required by 21 CFR 820.20, as required by 21 CFR 820.186. For example, your firm ’s Quality System does not include, or refer to the location of procedures and the documentation of activities required by the Quality System regulation. During the inspection, certain procedures and documentation of the organizational structure were not available for review.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm indicated its Quality System will be revised to include: 21 CFR 820; 21 CFR 803; 21 CFR 806; and 21 CFR 807. Revision of the Quality Manual and related procedures will also occur according to your firm. Until your firm establishes and maintains a Quality System and Quality Manual procedures as required by 21 CFR 820.186, and provides a copy of the procedures to the Agency for review, the adequacy of the response cannot be determined.\u003C\u002Fp>\n\n\u003Cp>8. Failure to have sufficient personnel with the necessary education, background, training, and experience to assure that all activities required by this part are correctly performed, as required by 21 CFR 820.25(a). For example, your firm has not demonstrated it had any prior knowledge of U.S. FDA regulations and requirements including 21 CFR Part 820 - Quality System regulation.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your firm described the completion of employee training for 21 CFR 820; 21 CFR 803, 21 CFR 807, 21 CFR 806 and 21 CFR 830. Until your firm can demonstrate adequate employee training for all personnel, related to its Quality System as required by 21 CFR 820.25, and provides a copy of the training for Agency review, the adequacy of the response cannot be determined.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s Class II Rigid Nasopharyngoscope devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>&nbsp; &nbsp; Failure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and conclude that it is not adequate. Your firm states MDR Control procedures will be established, and a complaint retrospective review will be conducted for MDR reportable events. However, the response does not include how the electronic submission of MDR reportable events to the Agency will occur. Until your firm develops, maintains, and implements written MDR procedures as required by 21 CFR 803.17, and provides a copy of the procedures for Agency review, the response is not adequate.\u003C\u002Fp>\n\n\u003Cp>Given the serious nature of the violations of the Act, Otoscopes, Rigid Laryngoscopes, and Rigid Nasopharyngoscopes manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review.\u003C\u002Fp>\n\n\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #614851 when replying. If you have any questions about the contents of this letter, please contact Shu-Chen Peng, Ph.D. at (301) 796-6481.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>for Malvina Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT 1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Lin Qi\n\nRecipient Title\n\nGeneral Manager\n\nTianjin Bolang Science-Technology Development Co., Ltd.\n\nD-401, Hi-Tech Green Industrial Base\n\nHuayuan Industrial Area\n\nTianjin Shi, 300384\n\nChina\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nJune 17, 2021\n\nDear Mr. Qi:\n\nDuring an inspection of your firm located in Tianjin, China on March 22, 2021, through March 30, 2021, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Otoscopes, Rigid Laryngoscopes, and Rigid Nasopharyngoscopes. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from Mr. Zhang Li, Management Representative, dated April 19, 2021, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address your response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a). For example, your firm has not established Design Control procedures for your firm’s private label manufactured endoscopic medical devices for the U.S. market, including the Class II Rigid Nasopharyngoscope. In addition, your firm did not conduct Design and Development activities for the Rigid Nasopharyngoscope. The activities not conducted include: Design Input, Design Output, Design Review, Design Verification, Design Validation, Design Transfer, Design Changes, and Design History File.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm identified its plan to establish a Design Control procedure according to 21 CFR 820.30, as well as establish a Design History File for products intended for distribution in the U.S. However, until your firm establishes Design Control procedures and a Design History File and provides a copy to the Agency for review, the adequacy of the response cannot be determined.\n\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, your firm has not established procedures for corrective and preventive action (CAPAs) and did not conduct any CAPAs. Your firm has also not established a system for the identification and input of quality data which may require corrective and\u002For preventive action.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm described its plan to revise the Improved Control procedures to meet requirements of 21 CFR 820.100. Also, your firm identified a planned retrospective review of quality data for the previous two years, performing corrective and preventive measures as needed. The response is not adequate because your firm did not provide details such as processes, work operations, quality records and other quality data to be analyzed. Since the investigator was not able to review and inspect production and process controls, procedures and records, FDA has no assurance quality data exists in order to perform a retrospective review. Additionally, the response does not describe how the CAPA procedure will be maintained and implemented.\n\n3. Failure to maintain complaint files and to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). For example, your firm has not established customer complaint handling procedures to ensure it is receiving complaints from its sole U.S. distributor, Ecleris. This U.S. distributor is marketing your firm’s manufactured, private label, Rigid Nasopharyngoscope. Also, your firm does not have a written agreement with its U.S. distributor requiring all complaints be provided for review and evaluation.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm indicated plans to update Measurement and Analysis of Customer Information Feedback Control procedures as required by 21 CFR 820.198 and to evaluate MDR reportable events as required by 21 CFR 803. However, during the inspection, complaint procedure and complaint records were not available for review. Therefore, a review of the procedures needs to be conducted in order to ensure it meets the requirements of 21 CFR 820.198 and details on how complaints will be retrospectively collected from customers, needs to be provided.\n\n4. Failure to establish and maintain procedures for control and distribution of finished devices to ensure that only those devices approved for release are distributed and that purchase orders are reviewed to ensure that ambiguities and errors are resolved before devices are released for distribution, as required by 21 CFR 820.160. For example, your firm has not established procedures for the control and distribution of its private label manufactured endoscopic medical devices for the U.S. market including the Rigid Nasopharyngoscope to ensure only those devices approved for release are distributed.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm states that its customer related Process Control procedures will be revised to meet the requirements of 21 CFR 820.160. According to your firm, these revised procedures will include distribution requirements for product intended for the U.S. The response is not adequate because your firm has not identified a plan to establish and maintain procedures for the control and distribution of finished devices intended for the U.S.\n\n5. Failure to maintain device master records (DMR's) and to ensure that each DMR is prepared and approved in accordance with 21 CFR 820.40, as required by 21 CFR 820.181. For example, your firm has not maintained Device Master Records (DMR’s) for its private label manufactured endoscopic medical devices intended for the U.S. market, including the Rigid Nasopharyngoscope.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm stated that DMR Control procedures will be established in accordance with 21 CFR 820.181. The adequacy of the response cannot be determined until your firm establishes and maintains DMR Control procedures as required by 21 CFR 820.181, and provides a copy of the procedure to the Agency for review.\n\n6. Failure to establish and maintain procedures to ensure that device history records (DHR’s) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record (DMR) and the requirements of this part, as required by 21 CFR 820.184. For example, your firm has not established DHR procedures to ensure DHRs are maintained for each device batch, lot, or unit. Your firm also has not demonstrated DHRs are maintained for manufactured devices in accordance with specifications, including its private label Rigid Nasopharyngoscope.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm states that DHR control procedures will be established to meet the requirements of 21 CFR 820.184. Until your firm establishes and maintains a DHR to demonstrate its device is manufactured in accordance with the device DMR as required by 21 CFR 820.184, and provides a copy of the procedures to the Agency for review, the adequacy of the response cannot be determined.\n\n7. Failure to maintain a quality system record (QSR) which includes, or refers to the location of, procedures and the documentation of activities required by this part that are not specific to a particular type of device(s), including, but not limited to, the records required by 21 CFR 820.20, as required by 21 CFR 820.186. For example, your firm ’s Quality System does not include, or refer to the location of procedures and the documentation of activities required by the Quality System regulation. During the inspection, certain procedures and documentation of the organizational structure were not available for review.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm indicated its Quality System will be revised to include: 21 CFR 820; 21 CFR 803; 21 CFR 806; and 21 CFR 807. Revision of the Quality Manual and related procedures will also occur according to your firm. Until your firm establishes and maintains a Quality System and Quality Manual procedures as required by 21 CFR 820.186, and provides a copy of the procedures to the Agency for review, the adequacy of the response cannot be determined.\n\n8. Failure to have sufficient personnel with the necessary education, background, training, and experience to assure that all activities required by this part are correctly performed, as required by 21 CFR 820.25(a). For example, your firm has not demonstrated it had any prior knowledge of U.S. FDA regulations and requirements including 21 CFR Part 820 - Quality System regulation.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your firm described the completion of employee training for 21 CFR 820; 21 CFR 803, 21 CFR 807, 21 CFR 806 and 21 CFR 830. Until your firm can demonstrate adequate employee training for all personnel, related to its Quality System as required by 21 CFR 820.25, and provides a copy of the training for Agency review, the adequacy of the response cannot be determined.\n\nOur inspection also revealed that your firm’s Class II Rigid Nasopharyngoscope devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant violations include, but are not limited to, the following:\n\nFailure to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17.\n\nWe reviewed your firm’s response and conclude that it is not adequate. Your firm states MDR Control procedures will be established, and a complaint retrospective review will be conducted for MDR reportable events. However, the response does not include how the electronic submission of MDR reportable events to the Agency will occur. Until your firm develops, maintains, and implements written MDR procedures as required by 21 CFR 803.17, and provides a copy of the procedures for Agency review, the response is not adequate.\n\nGiven the serious nature of the violations of the Act, Otoscopes, Rigid Laryngoscopes, and Rigid Nasopharyngoscopes manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are addressed. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and address the violations described in this letter. We will notify you regarding the adequacy of your firm’s responses and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review.\n\nIf you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent by email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #614851 when replying. If you have any questions about the contents of this letter, please contact Shu-Chen Peng, Ph.D. at (301) 796-6481.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nfor Malvina Eydelman, M.D.\n\nDirector\n\nOHT 1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Tianjin Bolang Science-Technology Development Co., Ltd.","tianjin-bolang-science-technology-development-co-ltd-614851-06172021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-bolang-science-technology-development-co-ltd-614851-06172021","2026-10-26T08:10:12.112649+00:00","2021-08-17","614851","Mr. Lin Qi","2026-08-20T02:41:21.596+00:00","2021-06-17",{"id":256,"raw":257,"subject":104,"body_html":261,"body_text":262,"firm_name":263,"letter_id":264,"created_at":132,"fei_number":19,"letter_url":265,"updated_at":266,"action_type":22,"case_status":23,"posted_date":267,"marcs_cms_no":268,"product_type":176,"closeout_date":19,"issuing_office":57,"recipient_name":269,"body_fetched_at":270,"delivery_method":236,"recipient_title":19,"reference_number":271,"action_taken_date":272,"medical_device_id":19,"response_letter_date":19},486,[258,259,260,57,104,13,13,13],"\u003Ctime datetime=\"2025-11-11T05:00:00Z\">11\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-09T04:00:00Z\">10\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftaizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025\">Taizhou Kangping Medical Science and Technology Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Yuegen Wang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Taizhou Kangping Medical Science and Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Building 3, No 27 Tai’an Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hailing Industrial Park\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hailing Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Taizhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>, \u003Cspan>225300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-26-01\u003C\u002Fp>\u003Cp>October 9, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Wang:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Taizhou Kangping Medical Science and Technology Co., Ltd., FEI 3013321339, at Building 3, No 27 Tai’an Road, Hailing Industrial Park, Taizhou City, Jiangsu, China 225300, from March 10 to March 14, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 4, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because you failed to take corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish procedures designed to prevent micro-contamination in products purporting to be sterile (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are labeled as “\u003Cem>Sterile unless\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not sterilized, which you confirmed in your response on May 10, 2025: “… \u003Cstrong>(b)(4)\u003C\u002Fstrong>… is \u003Cem>Nonsterile product\u003C\u002Fem> ....” Sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> may be used by healthcare practitioners as a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>, if labeled as sterile, must have controls in place to ensure sterility. The inspection documented that you do not perform sterility testing of the drug product, and that the Specification and Analysis Method on \u003Cstrong>(b)(4)\u003C\u002Fstrong> tests the Finished Product Quality Standards to Microbial Limits USP &lt;61&gt; method, with acceptance criteria of ≤\u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fgram of total aerobic bacteria and ≤\u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fgram of mold, yeast.\u003C\u002Fp>\u003Cp>Drugs purported to be sterile must comply with applicable 21 CFR 211 CGMP requirements (including sterility assurance).\u003C\u002Fp>\u003Cp>On July 16, 2025, FDA held a teleconference with you and your U.S. agent. We acknowledge your decision to initiate a recall of all your \u003Cstrong>(b)(4)\u003C\u002Fstrong> within expiry currently in distribution to the U.S. market.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish appropriate product specifications and scientifically sound testing procedures (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A. Your high-performance liquid chromatography (HPLC) analyses for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Assay Content lacked an appropriate determination of system suitability, as outlined in USP &lt;621&gt;, before sample injections. Your quality approved test method, Quality Specification and Operating Procedures for Testing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is not scientifically sound in that your Quality Control (QC) analysts are instructed to generate a chromatographic standard curve “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” This method of calculation from the standard curve has the practical effect of masking system drift and performance issues that affect the quantitative accuracy of batch-specific test results, because the frequency is conducted “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>In your response, you commit to revising the frequency of establishing a standard curve (linear solution test) from “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to “\u003Cem>at the same time with each sample test\u003C\u002Fem>.” However, your response is inadequate because you have not committed to ensuring that standard curves (linear solution tests) performed “\u003Cem>at the same time with each sample test\u003C\u002Fem>” are extended to include gas chromatography (GC), which is used to determine \u003Cstrong>(b)(4)\u003C\u002Fstrong> Assay Content.\u003C\u002Fp>\u003Cp>B. Your firm lacked sufficient controls over GC and HPLC data acquisition systems that are used to test assay label claims for drug products before release. Specifically, Excel worksheets used to perform chromatogram calculations were not retained, and access accounts to the GC and HPLC workstations were shared by job title and were not attributable to the individual analyst. The inspection documented the deletion of several recent Excel spreadsheets that were used to perform suitability and assay calculations. Your QC Supervisor\u002FManager confirmed that the Excel spreadsheets that were relied upon to generate the finished product quality standards, had not been validated, controlled, retained, or quality verified for data integrity before they were used for product release. Further, this individual was the only analyst who performed testing, yet maintained administrative privileges within the system. When further questioned on this practice, the QC Supervisor\u002FManager identified that the administrative role was the only primary access point to the Gas Chromatography data acquisition software for OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> product release and stability testing.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP-compliant data integrity practices, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity, and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan (CAPA). The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm, including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Product Specifications\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Upon further review of the records and information you provided, process controls for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> appear to be inconsistent with the applicable conditions for an OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> formulated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> as an active ingredient. For OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products marketed under 505G of the FD&amp;C Act, such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the allowable concentration for the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong>%-\u003Cstrong>(b)(4)\u003C\u002Fstrong>%. However, throughout the product lifecycle for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your operations seem to far exceed the allowable concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> as indicated in your process validation. For example, your Specification and Analysis Method allows for the release of products with concentrations of \u003Cstrong>(b)(4)\u003C\u002Fstrong> up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. In addition, your 2024 Annual Quality Review and 2023 Process Validation summary of Critical Quality Attributes reports also include concentrations of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that are well above what is allowed with values detected at \u003Cstrong>(b)(4)\u003C\u002Fstrong>-\u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Although your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are labeled with \u003Cstrong>(b)(4)\u003C\u002Fstrong> at a concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, as noted, your operations and process controls appear to deviate from the proposed conditions and requirements for an OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. For consistent regulatory compliance it is essential that OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> products like your \u003Cstrong>(b)(4)\u003C\u002Fstrong> conform to the applicable FDA requirements and OTC monograph conditions for the lawful distribution of this OTC drug product without an approved application.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your written responses to date commit to cease the commercial distribution of OTC products in the U.S. market starting March 14, 2025. If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On July 16, 2025, FDA held a teleconference with you and your U.S. agent, during which you committed to the recall of all your \u003Cstrong>(b)(4)\u003C\u002Fstrong> within expiry currently in distribution to the U.S. market.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on September 18, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA’s continuing to refuse admission of articles manufactured at Taizhou Kangping Medical Science and Technology Co., Ltd., located at Building 3, No 27 Tai’an Road, Hailing Industrial Park, Taizhou City, Jiangsu, China 225300, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013321339 and ATTN: Kara S. Quinn.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-26-01\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Yuegen Wang\n\nRecipient Title\n\nGeneral Manager\n\nTaizhou Kangping Medical Science and Technology Co., Ltd.\n\nBuilding 3, No 27 Tai’an Road\n\nHailing Industrial Park\n\nHailing Qu\n\nTaizhou Shi\n\nJiangsu Sheng, 225300\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-01\nOctober 9, 2025\nDear Mr. Wang:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Taizhou Kangping Medical Science and Technology Co., Ltd., FEI 3013321339, at Building 3, No 27 Tai’an Road, Hailing Industrial Park, Taizhou City, Jiangsu, China 225300, from March 10 to March 14, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 4, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because you failed to take corrective actions to bring your operations into compliance with CGMP.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following:\n1. Failure to establish procedures designed to prevent micro-contamination in products purporting to be sterile (21 CFR 211.113(b)).\nYour (b)(4) are labeled as “Sterile unless (b)(4).” However, your (b)(4) are not sterilized, which you confirmed in your response on May 10, 2025: “… (b)(4)… is Nonsterile product ....” Sterile (b)(4) may be used by healthcare practitioners as a (b)(4). Sterile (b)(4), if labeled as sterile, must have controls in place to ensure sterility. The inspection documented that you do not perform sterility testing of the drug product, and that the Specification and Analysis Method on (b)(4) tests the Finished Product Quality Standards to Microbial Limits USP \u003C61> method, with acceptance criteria of ≤(b)(4) cfu\u002Fgram of total aerobic bacteria and ≤(b)(4) cfu\u002Fgram of mold, yeast.\nDrugs purported to be sterile must comply with applicable 21 CFR 211 CGMP requirements (including sterility assurance).\nOn July 16, 2025, FDA held a teleconference with you and your U.S. agent. We acknowledge your decision to initiate a recall of all your (b)(4) within expiry currently in distribution to the U.S. market.\n2. Failure to establish appropriate product specifications and scientifically sound testing procedures (21 CFR 211.160(b)).\nA. Your high-performance liquid chromatography (HPLC) analyses for (b)(4) Assay Content lacked an appropriate determination of system suitability, as outlined in USP \u003C621>, before sample injections. Your quality approved test method, Quality Specification and Operating Procedures for Testing (b)(4), is not scientifically sound in that your Quality Control (QC) analysts are instructed to generate a chromatographic standard curve “(b)(4).” This method of calculation from the standard curve has the practical effect of masking system drift and performance issues that affect the quantitative accuracy of batch-specific test results, because the frequency is conducted “(b)(4).”\nIn your response, you commit to revising the frequency of establishing a standard curve (linear solution test) from “(b)(4)” to “at the same time with each sample test.” However, your response is inadequate because you have not committed to ensuring that standard curves (linear solution tests) performed “at the same time with each sample test” are extended to include gas chromatography (GC), which is used to determine (b)(4) Assay Content.\nB. Your firm lacked sufficient controls over GC and HPLC data acquisition systems that are used to test assay label claims for drug products before release. Specifically, Excel worksheets used to perform chromatogram calculations were not retained, and access accounts to the GC and HPLC workstations were shared by job title and were not attributable to the individual analyst. The inspection documented the deletion of several recent Excel spreadsheets that were used to perform suitability and assay calculations. Your QC Supervisor\u002FManager confirmed that the Excel spreadsheets that were relied upon to generate the finished product quality standards, had not been validated, controlled, retained, or quality verified for data integrity before they were used for product release. Further, this individual was the only analyst who performed testing, yet maintained administrative privileges within the system. When further questioned on this practice, the QC Supervisor\u002FManager identified that the administrative role was the only primary access point to the Gas Chromatography data acquisition software for OTC (b)(4) product release and stability testing.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP-compliant data integrity practices, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity, and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan (CAPA). The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm, including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\nProduct Specifications\nUpon further review of the records and information you provided, process controls for the (b)(4) appear to be inconsistent with the applicable conditions for an OTC (b)(4) formulated with (b)(4) as an active ingredient. For OTC (b)(4) drug products marketed under 505G of the FD&C Act, such as the (b)(4), the allowable concentration for the active ingredient (b)(4) is (b)(4)%-(b)(4)%. However, throughout the product lifecycle for the (b)(4), your operations seem to far exceed the allowable concentration of (b)(4) as indicated in your process validation. For example, your Specification and Analysis Method allows for the release of products with concentrations of (b)(4) up to (b)(4)%. In addition, your 2024 Annual Quality Review and 2023 Process Validation summary of Critical Quality Attributes reports also include concentrations of (b)(4) that are well above what is allowed with values detected at (b)(4)-(b)(4)%. Although your (b)(4) are labeled with (b)(4) at a concentration of (b)(4)%, as noted, your operations and process controls appear to deviate from the proposed conditions and requirements for an OTC (b)(4) product. For consistent regulatory compliance it is essential that OTC (b)(4) products like your (b)(4) conform to the applicable FDA requirements and OTC monograph conditions for the lawful distribution of this OTC drug product without an approved application.\nDrug Production Ceased\nYour written responses to date commit to cease the commercial distribution of OTC products in the U.S. market starting March 14, 2025. If you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nDrug Recall\nOn July 16, 2025, FDA held a teleconference with you and your U.S. agent, during which you committed to the recall of all your (b)(4) within expiry currently in distribution to the U.S. market.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on September 18, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA’s continuing to refuse admission of articles manufactured at Taizhou Kangping Medical Science and Technology Co., Ltd., located at Building 3, No 27 Tai’an Road, Hailing Industrial Park, Taizhou City, Jiangsu, China 225300, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), and are misbranded under section 502 of the FD&C Act, respectively.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013321339 and ATTN: Kara S. Quinn.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research","Taizhou Kangping Medical Science and Technology Co., Ltd.","taizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftaizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025","2026-10-26T08:10:09.574807+00:00","2025-11-11","711081","Mr. Yuegen Wang","2026-08-19T15:28:22.766+00:00","320-26-01","2025-10-09",{"id":274,"raw":275,"subject":58,"body_html":279,"body_text":280,"firm_name":281,"letter_id":282,"created_at":283,"fei_number":19,"letter_url":284,"updated_at":285,"action_type":22,"case_status":23,"posted_date":286,"marcs_cms_no":287,"product_type":288,"closeout_date":19,"issuing_office":57,"recipient_name":289,"body_fetched_at":290,"delivery_method":236,"recipient_title":19,"reference_number":19,"action_taken_date":291,"medical_device_id":19,"response_letter_date":19},1272,[276,277,278,57,58,13,13,13],"\u003Ctime datetime=\"2024-09-10T13:20:00Z\">09\u002F10\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-08-30T04:00:00Z\">08\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Froot-bioscience-brands-llc-dba-naternal-673646-08302024\">Root Bioscience Brands, LLC dba Naternal\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Garrett Perdue\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Root Bioscience Brands, LLC dba Naternal\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>951 Aviation Pkwy Ste 900\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morrisville\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27560\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@naternal.com\"> info@naternal.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n     \n        \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 30, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 673646\u003C\u002Fp>\n\n\u003Cp>Dear Garrett Perdue:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.naternal.com in August 2024 and has observed that your website offers various products which you represent contain, in part, cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN). The claims on your website establish that your products, CBD Oils,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>FDA has also determined that your Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg)\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> products for animals offered for sale on your website www.naternal.com, are unapproved new animal drugs that are unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a), and are adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5). Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&amp;C Act. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-healthfocus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your website, your CBD Oils, Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies products are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your website that provide evidence of the intended use of these products as drugs include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002F17-full-spectrum-cbd-oil-benefits-for-all-ages:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“In another recent study, correlations between CBD and blood pressure were examined. Two groups were evaluated, one being test subjects who were given CBD and the other being a control group with a placebo. All subjects were exposed to stressors that would induce a higher blood pressure. The study concluded that a dose of CBD was helpful to reducing blood pressure.”\u003C\u002Fli>\n\t\u003Cli>“CBD may protect nerve cells from deteriorating, and a study from Frontiers in Pharmacology found that CBD can significantly decrease the negative effects of Alzheimer[’]s and also improve cognitive ability.”\u003C\u002Fli>\n\t\u003Cli>“CBD oil has been shown to have addiction-recovery effects particularly for cocaine, opioids, and psycho-stimulants.”\u003C\u002Fli>\n\t\u003Cli>“CBD oil has been shown to reduce the nature of PTSD attacks. A preliminary study has shown that the use of CBD oil, in conjunction with psychological therapy, has reduced the severity of the test subjects' attacks over the course of eight weeks.”\u003C\u002Fli>\n\t\u003Cli>“CBD has been studied for its possible uses for children, and while the science is still preliminary, there are some promising opportunities. One of the best is the use of CBD for children with autism. One study of 188 children with autism, ages 5 to 18, found that some symptoms, such as seizures, restlessness and rage attacks, were lessened.”\u003C\u002Fli>\n\t\u003Cli>“Further small studies have been done into calming ADHD and anxiety in children, and while the results thus far are anecdotal, they do show potential. A 2016 study backed up the suggestion that CBD can help with sleep and anxiety for children, and a 2013 study showed that CBD for anxiety can help with regulatory control.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-for-veterans:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“What Is CBD? . . . It’s a great option for those that want the medicinal benefits of cannabis without the high, and many veterans are turning to CBD to help them battle PTSD, stress, anxiety, insomnia, chronic pain, and inflammation.”\u003C\u002Fli>\n\t\u003Cli>“CBD has also shown promise in helping to fight anxiety, insomnia, and chronic pain; as well as helping with addiction recovery for those that have developed a substance abuse disorder while trying to cope with PTSD and other stressors. And since veterans are twice as likely to die from an opioid overdose than the general population, CBD can provide a real way forward as it is kinder to the mind and the body.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-benefits-of-cbd-for-football:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“While CBD can’t prevent concussions, much research has gone into discovering ways that CBD can help treat them. One major study from the University of Miami has found that, in animal trials, combination therapy improved the cognitive function of subjects.(Combination therapy involves taking CBD along with dexanabinol, a synthetic cannabinoid.) In Canada, a study is being conducted on former hockey players to see if the severity of post-concussion brain disorders can be treated with CBD.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-and-cbg-for-skincare:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“In the eyes, endocannabinoid receptors allow CBG to help treat glaucoma by reducing intraocular pressure, as well as acting as a powerful vasodilator to protect and soothe. Additionally, some experiments have shown that CBG is effective at decreasing inflammatory bowel disease, in addition to protecting neurons in animals with Huntington's disease.”\u003C\u002Fli>\n\t\u003Cli>“On the cancer front, CBG has been shown to block receptors that contribute to cancer cell growth, slowing colon cancer in mice and inhibiting tumors in colon carcinogenesis.”\u003C\u002Fli>\n\t\u003Cli>“As an antibacterial agent, CBG goes where other drugs can't, helping to fight Staphylococcus aureus (MRSA) strains. Cannabis topical formulations have also been used for decades to help fight skin infections, though an understanding of why it works is only recently coming into focus with the use of CBG for skincare.”\u003C\u002Fli>\n\t\u003Cli>“Other medicinal benefits of CBG include appetite stimulation, which is of particular interest to cancer patients and other muscle wasting diseases.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-endocannabinoid-system-part-2:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Early studies into CBG indicate that it interacts with specific bodily systems, making it a promising medicinal substance. Research shows that it could be a highly effective treatment for glaucoma because it lowers intraocular pressure. Studies have also found it to decrease inflammation related to inflammatory bowel disease effectively.”\u003C\u002Fli>\n\t\u003Cli>“One 2015 study on mice showed that CBG provided neuroprotection related to Huntington’s disease. Furthermore, CBG may inhibit the growth of certain cancer cells, such as those that cause colon cancer. It also has been shown to be an effective antibacterial agent, an appetite stimulant, and a potential treatment for bladder dysfunction disorders.”\u003C\u002Fli>\n\t\u003Cli>“A different study also provided evidence that CBN could have anti-inflammatory, antibiotic, and anti-convulsant effects.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-benefits-of-cbd-for-people-with-autism:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“We are starting to understand how CBD may be a game-changer for people with autism to help ease their anxiety, calm their stimming, and reduce any severe behaviors.”\u003C\u002Fli>\n\t\u003Cli>“Many parents of children with autism report a lessening of aggressive behaviors and physical violence after taking CBD because it helps the child deal with the strong emotions that may come on without warning.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your CBD Oils, Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for any of the above-mentioned products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>The Department of Health and Human Services (HHS) has determined that a public health emergency exists nationwide involving the opioid crisis.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You market your CBD products for the treatment or cure of opioid addiction. However, these products have not been determined by FDA to be safe and effective for these (or any other) uses. Further, the unproven treatments could cause patients to forego or delay FDA-approved treatments for opioid addiction or withdrawal. The marketing and sale of unapproved opioid addiction treatment products is a potentially significant threat to the public health. Therefore, FDA is taking measures to protect consumers from products that, without approval by FDA, claim to diagnose, mitigate, prevent, treat or cure opioid addiction.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Animal Drugs\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>During our review of your firm’s website www.naternal.com, FDA has determined that your firm offers for sale the unapproved new animal drugs Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg). Based on our review of your website these products for animals are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Examples of claims from your website that provide evidence of the intended use of these products as animal drugs include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fproducts\u002Fcbd-for-pets:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>January 24, 2023 customer review states, “I have been using this CBD for my pup who has seizures for some time, since starting CBD she has not had one. I like that there are no unnecessary ingredients, and she takes it with no problems.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o Naternal.com replied, “Thank you for the review, \u003Cstrong>(b)(6)\u003C\u002Fstrong> That is amazing news - we are so glad to hear that your pup's seizures stopped!!! – Naternal”\u003C\u002Fp>\n\n\u003Cp>On your webpage https:\u002F\u002Fnaternal.com\u002Fproducts\u002Fcbd-for-pets-1200mg:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>January 25, 2023 customer review states, “Best place for CBD oil. Really helps my older dog's arthritis pain”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o Naternal.com replied, “Thank you, \u003Cstrong>(b)(6)\u003C\u002Fstrong>. We are grateful to provide great service and products that help to our community. Glad to hear that it's helping ease your dog's pain.”\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>October 3, 2022 customer review states, “The full spectrum pet CBD helps our old girl not only get around easier, but also has helped regulate her diabetes symptoms! I'm not saying this is a replacement for regular medical treatment but it has helped with her quality of life tremendously. Her steps and movements aren't so rigid when she has had her dose of CBD!”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; o Naternal.com replied, “…We are so happy that our Pet 1200mg CBD Tincture is helping your sweet pup with her diabetes and her mobility! Give her an extra treat for us. Thank you very much for your support and positive feedback!”\u003C\u002Fp>\n\n\u003Cp>On your blog post titled “CBD Dosing For Pets” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-dosing-for-pets:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD has a wide range of uses-cases in relation to health and wellness reasons, including the potential to aid conditions like chronic pain, anxiety, insomnia and more... Many people with pets have begun looking into CBD oil use for pain and inflammation reasons because veterinarian-prescribed medications can be costly and come with a variety of unwanted side effects. Other people use CBD for their pets to help calm them on particularly stressful occasions, such as during travel or when fireworks are going off in the neighborhood.”\u003C\u002Fli>\n\t\u003Cli>“If you are someone who is interested in more natural alternatives to prescription medications for your pets, then CBD might be worth looking into further. One study was done by Dr. Joseph Wakshlag of Cornell University and published in the journal Frontiers in Veterinary Science. Titled ‘Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs,’ the study looked at the effects of a hemp-based cannabidiol product to treat pain from arthritis in dogs. More than 80% of the dogs in the study saw a significant decrease in pain and improved mobility.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your blog post titled “9 Reasons to Use CBD for Pets” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002F9-reasons-to-use-cbd-for-pets:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD can be used to help your pets stay healthy, active, and happy. It may be beneficial for aiding some diseases and conditions in animals, especially dogs and cats, but also horses and other family animals.”\u003C\u002Fli>\n\t\u003Cli>“We’ve all been around anxious pets - they may be nervous around other people or other animals, they may not like car rides or loud noises, and some even get nervous being left alone at home. The outputs of their induced anxiety is often hiding, barking and whining excessively, shaking and sometimes even destruction of furniture and other items around the house. People have found CBD to be helpful in aiding their pet’s anxiety for many of the use-cases listed above.”\u003C\u002Fli>\n\t\u003Cli>“Typically used for skin ailments or injuries, CBD topicals are a great option for pets and they are easy to use! With the presence of fatty acids in hemp extract, these products can be used to calm inflammation caused by skin irritation and can even promote new cell growth, allowing for quicker healing.”\u003C\u002Fli>\n\t\u003Cli>“If your pet has a chronic condition like arthritis, or other musculoskeletal problems, CBD may be a great option to talk to your veterinarian about. Known for its anti-inflammatory properties, daily incorporation of CBD may help provide some relief to pets that deal with chronic pain.”\u003C\u002Fli>\n\t\u003Cli>“It May Help Avoid Seizures”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your blog post titled “CBD Oil for Dogs - Your Full Guide” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-oil-for-dogs-your-full-guide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“CBD may be an option for dogs that are recovering from surgery, battling certain ailments or illnesses, or are in need of comfort due to separation anxiety or other potential stressful events or situations they may need to deal with.”\u003C\u002Fli>\n\t\u003Cli>“Many dog owners have gained interest in the use of CBD for reasons including pain and inflammation, separation anxiety or situational anxiety, nausea, and general wellness needs for their aging loved ones. CBD isn't some magical cure, but it can help improve the quality of life for your dog, and the best part is that it's better than other pain pills and medications that may cause your pup to deal with a long list of unwanted side effects.”\u003C\u002Fli>\n\t\u003Cli>“One such study on the effects of CBD in dogs showed that four out of five dogs with osteoarthritis had an improvement in their pain and mobility after receiving a few mg of CBD per kg of body weight.”\u003C\u002Fli>\n\t\u003Cli>“Another study on CBD oil for dogs showed that epileptic dogs had significantly fewer seizures when given CBD as opposed to receiving seizure medication or a placebo. While dogs also had a reduction with placebo and other treatments, the effects weren't as pronounced as those who received CBD.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On your blog post titled “Does CBD help with Lyme Disease?” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fdoes-cbd-help-with-lyme-disease:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“My dog \u003Cstrong>(b)(6)&nbsp;\u003C\u002Fstrong>was diagnosed with Lyme disease in January 2020. Yes, our pets can get Lyme disease too! She was very lethargic, mostly slept all day and would hardly eat. I looked into a more natural remedy for her to ease her discomfort days, and Naternal offers our furry pets CBD oil in Full Spectrum! You'll see your furry pet do a complete turnaround with their pain level! Similar to how it is for us.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg) are “new animal drugs” under section 201(v) of the FD&amp;C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&amp;C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-1. These products are not approved, conditionally approved, or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&amp;C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&amp;C Act, 21 U.S.C. 351(a)(5). Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nJill Furman, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Neal Bataller, ME, DVM\u003Cbr>\nDirector\u003Cbr>\nDivision of Drug Compliance\u003Cbr>\nOffice of Surveillance and Compliance\u003Cbr>\nCenter for Veterinary Medicine\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This encompasses both broad spectrum and full spectrum CBD oils marketed on your website.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> On your website www.naternal.com, your Naternal Hemp Extract Oil for Pets products are also referred to as Pet Full Spectrum CBD Oil 300 MG, CBD for Pets 600mg, and Pet Full Spectrum CBD Oil 1200 MG.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued October 26, 2017, and subsequently renewed), available at https:\u002F\u002Faspr.hhs.gov\u002Flegal\u002FPHE\u002FPages\u002Fdefault.aspx.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nGarrett Perdue\n\nRecipient Title\n\nCEO\n\nRoot Bioscience Brands, LLC dba Naternal\n\n951 Aviation Pkwy Ste 900\n\nMorrisville, NC 27560\n\nUnited States\n\ninfo@naternal.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\n\nAugust 30, 2024\n\nRE: 673646\n\nDear Garrett Perdue:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at www.naternal.com in August 2024 and has observed that your website offers various products which you represent contain, in part, cannabidiol (CBD), cannabigerol (CBG), and cannabinol (CBN). The claims on your website establish that your products, CBD Oils,1 Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\n\nFDA has also determined that your Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg)2 products for animals offered for sale on your website www.naternal.com, are unapproved new animal drugs that are unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and are adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAs explained further below, introducing or delivering these products for introduction into interstate commerce violates the FD&C Act. You can find specific information about how FDA regulates cannabis-derived products at https:\u002F\u002Fwww.fda.gov\u002Fnews-events\u002Fpublic-healthfocus\u002Ffda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.\n\nUnapproved New Drugs\n\nBased on a review of your website, your CBD Oils, Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims from your website that provide evidence of the intended use of these products as drugs include, but are not limited to, the following:\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002F17-full-spectrum-cbd-oil-benefits-for-all-ages:\n\n“In another recent study, correlations between CBD and blood pressure were examined. Two groups were evaluated, one being test subjects who were given CBD and the other being a control group with a placebo. All subjects were exposed to stressors that would induce a higher blood pressure. The study concluded that a dose of CBD was helpful to reducing blood pressure.”\n\n“CBD may protect nerve cells from deteriorating, and a study from Frontiers in Pharmacology found that CBD can significantly decrease the negative effects of Alzheimer[’]s and also improve cognitive ability.”\n\n“CBD oil has been shown to have addiction-recovery effects particularly for cocaine, opioids, and psycho-stimulants.”\n\n“CBD oil has been shown to reduce the nature of PTSD attacks. A preliminary study has shown that the use of CBD oil, in conjunction with psychological therapy, has reduced the severity of the test subjects' attacks over the course of eight weeks.”\n\n“CBD has been studied for its possible uses for children, and while the science is still preliminary, there are some promising opportunities. One of the best is the use of CBD for children with autism. One study of 188 children with autism, ages 5 to 18, found that some symptoms, such as seizures, restlessness and rage attacks, were lessened.”\n\n“Further small studies have been done into calming ADHD and anxiety in children, and while the results thus far are anecdotal, they do show potential. A 2016 study backed up the suggestion that CBD can help with sleep and anxiety for children, and a 2013 study showed that CBD for anxiety can help with regulatory control.”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-for-veterans:\n\n“What Is CBD? . . . It’s a great option for those that want the medicinal benefits of cannabis without the high, and many veterans are turning to CBD to help them battle PTSD, stress, anxiety, insomnia, chronic pain, and inflammation.”\n\n“CBD has also shown promise in helping to fight anxiety, insomnia, and chronic pain; as well as helping with addiction recovery for those that have developed a substance abuse disorder while trying to cope with PTSD and other stressors. And since veterans are twice as likely to die from an opioid overdose than the general population, CBD can provide a real way forward as it is kinder to the mind and the body.”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-benefits-of-cbd-for-football:\n\n“While CBD can’t prevent concussions, much research has gone into discovering ways that CBD can help treat them. One major study from the University of Miami has found that, in animal trials, combination therapy improved the cognitive function of subjects.(Combination therapy involves taking CBD along with dexanabinol, a synthetic cannabinoid.) In Canada, a study is being conducted on former hockey players to see if the severity of post-concussion brain disorders can be treated with CBD.”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-and-cbg-for-skincare:\n\n“In the eyes, endocannabinoid receptors allow CBG to help treat glaucoma by reducing intraocular pressure, as well as acting as a powerful vasodilator to protect and soothe. Additionally, some experiments have shown that CBG is effective at decreasing inflammatory bowel disease, in addition to protecting neurons in animals with Huntington's disease.”\n\n“On the cancer front, CBG has been shown to block receptors that contribute to cancer cell growth, slowing colon cancer in mice and inhibiting tumors in colon carcinogenesis.”\n\n“As an antibacterial agent, CBG goes where other drugs can't, helping to fight Staphylococcus aureus (MRSA) strains. Cannabis topical formulations have also been used for decades to help fight skin infections, though an understanding of why it works is only recently coming into focus with the use of CBG for skincare.”\n\n“Other medicinal benefits of CBG include appetite stimulation, which is of particular interest to cancer patients and other muscle wasting diseases.”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-endocannabinoid-system-part-2:\n\n“Early studies into CBG indicate that it interacts with specific bodily systems, making it a promising medicinal substance. Research shows that it could be a highly effective treatment for glaucoma because it lowers intraocular pressure. Studies have also found it to decrease inflammation related to inflammatory bowel disease effectively.”\n\n“One 2015 study on mice showed that CBG provided neuroprotection related to Huntington’s disease. Furthermore, CBG may inhibit the growth of certain cancer cells, such as those that cause colon cancer. It also has been shown to be an effective antibacterial agent, an appetite stimulant, and a potential treatment for bladder dysfunction disorders.”\n\n“A different study also provided evidence that CBN could have anti-inflammatory, antibiotic, and anti-convulsant effects.”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fthe-benefits-of-cbd-for-people-with-autism:\n\n“We are starting to understand how CBD may be a game-changer for people with autism to help ease their anxiety, calm their stimming, and reduce any severe behaviors.”\n\n“Many parents of children with autism report a lessening of aggressive behaviors and physical violence after taking CBD because it helps the child deal with the strong emotions that may come on without warning.”\n\nYour CBD Oils, Move CBD+CBG Oil, Rest CBD+CBN Oil, Nurture Broad Spectrum Gummies, and Ease Full Spectrum Gummies products are not generally recognized as safe and effective (GRASE) for their above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). There are no FDA-approved applications in effect for any of the above-mentioned products. Accordingly, these products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nThe Department of Health and Human Services (HHS) has determined that a public health emergency exists nationwide involving the opioid crisis.3 You market your CBD products for the treatment or cure of opioid addiction. However, these products have not been determined by FDA to be safe and effective for these (or any other) uses. Further, the unproven treatments could cause patients to forego or delay FDA-approved treatments for opioid addiction or withdrawal. The marketing and sale of unapproved opioid addiction treatment products is a potentially significant threat to the public health. Therefore, FDA is taking measures to protect consumers from products that, without approval by FDA, claim to diagnose, mitigate, prevent, treat or cure opioid addiction.\n\nUnapproved New Animal Drugs\n\nDuring our review of your firm’s website www.naternal.com, FDA has determined that your firm offers for sale the unapproved new animal drugs Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg). Based on our review of your website these products for animals are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals and\u002For intended to affect the structure or any function of the body of an animal. Further, as discussed below, these products are unapproved new animal drugs and marketing them violates the FD&C Act.\n\nExamples of claims from your website that provide evidence of the intended use of these products as animal drugs include, but are not limited to, the following:\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fproducts\u002Fcbd-for-pets:\n\nJanuary 24, 2023 customer review states, “I have been using this CBD for my pup who has seizures for some time, since starting CBD she has not had one. I like that there are no unnecessary ingredients, and she takes it with no problems.”\n\no Naternal.com replied, “Thank you for the review, (b)(6) That is amazing news - we are so glad to hear that your pup's seizures stopped!!! – Naternal”\n\nOn your webpage https:\u002F\u002Fnaternal.com\u002Fproducts\u002Fcbd-for-pets-1200mg:\n\nJanuary 25, 2023 customer review states, “Best place for CBD oil. Really helps my older dog's arthritis pain”\n\no Naternal.com replied, “Thank you, (b)(6). We are grateful to provide great service and products that help to our community. Glad to hear that it's helping ease your dog's pain.”\n\nOctober 3, 2022 customer review states, “The full spectrum pet CBD helps our old girl not only get around easier, but also has helped regulate her diabetes symptoms! I'm not saying this is a replacement for regular medical treatment but it has helped with her quality of life tremendously. Her steps and movements aren't so rigid when she has had her dose of CBD!”\n\no Naternal.com replied, “…We are so happy that our Pet 1200mg CBD Tincture is helping your sweet pup with her diabetes and her mobility! Give her an extra treat for us. Thank you very much for your support and positive feedback!”\n\nOn your blog post titled “CBD Dosing For Pets” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-dosing-for-pets:\n\n“CBD has a wide range of uses-cases in relation to health and wellness reasons, including the potential to aid conditions like chronic pain, anxiety, insomnia and more... Many people with pets have begun looking into CBD oil use for pain and inflammation reasons because veterinarian-prescribed medications can be costly and come with a variety of unwanted side effects. Other people use CBD for their pets to help calm them on particularly stressful occasions, such as during travel or when fireworks are going off in the neighborhood.”\n\n“If you are someone who is interested in more natural alternatives to prescription medications for your pets, then CBD might be worth looking into further. One study was done by Dr. Joseph Wakshlag of Cornell University and published in the journal Frontiers in Veterinary Science. Titled ‘Pharmacokinetics, Safety, and Clinical Efficacy of Cannabidiol Treatment in Osteoarthritic Dogs,’ the study looked at the effects of a hemp-based cannabidiol product to treat pain from arthritis in dogs. More than 80% of the dogs in the study saw a significant decrease in pain and improved mobility.”\n\nOn your blog post titled “9 Reasons to Use CBD for Pets” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002F9-reasons-to-use-cbd-for-pets:\n\n“CBD can be used to help your pets stay healthy, active, and happy. It may be beneficial for aiding some diseases and conditions in animals, especially dogs and cats, but also horses and other family animals.”\n\n“We’ve all been around anxious pets - they may be nervous around other people or other animals, they may not like car rides or loud noises, and some even get nervous being left alone at home. The outputs of their induced anxiety is often hiding, barking and whining excessively, shaking and sometimes even destruction of furniture and other items around the house. People have found CBD to be helpful in aiding their pet’s anxiety for many of the use-cases listed above.”\n\n“Typically used for skin ailments or injuries, CBD topicals are a great option for pets and they are easy to use! With the presence of fatty acids in hemp extract, these products can be used to calm inflammation caused by skin irritation and can even promote new cell growth, allowing for quicker healing.”\n\n“If your pet has a chronic condition like arthritis, or other musculoskeletal problems, CBD may be a great option to talk to your veterinarian about. Known for its anti-inflammatory properties, daily incorporation of CBD may help provide some relief to pets that deal with chronic pain.”\n\n“It May Help Avoid Seizures”\n\nOn your blog post titled “CBD Oil for Dogs - Your Full Guide” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fcbd-oil-for-dogs-your-full-guide:\n\n“CBD may be an option for dogs that are recovering from surgery, battling certain ailments or illnesses, or are in need of comfort due to separation anxiety or other potential stressful events or situations they may need to deal with.”\n\n“Many dog owners have gained interest in the use of CBD for reasons including pain and inflammation, separation anxiety or situational anxiety, nausea, and general wellness needs for their aging loved ones. CBD isn't some magical cure, but it can help improve the quality of life for your dog, and the best part is that it's better than other pain pills and medications that may cause your pup to deal with a long list of unwanted side effects.”\n\n“One such study on the effects of CBD in dogs showed that four out of five dogs with osteoarthritis had an improvement in their pain and mobility after receiving a few mg of CBD per kg of body weight.”\n\n“Another study on CBD oil for dogs showed that epileptic dogs had significantly fewer seizures when given CBD as opposed to receiving seizure medication or a placebo. While dogs also had a reduction with placebo and other treatments, the effects weren't as pronounced as those who received CBD.”\n\nOn your blog post titled “Does CBD help with Lyme Disease?” at the URL https:\u002F\u002Fnaternal.com\u002Fblogs\u002Fnews\u002Fdoes-cbd-help-with-lyme-disease:\n\n“My dog (b)(6) was diagnosed with Lyme disease in January 2020. Yes, our pets can get Lyme disease too! She was very lethargic, mostly slept all day and would hardly eat. I looked into a more natural remedy for her to ease her discomfort days, and Naternal offers our furry pets CBD oil in Full Spectrum! You'll see your furry pet do a complete turnaround with their pain level! Similar to how it is for us.”\n\nYour Naternal Hemp Extract Oil for Pets (300mg, 600mg, and 1200mg) are “new animal drugs” under section 201(v) of the FD&C Act, 21 U.S.C. 321(v), because they are not generally recognized, among experts qualified by scientific training and experience to evaluate the safety and effectiveness of animal drugs, as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling. To be legally marketed, a new animal drug must have an approved new animal drug application, conditionally approved new animal drug application, or index listing under sections 512, 571, and 572 of the FD&C Act, 21 U.S.C. 360b, 360ccc, and 360ccc-1. These products are not approved, conditionally approved, or index listed by the FDA, and therefore these products are considered unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). Introduction of these adulterated drugs into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAADVISORY@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nJill Furman, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\n\u002FS\u002F\n\nNeal Bataller, ME, DVM\n\nDirector\n\nDivision of Drug Compliance\n\nOffice of Surveillance and Compliance\n\nCenter for Veterinary Medicine\n\nU.S. Food and Drug Administration\n\n____________________\n\n1 This encompasses both broad spectrum and full spectrum CBD oils marketed on your website.\n\n2 On your website www.naternal.com, your Naternal Hemp Extract Oil for Pets products are also referred to as Pet Full Spectrum CBD Oil 300 MG, CBD for Pets 600mg, and Pet Full Spectrum CBD Oil 1200 MG.\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued October 26, 2017, and subsequently renewed), available at https:\u002F\u002Faspr.hhs.gov\u002Flegal\u002FPHE\u002FPages\u002Fdefault.aspx.","Root Bioscience Brands, LLC dba Naternal","root-bioscience-brands-llc-dba-naternal-673646-08302024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Froot-bioscience-brands-llc-dba-naternal-673646-08302024","2026-10-26T08:09:51.034023+00:00","2024-09-10","673646","Animal & VeterinaryDrugs","Garrett Perdue","2026-08-19T23:49:49.071+00:00","2024-08-30",{"id":293,"raw":294,"subject":58,"body_html":300,"body_text":301,"firm_name":302,"letter_id":303,"created_at":192,"fei_number":19,"letter_url":304,"updated_at":305,"action_type":22,"case_status":23,"posted_date":306,"marcs_cms_no":307,"product_type":68,"closeout_date":19,"issuing_office":298,"recipient_name":308,"body_fetched_at":309,"delivery_method":310,"recipient_title":19,"reference_number":19,"action_taken_date":311,"medical_device_id":19,"response_letter_date":19},3132,[295,296,297,298,299,13,13,13],"\u003Ctime datetime=\"2021-09-28T13:20:00Z\">09\u002F28\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-22T04:00:00Z\">09\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsupplement-science-corp-dba-condemned-labz-613165-09222021\">Supplement Science Corp. d\u002Fb\u002Fa Condemned Labz\u003C\u002Fa>","Office of Human and Animal Food Operations East – Division 1","Unapproved New Drugs\u002FMisbranded \u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr.Vincent Miletti\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Counsel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Supplement Science Corp. d\u002Fb\u002Fa Condemned Labz\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2139 East 3rd Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brooklyn\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11223\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations East – Division 1\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS# 613165\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 22, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Miletti:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fcondemnedlabz.com\u002F and your social media website at https:\u002F\u002Fwww.facebook.com\u002Fcondemnedl abzofficial\u002F in June, July and September 2021. Based on our review, FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs and Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website at https:\u002F\u002Fcondemnedlabz.com\u002F in June, July and September 2021 and has determined that you take orders there for the products Arsyn, ConvictStim, Humaslin, Thyrogenic, and DNA Dispatch. We also reviewed your social media website https:\u002F\u002Fwww.facebook.com\u002Fcondemnedlabzofficial\u002F, which directs consumers to your website https:\u002F\u002Fcondemnedlabz.com\u002F to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>On your website https:\u002F\u002Fcondemnedlabz.com\u002F:\u003C\u002Fem>\u003Cbr>\n\u003Cbr>\n\u003Cstrong>On the product webpage for DNA Dispatch:\u003C\u002Fstrong>\u003Cbr>\n• “Increases tolerance to pain”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>On the product webpage for Humaslin:\u003C\u002Fstrong>\u003Cbr>\n• “Reduces blood sugar levels”\u003Cbr>\n• “Optimizes insulin sensitivity”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>In the blog “Nutrition” post titled, “Maximizing Insulin Sensitivity For Superior Muscle Growth,” dated September 6, 2021, which discusses your Humaslin:\u003C\u002Fstrong>\u003Cbr>\n• At the top of the blog post, you display an image of a needle inserted into a glass vial.\u003Cbr>\n• “Having insulin resistance is a tell-tale sign that you’re experiencing difficulty metabolising glucose, and is often a warning sign of future health complications including high blood pressure, heart disease, heart failure, obesity, type 2 diabetes and even cancer. . . . The good news, is that just because you may have poor insulin sensitivity right now, you’re not doomed to be that way forever. . . . And, if you need some extra help getting insulin under control, Condemned Labz has created the ultimate glucose disposal agent \u002F insulin mimetic in HumaSlin!”\u003Cbr>\n• “Make insulin work for you with Humaslin!”\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>In the blog “Supplements” post titled, “Pre Workout Stimulants 101,” dated August 25, 2021, regarding your Arsyn and ConvictStim:\u003C\u002Fstrong>\u003Cbr>\n• “[H]igenamine [an ingredient in your ConvictStim] also acts as a bronchodilator…”\u003Cbr>\n• “Originally developed as a nasal decongestant for the treatment of bronchitis, 2-aminoisoheptane has emerged as a powerhouse pre workout simulant …” [your blog post discusses 2-aminoisoheptane in the context of your Arsyn and ConvictStim, which are labeled to contain 2-aminoisoheptane HCl]\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>On the product webpage for Thyrogenic, which describes the product as a “powerful thyroid complex”:\u003C\u002Fstrong>\u003Cbr>\n• “An underactive thyroid can bring about a host of complications including depression… What’s more, an estimated 20 million Americans have some form of thyroid disorder, with as many as 60% of those affected are unaware of their condition.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>On your social media site https:\u002F\u002Fwww.facebook.com\u002Fcondemnedlabzofficial\u002F:\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>References to Humaslin:\u003C\u002Fstrong>\u003Cbr>\n• A post dated November 25, 2016 –\u003Cbr>\no “FORMULATED BY A Type 1 DIABETIC NATIONAL LEVEL COMPETITOR WHOS [sic] KNOWN FOR CONDITIONING… HumaSlin is Condemned Labz advanced Insulin…manipulating formula.”\u003Cbr>\no “TESTIMONIAL FROM . . . NATIONAL LEVEL TYPE 1 DIABETIC BODYBUILDER…For years I have used these individual ingredients to help me balance blood sugar and take less insulin…The combination of this formula played a major role in …controlling my diabetes.” [this testimonial appears next to an image of your HumaSlin product]\u003Cbr>\n• A post dated January 13, 2018 - “What are the benefits of Humaslin?... Insulin Mimicking…Blood Sugar Regulation…”\u003Cbr>\n• A post dated July 5, 2018 - “It’s effective for regulating blood sugar levels, due to its high saponin content, and it’s also shown to control blood glucose levels…”\u003Cbr>\n• A post dated November 14, 2018 - “Brief backstory: the owner of #CondemnedLabz, Michael J., is a Type 1 Diabetic. HumaSlin was his attempt to reduce the need for exogenous insulin via natural insulin mimetics…”\u003Cbr>\n• A post dated November 25, 2019 - “Humalsim is an advanced insulin- . . . manipulating formula … regulating blood sugar levels…”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Arsyn, ConvictStim, Humaslin, Thyrogenic, and DNA Dispatch are intended for treatment of one or more diseases that, with certain exceptions not applicable here, are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Arsyn, ConvictStim, Humaslin, Thyrogenic, and DNA Dispatch fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your products Arsyn and ConvictStim are labeled as dietary supplements. Even if your products Arsyn and ConvictStim did not have therapeutic claims that make these products unapproved new drugs and misbranded drugs, they would be adulterated dietary supplements.\u003C\u002Fp>\n\n\u003Cp>The Supplement Facts panel on your product ConvictStim declares higenamine as a dietary ingredient in the product. Higenamine is a dietary ingredient under section 201(ff)(1) of the Act [21 U.S.C. 321(ff)(1)]. Further, as a dietary ingredient that was not marketed in the United States before October 15, 1994, higenamine is a “new dietary ingredient” under section 413(d) of the Act [21 U.S.C. 350b(d)].\u003C\u002Fp>\n\n\u003Cp>Under section 413(a) of the Act [21 U.S.C. 350b(a)], a dietary supplement that contains a new dietary ingredient shall be deemed adulterated under section 402(f) of the Act [21 U.S.C. 342(f)] unless it meets one of two requirements:\u003Cbr>\n\u003Cbr>\n1. The dietary supplement contains only dietary ingredients that have been present in the food supply as an article used for food in a form in which the food has not been chemically altered; or\u003C\u002Fp>\n\n\u003Cp>2. There is a history of use or other evidence of safety establishing that the dietary ingredient when used under the conditions recommended or suggested in the labeling of the dietary supplement will reasonably be expected to be safe and, at least 75 days before being introduced or delivered for introduction into interstate commerce, the manufacturer or distributor of the dietary ingredient or dietary supplement provides FDA with information, including any citation to published articles, which is the basis on which the manufacturer or distributor has concluded that a dietary supplement containing such dietary ingredient will reasonably be expected to be safe.\u003C\u002Fp>\n\n\u003Cp>To the best of FDA’s knowledge, there is no information demonstrating that higenamine was lawfully marketed as a dietary ingredient in the United States before October 15, 1994, nor is there information demonstrating that this ingredient has been present in the food supply as an article used for human food in a form in which the food has not been chemically altered. As such, higenamine is subject to the notification requirement in section 413(a)(2) of the Act [21 U.S.C. 350b(a)(2)] and 21 CFR 190.6. Products for which the manufacturer or distributor is required to submit a new dietary ingredient notification under section 413(a)(2) and 21 CFR 190.6, but for which the required notification has not been submitted, are adulterated under sections 402(f) and 413(a) of the Act [21 U.S.C. 342(f) and 350b(a)]. Introduction of such products into interstate commerce is prohibited under sections 301(a) and (v) of the Act [21 U.S.C. 331(a) and (v)].\u003C\u002Fp>\n\n\u003Cp>Moreover, based on our evaluation of the relevant safety evidence, there is no history of use or other evidence of safety establishing that higenamine will reasonably be expected to be safe when used as a dietary ingredient. Therefore, even if a new dietary ingredient notification had been submitted, dietary supplements containing higenamine would be adulterated under sections 402(f) and 413(a) of the Act [21 U.S.C. 342(f) and 350b(a)]. In fact, the available evidence underscores higenamine’s potential for serious cardiotoxic effects. In the absence of adequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury, dietary supplements containing higenamine are adulterated under section 402(f)(1)(B) of the Act [21 U.S.C. 342(f)(1)(B].\u003C\u002Fp>\n\n\u003Cp>Further, your Arsyn and ConvictStim product labels declare 2-aminoisoheptane hydrochloride (HCl) as an ingredient in each of the products and your Arsyn product label also declares hordenine HCl and higenamine HCl as an ingredient in your Arsyn product. Your Arsyn product is adulterated under section 402(a)(2)(C)(i) of the Act [21 U.S.C. 342(a)(2)(C)(i)] because 2-aminoisoheptane HCl, hordenine HCl, and higenamine HCl are unsafe food additives under section 409(a) of the Act [21 U.S.C. 348(a)]. Your ConvictStim product is adulterated under section 402(a)(2)(C)(i) of the Act [21 U.S.C. 342(a)(2)(C)(i)] because 2-aminoisoheptane HCl is an unsafe food additive under section 409(a) of the Act [21 U.S.C. 348(a)].\u003C\u002Fp>\n\n\u003Cp>If a substance added to food is not generally recognized as safe (GRAS) by qualified experts for its intended use in food and does not qualify for any of the other exemptions from the food additive definition, it is a food additive.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe and causes the food to be adulterated under section 402(a)(2)(C)(i) of the Act [21 U.S.C. 342(a)(C)(i)].\u003C\u002Fp>\n\n\u003Cp>The definition of “food additive” in section 201(s) of the Act [21 U.S.C 321(s)] does not include dietary ingredients used in dietary supplements as defined in section 201(ff)(1) of the Act [21 U.S.C 321(ff)(1)] or substances that are GRAS under the conditions of intended use. The ingredients 2-aminoisoheptane HCl, hordenine HCl, and higenamine HCl do not qualify as dietary ingredients under section 201(ff)(1) of the Act [21 U.S.C. 321(ff)(1)] because they are not a vitamin, mineral, amino acid, herb or other botanical, dietary substance for use by man to supplement the diet by increasing the total dietary intake, or concentrate, metabolite, constituent, extract, or combination of any of the preceding dietary ingredient types. Neither are 2-aminoisoheptane HCl, hordenine HCl, and higenamine HCl GRAS under their conditions of use in your dietary supplement products. Because 2-aminoisoheptane HCl, hordenine HCl, and higenamine HCl do not qualify as dietary ingredients and are not GRAS or otherwise exempt from the food additive definition, your Arsyn and ConvictStim products are adulterated under section 402(a)(2)(C)(i) of the Act because they contain one or more unsafe food additives. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Lillian C. Aveta, Compliance Officer, 158-15 Liberty Ave., Jamaica, NY 11433 or via email at Lillian.aveta@fda.hhs.gov (preferred). If you have any questions about the content of this letter, please contact Ms. Aveta at 718-662-5576 or email at Lillian.aveta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ronald M. Pace\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations East – Division 1\u003Cbr>\n\u003Cbr>\ncc:\u003C\u002Fp>\n\n\u003Cp>Michael Jirovec\u003Cbr>\nFounder &amp; CEO\u003Cbr>\nSupplement Science Corp.\u003Cbr>\nd\u002Fb\u002Fa Condemned Labz\u003Cbr>\n351 Majestic Eagle Drive\u003Cbr>\nPonte Vedra, FL 32081-0671\u003C\u002Fp>\n\n\u003Cp>________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under section 201(s) of the Act [21 U.S.C. 321(s)], the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food; (2) pesticide chemicals; (3) color additives; (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the Act, the Poultry Products Inspection Act, or the Meat Inspection Act; (5) new animal drugs; and (6) dietary ingredients in or intended for use in a dietary supplement.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr.Vincent Miletti\n\nRecipient Title\n\nGeneral Counsel\n\nSupplement Science Corp. d\u002Fb\u002Fa Condemned Labz\n\n2139 East 3rd Street\n\nBrooklyn, NY 11223\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations East – Division 1\n\nUnited States\n\nWARNING LETTER\n\nCMS# 613165\n\nSeptember 22, 2021\n\nDear Mr. Miletti:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fcondemnedlabz.com\u002F and your social media website at https:\u002F\u002Fwww.facebook.com\u002Fcondemnedl abzofficial\u002F in June, July and September 2021. Based on our review, FDA identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act). You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drugs and Misbranded Drugs\n\nFDA reviewed your website at https:\u002F\u002Fcondemnedlabz.com\u002F in June, July and September 2021 and has determined that you take orders there for the products Arsyn, ConvictStim, Humaslin, Thyrogenic, and DNA Dispatch. We also reviewed your social media website https:\u002F\u002Fwww.facebook.com\u002Fcondemnedlabzofficial\u002F, which directs consumers to your website https:\u002F\u002Fcondemnedlabz.com\u002F to purchase your products. The claims on your websites establish that the products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\nOn your website https:\u002F\u002Fcondemnedlabz.com\u002F:\n\nOn the product webpage for DNA Dispatch:\n\n• “Increases tolerance to pain”\n\nOn the product webpage for Humaslin:\n\n• “Reduces blood sugar levels”\n\n• “Optimizes insulin sensitivity”\n\nIn the blog “Nutrition” post titled, “Maximizing Insulin Sensitivity For Superior Muscle Growth,” dated September 6, 2021, which discusses your Humaslin:\n\n• At the top of the blog post, you display an image of a needle inserted into a glass vial.\n\n• “Having insulin resistance is a tell-tale sign that you’re experiencing difficulty metabolising glucose, and is often a warning sign of future health complications including high blood pressure, heart disease, heart failure, obesity, type 2 diabetes and even cancer. . . . The good news, is that just because you may have poor insulin sensitivity right now, you’re not doomed to be that way forever. . . . And, if you need some extra help getting insulin under control, Condemned Labz has created the ultimate glucose disposal agent \u002F insulin mimetic in HumaSlin!”\n\n• “Make insulin work for you with Humaslin!”\n\nIn the blog “Supplements” post titled, “Pre Workout Stimulants 101,” dated August 25, 2021, regarding your Arsyn and ConvictStim:\n\n• “[H]igenamine [an ingredient in your ConvictStim] also acts as a bronchodilator…”\n\n• “Originally developed as a nasal decongestant for the treatment of bronchitis, 2-aminoisoheptane has emerged as a powerhouse pre workout simulant …” [your blog post discusses 2-aminoisoheptane in the context of your Arsyn and ConvictStim, which are labeled to contain 2-aminoisoheptane HCl]\n\nOn the product webpage for Thyrogenic, which describes the product as a “powerful thyroid complex”:\n\n• “An underactive thyroid can bring about a host of complications including depression… What’s more, an estimated 20 million Americans have some form of thyroid disorder, with as many as 60% of those affected are unaware of their condition.”\n\nOn your social media site https:\u002F\u002Fwww.facebook.com\u002Fcondemnedlabzofficial\u002F:\n\nReferences to Humaslin:\n\n• A post dated November 25, 2016 –\n\no “FORMULATED BY A Type 1 DIABETIC NATIONAL LEVEL COMPETITOR WHOS [sic] KNOWN FOR CONDITIONING… HumaSlin is Condemned Labz advanced Insulin…manipulating formula.”\n\no “TESTIMONIAL FROM . . . NATIONAL LEVEL TYPE 1 DIABETIC BODYBUILDER…For years I have used these individual ingredients to help me balance blood sugar and take less insulin…The combination of this formula played a major role in …controlling my diabetes.” [this testimonial appears next to an image of your HumaSlin product]\n\n• A post dated January 13, 2018 - “What are the benefits of Humaslin?... Insulin Mimicking…Blood Sugar Regulation…”\n\n• A post dated July 5, 2018 - “It’s effective for regulating blood sugar levels, due to its high saponin content, and it’s also shown to control blood glucose levels…”\n\n• A post dated November 14, 2018 - “Brief backstory: the owner of #CondemnedLabz, Michael J., is a Type 1 Diabetic. HumaSlin was his attempt to reduce the need for exogenous insulin via natural insulin mimetics…”\n\n• A post dated November 25, 2019 - “Humalsim is an advanced insulin- . . . manipulating formula … regulating blood sugar levels…”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Arsyn, ConvictStim, Humaslin, Thyrogenic, and DNA Dispatch are intended for treatment of one or more diseases that, with certain exceptions not applicable here, are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, Arsyn, ConvictStim, Humaslin, Thyrogenic, and DNA Dispatch fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nAdulterated Dietary Supplements\n\nYour products Arsyn and ConvictStim are labeled as dietary supplements. Even if your products Arsyn and ConvictStim did not have therapeutic claims that make these products unapproved new drugs and misbranded drugs, they would be adulterated dietary supplements.\n\nThe Supplement Facts panel on your product ConvictStim declares higenamine as a dietary ingredient in the product. Higenamine is a dietary ingredient under section 201(ff)(1) of the Act [21 U.S.C. 321(ff)(1)]. Further, as a dietary ingredient that was not marketed in the United States before October 15, 1994, higenamine is a “new dietary ingredient” under section 413(d) of the Act [21 U.S.C. 350b(d)].\n\nUnder section 413(a) of the Act [21 U.S.C. 350b(a)], a dietary supplement that contains a new dietary ingredient shall be deemed adulterated under section 402(f) of the Act [21 U.S.C. 342(f)] unless it meets one of two requirements:\n\n1. The dietary supplement contains only dietary ingredients that have been present in the food supply as an article used for food in a form in which the food has not been chemically altered; or\n\n2. There is a history of use or other evidence of safety establishing that the dietary ingredient when used under the conditions recommended or suggested in the labeling of the dietary supplement will reasonably be expected to be safe and, at least 75 days before being introduced or delivered for introduction into interstate commerce, the manufacturer or distributor of the dietary ingredient or dietary supplement provides FDA with information, including any citation to published articles, which is the basis on which the manufacturer or distributor has concluded that a dietary supplement containing such dietary ingredient will reasonably be expected to be safe.\n\nTo the best of FDA’s knowledge, there is no information demonstrating that higenamine was lawfully marketed as a dietary ingredient in the United States before October 15, 1994, nor is there information demonstrating that this ingredient has been present in the food supply as an article used for human food in a form in which the food has not been chemically altered. As such, higenamine is subject to the notification requirement in section 413(a)(2) of the Act [21 U.S.C. 350b(a)(2)] and 21 CFR 190.6. Products for which the manufacturer or distributor is required to submit a new dietary ingredient notification under section 413(a)(2) and 21 CFR 190.6, but for which the required notification has not been submitted, are adulterated under sections 402(f) and 413(a) of the Act [21 U.S.C. 342(f) and 350b(a)]. Introduction of such products into interstate commerce is prohibited under sections 301(a) and (v) of the Act [21 U.S.C. 331(a) and (v)].\n\nMoreover, based on our evaluation of the relevant safety evidence, there is no history of use or other evidence of safety establishing that higenamine will reasonably be expected to be safe when used as a dietary ingredient. Therefore, even if a new dietary ingredient notification had been submitted, dietary supplements containing higenamine would be adulterated under sections 402(f) and 413(a) of the Act [21 U.S.C. 342(f) and 350b(a)]. In fact, the available evidence underscores higenamine’s potential for serious cardiotoxic effects. In the absence of adequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury, dietary supplements containing higenamine are adulterated under section 402(f)(1)(B) of the Act [21 U.S.C. 342(f)(1)(B].\n\nFurther, your Arsyn and ConvictStim product labels declare 2-aminoisoheptane hydrochloride (HCl) as an ingredient in each of the products and your Arsyn product label also declares hordenine HCl and higenamine HCl as an ingredient in your Arsyn product. Your Arsyn product is adulterated under section 402(a)(2)(C)(i) of the Act [21 U.S.C. 342(a)(2)(C)(i)] because 2-aminoisoheptane HCl, hordenine HCl, and higenamine HCl are unsafe food additives under section 409(a) of the Act [21 U.S.C. 348(a)]. Your ConvictStim product is adulterated under section 402(a)(2)(C)(i) of the Act [21 U.S.C. 342(a)(2)(C)(i)] because 2-aminoisoheptane HCl is an unsafe food additive under section 409(a) of the Act [21 U.S.C. 348(a)].\n\nIf a substance added to food is not generally recognized as safe (GRAS) by qualified experts for its intended use in food and does not qualify for any of the other exemptions from the food additive definition, it is a food additive.1 Food additives require premarket approval based on data demonstrating safety. Any food additive that has not been approved for its intended use in food is deemed to be unsafe and causes the food to be adulterated under section 402(a)(2)(C)(i) of the Act [21 U.S.C. 342(a)(C)(i)].\n\nThe definition of “food additive” in section 201(s) of the Act [21 U.S.C 321(s)] does not include dietary ingredients used in dietary supplements as defined in section 201(ff)(1) of the Act [21 U.S.C 321(ff)(1)] or substances that are GRAS under the conditions of intended use. The ingredients 2-aminoisoheptane HCl, hordenine HCl, and higenamine HCl do not qualify as dietary ingredients under section 201(ff)(1) of the Act [21 U.S.C. 321(ff)(1)] because they are not a vitamin, mineral, amino acid, herb or other botanical, dietary substance for use by man to supplement the diet by increasing the total dietary intake, or concentrate, metabolite, constituent, extract, or combination of any of the preceding dietary ingredient types. Neither are 2-aminoisoheptane HCl, hordenine HCl, and higenamine HCl GRAS under their conditions of use in your dietary supplement products. Because 2-aminoisoheptane HCl, hordenine HCl, and higenamine HCl do not qualify as dietary ingredients and are not GRAS or otherwise exempt from the food additive definition, your Arsyn and ConvictStim products are adulterated under section 402(a)(2)(C)(i) of the Act because they contain one or more unsafe food additives. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Lillian C. Aveta, Compliance Officer, 158-15 Liberty Ave., Jamaica, NY 11433 or via email at Lillian.aveta@fda.hhs.gov (preferred). If you have any questions about the content of this letter, please contact Ms. Aveta at 718-662-5576 or email at Lillian.aveta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRonald M. Pace\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations East – Division 1\n\ncc:\n\nMichael Jirovec\n\nFounder & CEO\n\nSupplement Science Corp.\n\nd\u002Fb\u002Fa Condemned Labz\n\n351 Majestic Eagle Drive\n\nPonte Vedra, FL 32081-0671\n\n________________________\n\n1 Under section 201(s) of the Act [21 U.S.C. 321(s)], the following types of substances are excluded from the food additive definition: (1) pesticide chemical residues in or on a raw agricultural commodity or processed food; (2) pesticide chemicals; (3) color additives; (4) substances used in accordance with a “prior sanction” (i.e., a sanction or approval granted prior to the enactment of the Food Additives Amendment of 1958 under the Act, the Poultry Products Inspection Act, or the Meat Inspection Act; (5) new animal drugs; and (6) dietary ingredients in or intended for use in a dietary supplement.","Supplement Science Corp. d\u002Fb\u002Fa Condemned Labz","supplement-science-corp-dba-condemned-labz-613165-09222021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsupplement-science-corp-dba-condemned-labz-613165-09222021","2026-10-26T08:10:07.99083+00:00","2021-09-28","613165","Mr.Vincent Miletti","2026-08-20T02:35:30.626+00:00","United Parcel Service","2021-09-22",{"id":313,"raw":314,"subject":318,"body_html":319,"body_text":320,"firm_name":321,"letter_id":322,"created_at":132,"fei_number":19,"letter_url":323,"updated_at":324,"action_type":22,"case_status":23,"posted_date":325,"marcs_cms_no":326,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":327,"body_fetched_at":328,"delivery_method":215,"recipient_title":19,"reference_number":329,"action_taken_date":330,"medical_device_id":19,"response_letter_date":19},131,[315,316,317,57,318,13,13,13],"\u003Ctime datetime=\"2026-06-02T04:00:00Z\">06\u002F02\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-19T04:00:00Z\">05\u002F19\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthpartners-neuroscience-center-research-and-innovation-725333-05192026\">HealthPartners Neuroscience Center Research and Innovation\u003C\u002Fa>","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE AND VIA E-MAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>26-HFD-45-05-02\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Leah R. Hanson, Ph.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Director, Neuroscience Research\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>HealthPartners Neuroscience Center Research and Innovation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>295 Phalen Boulevard\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55130-2455\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA Ref. No.: 26-HFD-45-05-02\u003C\u002Fp>\u003Cp>Dear Dr. Hanson:\u003C\u002Fp>\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at HealthPartners Neuroscience Center Research and Innovation (HPNC) between March 17 and 21, 2025. The investigators representing FDA reviewed the role of HPNC as the testing facility for the following nonclinical laboratory studies of the investigational drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>, performed for sponsor-investigator \u003Cstrong>(b)(4)\u003C\u002Fstrong> (formerly performed for \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\u003Cul>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003C\u002Fli>\u003Cli>Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>: “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your April 11, 2025, written response to the Form FDA 483, and your subsequent correspondence dated June 13, 2025.\u003C\u002Fp>\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated April 11 and June 13, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure of the testing facility management to assure that tests for mixtures of articles with carriers were conducted by appropriate analytical methods to determine the uniformity of the mixture and the concentration of the test or control article in the mixture, as applicable [21 CFR 58.31(d) and 21 CFR 58.113(a)(1)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The testing facility management for each nonclinical laboratory study must ensure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable. For each test or control article that is mixed with a carrier, tests by appropriate analytical methods must be conducted to determine the uniformity of the mixture and to determine, periodically, the concentration of the test or control article in the mixture. The testing facility management failed to adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, the protocol and final study report for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong> stated that the test article, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was dissolved in sterile water to a final dose concentration of 1%, 10%, or 20% \u003Cstrong>(b)(4) \u003C\u002Fstrong>(0.5 mg, 5 mg, and 10 mg, respectively), and for Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>, to a final dose concentration of 1%, 10%, or 20% \u003Cstrong>(b)(4)\u003C\u002Fstrong> (2 mg, 20 mg, and 40 mg, respectively). However, after reconstituting the test article with sterile water to the desired final dose concentration, the testing facility failed to test, by appropriate analytical methods, the resulting mixtures to determine their uniformity and concentration before dosing all animals in studies \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged that the characteristics of the test article were not analyzed. As corrective and preventive actions, you stated that the following actions were taken: (1) you created a new SOP titled “Receipt, Identification, Storage, Handling, Mixing, and Method of Sampling Chemicals,” which includes procedures for test article characterization; (2) you provided the certificate of analysis for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> lot used in study \u003Cstrong>(b)(4)\u003C\u002Fstrong>; (3) you performed mass spectrometry testing on April 19, 2025, on stored frozen dosing aliquots representative of formulated test articles administered to animals in both studies; and (4) you amended the final study reports for both studies to include the results of this subsequent testing, noting that the selected test article samples were within the concentration specified in the protocol.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, while you provided the results of the testing performed on the stored aliquots that were representative of the test articles administered to animals, this testing occurred after animal dosing and the studies had been completed. We also note that while you provided the testing results for the concentration of these samples, you did not provide the testing results regarding the uniformity of the samples.&nbsp;\u003C\u002Fp>\u003Cp>In addition, while we acknowledge that you created an SOP that includes test article characterization, your written response does not include details about how you will implement these procedures to ensure that testing to determine the concentration and uniformity of test articles is performed in accordance with FDA regulations. For example, your response does not provide sufficient details regarding any completed or planned training of study personnel on this new SOP, or any training on FDA regulations governing the conduct of nonclinical laboratory studies. Without this information, we are unable to determine whether your testing facility will be able to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Your testing facility management failed to ensure that tests by an appropriate analytical method were conducted to determine the uniformity and concentration of the mixtures of articles with carriers at the beginning and throughout the study period, to verify the protocol-specified dose concentrations. Because of this failure, FDA is concerned about the uniformity of the mixtures and about the concentration of the test articles in the mixtures used in the nonclinical laboratory studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure of the Quality Assurance unit (QAU) to review the final study report to assure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements. Specifically, for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the following observations were not accurately documented in the final study report:\u003C\u002Fp>\u003Cp>a. The deaths of two male rats (Rats #41 and #42 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group) during the conduct of the study were not reflected in the final study report.\u003C\u002Fp>\u003Cp>b. A Day 13 clinical observation of abnormal nose was observed in Female Rat #53 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group, and a Day 13 clinical observation of abnormal porphyrin was observed in Female Rat #51 in the 1% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group. However, the final study report inaccurately documents that abnormal nose was observed on Day 13 in the 1% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group, and that abnormal porphyrin was observed on Day 13 in the 10% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group.\u003C\u002Fp>\u003Cp>c. Female Rat #84 in the 20% \u003Cstrong>(b)(4)\u003C\u002Fstrong> dosing group died on Day 3 of dosing. However, the final study report inaccurately documents that Rat #84 died on Day 1 of dosing.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, you acknowledged the observation and stated that you amended the final study reports to make the necessary corrections. You stated that to address the root cause of the violation, you developed a new SOP titled “QAU Review of Final Report” and a checklist to be used in the QAU review of final study reports.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan, including how procedures will be implemented at your site to ensure compliance with FDA regulations. For example, your corrective action plan does not include QAU training on the new SOP or the new checklist, or QAU training on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. Additionally, your corrective action plan does not include a description of any planned audits to check for compliance with new QAU procedures. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\u003C\u002Fp>\u003Cp>Because your testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory studies, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure of the testing facility management to assure the availability of equipment as scheduled and that the equipment used in the generation, measurement, or assessment of data shall be of appropriate design and adequate capacity to function according to the study protocol [21 CFR 58.31(e) and 21 CFR 58.61].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Testing facility management must ensure that equipment is available as scheduled. Additionally, equipment used in the generation, measurement, or assessment of data in a nonclinical laboratory study must be of appropriate design and adequate capacity to function according to the study protocol. The testing facility management failed to adhere to these requirements.\u003C\u002Fp>\u003Cp>Specifically, during the conduct of nonclinical laboratory studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the testing facility management failed to ensure that equipment of appropriate design and adequate capacity was available to analyze the blood of rat and rabbit species for the protocol-required hematology and serum chemistry laboratory parameters. As a result, the testing facility failed to generate the following Day 15 data:\u003C\u002Fp>\u003Cul>\u003Cli>Hematology test results for male and female rats for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Serum chemistry test results for male rats for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>Hematology test results for male and female rabbits for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Additionally, the testing facility management did not cross-validate the equipment used to analyze blood samples, to demonstrate their ability to accurately analyze rat blood in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> or rabbit blood in Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We acknowledge that the finding described above was not included on the Form FDA 483 you received, and that the observation on the Form FDA 483 was limited to the unreported hematology laboratory results for Day 15 female rats in the final study report for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, your written responses to the Form FDA 483 do not directly address the extent of this finding as discussed in this letter.\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, regarding the unreported hematology results, you stated that you amended the final study reports to make the necessary corrections. The amended final study reports gave details of the equipment that your testing facility used for hematology laboratory parameters testing in the study animals, and they explained that the hematology results obtained using the equipment were below or above the range of the machine, and therefore no results were displayed on the equipment.\u003C\u002Fp>\u003Cp>While we acknowledge the corrective actions that your testing facility has taken regarding the unreported hematology results, your response is inadequate because we are unable to determine whether your testing facility will be able to ensure the availability of equipment of appropriate design and adequate capacity to evaluate protocol-required laboratory parameters in the animal species included in future nonclinical studies conducted at your testing facility. Because the testing facility management failed to ensure that appropriate equipment was available to conduct protocol-required laboratory assessments, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure of the testing facility to establish standard operating procedures in writing, setting forth nonclinical laboratory study methods that management is satisfied are adequate to insure the quality and integrity of the data generated in the course of the studies [21 CFR 58.81(a) and 58.81(b)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A testing facility must establish and follow written SOPs for nonclinical laboratory studies, to ensure the quality and integrity of the data generated in the studies. Your testing facility did not adhere to these requirements. For example, your testing facility failed to establish SOPs for:\u003C\u002Fp>\u003Cp>a. Receipt, identification, storage, handling, mixing, and method of sampling of the test and control articles\u003C\u002Fp>\u003Cp>b. Test system observations\u003C\u002Fp>\u003Cp>c. Laboratory tests\u003C\u002Fp>\u003Cp>d. Handling of animals found to be moribund or dead during a study\u003C\u002Fp>\u003Cp>e. Collection and identification of specimens\u003C\u002Fp>\u003Cp>In your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged the observation and stated that you created an SOP titled “SOP Creation, Review, and Approval.” Additionally, you created SOPs for the five procedures that were identified as lacking, along with additional SOPs that were not previously established. You also revised existing SOPs to include versioning and dates. We acknowledge your corrective and preventive actions. However, we emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, it is your responsibility to establish SOPs \u003Cem>before\u003C\u002Fem> conducting nonclinical laboratory studies. You are also responsible for following your written SOPs to ensure consistency in study conduct and to ensure the quality and integrity of data generated during your studies.\u003C\u002Fp>\u003Cp>As evidenced by FDA’s inspection findings, the deficiencies found in the oversight and conduct of the testing facility management and QAU at your testing facility demonstrate a failure to comply with FDA’s GLP regulations governing the conduct of nonclinical laboratory studies. As a result, FDA is concerned about the validity and integrity of the nonclinical data generated by your testing facility.\u003C\u002Fp>\u003Cp>We emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&amp;C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>David C. Burrow, Pharm.D., J.D.\u003Cbr>Director\u003Cbr>Office of Scientific Investigations\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>DAVID C BURROW\u003Cbr>05\u002F19\u002F2026 12:58:47 PM\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE AND VIA E-MAIL\n\nReference #:\n\n26-HFD-45-05-02\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLeah R. Hanson, Ph.D.\n\nRecipient Title\n\nSenior Director, Neuroscience Research\n\nHealthPartners Neuroscience Center Research and Innovation\n\n295 Phalen Boulevard\n\nSaint Paul, MN 55130-2455\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFDA Ref. No.: 26-HFD-45-05-02\nDear Dr. Hanson:\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted at HealthPartners Neuroscience Center Research and Innovation (HPNC) between March 17 and 21, 2025. The investigators representing FDA reviewed the role of HPNC as the testing facility for the following nonclinical laboratory studies of the investigational drug (b)(4), performed for sponsor-investigator (b)(4) (formerly performed for (b)(4)).\nProtocol (b)(4): “(b)(4)”\nProtocol (b)(4): “(b)(4)”\nThis inspection was conducted as a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure the quality and integrity of study data, in accordance with Title 21 of the Code of Federal Regulations, part 58 (21 CFR 58), Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies.\nAt the conclusion of the inspection, the FDA investigators presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of your April 11, 2025, written response to the Form FDA 483, and your subsequent correspondence dated June 13, 2025.\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and your written responses dated April 11 and June 13, 2025, it appears that you did not adhere to the applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and applicable regulations contained in 21 CFR 58 governing the conduct of nonclinical laboratory studies. We wish to emphasize the following:\n1. Failure of the testing facility management to assure that tests for mixtures of articles with carriers were conducted by appropriate analytical methods to determine the uniformity of the mixture and the concentration of the test or control article in the mixture, as applicable [21 CFR 58.31(d) and 21 CFR 58.113(a)(1)].\nThe testing facility management for each nonclinical laboratory study must ensure that test and control articles or mixtures have been appropriately tested for identity, strength, purity, stability, and uniformity, as applicable. For each test or control article that is mixed with a carrier, tests by appropriate analytical methods must be conducted to determine the uniformity of the mixture and to determine, periodically, the concentration of the test or control article in the mixture. The testing facility management failed to adhere to these requirements.\nSpecifically, the protocol and final study report for Study (b)(4) stated that the test article, (b)(4), was dissolved in sterile water to a final dose concentration of 1%, 10%, or 20% (b)(4) (0.5 mg, 5 mg, and 10 mg, respectively), and for Study (b)(4), to a final dose concentration of 1%, 10%, or 20% (b)(4) (2 mg, 20 mg, and 40 mg, respectively). However, after reconstituting the test article with sterile water to the desired final dose concentration, the testing facility failed to test, by appropriate analytical methods, the resulting mixtures to determine their uniformity and concentration before dosing all animals in studies (b)(4) and (b)(4).\nIn your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged that the characteristics of the test article were not analyzed. As corrective and preventive actions, you stated that the following actions were taken: (1) you created a new SOP titled “Receipt, Identification, Storage, Handling, Mixing, and Method of Sampling Chemicals,” which includes procedures for test article characterization; (2) you provided the certificate of analysis for the (b)(4) lot used in study (b)(4); (3) you performed mass spectrometry testing on April 19, 2025, on stored frozen dosing aliquots representative of formulated test articles administered to animals in both studies; and (4) you amended the final study reports for both studies to include the results of this subsequent testing, noting that the selected test article samples were within the concentration specified in the protocol.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan. For example, while you provided the results of the testing performed on the stored aliquots that were representative of the test articles administered to animals, this testing occurred after animal dosing and the studies had been completed. We also note that while you provided the testing results for the concentration of these samples, you did not provide the testing results regarding the uniformity of the samples.\nIn addition, while we acknowledge that you created an SOP that includes test article characterization, your written response does not include details about how you will implement these procedures to ensure that testing to determine the concentration and uniformity of test articles is performed in accordance with FDA regulations. For example, your response does not provide sufficient details regarding any completed or planned training of study personnel on this new SOP, or any training on FDA regulations governing the conduct of nonclinical laboratory studies. Without this information, we are unable to determine whether your testing facility will be able to prevent similar violations in the future.\nYour testing facility management failed to ensure that tests by an appropriate analytical method were conducted to determine the uniformity and concentration of the mixtures of articles with carriers at the beginning and throughout the study period, to verify the protocol-specified dose concentrations. Because of this failure, FDA is concerned about the uniformity of the mixtures and about the concentration of the test articles in the mixtures used in the nonclinical laboratory studies conducted at your testing facility.\n2. Failure of the Quality Assurance unit (QAU) to review the final study report to assure that the reported results accurately reflect the raw data of the nonclinical laboratory study [21 CFR 58.35(b)(6)].\nThe QAU must review the final study report to ensure that the reported results accurately reflect the raw data of the nonclinical laboratory study. The QAU at your testing facility did not adhere to these requirements. Specifically, for Protocol (b)(4), the following observations were not accurately documented in the final study report:\na. The deaths of two male rats (Rats #41 and #42 in the 10% (b)(4) dosing group) during the conduct of the study were not reflected in the final study report.\nb. A Day 13 clinical observation of abnormal nose was observed in Female Rat #53 in the 10% (b)(4) dosing group, and a Day 13 clinical observation of abnormal porphyrin was observed in Female Rat #51 in the 1% (b)(4) dosing group. However, the final study report inaccurately documents that abnormal nose was observed on Day 13 in the 1% (b)(4) dosing group, and that abnormal porphyrin was observed on Day 13 in the 10% (b)(4) dosing group.\nc. Female Rat #84 in the 20% (b)(4) dosing group died on Day 3 of dosing. However, the final study report inaccurately documents that Rat #84 died on Day 1 of dosing.\nIn your April 11, 2025, written response to the Form FDA 483, you acknowledged the observation and stated that you amended the final study reports to make the necessary corrections. You stated that to address the root cause of the violation, you developed a new SOP titled “QAU Review of Final Report” and a checklist to be used in the QAU review of final study reports.\nWhile we acknowledge the corrective and preventive actions that your testing facility has taken, your response is inadequate because you did not include sufficient details about your corrective action plan, including how procedures will be implemented at your site to ensure compliance with FDA regulations. For example, your corrective action plan does not include QAU training on the new SOP or the new checklist, or QAU training on FDA regulations governing the conduct of nonclinical laboratory studies, including the QAU’s role and responsibilities. Additionally, your corrective action plan does not include a description of any planned audits to check for compliance with new QAU procedures. Without these details, we are unable to determine whether your corrective actions are adequate to prevent similar violations in the future.\nBecause your testing facility’s QAU failed to ensure that the reported results in the final study report accurately reflect the raw data of the nonclinical laboratory studies, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\n3. Failure of the testing facility management to assure the availability of equipment as scheduled and that the equipment used in the generation, measurement, or assessment of data shall be of appropriate design and adequate capacity to function according to the study protocol [21 CFR 58.31(e) and 21 CFR 58.61].\nTesting facility management must ensure that equipment is available as scheduled. Additionally, equipment used in the generation, measurement, or assessment of data in a nonclinical laboratory study must be of appropriate design and adequate capacity to function according to the study protocol. The testing facility management failed to adhere to these requirements.\nSpecifically, during the conduct of nonclinical laboratory studies (b)(4) and (b)(4), the testing facility management failed to ensure that equipment of appropriate design and adequate capacity was available to analyze the blood of rat and rabbit species for the protocol-required hematology and serum chemistry laboratory parameters. As a result, the testing facility failed to generate the following Day 15 data:\nHematology test results for male and female rats for Protocol (b)(4)\nSerum chemistry test results for male rats for Protocol (b)(4)\nHematology test results for male and female rabbits for Protocol (b)(4)\nAdditionally, the testing facility management did not cross-validate the equipment used to analyze blood samples, to demonstrate their ability to accurately analyze rat blood in Protocol (b)(4) or rabbit blood in Protocol (b)(4).\nWe acknowledge that the finding described above was not included on the Form FDA 483 you received, and that the observation on the Form FDA 483 was limited to the unreported hematology laboratory results for Day 15 female rats in the final study report for Protocol (b)(4). Therefore, your written responses to the Form FDA 483 do not directly address the extent of this finding as discussed in this letter.\nIn your April 11, 2025, written response to the Form FDA 483, regarding the unreported hematology results, you stated that you amended the final study reports to make the necessary corrections. The amended final study reports gave details of the equipment that your testing facility used for hematology laboratory parameters testing in the study animals, and they explained that the hematology results obtained using the equipment were below or above the range of the machine, and therefore no results were displayed on the equipment.\nWhile we acknowledge the corrective actions that your testing facility has taken regarding the unreported hematology results, your response is inadequate because we are unable to determine whether your testing facility will be able to ensure the availability of equipment of appropriate design and adequate capacity to evaluate protocol-required laboratory parameters in the animal species included in future nonclinical studies conducted at your testing facility. Because the testing facility management failed to ensure that appropriate equipment was available to conduct protocol-required laboratory assessments, FDA has concerns about the integrity of the data generated and reported from the nonclinical studies conducted at your testing facility.\n4. Failure of the testing facility to establish standard operating procedures in writing, setting forth nonclinical laboratory study methods that management is satisfied are adequate to insure the quality and integrity of the data generated in the course of the studies [21 CFR 58.81(a) and 58.81(b)].\nA testing facility must establish and follow written SOPs for nonclinical laboratory studies, to ensure the quality and integrity of the data generated in the studies. Your testing facility did not adhere to these requirements. For example, your testing facility failed to establish SOPs for:\na. Receipt, identification, storage, handling, mixing, and method of sampling of the test and control articles\nb. Test system observations\nc. Laboratory tests\nd. Handling of animals found to be moribund or dead during a study\ne. Collection and identification of specimens\nIn your April 11, 2025, written response to the Form FDA 483, and in your subsequent correspondence dated June 13, 2025, you acknowledged the observation and stated that you created an SOP titled “SOP Creation, Review, and Approval.” Additionally, you created SOPs for the five procedures that were identified as lacking, along with additional SOPs that were not previously established. You also revised existing SOPs to include versioning and dates. We acknowledge your corrective and preventive actions. However, we emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, it is your responsibility to establish SOPs before conducting nonclinical laboratory studies. You are also responsible for following your written SOPs to ensure consistency in study conduct and to ensure the quality and integrity of data generated during your studies.\nAs evidenced by FDA’s inspection findings, the deficiencies found in the oversight and conduct of the testing facility management and QAU at your testing facility demonstrate a failure to comply with FDA’s GLP regulations governing the conduct of nonclinical laboratory studies. As a result, FDA is concerned about the validity and integrity of the nonclinical data generated by your testing facility.\nWe emphasize that as a testing facility conducting nonclinical laboratory studies under 21 CFR 58, you are responsible for ensuring that nonclinical laboratory studies submitted to FDA are conducted and reported in accordance with FDA regulations to ensure the quality and integrity of study data. Your failure to conduct and report nonclinical studies in accordance with FDA regulations raises concerns about the validity and integrity of the data collected at your site.\nThis letter is not intended to be an all-inclusive list of deficiencies with the nonclinical laboratory studies of investigational drugs conducted at your testing facility. It is your responsibility to ensure adherence to each requirement of the law and relevant FDA regulations. You should address any deficiencies and establish procedures to ensure that any ongoing or future studies comply with FDA regulations.\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies noted above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions you have taken to prevent similar violations in the future. Failure to address this matter adequately may lead to regulatory action without further notice to you. If you believe that you have complied with the FD&C Act and relevant regulations, please include your reasoning and any supporting information for our consideration.\nYour written response, and any questions or concerns about this letter or the inspection, should be sent via email to the FDA at CDER-OSI-Communications@fda.hhs.gov.\nSincerely,\n{See appended electronic signature page}\nDavid C. Burrow, Pharm.D., J.D.\nDirector\nOffice of Scientific Investigations\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nDAVID C BURROW\n05\u002F19\u002F2026 12:58:47 PM","HealthPartners Neuroscience Center Research and Innovation","healthpartners-neuroscience-center-research-and-innovation-725333-05192026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fhealthpartners-neuroscience-center-research-and-innovation-725333-05192026","2026-10-26T08:08:53.733946+00:00","2026-06-02","725333","Leah R. Hanson, Ph.D.","2026-08-19T04:39:07.121+00:00","26-HFD-45-05-02","2026-05-19",{"id":332,"raw":333,"subject":337,"body_html":338,"body_text":339,"firm_name":340,"letter_id":341,"created_at":283,"fei_number":19,"letter_url":342,"updated_at":343,"action_type":22,"case_status":23,"posted_date":344,"marcs_cms_no":345,"product_type":68,"closeout_date":19,"issuing_office":57,"recipient_name":346,"body_fetched_at":347,"delivery_method":348,"recipient_title":19,"reference_number":349,"action_taken_date":350,"medical_device_id":19,"response_letter_date":19},1219,[334,335,336,57,337,13,13,13],"\u003Ctime datetime=\"2024-10-08T13:20:00Z\">10\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-27T04:00:00Z\">09\u002F27\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flouisiana-state-university-health-science-center-irb-686088-09272024\">Louisiana State University Health Science Center IRB\u003C\u002Fa>","Institutional Review Board (IRB)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>24-HFD-45-09-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Charles C. Coleman, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>IRB Chair\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Louisiana State University Health Science Center IRB\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>433 Bolivar Street, Suite 206\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Orleans\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70112\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA Ref. No.: 24-HFD-45-09-01\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Coleman:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between July 17, 2023, and July 26, 2023, of the Louisiana State University Health Science Center, New Orleans (LSUHSC) Institutional Review Board (IRB). Investigator Koffi A. Amegadje, representing FDA, conducted the inspection to determine whether the IRB’s procedures for the protection of human subjects complied with FDA regulations contained in Title 21 of the Code of Federal Regulations (21 CFR), parts 50 and 56. These regulations apply to clinical investigations of products regulated by FDA.\u003C\u002Fp>\n\n\u003Cp>This inspection is a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, Investigator Amegadje presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of the IRB’s August 16, 2023, written response to the Form FDA 483.\u003C\u002Fp>\n\n\u003Cp>From our review of the FDA Establishment Inspection Report, the documents submitted with that report, and the IRB’s August 16, 2023, written response, it appears that the IRB did not adhere to applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and FDA regulations governing the protection of human subjects.\u003C\u002Fp>\n\n\u003Cp>We wish to emphasize the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. The IRB failed to conduct continuing review of research at intervals of not less than once per year [21 CFR 56.109(f)]\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In order to fulfill the requirements of the IRB regulations, the IRB is required to conduct continuing review of previously approved research at intervals appropriate to the degree of risk, but not less than once per year [21 CFR 56.109(f)].\u003C\u002Fp>\n\n\u003Cp>Specifically, the LSUHSC IRB failed to conduct continuing review of research at least once per year for the following FDA-regulated studies:\u003C\u002Fp>\n\n\u003Cp>a. On August 8, 2019, the LSUHSC IRB approved Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” at a convened meeting. Continuing review for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;was due by August 7, 2020. However, the IRB did not conduct continuing review for this study until August 19, 2020 (a lapse of IRB approval for 12 days). The next IRB continuing review for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was due by August 18, 2021. However, the IRB did not conduct continuing review for this study until October 22, 2021 (a lapse of IRB approval for 78 days). We note that during the second lapse in IRB approval, between August 19, 2021, and September 29, 2021, study activity was ongoing, including enrollment of two subjects at clinical sites, and clinical site protocol deviations occurred.\u003C\u002Fp>\n\n\u003Cp>b. On January 15, 2021, the LSUHSC IRB approved Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong>, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” at a convened meeting. Continuing review for Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was due by January 14, 2022. However, the IRB did not conduct continuing review for this study until March 14, 2022 (a lapse of IRB approval for 59 days). The next IRB continuing review for Protocol \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>was due by March 13, 2023. However, the IRB did not conduct continuing review for this study until April 28, 2023 (a lapse of IRB approval for 46 days).\u003C\u002Fp>\n\n\u003Cp>We acknowledge that the studies listed above for failure to conduct continuing review of research at intervals of not less than once per year were not included on the Form FDA 483 you received, and therefore your written response does not address this violation for these clinical studies.\u003C\u002Fp>\n\n\u003Cp>However, in your August 16, 2023, written response, you stated that between June 2020 and July 2021, there were three episodes when the KUALI system did not send Continuing Review reminders as scheduled (45, 30, and 15 days before the Continuing Review date), and the KUALI system has been functioning properly since August 2021. You stated that the KUALI system sent at least one reminder to each clinical investigator for most of the studies identified during the inspection. You also stated that the IRB manually identified studies requiring continuing review during the KUALI system failure, and the IRB notified clinical investigators by email; however, you also stated that all relevant studies might not have been identified. You stated that you revised the notification schedule to send alerts at 60 days, 45 days, 30 days, 15 days, 7 days, and 1 day before the Continuing Review date.\u003C\u002Fp>\n\n\u003Cp>In your written response, you stated that the IRB plans to take the following corrective actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Performing random spot checks of renewal notification on a monthly basis\u003C\u002Fli>\n\t\u003Cli>Contacting the vendor with a “high priority ticket” if notifications issues are detected, and manual scheduling; and, if the issue is not resolved within 7 days, manually sending alerts until the issue is resolved\u003C\u002Fli>\n\t\u003Cli>Revision to your Standard Operating Procedure, SOP 3.02, to reflect the new notification schedule of 60 days, 45 days, 30 days, 15 days, 7 days, and 1 day before the Continuing Review date\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details regarding how the IRB (as opposed to the clinical investigator) would ensure that the IRB will conduct continuing review of research within the required time interval. While a clinical investigator has a responsibility to ensure that an IRB will conduct continuing review and approval of their study [21 CFR 312.66], the IRB still must conduct continuing review of research within the required interval, as required under 21 CFR part 56.\u003C\u002Fp>\n\n\u003Cp>Failure of the IRB to conduct continuing review at intervals of not less than once per year raises concerns about the adequacy of the IRB’s oversight of ongoing research that the IRB had previously approved.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. The IRB failed to prepare, maintain, and follow required written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and [the] Food and Drug Administration (FDA) [21 CFR 56.115(a)(6) and 56.108(b)(3)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>An IRB is required to prepare and maintain adequate documentation of IRB activities, including written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the FDA of any suspension or termination of IRB approval. The IRB must also follow such written procedures [21 CFR 56.108(b) and 56.115(a)(6)]. Furthermore, under 21 CFR 56.113, suspensions or terminations of IRB approval of FDA-regulated research must be reported promptly to the FDA.\u003C\u002Fp>\n\n\u003Cp>The IRB failed to adhere to these requirements. Specifically, the LSUHSC IRB’s written procedures fail to explicitly provide a procedure for reporting suspensions or terminations of IRB approval to the FDA. Additionally, the IRB failed to ensure that the suspension or termination of IRB approval for the following FDA-regulated studies was reported to the FDA:\u003C\u002Fp>\n\n\u003Cp>a. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on December 20, 2021.\u003Cbr>\nb. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on March 2, 2021.\u003Cbr>\nc. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on January 26, 2022.\u003Cbr>\nd. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on March 20, 2023.\u003Cbr>\ne. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on October 4, 2022.\u003Cbr>\nf. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on January 26, 2022.\u003Cbr>\ng. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on October 4, 2022.\u003Cbr>\nh. Protocol \u003Cstrong>(b)(4)\u003C\u002Fstrong> was administratively closed by the IRB on August 25, 2022.\u003C\u002Fp>\n\n\u003Cp>However, termination of IRB approval for the above-listed studies was not reported to the FDA.\u003C\u002Fp>\n\n\u003Cp>In your August 16, 2023, written response to the Form 483, you stated that the IRB failed to recognize administrative closures as instances of termination of IRB approval, and therefore did not take reporting actions as dictated by IRB policies and FDA regulations. You stated that the IRB plans to take the following corrective actions:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Educating IRB administrative staff annually on suspension and termination of IRB approval and related reporting requirements\u003C\u002Fli>\n\t\u003Cli>Creating an SOP on reporting incidents to the FDA that is similar to the IRB’s SOP HRP-2.01, “Reporting Incidents to [the] Office of [for] Human Research Protections (OHRP)”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>We are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the IRB procedures you are proposing to develop, and how you will ensure that these proposed written procedures will be followed to prevent repeat violations. Without these details, we are unable to determine whether your corrective action plan is adequate to prevent similar violations in the future.\u003C\u002Fp>\n\n\u003Cp>Failure of the IRB to prepare, maintain, and follow required written procedures raises concerns about the adequacy of the IRB’s review processes for ensuring the protection of the rights, safety, and welfare of human research subjects.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive list of deficiencies related to the IRB’s procedures or to the IRB’s review and approval of protocols. It is the IRB’s responsibility to ensure adherence to each requirement of the law and relevant FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the deficiencies described above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions that the IRB has taken or plans to take, to address any violations and to prevent the recurrence of similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that the IRB has complied with the FD&amp;C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We recommend that the IRB visit the following FDA Web page for information on human subject protections that may assist the IRB in its efforts to come into compliance with FDA regulations: http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm.\u003C\u002Fp>\n\n\u003Cp>If the IRB has any questions, you may email FDA at CDER-OSICommunications@fda.hhs.gov. The IRB’s written response and any pertinent documentation should be addressed to:\u003C\u002Fp>\n\n\u003Cp>Brittany L. Garr-Colón, M.P.H.\u003Cbr>\nBranch Chief\u003Cbr>\nCompliance Enforcement Branch\u003Cbr>\nDivision of Enforcement and Postmarketing Safety\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nBuilding 51, Room 5352\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nDavid C. Burrow, Pharm.D., J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Scientific Investigations\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>Cc: \u003Cstrong>(b)(6)\u003C\u002Fstrong>, Chancellor\u003Cbr>\nLouisiana State University Health Science Center\u003Cbr>\n433 Bolivar Street, Suite 815\u003Cbr>\nNew Orleans, Louisiana 70112\u003Cbr>\nReference ID: 5453362\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003Cbr>\nDAVID C BURROW\u003Cbr>\n09\u002F27\u002F2024 11:03:55 AM\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\n24-HFD-45-09-01\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nCharles C. Coleman, M.D.\n\nRecipient Title\n\nIRB Chair\n\nLouisiana State University Health Science Center IRB\n\n433 Bolivar Street, Suite 206\n\nNew Orleans, LA 70112\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nFDA Ref. No.: 24-HFD-45-09-01\n\nDear Dr. Coleman:\n\nThis Warning Letter informs you of objectionable conditions observed during the U.S. Food and Drug Administration (FDA) inspection conducted between July 17, 2023, and July 26, 2023, of the Louisiana State University Health Science Center, New Orleans (LSUHSC) Institutional Review Board (IRB). Investigator Koffi A. Amegadje, representing FDA, conducted the inspection to determine whether the IRB’s procedures for the protection of human subjects complied with FDA regulations contained in Title 21 of the Code of Federal Regulations (21 CFR), parts 50 and 56. These regulations apply to clinical investigations of products regulated by FDA.\n\nThis inspection is a part of FDA’s Bioresearch Monitoring Program, which includes inspections designed to evaluate the conduct of research and to help ensure that the rights, safety, and welfare of human subjects have been protected.\n\nAt the conclusion of the inspection, Investigator Amegadje presented and discussed with you the Form FDA 483, Inspectional Observations. We acknowledge receipt of the IRB’s August 16, 2023, written response to the Form FDA 483.\n\nFrom our review of the FDA Establishment Inspection Report, the documents submitted with that report, and the IRB’s August 16, 2023, written response, it appears that the IRB did not adhere to applicable statutory requirements in the Federal Food, Drug, and Cosmetic Act (FD&C Act) and FDA regulations governing the protection of human subjects.\n\nWe wish to emphasize the following:\n\n1. The IRB failed to conduct continuing review of research at intervals of not less than once per year [21 CFR 56.109(f)]\n\nIn order to fulfill the requirements of the IRB regulations, the IRB is required to conduct continuing review of previously approved research at intervals appropriate to the degree of risk, but not less than once per year [21 CFR 56.109(f)].\n\nSpecifically, the LSUHSC IRB failed to conduct continuing review of research at least once per year for the following FDA-regulated studies:\n\na. On August 8, 2019, the LSUHSC IRB approved Protocol (b)(4), “(b)(4),” at a convened meeting. Continuing review for Protocol (b)(4) was due by August 7, 2020. However, the IRB did not conduct continuing review for this study until August 19, 2020 (a lapse of IRB approval for 12 days). The next IRB continuing review for Protocol (b)(4) was due by August 18, 2021. However, the IRB did not conduct continuing review for this study until October 22, 2021 (a lapse of IRB approval for 78 days). We note that during the second lapse in IRB approval, between August 19, 2021, and September 29, 2021, study activity was ongoing, including enrollment of two subjects at clinical sites, and clinical site protocol deviations occurred.\n\nb. On January 15, 2021, the LSUHSC IRB approved Protocol (b)(4), “(b)(4),” at a convened meeting. Continuing review for Protocol (b)(4) was due by January 14, 2022. However, the IRB did not conduct continuing review for this study until March 14, 2022 (a lapse of IRB approval for 59 days). The next IRB continuing review for Protocol (b)(4) was due by March 13, 2023. However, the IRB did not conduct continuing review for this study until April 28, 2023 (a lapse of IRB approval for 46 days).\n\nWe acknowledge that the studies listed above for failure to conduct continuing review of research at intervals of not less than once per year were not included on the Form FDA 483 you received, and therefore your written response does not address this violation for these clinical studies.\n\nHowever, in your August 16, 2023, written response, you stated that between June 2020 and July 2021, there were three episodes when the KUALI system did not send Continuing Review reminders as scheduled (45, 30, and 15 days before the Continuing Review date), and the KUALI system has been functioning properly since August 2021. You stated that the KUALI system sent at least one reminder to each clinical investigator for most of the studies identified during the inspection. You also stated that the IRB manually identified studies requiring continuing review during the KUALI system failure, and the IRB notified clinical investigators by email; however, you also stated that all relevant studies might not have been identified. You stated that you revised the notification schedule to send alerts at 60 days, 45 days, 30 days, 15 days, 7 days, and 1 day before the Continuing Review date.\n\nIn your written response, you stated that the IRB plans to take the following corrective actions:\n\nPerforming random spot checks of renewal notification on a monthly basis\n\nContacting the vendor with a “high priority ticket” if notifications issues are detected, and manual scheduling; and, if the issue is not resolved within 7 days, manually sending alerts until the issue is resolved\n\nRevision to your Standard Operating Procedure, SOP 3.02, to reflect the new notification schedule of 60 days, 45 days, 30 days, 15 days, 7 days, and 1 day before the Continuing Review date\n\nWe are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details regarding how the IRB (as opposed to the clinical investigator) would ensure that the IRB will conduct continuing review of research within the required time interval. While a clinical investigator has a responsibility to ensure that an IRB will conduct continuing review and approval of their study [21 CFR 312.66], the IRB still must conduct continuing review of research within the required interval, as required under 21 CFR part 56.\n\nFailure of the IRB to conduct continuing review at intervals of not less than once per year raises concerns about the adequacy of the IRB’s oversight of ongoing research that the IRB had previously approved.\n\n2. The IRB failed to prepare, maintain, and follow required written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and [the] Food and Drug Administration (FDA) [21 CFR 56.115(a)(6) and 56.108(b)(3)].\n\nAn IRB is required to prepare and maintain adequate documentation of IRB activities, including written procedures for ensuring prompt reporting to the IRB, appropriate institutional officials, and the FDA of any suspension or termination of IRB approval. The IRB must also follow such written procedures [21 CFR 56.108(b) and 56.115(a)(6)]. Furthermore, under 21 CFR 56.113, suspensions or terminations of IRB approval of FDA-regulated research must be reported promptly to the FDA.\n\nThe IRB failed to adhere to these requirements. Specifically, the LSUHSC IRB’s written procedures fail to explicitly provide a procedure for reporting suspensions or terminations of IRB approval to the FDA. Additionally, the IRB failed to ensure that the suspension or termination of IRB approval for the following FDA-regulated studies was reported to the FDA:\n\na. Protocol (b)(4) was administratively closed by the IRB on December 20, 2021.\n\nb. Protocol (b)(4) was administratively closed by the IRB on March 2, 2021.\n\nc. Protocol (b)(4) was administratively closed by the IRB on January 26, 2022.\n\nd. Protocol (b)(4) was administratively closed by the IRB on March 20, 2023.\n\ne. Protocol (b)(4) was administratively closed by the IRB on October 4, 2022.\n\nf. Protocol (b)(4) was administratively closed by the IRB on January 26, 2022.\n\ng. Protocol (b)(4) was administratively closed by the IRB on October 4, 2022.\n\nh. Protocol (b)(4) was administratively closed by the IRB on August 25, 2022.\n\nHowever, termination of IRB approval for the above-listed studies was not reported to the FDA.\n\nIn your August 16, 2023, written response to the Form 483, you stated that the IRB failed to recognize administrative closures as instances of termination of IRB approval, and therefore did not take reporting actions as dictated by IRB policies and FDA regulations. You stated that the IRB plans to take the following corrective actions:\n\nEducating IRB administrative staff annually on suspension and termination of IRB approval and related reporting requirements\n\nCreating an SOP on reporting incidents to the FDA that is similar to the IRB’s SOP HRP-2.01, “Reporting Incidents to [the] Office of [for] Human Research Protections (OHRP)”\n\nWe are unable to perform an informed evaluation of the IRB’s written response because you did not provide a corrective action plan that, if properly carried out, would prevent the recurrence of this type of violation in the future. Specifically, you did not provide sufficient details on the IRB procedures you are proposing to develop, and how you will ensure that these proposed written procedures will be followed to prevent repeat violations. Without these details, we are unable to determine whether your corrective action plan is adequate to prevent similar violations in the future.\n\nFailure of the IRB to prepare, maintain, and follow required written procedures raises concerns about the adequacy of the IRB’s review processes for ensuring the protection of the rights, safety, and welfare of human research subjects.\n\nThis letter is not intended to be an all-inclusive list of deficiencies related to the IRB’s procedures or to the IRB’s review and approval of protocols. It is the IRB’s responsibility to ensure adherence to each requirement of the law and relevant FDA regulations.\n\nThis letter notifies you of our findings and provides you with an opportunity to address the deficiencies described above. Within 15 business days of your receipt of this letter, you should notify this office in writing of the actions that the IRB has taken or plans to take, to address any violations and to prevent the recurrence of similar violations in the future. Failure to address this matter adequately may lead to regulatory action. If you believe that the IRB has complied with the FD&C Act and FDA regulations, include your reasoning and any supporting information for our consideration.\n\nWe recommend that the IRB visit the following FDA Web page for information on human subject protections that may assist the IRB in its efforts to come into compliance with FDA regulations: http:\u002F\u002Fwww.fda.gov\u002FScienceResearch\u002FSpecialTopics\u002FRunningClinicalTrials\u002Fdefault.htm.\n\nIf the IRB has any questions, you may email FDA at CDER-OSICommunications@fda.hhs.gov. The IRB’s written response and any pertinent documentation should be addressed to:\n\nBrittany L. Garr-Colón, M.P.H.\n\nBranch Chief\n\nCompliance Enforcement Branch\n\nDivision of Enforcement and Postmarketing Safety\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nU.S. Food and Drug Administration\n\nBuilding 51, Room 5352\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993\n\nSincerely,\n\n{See appended electronic signature page}\n\nDavid C. Burrow, Pharm.D., J.D.\n\nDirector\n\nOffice of Scientific Investigations\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\nCc: (b)(6), Chancellor\n\nLouisiana State University Health Science Center\n\n433 Bolivar Street, Suite 815\n\nNew Orleans, Louisiana 70112\n\nReference ID: 5453362\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\nDAVID C BURROW\n\n09\u002F27\u002F2024 11:03:55 AM","Louisiana State University Health Science Center IRB","louisiana-state-university-health-science-center-irb-686088-09272024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flouisiana-state-university-health-science-center-irb-686088-09272024","2026-10-26T08:09:16.257991+00:00","2024-10-08","686088","Charles C. Coleman, M.D.","2026-08-19T22:30:56.744+00:00","VIA UPS and Electronic Mail","24-HFD-45-09-01","2024-09-27",{"id":352,"raw":353,"subject":359,"body_html":360,"body_text":361,"firm_name":362,"letter_id":363,"created_at":42,"fei_number":19,"letter_url":364,"updated_at":365,"action_type":22,"case_status":23,"posted_date":366,"marcs_cms_no":367,"product_type":368,"closeout_date":19,"issuing_office":369,"recipient_name":370,"body_fetched_at":371,"delivery_method":49,"recipient_title":19,"reference_number":19,"action_taken_date":372,"medical_device_id":19,"response_letter_date":19},1979,[354,355,356,357,358,13,13,13],"\u003Ctime datetime=\"2023-07-25T13:20:00Z\">07\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-05T04:00:00Z\">06\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023\">Stratus Biosystems, LLC dba CellGenuity Regenerative Science\u003C\u002Fa>"," Division of Biological Products Operations II","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jon D. Tryggestad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer and Co-Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Stratus Biosystems, LLC dba CellGenuity Regenerative Science\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>913 S Main St Ste 215\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Grapevine\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76051-7575\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Biological Products Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 5, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Warning Letter #OBPO 23-631303\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Lisa Sooter\u003Cbr>\nGeneral Counsel and Co-Owner\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Tryggestad and Ms. Sooter:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Stratus Biosystems, LLC (dba CellGenuity Regenerative Science or CellGenuity), located at 913 S Main St, Ste 215, Grapevine, TX 76051-7575, conducted between October 26, 2021 and November 10, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of products for allogeneic use, including an umbilical cord and amniotic membrane derived product, AmnioAMP-WJ™, and an amniotic fluid derived product, AmnioAllograft (collectively, “your products”).\u003Csup>\u003Cem>\u003Cstrong>1,2,3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> You distribute your products to healthcare providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered at the time of and after the inspection, including information regarding your products available online at cellgenuity.com, reflect that your products are intended to treat various diseases or conditions.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Your product derived from both umbilical cord and amniotic membrane, AmnioAMP-WJ™, is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of materials described above, Stratus Biosystems, LLC does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FP derived from umbilical cord and amniotic membrane fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>Specifically, an HCT\u002FP meets the criterion established by 21 CFR 1271.10(a)(2) if it is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” AmnioAMP-WJ™ is not intended to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using your product to treat orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\u003C\u002Fp>\n\n\u003Cp>Be advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your product derived from amniotic fluid, AmnioAllograft™, is regulated as a drug and biological product under section 351 of the PHS Act and the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved BLA nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during inspection, as discussed below. These deviations, involving over \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials of your products manufactured since March 2019, include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. \u003C\u002Fstrong>For example:\u003C\u002Fp>\n\n\u003Cp>a. The aseptic processes used to manufacture your products have not been validated (i.e., by performing media fill simulations). By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\u003C\u002Fp>\n\n\u003Cp>b. You have not established appropriate written procedures for environmental monitoring in the aseptic processing areas where your products are manufactured. For example, you do not have written procedures that require surface sampling, personnel monitoring, viable air monitoring, and non-viable particulate monitoring to be performed in association with each production run. Such procedures are important to detect problems and demonstrate control of the aseptic processing areas.\u003C\u002Fp>\n\n\u003Cp>c. Your written gowning procedure for personnel who perform aseptic processing is inadequate to protect your products from contamination. For example, in accordance with your written procedure:\u003C\u002Fp>\n\n\u003Cp>&nbsp; i. Personnel wear non-sterile gowning components, such as surgical masks and hairnets, while processing your products without any barrier between open products and personnel. Additionally, during the inspection, FDA investigators observed a technician with exposed skin processing your products.\u003C\u002Fp>\n\n\u003Cp>&nbsp; ii. Personnel don gowning in the unclassified shipping and receiving room prior to entering the cleanroom, which may increase the risk of introducing product contaminants.\u003C\u002Fp>\n\n\u003Cp>d. You have not established and followed written procedures for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> filter that comes into direct contact with your AmnioAllograft and AmnioAMP-WJ products during processing.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>2. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. You have not validated your process for cleaning and disinfecting the cleanrooms, the critical processing areas where your products are manufactured.\u003C\u002Fp>\n\n\u003Cp>b. According to your Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance”, your cleanrooms require cleaning with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> only \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong>-forming microorganisms are routinely detected in your environmental samples.\u003C\u002Fp>\n\n\u003Cp>c. Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance” lacks adequate instructions for cleaning and disinfection of your cleanrooms, including the disinfectant contact time and cleaning agents used. Additionally, this procedure does not require cleaning \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacture of batches nor is there data or rationale for the cleaning agents used.\u003C\u002Fp>\n\n\u003Cp>d. Your SOP SB-027 titled “Equipment Management and Cleaning” lacks adequate cleaning procedures for the equipment (e.g., incubators) used during aseptic processing operations, including but not limited to, use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> agent, frequency of disinfectants used, and disinfectant contact times. Additionally, this procedure does not address cleaning between batches.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)].\u003C\u002Fstrong> For example, you have not established scientifically sound and appropriate specifications and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing and endotoxin testing as measurements of product attributes.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> For example:\u003C\u002Fp>\n\n\u003Cp>a. The manufacturing processes for your products have not been validated with respect to identity, strength, quality, and purity.\u003C\u002Fp>\n\n\u003Cp>b. Prior to June 2021, you had not established written procedures for manufacturing AmnioAllograft™ or AmnioAMP-WJ™.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed, [21 CFR 211.192].\u003C\u002Fstrong> For example, you failed to thoroughly investigate the following sterility and environmental monitoring failures:\u003C\u002Fp>\n\n\u003Cp>a. From January 2021 and November 2021, your firm has had approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterility failures and \u003Cstrong>(b)(4)\u003C\u002Fstrong> endotoxin failures; however, you did not conduct any investigations to determine root cause or determine if any other product lots\u002Fbatches were affected by the failures. Examples of organisms identified in the sterility failures include&nbsp;\u003Cem>Cutibacterium acnes, Staphylococcus pasteuri,\u003C\u002Fem> and \u003Cem>Corynebacterium acnes.\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>b. From July 2021 and August 2021, your firm has had approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental monitoring failures in your critical processing areas where your products are manufactured. While you identified the contaminating organisms, you failed to provide evidence that you investigated these failures to determine the root cause, product impact, or corrective and preventative actions. Examples of organisms identified in your critical processing areas include \u003Cem>Bacillus\u003C\u002Fem> species \u003Cem>non-anthracis, Paenbacillus\u003C\u002Fem> species, and fungi.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)].\u003C\u002Fstrong> Specifically, you assigned a \u003Cstrong>(b)(4)\u003C\u002Fstrong>- to \u003Cstrong>(b)(4)\u003C\u002Fstrong>-year expiration date to your products without stability testing.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response, dated December 2, 2021, to FDA’s inspectional observations on the FDA-483 and have determined your response is inadequate to address the above-noted deficiencies. We acknowledge that you represent that “Stratus has stopped manufacture of products until such time as the FDA inspector observations can be addressed.” We also acknowledge your statement that Stratus “has responded to the facts cited in the observation and formulated its plans for action upon the most similar applicable rules under 21 CFR 1271 et seq.”\u003C\u002Fp>\n\n\u003Cp>While you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is also a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\u003C\u002Fp>\n\n\u003Cp>Your response also does not address the quantity of product inventory you may still have at your facility and your plans for its disposition. Furthermore, your response does not describe actions you have taken or plan to take to address the impact of the above-noted CGMP deficiencies on your distributed products that carry a \u003Cstrong>(b)(4)\u003C\u002Fstrong>- to \u003Cstrong>(b)(4)\u003C\u002Fstrong>-year shelf life and were manufactured under the above-described conditions.\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Sam Labinjo, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations, Division 2, 550 W. Jackson, Chicago, IL 66061 or emailed to Samuel.Labinjo@fda.hhs.gov. If you have any questions, please contact Mr. Labinjo at (312) 596-4254 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Karlton T. Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003C\u002Fp>\n\n\u003Cp>______________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your products or similar products were previously marketed under different names as follows: AmnioAllograft (previously AmnioAMP-PF) and AmnioAMP-WJ™ (previously AmnioAMP-EXS and Suspension EXS).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> You also manufactured and marketed amniotic membrane derived products, AmnioAMP-EXS-P and AmnioAMP-X. Based on the information provided, Amnio-EXS-P appeared to be intended to treat immunological diseases or conditions, and AmnioAMP-X appeared to be intended to treat orthopedic diseases or conditions. Such uses are not considered homologous use of amniotic membrane. It appears that these or similar products are currently marketed as AmnioAMP-WJ-P™ and Suspension Allograft, respectively. (AmnioAMP-X also appears the same or similar to amniotic membrane products, Suspension Sports Medicine and Suspension Spine.) Your amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Additionally, you manufacture a product derived from umbilical cord blood, Progenitor Cell Stem Cells (PCSC). Please be advised that PCSC must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This product or a similar product was previously marketed as CBX.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> For example, AmnioAMP-WJ™ and AmnioAllograft are marketed on your website as being made using your propriety PūrAMP process. Your website states, “PūRAMP PROCESSING preserves the products that can be used in a wide range of surgical and non-surgical applications.” This same webpage states, “PūrAMP SOLUTIONS DESIGNED FOR BROAD APPLICATIONS…NEURO\u002FSPINE…ORTHOPEDICS…CARDIAC…ONCOLOGY… NERVES…”\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJon D. Tryggestad\n\nRecipient Title\n\nChief Executive Officer and Co-Owner\n\nStratus Biosystems, LLC dba CellGenuity Regenerative Science\n\n913 S Main St Ste 215\n\nGrapevine, TX 76051-7575\n\nUnited States\n\nIssuing Office:\n\nDivision of Biological Products Operations II\n\nUnited States\n\nWARNING LETTER\n\nJune 5, 2023\n\nWarning Letter #OBPO 23-631303\n\nLisa Sooter\n\nGeneral Counsel and Co-Owner\n\nDear Mr. Tryggestad and Ms. Sooter:\n\nDuring an inspection of your firm, Stratus Biosystems, LLC (dba CellGenuity Regenerative Science or CellGenuity), located at 913 S Main St, Ste 215, Grapevine, TX 76051-7575, conducted between October 26, 2021 and November 10, 2021, the United States Food and Drug Administration (FDA) documented your manufacture of products for allogeneic use, including an umbilical cord and amniotic membrane derived product, AmnioAMP-WJ™, and an amniotic fluid derived product, AmnioAllograft (collectively, “your products”).1,2,3 You distribute your products to healthcare providers and facilities throughout the United States. These products are intended for injection and are purported to be sterile.\n\nInformation and records gathered at the time of and after the inspection, including information regarding your products available online at cellgenuity.com, reflect that your products are intended to treat various diseases or conditions.4 Additionally, information collected indicates your products fit within the definition of a biological product in the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. Your products are drugs as defined in section 201(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nYour product derived from both umbilical cord and amniotic membrane, AmnioAMP-WJ™, is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271. Such products are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of materials described above, Stratus Biosystems, LLC does not qualify for any exception in 21 CFR 1271.15, and your HCT\u002FP derived from umbilical cord and amniotic membrane fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, this HCT\u002FP is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nSpecifically, an HCT\u002FP meets the criterion established by 21 CFR 1271.10(a)(2) if it is “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” AmnioAMP-WJ™ is not intended to perform the same basic function or functions of umbilical cord and amniotic membrane in the recipient as in the donor, such as serving as a conduit (for umbilical cord) or serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero (for amniotic membrane). Rather, using your product to treat orthopedic diseases or conditions, for example, is not homologous use as defined in 21 CFR 1271.3(c).\n\nBe advised that the definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted bodily fluids, such as amniotic fluid, are generally not considered HCT\u002FPs subject to regulation under 21 CFR Part 1271. Amniotic fluid intended to treat diseases or conditions in humans is generally regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval. As such, your product derived from amniotic fluid, AmnioAllograft™, is regulated as a drug and biological product under section 351 of the PHS Act and the FD&C Act.\n\nTo lawfully market a drug that is a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312]. None of your products are the subject of an approved BLA nor is there an IND in effect for any of them. Based on this information, we have determined that your actions have violated the FD&C Act and the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the conclusion of the inspection, FDA investigators issued a Form FDA-483, List of Inspectional Observations, which described significant CGMP deviations applicable to your products. FDA identified additional significant deviations upon further review of the information collected during inspection, as discussed below. These deviations, involving over (b)(4) vials of your products manufactured since March 2019, include, but are not limited to, the following:\n\n1. Failure to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including procedures for validation of all aseptic and sterilization processes [21 CFR 211.113(b)]. For example:\n\na. The aseptic processes used to manufacture your products have not been validated (i.e., by performing media fill simulations). By the nature of their routes of administration, your products purport to be sterile and are expected to be sterile.\n\nb. You have not established appropriate written procedures for environmental monitoring in the aseptic processing areas where your products are manufactured. For example, you do not have written procedures that require surface sampling, personnel monitoring, viable air monitoring, and non-viable particulate monitoring to be performed in association with each production run. Such procedures are important to detect problems and demonstrate control of the aseptic processing areas.\n\nc. Your written gowning procedure for personnel who perform aseptic processing is inadequate to protect your products from contamination. For example, in accordance with your written procedure:\n\ni. Personnel wear non-sterile gowning components, such as surgical masks and hairnets, while processing your products without any barrier between open products and personnel. Additionally, during the inspection, FDA investigators observed a technician with exposed skin processing your products.\n\nii. Personnel don gowning in the unclassified shipping and receiving room prior to entering the cleanroom, which may increase the risk of introducing product contaminants.\n\nd. You have not established and followed written procedures for the (b)(4) sterilization of the (b)(4) filter that comes into direct contact with your AmnioAllograft and AmnioAMP-WJ products during processing.\n\n2. Failure to have an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions [21 CFR 211.42(c)(10)(v)]. For example:\n\na. You have not validated your process for cleaning and disinfecting the cleanrooms, the critical processing areas where your products are manufactured.\n\nb. According to your Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance”, your cleanrooms require cleaning with a (b)(4) only (b)(4). (b)(4)-forming microorganisms are routinely detected in your environmental samples.\n\nc. Standard Operating Procedure (SOP) SB-024 titled “Clean Environment Cleaning and Maintenance” lacks adequate instructions for cleaning and disinfection of your cleanrooms, including the disinfectant contact time and cleaning agents used. Additionally, this procedure does not require cleaning (b)(4) manufacture of batches nor is there data or rationale for the cleaning agents used.\n\nd. Your SOP SB-027 titled “Equipment Management and Cleaning” lacks adequate cleaning procedures for the equipment (e.g., incubators) used during aseptic processing operations, including but not limited to, use of a (b)(4) agent, frequency of disinfectants used, and disinfectant contact times. Additionally, this procedure does not address cleaning between batches.\n\n3. Failure to establish laboratory controls that include scientifically sound and appropriate specifications designed to assure that drug products conform to appropriate standards of identity, strength, quality, and purity [21 CFR 211.160(b)]. For example, you have not established scientifically sound and appropriate specifications and test procedures to assure that your products conform to appropriate standards of identity, strength, quality, and purity. Your finished product testing is limited to sterility testing and endotoxin testing as measurements of product attributes.\n\n4. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. For example:\n\na. The manufacturing processes for your products have not been validated with respect to identity, strength, quality, and purity.\n\nb. Prior to June 2021, you had not established written procedures for manufacturing AmnioAllograft™ or AmnioAMP-WJ™.\n\n5. Failure to thoroughly investigate any unexplained discrepancy, or the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed, [21 CFR 211.192]. For example, you failed to thoroughly investigate the following sterility and environmental monitoring failures:\n\na. From January 2021 and November 2021, your firm has had approximately (b)(4) sterility failures and (b)(4) endotoxin failures; however, you did not conduct any investigations to determine root cause or determine if any other product lots\u002Fbatches were affected by the failures. Examples of organisms identified in the sterility failures include Cutibacterium acnes, Staphylococcus pasteuri, and Corynebacterium acnes.\n\nb. From July 2021 and August 2021, your firm has had approximately (b)(4) environmental monitoring failures in your critical processing areas where your products are manufactured. While you identified the contaminating organisms, you failed to provide evidence that you investigated these failures to determine the root cause, product impact, or corrective and preventative actions. Examples of organisms identified in your critical processing areas include Bacillus species non-anthracis, Paenbacillus species, and fungi.\n\n6. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, you assigned a (b)(4)- to (b)(4)-year expiration date to your products without stability testing.\n\nWe have reviewed your written response, dated December 2, 2021, to FDA’s inspectional observations on the FDA-483 and have determined your response is inadequate to address the above-noted deficiencies. We acknowledge that you represent that “Stratus has stopped manufacture of products until such time as the FDA inspector observations can be addressed.” We also acknowledge your statement that Stratus “has responded to the facts cited in the observation and formulated its plans for action upon the most similar applicable rules under 21 CFR 1271 et seq.”\n\nWhile you assert that your products should only be regulated under section 361 of the PHS Act, the available evidence shows that your products do not meet the relevant criteria. Your response also does not adequately address your failure to have an IND in effect to study your products and your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is also a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect for that product, as specified by FDA regulations, that covers such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR Part 312].\n\nYour response also does not address the quantity of product inventory you may still have at your facility and your plans for its disposition. Furthermore, your response does not describe actions you have taken or plan to take to address the impact of the above-noted CGMP deficiencies on your distributed products that carry a (b)(4)- to (b)(4)-year shelf life and were manufactured under the above-described conditions.\n\nNeither this letter nor the observations noted on the FDA-483, which were discussed with you at the conclusion of the inspection, are intended to be an all-inclusive list of deficiencies associated with your products. It is your responsibility to ensure full compliance with the law.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Tissues and Advanced Therapies, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot complete all corrections within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nYour response should be sent to the following address: Sam Labinjo, Compliance Officer, U.S. Food and Drug Administration, Office of Biological Products Operations, Division 2, 550 W. Jackson, Chicago, IL 66061 or emailed to Samuel.Labinjo@fda.hhs.gov. If you have any questions, please contact Mr. Labinjo at (312) 596-4254 or via e-mail.\n\nSincerely,\n\n\u002FS\u002F\n\nKarlton T. Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2\n\n______________________________\n\n1 Your products or similar products were previously marketed under different names as follows: AmnioAllograft (previously AmnioAMP-PF) and AmnioAMP-WJ™ (previously AmnioAMP-EXS and Suspension EXS).\n\n2 You also manufactured and marketed amniotic membrane derived products, AmnioAMP-EXS-P and AmnioAMP-X. Based on the information provided, Amnio-EXS-P appeared to be intended to treat immunological diseases or conditions, and AmnioAMP-X appeared to be intended to treat orthopedic diseases or conditions. Such uses are not considered homologous use of amniotic membrane. It appears that these or similar products are currently marketed as AmnioAMP-WJ-P™ and Suspension Allograft, respectively. (AmnioAMP-X also appears the same or similar to amniotic membrane products, Suspension Sports Medicine and Suspension Spine.) Your amniotic membrane derived products must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271.\n\n3 Additionally, you manufacture a product derived from umbilical cord blood, Progenitor Cell Stem Cells (PCSC). Please be advised that PCSC must meet all the criteria at 21 CFR 1271.10(a), including the homologous use only criterion at 21 CFR 1271.10(a)(2), to be regulated solely under section 361 of the Public Health Service Act and the regulations in 21 CFR Part 1271. This product or a similar product was previously marketed as CBX.\n\n4 For example, AmnioAMP-WJ™ and AmnioAllograft are marketed on your website as being made using your propriety PūrAMP process. Your website states, “PūRAMP PROCESSING preserves the products that can be used in a wide range of surgical and non-surgical applications.” This same webpage states, “PūrAMP SOLUTIONS DESIGNED FOR BROAD APPLICATIONS…NEURO\u002FSPINE…ORTHOPEDICS…CARDIAC…ONCOLOGY… NERVES…”","Stratus Biosystems, LLC dba CellGenuity Regenerative Science","stratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstratus-biosystems-llc-dba-cellgenuity-regenerative-science-631303-06052023","2026-10-26T08:10:06.541654+00:00","2023-07-25","631303","Biologics","Division of Biological Products Operations II","Jon D. Tryggestad","2026-08-20T00:51:52.85+00:00","2023-06-05",{"id":374,"raw":375,"subject":58,"body_html":380,"body_text":381,"firm_name":382,"letter_id":383,"created_at":42,"fei_number":19,"letter_url":384,"updated_at":385,"action_type":22,"case_status":23,"posted_date":386,"marcs_cms_no":19,"product_type":68,"closeout_date":19,"issuing_office":387,"recipient_name":388,"body_fetched_at":389,"delivery_method":390,"recipient_title":19,"reference_number":19,"action_taken_date":391,"medical_device_id":19,"response_letter_date":19},1837,[376,377,378,379,58,13,13,13],"\u003Ctime datetime=\"2023-09-19T13:20:00Z\">09\u002F19\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-01T04:00:00Z\">08\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national\">Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East VI","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL AND UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Maria S. LeMay-Bey, Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Isaiah Orton-Bey, Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16136 W. 7 Mile Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Detroit\u003C\u002Fspan>, \u003Cspan>MI\u003C\u002Fspan> \u003Cspan>48235\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Moorherbs13@gmail.com\"> Moorherbs13@gmail.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East VI\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS Case #655674\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 1, 2023\u003Cbr>\n\u003Cbr>\nDear Isaiah Orton-Bey and Maria LeMay-Bey:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) has conducted an inspection of your manufacturing facility at 16136 W. 7 Mile Road, Livonia, MI 48235-2903 from February 13, 2023 to March 16, 2023. Additionally, FDA reviewed your website at https:\u002F\u002Fmoorherbs.com in May 2023. The inspection and our review of your website revealed serious violations of the Federal Food, Drug, and Cosmetic Act (the FD&amp;C Act) and FDA regulations. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your response to the FDA 483 on April 3, 2023. We address your response below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs and Misbranded Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA reviewed your website, https:\u002F\u002Fmoorherbs.com, in May 2023 and has determined that you take orders there for the products “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Appendix Support,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Cardiovascular System,” “Headache &amp; Pain Relief,” “Healthy Mommy Healthy Baby,” “Quit Smoking,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThyroidism” (also referred to as “HypoThyroid Support”), “Mucus Release,” “Parasite Cleanse,” “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Un-Vax,” “Venereal Defense,” “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”), and “Lungs &amp; Respiratory.” The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>\u003Cbr>\nOn the “Full Body Antibiotic” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Full Body Antibiotic” or “AntiBiotic, Full Body”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ AntiBiotic Formulae targets it all! Use it to help heal respiratory and sinus infections, bronchitis, pneumonia, strep throat, colds, flues [sic], colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, smallpox, enlarged spleen, swelling, asthma, eye cataracts, depression, digestion problems, stomach ulcers, heart trouble, infections, migraine, stroke, pain, . . . as well as urinary tract, kidney, and bladder infections.”\u003Cbr>\n• “Also beneficial for women with yeast infections, trichonomosas, bacterial vaginosis, and chlamydia.”\u003Cbr>\n• “It can be helpful for people with chronic fatigue, HIV, cancer, herpes, and other chronic conditions related with depressed immunity.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Anti-Viral”\u003C\u002Fu>\u003Cbr>\nOn the “Anti-Viral” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Anti-Viral”\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Anti-Viral Formulae is a potent and effective herbal anti-viral conducive for countering all viral conditions.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Appendix Support”\u003C\u002Fu>\u003Cbr>\nOn the “Appendix Support” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs High Science Appendix Support herbal blend is formulated to address the issues that lead to appendicitis: Constipation, Inflammation, and Infection.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Blood Pressure” (also referred to as “Blood Pressure Normalizer”)\u003C\u002Fu>\u003Cbr>\nOn the “Blood Pressure” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Blood Pressure Normalizer”\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Blood Pressure Normalizor [sic] is supported by an Indian medicinal herb belonging to Caesalpiniaceae family of plants.…What makes these seeds really popular, is their ability to lower blood pressure. Acting as a hypotensive agent, this humble seed works wonders for those looking to control their BP naturally.”\u003Cbr>\n• “It is a strong anti bacterial agent...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Brain Tune-Up”\u003C\u002Fu>\u003Cbr>\nOn the “Brain Tune-Up” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “The 2 main ingredients in this blend are Gotu Kola and Ginko Biloba[.] Gotu Kola Leaf… is anti-inflammatory, antiviral, antibacterial, . . . and antifungal. In human studies, gotu kola . . . reduced symptoms of anxiety and depression. It has been used to treat brain-related disorders including mental fatigue, anxiety, depression, memory loss, and insomnia.”\u003Cbr>\n• “Protects the brain from damage”\u003Cbr>\n• “Alleviates stress, anxiety, and depression”\u003Cbr>\n• “Improves memory and mood in Alzheimer’s patients”\u003Cbr>\n• “Ginko Biloba has been repeatedly evaluated for its ability to reduce anxiety, stress and other symptoms associated with Alzheimer’s disease …”\u003Cbr>\n• “Can Help Fight Inflammation.”\u003Cbr>\n• “Reduces Symptoms of Psychiatric Disorders and Dementia.”\u003Cbr>\n• “Can Reduce Anxiety.”\u003Cbr>\n• “Can Treat Depression.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Cardiovascular System”\u003C\u002Fu>\u003Cbr>\nOn the “Cardiovascular System” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “This ‘High Science’ Formula is designed to rebuild a degenerative heart...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Headache &amp; Pain Relief”\u003C\u002Fu>\u003Cbr>\nOn the “Headache &amp; Pain Relief” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Headache &amp; Pain Relief”\u003Cbr>\n• “Our Headache and Pain formula is a natural anodyne concoction that contains plants naturally rich in salicin that naturally breaks down into salicylic acid in the body that is anti-inflammatory in nature and thus effective where there is pain, which is a sensor that something is wrong on a deeper level.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Healthy Mommy Healthy Baby”\u003C\u002Fu>\u003Cbr>\nOn the “Healthy Mommy Healthy Baby” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Note: This blend is also helpful for the following conditions: anemia, low blood, arthritis, asthma, hay fever, sinusitis, gout, emphysema, bronchitis, sinus relief, allergies, high blood pressure, nosebleeds, hemorrhaging, miscarriage (vitamin K), hardened arteries, tooth decay, peptic ulcers, duodenum ulcers, infections, drug and chemical toxins, skin problems, edema, water retention, bowels, gas pains...”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Quit Smoking”\u003C\u002Fu>\u003Cbr>\nOn the “Quit Smoking” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Quit Smoking”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Quit Smoking Formulae is a herbal compound of Nature’s best herbs that have been utilized traditionally to help purify the bloodstream of pollutants and toxins, cleanse the liver…and develop a distaste of insidious addictive man- chemicals.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“HyperThyroidism” (also referred to as “HyperThyroid Support”)\u003C\u002Fu>\u003Cbr>\nOn the “HyperThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “HyperThyroidism” or “HyperThyroid Support”\u003Cbr>\n• “For an overactive Thyroid”\u003Cbr>\n• “Moor Herbs High Science HyperThyroidism Relief Formulae is designed for an over-active thyroid gland. Effective for calming down an overactive thyroid and reducing symptoms of hyperthyroidism such as agitation, restlessness, sweating and insomnia.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“HypoThyroidism” (also referred to as “HypoThyroid Support”)\u003C\u002Fu>\u003Cbr>\nOn the “HypoThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “HypoThyroidism” or “HypoThyroid Support”\u003Cbr>\n• “For an underactive Thyroid”\u003Cbr>\n• “Moor Herbs High Science Thyroid Support Formula consists of Nature’s plants high in organic iodine and which perform a myriad of beneficial functions for the thyroid gland including…normalizing the function of metabolism. An impaired thyroid gland can lead to a host of negative health problems so good thyroid health is imperative for overall good health.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Mucus Release”\u003C\u002Fu>\u003Cbr>\nOn the “Mucus Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Mucus Release is a powerful ‘High Science’ formula that consists of effective expectorant herbs that help dissolve hardened, stubborn mucus and phlegm that obstruct the mucous membranes and lead to pathology throughout the body…Mucus Release is great for all mucus conditions!”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Parasite Cleanse”\u003C\u002Fu>\u003Cbr>\nOn the “Parasite Cleanse” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Parasite Cleanse”\u003Cbr>\n• “Parasite Cleanse ‘High Science’ Formula contain[s] some of Nature’s best anthelmintic herbs that have been traditionally used for centuries by various cultures to remove parasites and worms from the tissues of the body. These creepy critters most certainly rob the body of nutrients and impair critical functions of the organs, glands, and systems of the body.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“ResErection Extra Strength w\u002F Yohimbe Bark”\u003C\u002Fu>\u003Cbr>\nOn the “ResErection Extra Strength w\u002F Yohimbe Bark” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Resurrection formulae, is a 100% all-natural herbal-based formula for men experiencing difficulty with attaining and maintaining an erection (penile erectile dysfunction) with the root cause being poor circulation due to poor diet (and lifestyle) – a diet too high in animal protein (meat, flesh, cadavaer, carion, etc.) and animal fat which clogs the veins and arteries and thus impairing circulation which is vital for a healthy, solid, firm, and stiff erection.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Tumor Release” (also referred to as “Tumor &amp; Cyst Support”)\u003C\u002Fu>\u003Cbr>\nOn the “Tumor Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Tumor Release” or “Tumor &amp; Cyst Support”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Tumor Release Formulae is a safe, sane and effective plant-based anti-neoplastic formulae that is helpful in natural, noninvasive, benign and malignant tumor dissolution.”\u003Cbr>\n• “The formula is useful for all tumor and cyst formations in the body, including uterine and ovarian cysts\u002Ftumors. Good for both internal and external tumors.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Un-Vax”\u003C\u002Fu>\u003Cbr>\nOn the “Un-Vax” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• “Our Moor Herbs ‘HIGH SCIENCE’ Herbal UN-VAX Formulae is an unique formula designed to remove heavy metal toxins from the body. It is an ideal Formulae to combat mercury (ethyl and methyl) toxicity and aluminum toxicity, both of which are known to cause a plethora of adverse health conditions, especially in children.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Venereal Defense”\u003C\u002Fu>\u003Cbr>\nOn the “Venereal Defense” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Venereal Defense”\u003Cbr>\n• “Our Moor Herbs High Science Venereal Defense Formulae helps foment natural healing of adverse conditions that are passed on from one person to another through intimate contact.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”)\u003C\u002Fu>\u003Cbr>\nOn the “Womb Care Cramp Relief &amp; Fibroid Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003Cbr>\n• The product name: “Womb Care Cramp Relief &amp; Fibroid Release” or “Womb Care: Fibroid and Tumor Release”\u003Cbr>\n• “Our Moor Herbs ‘High Science’ Fibroid\u002FTumor Release Formulae is an all-natural herbal formulation consisting of Nature’s herbs that have an affinity for the female uterus, e.g. Chaste berry and Dong Quai and that are also anti-neoplastic (anti-tumor growth and formation) in nature, e.g. Burdock and Comfrey, thus combating tumorous growth on the uterus, e.g. fibroid tumors or uterine fibroids, facilitating dissolution via the vaginal canal and other eliminative channels.”\u003Cbr>\n• “Fibroids\u002FTumor Release, is a product that can be used in an overall regimen to help females naturally dissolve tumors of the reproductive system and is a great post Womb Cleanse formulae to consume daily.”\u003Cbr>\n• “Recommended for: Uterine fibroids or fibroid tumors, cervical tumors, uterine cysts.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>“Lungs &amp; Respiratory”\u003C\u002Fu>\u003Cbr>\nOn the “Lungs &amp; Respiratory” product webpage of your website https:\u002F\u002Fmoorherbs.com:\u003C\u002Fp>\n\n\u003Cp>• “This High Science Formula is a highly effective anti-tussive and expectorant science formulae.”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&amp;C Act [21 U.S.C. 321(p)].\u003C\u002Fp>\n\n\u003Cp>With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&amp;C Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor &amp; Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief &amp; Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Adulterated Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>The dietary supplements manufactured at your facility are adulterated under section 402(g)(1) of the FD&amp;C Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111). During the inspection of your facility, FDA investigators observed the following significant violations of the CGMP regulation for dietary supplements:\u003C\u002Fp>\n\n\u003Cp>1. You failed to establish the specifications required under 21 CFR 111.70. Specifically:\u003C\u002Fp>\n\n\u003Cp>a. You failed to establish the following required component specifications under 21 CFR 111.70(b) for each component that you use in the manufacture of a dietary supplement: (1) identity specifications, as required by 21 CFR 111.70(b)(1); and (2) component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, when our investigators requested such component specifications for the Coltsfoot, Wild Cherry Bark, and Boneset Herb ingredients used in the manufacturing of your “Lungs &amp; Respiratory” finished dietary supplement product, you were unable to provide such component specifications. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing component specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>b. You failed to establish specifications for dietary supplement labels (labeling specifications), as required by 21 CFR 111.70(d). Specifically, you were unable to provide labeling specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you are in the process of establishing written labeling specifications. We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>c. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you were unable to provide finished product specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing product specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>We note that once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, once you have established component specifications and before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c).\u003C\u002Fp>\n\n\u003Cp>You must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\u003C\u002Fp>\n\n\u003Cp>2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103, and make and keep records of such procedures, as required by 21 CFR 111.140(b)(1). Specifically, you told our investigators that you have no written procedures for quality control operations and that you do not have a quality control program in place.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of implementing quality control operations to ensure the quality of dietary supplements” and “are also in the process of establishing written procedures and training quality control personnel to ensure all is produced safely, accurately, and according to the standards we have, and are putting, in place.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>3. You did not prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Upon request, you could not provide written MMRs for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs &amp; Respiratory” finished dietary supplement products to our investigators. You stated that you did not have these records, and none were provided.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of establishing Master Manufacturing Records for each dietary supplement and size.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>4. Your batch production record did not include complete information relating to the production and control of each batch, as required under 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, batch production records for “Anti-Viral” manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”) manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, and “Lungs &amp; Respiratory” manufactured on \u003Cstrong>(b)(4)\u003C\u002Fstrong> with lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, were collected and reviewed. These records do not include complete information required to be in batch production records. The required information that your records are missing includes, but is not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>• The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)];\u003Cbr>\n• The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)]; The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)];\u003Cbr>\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)];\u003Cbr>\n• The actual results obtained during any monitoring operation [21 CFR 111.260(g)];\u003Cbr>\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\u003Cbr>\n• Documentation at the time of performance of the manufacture of the batch, including [21 CFR 111.260(j)]:\u003Cbr>\no The date on which each step of the MMR was performed [21 CFR 111.260(j)(1)]; and\u003Cbr>\no The initials of the persons performing each step [21 CFR 111.260(j)(2)], including:\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for weighing or measuring each component used in the batch;\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for verifying the weight or measure of each component used in the batch;\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for adding the component to the batch; and\u003Cbr>\n&nbsp; &nbsp; &nbsp;  The initials of the person responsible for verifying the addition of components to the batch;\u003Cbr>\n• Documentation at the time of performance of packaging and labeling operations [21 CFR 111.260(k)], including:\u003Cbr>\n&nbsp; &nbsp; o The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels [21 CFR 111.260(k)(1)];\u003Cbr>\n&nbsp; &nbsp; o An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the MMR [21 CFR 111.260(k)(2)]; and\u003Cbr>\n&nbsp; &nbsp; o The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)(3)];\u003Cbr>\n• Documentation at the time of performance that quality control personnel [21 CFR 111.260(l):\u003Cbr>\n&nbsp; &nbsp; o Reviewed the batch production record [21 CFR 111.260(l)(1), including:\u003Cbr>\n Review of any monitoring operation required under subpart E of 21 CFR part 111 [21 CFR 111.260(l)(i)]; and\u003Cbr>\n Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements [21 CFR 111.260(l)(ii)];\u003Cbr>\n&nbsp; &nbsp; o Approved or rejected any reprocessing or repackaging [21 CFR 111.260(l)(2)]; and\u003Cbr>\n&nbsp; &nbsp; o Approved and released, or rejected, the batch for distribution, including any reprocessed batch [21 CFR 111.260(l)(3)]; and\u003Cbr>\n&nbsp; &nbsp; o Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement [21 CFR 111.260(l)(4)].\u003Cbr>\n• Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)];\u003Cbr>\n• Documentation at the time of performance of any reprocessing [21 CFR 111.260(n)].\u003C\u002Fp>\n\n\u003Cp>We have reviewed your written response received on April 3, 2023, in which you state that you “are still in the process of establishing and implementing the systems (as discussed throughout this document and the investigators observations) that will allow us to produce complete batch records.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>5. You failed to establish and follow written procedures for the requirements to review and investigate a product complaint, as required under 21 CFR 111.553. Specifically, our investigators requested your written procedures to review and investigate a product complaint. You stated that you did not have this procedure, and you did not provide it.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state, “We’ve been operating since March of 2015 and have never received a complaint. However, we are in the process of establishing written procedures for reviewing and investigating product\u002Fcustomer complaints.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>6. You failed to establish and follow written procedures for when a returned dietary supplement is received, as required under 21 CFR 111.503. Specifically, our investigators requested your written procedures for when a returned dietary supplement is received. You stated that you did not have these written procedures, and none were provided.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for when a returned dietary supplement is received.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>7. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR 111.453. Specifically, during the inspection, you said you had not established written procedures for holding and distributing operations.\u003C\u002Fp>\n\n\u003Cp>Once have you established written procedures for your holding and distributing operations, you must make and keep records of such written procedures, as required by 21 CFR 111.475(b)(1).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for holding and distributing operations.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>8. You did not maintain and clean equipment, utensils, and contact surfaces used to manufacture, package, label, or hold components or dietary supplements, as required under 21 CFR 111.27(d). P\u003C\u002Fp>\n\n\u003Cp>Specifically, on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, during the manufacturing of your “Lungs &amp; Respiratory” finished dietary supplement product, your multi-functional grinder was observed with a light green and brown residue inside the bowl and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> plastic capsule filling equipment was observed with a light brown powder and brown staining. Furthermore, the method you used for cleaning and sanitizing your utensils and equipment does not align with, and directly contradicts, the manufacturer’s written instructions on the cleaning and sanitizing products. Additionally, you do not have any written procedures for cleaning or sanitizing your utensils and equipment, as required under 21 CFR 111.25(c).\u003C\u002Fp>\n\n\u003Cp>We have reviewed your April 3, 2023, written response, in which you state that you “have since corrected the way we wash and sanitize our utensils and equipment, according to the instructions indicated on the cleaning agents we use, combined with regulations outlined under Michigan Food Law.” These corrections will be evaluated during the next FDA inspection of your firm. You also stated in your response that you “are in the process of establishing written procedures for cleaning and sanitizing utensils and equipment.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Dietary Supplements\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition, your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”),, “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded dietary supplements under Section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101 as follows:\u003C\u002Fp>\n\n\u003Cp>1. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the labels is are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Lungs and Respiratory, Full Body Antibiotic, Antiviral, Blood Pressure Normalizer, Headache &amp; Pain Relief, and Bright Eyes product labels’ serving sizes is declared as “3 Capsules or 3 Scoops” and are not specific to each product.\u003C\u002Fp>\n\n\u003Cp>2. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of sections 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling of the products does not comply with 21 CFR 101.36. Specifically,\u003Cbr>\n• The title “Supplement Facts” is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\u003Cbr>\n• The dietary ingredients are not indented under the title “Proprietary Herbal Blend”, in accordance with 21 CFR 101.36(c)(2).\u003Cbr>\n• The quantitative amount by weight per serving of proprietary blend does not use metric measures in appropriate units (i.e., 1000 units must be declared in the next higher set of units, e.g., 10000 mg must be expressed as 10 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A).\u003C\u002Fp>\n\n\u003Cp>3. Your Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>,, “Headache &amp; Pain Relief,\" and “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) products are misbranded within the meaning of section 403(s)(2)(C) of the Act [U.S.C. § 343(s)(2)(C)] in that the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1) and 101.36(d)(1). If the whole or entire part is used, this must be declared.\u003C\u002Fp>\n\n\u003Cp>4. Your “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) and “Headache &amp; Pain Relief” products are misbranded within the meaning of section 403(i)(2) of the Act in that the labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h). For example:\u003Cbr>\n• The Blood Pressure Normalizer product label lists “manjishtha”, but this is not the standardized common name of the dietary ingredient. The label must list the standardized common name (SCN) given in the reference Herbs of Commerce, “Indian madder”. The Ayurvedic name for Indian madder (manjishtha) may follow the SCN in parentheses.\u003Cbr>\n• The SCN for the term “Chaksu” must be declared; in the absence of a SCN, the Latin binomial name must be declared.\u003Cbr>\n• The Headache &amp; Pain Relief product declares “dashmoola”. The dietary ingredient(s) that make up the “dashmoola” must be declared by the SCN; in the absence of a SCN, the Latin binomial name for the dietary ingredient must be declared.\u003C\u002Fp>\n\n\u003Cp>5. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(i)(2) [21 U.S.C. § 343(i)(2)] of the Act because the labels fail to declare all ingredients, as required by 21 CFR 101.4. Specifically, the products fail to declare the ingredients of the capsule material.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>We offer the following additional comments:\u003C\u002Fp>\n\n\u003Cp>1. Your “Lungs and Respiratory,” \u003Cu>“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\u003C\u002Fu>, “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache &amp; Pain Relief,” and “Bright Eyes” product labels do not bear a symbol next to the structure\u002Ffunction claim linking the claim to the disclaimer. Furthermore, the disclaimer fails to be enclosed in a box, in accordance with 21 CFR 101.93(d).\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the U.S. Food and Drug Administration; Attn: Katie Cutajar, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov, or at 300 River Place Suite 5900, Detroit, MI 48207. If you have questions regarding this letter, please contact CO Cutajar at (313) 680-6962 or via email at Kathryn.Cutajar@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>William R. Weissinger, MS\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast Division 6\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL AND UNITED PARCEL SERVICE\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMaria S. LeMay-Bey, Owner\n\nRecipient Title\n\nIsaiah Orton-Bey, Owner\n\nMoorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.\n\n16136 W. 7 Mile Road\n\nDetroit, MI 48235\n\nUnited States\n\nMoorherbs13@gmail.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East VI\n\nUnited States\n\nWARNING LETTER\n\nCMS Case #655674\n\nAugust 1, 2023\n\nDear Isaiah Orton-Bey and Maria LeMay-Bey:\n\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) has conducted an inspection of your manufacturing facility at 16136 W. 7 Mile Road, Livonia, MI 48235-2903 from February 13, 2023 to March 16, 2023. Additionally, FDA reviewed your website at https:\u002F\u002Fmoorherbs.com in May 2023. The inspection and our review of your website revealed serious violations of the Federal Food, Drug, and Cosmetic Act (the FD&C Act) and FDA regulations. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nAt the close of the inspection, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We received your response to the FDA 483 on April 3, 2023. We address your response below.\n\nUnapproved New Drugs and Misbranded Drugs\n\nFDA reviewed your website, https:\u002F\u002Fmoorherbs.com, in May 2023 and has determined that you take orders there for the products “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Appendix Support,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Cardiovascular System,” “Headache & Pain Relief,” “Healthy Mommy Healthy Baby,” “Quit Smoking,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThyroidism” (also referred to as “HypoThyroid Support”), “Mucus Release,” “Parasite Cleanse,” “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Un-Vax,” “Venereal Defense,” “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”), and “Lungs & Respiratory.” The claims on your website establish that the products are drugs under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease.\n\nExamples of some of the website claims that provide evidence that your products are intended for use as drugs include:\n\n“Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”)\n\nOn the “Full Body Antibiotic” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Full Body Antibiotic” or “AntiBiotic, Full Body”\n\n• “Our Moor Herbs ‘High Science’ AntiBiotic Formulae targets it all! Use it to help heal respiratory and sinus infections, bronchitis, pneumonia, strep throat, colds, flues [sic], colic, seizures, cough, diabetes, urinary problems, menstrual problems, fever, liver problems, constipation, vaginal discharge, smallpox, enlarged spleen, swelling, asthma, eye cataracts, depression, digestion problems, stomach ulcers, heart trouble, infections, migraine, stroke, pain, . . . as well as urinary tract, kidney, and bladder infections.”\n\n• “Also beneficial for women with yeast infections, trichonomosas, bacterial vaginosis, and chlamydia.”\n\n• “It can be helpful for people with chronic fatigue, HIV, cancer, herpes, and other chronic conditions related with depressed immunity.”\n\n“Anti-Viral”\n\nOn the “Anti-Viral” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Anti-Viral”\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Anti-Viral Formulae is a potent and effective herbal anti-viral conducive for countering all viral conditions.”\n\n“Appendix Support”\n\nOn the “Appendix Support” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs High Science Appendix Support herbal blend is formulated to address the issues that lead to appendicitis: Constipation, Inflammation, and Infection.”\n\n“Blood Pressure” (also referred to as “Blood Pressure Normalizer”)\n\nOn the “Blood Pressure” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Blood Pressure Normalizer”\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Blood Pressure Normalizor [sic] is supported by an Indian medicinal herb belonging to Caesalpiniaceae family of plants.…What makes these seeds really popular, is their ability to lower blood pressure. Acting as a hypotensive agent, this humble seed works wonders for those looking to control their BP naturally.”\n\n• “It is a strong anti bacterial agent...”\n\n“Brain Tune-Up”\n\nOn the “Brain Tune-Up” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “The 2 main ingredients in this blend are Gotu Kola and Ginko Biloba[.] Gotu Kola Leaf… is anti-inflammatory, antiviral, antibacterial, . . . and antifungal. In human studies, gotu kola . . . reduced symptoms of anxiety and depression. It has been used to treat brain-related disorders including mental fatigue, anxiety, depression, memory loss, and insomnia.”\n\n• “Protects the brain from damage”\n\n• “Alleviates stress, anxiety, and depression”\n\n• “Improves memory and mood in Alzheimer’s patients”\n\n• “Ginko Biloba has been repeatedly evaluated for its ability to reduce anxiety, stress and other symptoms associated with Alzheimer’s disease …”\n\n• “Can Help Fight Inflammation.”\n\n• “Reduces Symptoms of Psychiatric Disorders and Dementia.”\n\n• “Can Reduce Anxiety.”\n\n• “Can Treat Depression.”\n\n“Cardiovascular System”\n\nOn the “Cardiovascular System” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “This ‘High Science’ Formula is designed to rebuild a degenerative heart...”\n\n“Headache & Pain Relief”\n\nOn the “Headache & Pain Relief” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Headache & Pain Relief”\n\n• “Our Headache and Pain formula is a natural anodyne concoction that contains plants naturally rich in salicin that naturally breaks down into salicylic acid in the body that is anti-inflammatory in nature and thus effective where there is pain, which is a sensor that something is wrong on a deeper level.”\n\n“Healthy Mommy Healthy Baby”\n\nOn the “Healthy Mommy Healthy Baby” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Note: This blend is also helpful for the following conditions: anemia, low blood, arthritis, asthma, hay fever, sinusitis, gout, emphysema, bronchitis, sinus relief, allergies, high blood pressure, nosebleeds, hemorrhaging, miscarriage (vitamin K), hardened arteries, tooth decay, peptic ulcers, duodenum ulcers, infections, drug and chemical toxins, skin problems, edema, water retention, bowels, gas pains...”\n\n“Quit Smoking”\n\nOn the “Quit Smoking” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Quit Smoking”\n\n• “Our Moor Herbs ‘High Science’ Quit Smoking Formulae is a herbal compound of Nature’s best herbs that have been utilized traditionally to help purify the bloodstream of pollutants and toxins, cleanse the liver…and develop a distaste of insidious addictive man- chemicals.”\n\n“HyperThyroidism” (also referred to as “HyperThyroid Support”)\n\nOn the “HyperThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “HyperThyroidism” or “HyperThyroid Support”\n\n• “For an overactive Thyroid”\n\n• “Moor Herbs High Science HyperThyroidism Relief Formulae is designed for an over-active thyroid gland. Effective for calming down an overactive thyroid and reducing symptoms of hyperthyroidism such as agitation, restlessness, sweating and insomnia.”\n\n“HypoThyroidism” (also referred to as “HypoThyroid Support”)\n\nOn the “HypoThyroidism” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “HypoThyroidism” or “HypoThyroid Support”\n\n• “For an underactive Thyroid”\n\n• “Moor Herbs High Science Thyroid Support Formula consists of Nature’s plants high in organic iodine and which perform a myriad of beneficial functions for the thyroid gland including…normalizing the function of metabolism. An impaired thyroid gland can lead to a host of negative health problems so good thyroid health is imperative for overall good health.”\n\n“Mucus Release”\n\nOn the “Mucus Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Mucus Release is a powerful ‘High Science’ formula that consists of effective expectorant herbs that help dissolve hardened, stubborn mucus and phlegm that obstruct the mucous membranes and lead to pathology throughout the body…Mucus Release is great for all mucus conditions!”\n\n“Parasite Cleanse”\n\nOn the “Parasite Cleanse” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Parasite Cleanse”\n\n• “Parasite Cleanse ‘High Science’ Formula contain[s] some of Nature’s best anthelmintic herbs that have been traditionally used for centuries by various cultures to remove parasites and worms from the tissues of the body. These creepy critters most certainly rob the body of nutrients and impair critical functions of the organs, glands, and systems of the body.”\n\n“ResErection Extra Strength w\u002F Yohimbe Bark”\n\nOn the “ResErection Extra Strength w\u002F Yohimbe Bark” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs ‘High Science’ Resurrection formulae, is a 100% all-natural herbal-based formula for men experiencing difficulty with attaining and maintaining an erection (penile erectile dysfunction) with the root cause being poor circulation due to poor diet (and lifestyle) – a diet too high in animal protein (meat, flesh, cadavaer, carion, etc.) and animal fat which clogs the veins and arteries and thus impairing circulation which is vital for a healthy, solid, firm, and stiff erection.”\n\n“Tumor Release” (also referred to as “Tumor & Cyst Support”)\n\nOn the “Tumor Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Tumor Release” or “Tumor & Cyst Support”\n\n• “Our Moor Herbs ‘High Science’ Tumor Release Formulae is a safe, sane and effective plant-based anti-neoplastic formulae that is helpful in natural, noninvasive, benign and malignant tumor dissolution.”\n\n• “The formula is useful for all tumor and cyst formations in the body, including uterine and ovarian cysts\u002Ftumors. Good for both internal and external tumors.”\n\n“Un-Vax”\n\nOn the “Un-Vax” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “Our Moor Herbs ‘HIGH SCIENCE’ Herbal UN-VAX Formulae is an unique formula designed to remove heavy metal toxins from the body. It is an ideal Formulae to combat mercury (ethyl and methyl) toxicity and aluminum toxicity, both of which are known to cause a plethora of adverse health conditions, especially in children.”\n\n“Venereal Defense”\n\nOn the “Venereal Defense” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Venereal Defense”\n\n• “Our Moor Herbs High Science Venereal Defense Formulae helps foment natural healing of adverse conditions that are passed on from one person to another through intimate contact.”\n\n“Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”)\n\nOn the “Womb Care Cramp Relief & Fibroid Release” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• The product name: “Womb Care Cramp Relief & Fibroid Release” or “Womb Care: Fibroid and Tumor Release”\n\n• “Our Moor Herbs ‘High Science’ Fibroid\u002FTumor Release Formulae is an all-natural herbal formulation consisting of Nature’s herbs that have an affinity for the female uterus, e.g. Chaste berry and Dong Quai and that are also anti-neoplastic (anti-tumor growth and formation) in nature, e.g. Burdock and Comfrey, thus combating tumorous growth on the uterus, e.g. fibroid tumors or uterine fibroids, facilitating dissolution via the vaginal canal and other eliminative channels.”\n\n• “Fibroids\u002FTumor Release, is a product that can be used in an overall regimen to help females naturally dissolve tumors of the reproductive system and is a great post Womb Cleanse formulae to consume daily.”\n\n• “Recommended for: Uterine fibroids or fibroid tumors, cervical tumors, uterine cysts.”\n\n“Lungs & Respiratory”\n\nOn the “Lungs & Respiratory” product webpage of your website https:\u002F\u002Fmoorherbs.com:\n\n• “This High Science Formula is a highly effective anti-tussive and expectorant science formulae.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are “new drugs” under section 201(p) of the FD&C Act [21 U.S.C. 321(p)].\n\nWith certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. 331(d) and 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use these products safely for their intended purposes. Accordingly, your “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Anti-Viral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Brain Tune-Up,” “Healthy Mommy Healthy Baby,” “HyperThyroidism” (also referred to as “HyperThyroid Support”), “HypoThroidism” (also referred to as “HypoThyroid Support”), “ResErection Extra Strength w\u002FYohimbe Bark,” “Tumor Release” (also referred to as “Tumor & Cyst Support”), “Venereal Defense,” and “Womb Care Cramp Relief & Fibroid Release” (also referred to as “Womb Care: Fibroid and Tumor Release”) products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the FD&C Act [21 U.S.C. 331(a)].\n\nAdulterated Dietary Supplements\n\nThe dietary supplements manufactured at your facility are adulterated under section 402(g)(1) of the FD&C Act [21 U.S.C. 342(g)(1)] because they have been prepared, packed, or held under conditions that do not meet the Current Good Manufacturing Practice (CGMP) regulation for dietary supplements (21 CFR Part 111). During the inspection of your facility, FDA investigators observed the following significant violations of the CGMP regulation for dietary supplements:\n\n1. You failed to establish the specifications required under 21 CFR 111.70. Specifically:\n\na. You failed to establish the following required component specifications under 21 CFR 111.70(b) for each component that you use in the manufacture of a dietary supplement: (1) identity specifications, as required by 21 CFR 111.70(b)(1); and (2) component specifications that are necessary to ensure that specifications for the purity, strength, and composition of the dietary supplements manufactured using the components are met, as required by 21 CFR 111.70(b)(2). Specifically, when our investigators requested such component specifications for the Coltsfoot, Wild Cherry Bark, and Boneset Herb ingredients used in the manufacturing of your “Lungs & Respiratory” finished dietary supplement product, you were unable to provide such component specifications. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing component specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nb. You failed to establish specifications for dietary supplement labels (labeling specifications), as required by 21 CFR 111.70(d). Specifically, you were unable to provide labeling specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you are in the process of establishing written labeling specifications. We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nc. You failed to establish specifications for each dietary supplement that you manufacture for the identity, purity, strength, and composition of the finished batch of the dietary supplement, and for limits on those types of contamination that may adulterate, or that may lead to adulteration of, the finished batch of the dietary supplement to ensure the quality of the dietary supplement, as required by 21 CFR 111.70(e). Specifically, you were unable to provide finished product specifications for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products when requested by our investigators. We have reviewed your written response on April 3, 2023, in which you state that you “are in the process of establishing product specifications for identity, purity, strength and composition of the finished dietary supplement.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nWe note that once you have established these specifications, you must determine whether the specifications that you establish under 21 CFR 111.70 are met, as required by 21 CFR 111.73 and 21 CFR 111.75(c). Specifically, once you have established component specifications and before using a component, you must conduct at least one appropriate test or examination to verify the identity of any component that is a dietary ingredient, as required by 21 CFR 111.75(a)(1)(i), unless you petition the agency under 21 CFR 111.75(a)(1)(ii) and the agency exempts you from such testing. You must also confirm the identity of other components and determine whether other applicable component specifications established in accordance with 21 CFR 111.70(b) are met, as required by 21 CFR 111.75(a)(2). Further, you must verify that your finished batch of the dietary supplement meets product specifications for the identity, purity, strength, composition, and for limits on those types of contamination that may adulterate or that lead to adulteration of the finished batch of the dietary supplement, as required by 21 CFR 111.75(c).\n\nYou must also make and keep records, including records for the specifications you establish, in accordance with 21 CFR 111.95.\n\n2. You failed to establish and follow written procedures for the responsibilities of the quality control operations, including written procedures for conducting a material review and making a disposition decision, and for approving or rejecting any reprocessing, as required by 21 CFR 111.103, and make and keep records of such procedures, as required by 21 CFR 111.140(b)(1). Specifically, you told our investigators that you have no written procedures for quality control operations and that you do not have a quality control program in place.\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of implementing quality control operations to ensure the quality of dietary supplements” and “are also in the process of establishing written procedures and training quality control personnel to ensure all is produced safely, accurately, and according to the standards we have, and are putting, in place.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n3. You did not prepare and follow a master manufacturing record (MMR) for each unique formulation of dietary supplement that you manufacture, and for each batch size, to ensure uniformity in the finished batch from batch to batch, as required by 21 CFR 111.205(a). Upon request, you could not provide written MMRs for your “Anti-Viral,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), and “Lungs & Respiratory” finished dietary supplement products to our investigators. You stated that you did not have these records, and none were provided.\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are in the process of establishing Master Manufacturing Records for each dietary supplement and size.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n4. Your batch production record did not include complete information relating to the production and control of each batch, as required under 21 CFR 111.255(b) and 21 CFR 111.260. Specifically, batch production records for “Anti-Viral” manufactured on (b)(4) with lot #(b)(4), “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”) manufactured on (b)(4) with lot #(b)(4), and “Lungs & Respiratory” manufactured on (b)(4) with lot #(b)(4), were collected and reviewed. These records do not include complete information required to be in batch production records. The required information that your records are missing includes, but is not limited to, the following:\n\n• The identity of equipment and processing lines used in producing the batch [21 CFR 111.260(b)];\n\n• The date and time of the maintenance, cleaning, and sanitizing of the equipment and processing lines used in producing the batch, or a cross-reference to records where this information is retained [21 CFR 111.260(c)]; The unique identifier that you assigned to each component, packaging, and label used [21 CFR 111.260(d)];\n\n• A statement of the actual yield and a statement of the percentage of theoretical yield at appropriate phases of processing [21 CFR 111.260(f)];\n\n• The actual results obtained during any monitoring operation [21 CFR 111.260(g)];\n\n• The results of any testing or examination performed during the batch production, or a cross-reference to such results [21 CFR 111.260(h)];\n\n• Documentation at the time of performance of the manufacture of the batch, including [21 CFR 111.260(j)]:\n\no The date on which each step of the MMR was performed [21 CFR 111.260(j)(1)]; and\n\no The initials of the persons performing each step [21 CFR 111.260(j)(2)], including:\n\n The initials of the person responsible for weighing or measuring each component used in the batch;\n\n The initials of the person responsible for verifying the weight or measure of each component used in the batch;\n\n The initials of the person responsible for adding the component to the batch; and\n\n The initials of the person responsible for verifying the addition of components to the batch;\n\n• Documentation at the time of performance of packaging and labeling operations [21 CFR 111.260(k)], including:\n\no The unique identifier that you assigned to packaging and labels used, the quantity of the packaging and labels used, and, when label reconciliation is required, reconciliation of any discrepancies between issuance and use of labels [21 CFR 111.260(k)(1)];\n\no An actual or representative label, or a cross-reference to the physical location of the actual or representative label specified in the MMR [21 CFR 111.260(k)(2)]; and\n\no The results of any tests or examinations conducted on packaged and labeled dietary supplements (including repackaged or relabeled dietary supplements), or a cross-reference to the physical location of such results [21 CFR 111.260(k)(3)];\n\n• Documentation at the time of performance that quality control personnel [21 CFR 111.260(l):\n\no Reviewed the batch production record [21 CFR 111.260(l)(1), including:\n\n Review of any monitoring operation required under subpart E of 21 CFR part 111 [21 CFR 111.260(l)(i)]; and\n\n Review of the results of any tests and examinations, including tests and examinations conducted on components, in-process materials, finished batches of dietary supplements, and packaged and labeled dietary supplements [21 CFR 111.260(l)(ii)];\n\no Approved or rejected any reprocessing or repackaging [21 CFR 111.260(l)(2)]; and\n\no Approved and released, or rejected, the batch for distribution, including any reprocessed batch [21 CFR 111.260(l)(3)]; and\n\no Approved and released, or rejected, the packaged and labeled dietary supplement, including any repackaged or relabeled dietary supplement [21 CFR 111.260(l)(4)].\n\n• Documentation at the time of performance of any required material review and disposition decision [21 CFR 111.260(m)];\n\n• Documentation at the time of performance of any reprocessing [21 CFR 111.260(n)].\n\nWe have reviewed your written response received on April 3, 2023, in which you state that you “are still in the process of establishing and implementing the systems (as discussed throughout this document and the investigators observations) that will allow us to produce complete batch records.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n5. You failed to establish and follow written procedures for the requirements to review and investigate a product complaint, as required under 21 CFR 111.553. Specifically, our investigators requested your written procedures to review and investigate a product complaint. You stated that you did not have this procedure, and you did not provide it.\n\nWe have reviewed your April 3, 2023, written response, in which you state, “We’ve been operating since March of 2015 and have never received a complaint. However, we are in the process of establishing written procedures for reviewing and investigating product\u002Fcustomer complaints.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n6. You failed to establish and follow written procedures for when a returned dietary supplement is received, as required under 21 CFR 111.503. Specifically, our investigators requested your written procedures for when a returned dietary supplement is received. You stated that you did not have these written procedures, and none were provided.\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for when a returned dietary supplement is received.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n7. You failed to establish and follow written procedures for holding and distributing operations, as required by 21 CFR 111.453. Specifically, during the inspection, you said you had not established written procedures for holding and distributing operations.\n\nOnce have you established written procedures for your holding and distributing operations, you must make and keep records of such written procedures, as required by 21 CFR 111.475(b)(1).\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “are in the process of establishing written procedures for holding and distributing operations.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\n8. You did not maintain and clean equipment, utensils, and contact surfaces used to manufacture, package, label, or hold components or dietary supplements, as required under 21 CFR 111.27(d). P\n\nSpecifically, on (b)(4), during the manufacturing of your “Lungs & Respiratory” finished dietary supplement product, your multi-functional grinder was observed with a light green and brown residue inside the bowl and the (b)(4) plastic capsule filling equipment was observed with a light brown powder and brown staining. Furthermore, the method you used for cleaning and sanitizing your utensils and equipment does not align with, and directly contradicts, the manufacturer’s written instructions on the cleaning and sanitizing products. Additionally, you do not have any written procedures for cleaning or sanitizing your utensils and equipment, as required under 21 CFR 111.25(c).\n\nWe have reviewed your April 3, 2023, written response, in which you state that you “have since corrected the way we wash and sanitize our utensils and equipment, according to the instructions indicated on the cleaning agents we use, combined with regulations outlined under Michigan Food Law.” These corrections will be evaluated during the next FDA inspection of your firm. You also stated in your response that you “are in the process of establishing written procedures for cleaning and sanitizing utensils and equipment.” We cannot evaluate the adequacy of your corrective action, because you did not provide any additional evidence or supporting documentation for review.\n\nMisbranded Dietary Supplements\n\nIn addition, your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”),, “Headache & Pain Relief,” and “Bright Eyes” products are misbranded dietary supplements under Section 403 of the Act [21 U.S.C. § 343] because they do not comply with the labeling requirements for dietary supplements as required by 21 CFR 101 as follows:\n\n1. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(q)(1)(A) of the Act [21 U.S.C. § 343(q)(1)(A)] because the serving size declared on the labels is are incorrect. Serving size for a dietary supplement is the maximum amount consumed per eating occasion as recommended on the product label as defined in 21 CFR 101.9(b) and 21 CFR 101.12(b) Table 2. Your Lungs and Respiratory, Full Body Antibiotic, Antiviral, Blood Pressure Normalizer, Headache & Pain Relief, and Bright Eyes product labels’ serving sizes is declared as “3 Capsules or 3 Scoops” and are not specific to each product.\n\n2. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of sections 403(q)(5)(F) of the Act [21 U.S.C. § 343(q)(5)(F)] in that the presentation of nutrition information on the labeling of the products does not comply with 21 CFR 101.36. Specifically,\n\n• The title “Supplement Facts” is not set at full width of the nutrition label, in accordance with 21 CFR 101.36(e)(1).\n\n• The dietary ingredients are not indented under the title “Proprietary Herbal Blend”, in accordance with 21 CFR 101.36(c)(2).\n\n• The quantitative amount by weight per serving of proprietary blend does not use metric measures in appropriate units (i.e., 1000 units must be declared in the next higher set of units, e.g., 10000 mg must be expressed as 10 g), in accordance with 21 CFR 101.36(b)(3)(ii)(A).\n\n3. Your Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”),, “Headache & Pain Relief,\" and “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) products are misbranded within the meaning of section 403(s)(2)(C) of the Act [U.S.C. § 343(s)(2)(C)] in that the label fails to identify the part of the plant (e.g., root, leaves) from which each botanical dietary ingredient in the product is derived, as required by 21 CFR 101.4(h)(1) and 101.36(d)(1). If the whole or entire part is used, this must be declared.\n\n4. Your “Blood Pressure” (also referred to as “Blood Pressure Normalizer”) and “Headache & Pain Relief” products are misbranded within the meaning of section 403(i)(2) of the Act in that the labels fail to declare all the common or usual names of each ingredient used as required by 21 CFR 101.36 and 21 CFR 101.4(h). For example:\n\n• The Blood Pressure Normalizer product label lists “manjishtha”, but this is not the standardized common name of the dietary ingredient. The label must list the standardized common name (SCN) given in the reference Herbs of Commerce, “Indian madder”. The Ayurvedic name for Indian madder (manjishtha) may follow the SCN in parentheses.\n\n• The SCN for the term “Chaksu” must be declared; in the absence of a SCN, the Latin binomial name must be declared.\n\n• The Headache & Pain Relief product declares “dashmoola”. The dietary ingredient(s) that make up the “dashmoola” must be declared by the SCN; in the absence of a SCN, the Latin binomial name for the dietary ingredient must be declared.\n\n5. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” products are misbranded within the meaning of section 403(i)(2) [21 U.S.C. § 343(i)(2)] of the Act because the labels fail to declare all ingredients, as required by 21 CFR 101.4. Specifically, the products fail to declare the ingredients of the capsule material.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nWe offer the following additional comments:\n\n1. Your “Lungs and Respiratory,” “Full Body Antibiotic” (also referred to as “Antibiotic, Full Body”), “Antiviral,” “Blood Pressure” (also referred to as “Blood Pressure Normalizer”), “Headache & Pain Relief,” and “Bright Eyes” product labels do not bear a symbol next to the structure\u002Ffunction claim linking the claim to the disclaimer. Furthermore, the disclaimer fails to be enclosed in a box, in accordance with 21 CFR 101.93(d).\n\nYour response should be sent to the U.S. Food and Drug Administration; Attn: Katie Cutajar, Compliance Officer, via email at ORAHAFEAST6FirmResponses@fda.hhs.gov, or at 300 River Place Suite 5900, Detroit, MI 48207. If you have questions regarding this letter, please contact CO Cutajar at (313) 680-6962 or via email at Kathryn.Cutajar@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nWilliam R. Weissinger, MS\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast Division 6","Moorish Science Temple, The Divine and National Movement of North America, Inc; #13 The Moorish American National Republic dba Moor Herbs, Inc.","moorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmoorish-science-temple-divine-and-national-movement-north-america-inc-13-moorish-american-national","2026-10-26T08:09:27.900006+00:00","2023-09-19","Division of Human and Animal Food Operations East VI","Maria S. LeMay-Bey, Owner","2026-08-20T00:39:30.007+00:00","VIA EMAIL AND UNITED PARCEL SERVICE","2023-08-01",19,{"510k":394,"classification":395,"enforcement":396,"event":397,"event_backfill":398,"pma":399,"warning_letter":400},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-19T04:00:36.695+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]